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In the first chapter of this dissertation, the design and synthesis of bifunctional additives 
and cosolvents containing an oxetane moiety are described.  The use of dimeric oxetanes as 
additives for reactions involving organometallic agents—namely, organolithium, 
organozirconium, and organomagnesium reagents was studied. A dimeric bisoxetanyl ether 
showed promise for solvating organolithium aggregates, but dimeric oxetanyl ethers were not 
useful additives in hydrozirconation reactions.  A bisoxetanyl sulfide is being investigated 
further as an additive for Grignard reactions.  A bisoxetanyl sulfoxide (MMS350) was developed 
as a dimethylsulfoxide substitute that showed utility for enhancing the aqueous solubility of 
small organic molecules. 
 
In the second chapter, efforts toward the development of agents for protection and 
mitigation of ionizing radiation damage are outlined.  It was discovered that administration of 
MMS350 prolonged survival in irradiated mice.  Moreover, mice given MMS350 in their 
drinking water had lower incidences of pulmonary fibrosis.  Additional analogs of MMS350 
were synthesized for further investigation of the molecular and structural requirements for 
successful sulfoxide-containing radiation protectors. 
 
In the third chapter, the design and proof-of-concept study of using an oxazoline linker 
for functionalization and pH-dependent release of reactive oxygen species (ROS) scavengers 
from silica nanoparticles is discussed.  pH-Dependent hydrolysis of model oxazolines was 
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achieved by modulating the substitution on the oxazoline moiety.  Moreover, functionalized 
silica nanoparticles were successfully endocytosed by macrophages.  Our studies have laid the 
groundwork for the design of covalently modified nanoparticles for delivery of ROS. 
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1.0  OXETANES AS ADDITIVES AND COSOLVENTS 
In his introduction to Solvents and Solvent Effects in Organic Chemistry, Christian 
Reichardt states, “The development of our knowledge of solutions reflects to some extent the 
development of chemistry itself.”1   Although a number of solvents and cosolvents with varying 
polarities, electron-donating and accepting properties, and boiling points are available, the 
development of new reaction media can advance the scope of our synthetic capabilities. 
Moreover, environmental and health concerns regarding solvent toxicity prompt the exploration 
of new media, particularly in the case of process chemistry2 and biological applications.  In the 
1980’s, the desire to replace carcinogenic HMPA led to the introduction of more benign DMPU.3 
Similar movements for solvent replacement currently exist, and the definition of a “green”4,5 
solvent varies depending on the application; there is a need for the continuous development of 
new solvents and additives to address the ever-changing demands of both academia and industry.   
 
Among common ethereal solvent scaffolds, oxetanes have not been extensively used as 
solvents.  Yet, oxetanes, particularly 3,3-disubstituted oxetanes, have favorable solvolytic 
properties.  Moreover, Carreira and Müller have introduced the oxetane as a replacement for 
carbonyl or gem-dimethyl groups in medicinally relevant molecules.6,7 Many of the attributes 
(e.g., enhanced hydrogen-bond affinity, large polar surface area) that make oxetanes attractive 
moieties in drug discovery translate to their potential application as solvents. 
 
To examine the feasibility of using oxetanes as additives or cosolvents, I generated 
bifunctional molecules wherein oxetanes were appended to common solvent motifs including 
ethers and sulfides.   I tested the effect of adding the bifunctional compounds to reactions 
involving organometallic reagents—namely organolithium, organozirconium, and 
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organomagnesium reagents.  I then shifted my focus to the utility of a bifunctional sulfoxide as a 
dimethyl sulfoxide substitute for applications including chemical storage and biological assays.   
1.1 INTRODUCTION 
In this section, important physical properties for Lewis basic solvents are highlighted, and 
emphasis is placed on the known physical properties of cyclic ethers and oxetanes.  Key factors 
leading to observed solvent effects in reactions involving organometallic reagents are detailed, 
and key precedents for using oxtetanes in reactions involving organolithium and 
organozirconium reagents are addressed.  Methods by which oxetanes can be prepared and 
elaborated are then discussed.  Finally, issues regarding toxicity and mutagenicity of oxetanes 
are addressed. 
1.1.1 Physical Properties of Solvents 
“Solvent effect” is a general term referring to differences in reaction rate, regioselectivity, 
chemoselectivity, diastereoselectivity, or enantioselectivity observed upon changing reaction 
media.  The properties of solvents, notably bulk permittivity (dielectric constant, ), dipole 
moment (), and electron-donating and accepting properties can have an important role in 
dictating the relative stabilities of the starting materials, activated complex, and reaction 
products.8 
1.1.1.1 The EPD-EPA Interaction: Measures of Donating Ability  
Ethereal solvents are often used in reactions involving organometallic reagents because 
they exhibit low reactivity and have the ability to coordinate and solvate cations; the donor-
acceptor interaction of coordinating ethereal solvents with organometallic species can be 
modeled as a Lewis acid/Lewis base interaction (eq 1).   
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As outlined by Reichardt,1 electron-pair donors (EPDs) are classified according to the 
energetically highest orbitals as n-EPDs (e.g., ethers, tertiary amines), -EPDs (e.g., 
cyclopropane, dichloromethane) and -EPDs  (e.g., alkenes, alkylbenzenes).  Electron-pair 
acceptors (EPAs) are classified according to the energetically lowest unoccupied orbitals as -
EPAs (e.g., metal cations, boron trihalides), -EPAs (e.g., Br2) , and -EPAs (e.g., unsaturated 
compounds with electron-withdrawing substituents such as tetracyanoethane).1 In the case of 
interactions between ethereal solvents and organometallic reagents, the n-donor-to--acceptor 
relationship is of consequence.   
 
Due to the importance of coordinating solvents in metal-mediated reactions, researchers 
have developed scales of relative donating ability.  Gutmann established the concept of Donor 
Number (DN), which is the enthalpy of reaction of an electron donating solvent with SbCl5 
correlated to dichloroethane as a reference solvent (eq 2).9 Gal and Maria have developed a 
similar scale based on measurements of reaction enthalpy for the reaction between boron 
trifluoride and a donating organic species (eq 3).10  Along with donating ability, the solvating 
power of solvents depends on the dielectric constant (), which is an indication of solvent 
polarity and dissociating ability.  As indicated by the tabulation of solvent data (Table 1-1), donor 
number and ionizing ability are not necessarily correlated.  
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Table 1-1. Physical parameters for selected solvents. 
 
 
Ethereal solvents are better n-EPDs than esters and ketones (entries 3-4) but poorer 
donors than sulfoxides (entry 9), amines (entry 11), and phosphoramides (entry 10).  Although 
ether (entry 5) and tetrahydrofuran (entry 7) have similar experimental Lewis basicities, 
additional studies indicate that tetrahydrofuran has significantly higher proton affinity.  By 
nature of their constrained geometry, cyclic ethers have larger exposed surface areas at the 
 
Entry 
 
 
Solvent 
 
 (25 °C)11 
 
DN (kcal/mol)9 
 
-HoBF3 
(kcal/mol)10 
 
 
1 
 
nitromethane 
  
35.87 
   
 2.7 
  
 8.99 
 
2 
 
1,4-dioxane 
  
  2.22 
  
14.8 
  
17.71 
 
3 
 
ethyl acetate 
  
  6.02 
  
17.1 
  
18.06 
 
4 
 
acetone 
 
20.56 
  
17.0 
  
18.17 
 
5 
 
diethyl ether 
  
  4.27 
  
19.2 
  
18.83 
 
6 
 
tetrahydropyran 
  
  5.66 
 
22 
  
20.40 
 
7 
 
tetrahydrofuran 
  
  7.52 
  
20.0 
  
21.61 (19.6)a 
 
8 
 
oxetane 
 
b 
 
c 
 
      d  (20.3)a 
 
9 
 
dimethylsulfoxide 
  
46.45 
  
29.8 
  
25.18 
 
10 
 
hexamethylphosphoramide 
  
29.30 
  
38.8 
  
28.08 
 
11 
 
pyridine 
  
12.91 
 
33.1 
  
30.61 
      
aGas-phase BF3-affinities calculated at the MP3 level of theory.
12  bThe dielectric constant of oxetane has 
not been measured. cDN for oxetane has not been reported. dThe BF3-affinity of oxetane has not been 
measured experimentally; McLaughlin et al. report polymerization of oxetane when attempting to 
determine the stability of oxetane-BF3 addition compounds.
13 
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coordinating oxygen, which enhances hydrogen-bonding capabilities and, consequently, aqueous 
solubility.14 Bellon demonstrated the effect of cyclization on hydrogen-bonding by measuring 
equilibrium constants for the interaction of ethers with p-chlorophenol (Table 1-2).15 
 
 
Table 1-2. Equilibrium constants for the interaction of ethers with p-chlorophenol. 
 
 
 
 
The data shown in Table 1-2 support that cyclic ethers are superior hydrogen-bond 
acceptors, which can be rationalized both by steric arguments (the oxygen of acyclic ethers may 
be crowded by freely rotating alkyl groups) and the higher bulk permittivities and dipole 
moments of the cyclic ethers (compare THF:  = 7.52,  = 1.75 D to diethyl ether:  = 4.27,  = 
1.15 D).  Another aspect of the data is the greater basicity of 2-substituted tetrahydofurans, 
indicating that substitution at the 2-position of cyclic ethers enhances donating ability.  Among 
 
Entry 
 
Acyclic ether 
 
K (10-2) 
 
Cyclic ether 
 
K (10-2) 
 
Kcyclic/Kacyclic 
 
 
1 
 
MeOEt 
 
----a 
 
oxetane 
 
5.8 ± 0.2 
 
2.3b 
 
2 
 
EtOEt 
 
2.49 ± 0.08 
 
THF 
 
5.1 ± 0.2 
 
2.1 ± 0.1 
 
3 
 
EtO-n-Pr 
 
2.08 ± 0.06 
 
THP 
 
4.4 ± 0.1 
 
2.1 ± 0.1 
 
4 
 
EtO-i-Pr 
 
2.49 ± 0.08 
 
2-MeTHF 
 
6.2 ± 0.2 
 
2.5 ± 0.1 
 
5 
 
EtO-t-Bu 
 
2.71 ± 0.09 
 
2,2-Me2THF 
 
6.6 ± 0.2 
 
2.5 ± 0.1 
 
6 
 
 
n-PrO-n-Pr 
 
2.84 ± 0.09 
 
oxepane 
 
5.0 ± 0.2 
 
3.0 ± 0.2 
aThe value was not obtained because MeOEt is a gas at 20 °C.15  bThe ratio was estimated based on the 
known gas-phase basicity of MeOEt.  
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unsubstituted cyclic ethers, oxetane has the greatest basicity, which Bellon attributes both to its 
smaller size and larger dipole moment (See Table 1–4, entry 2).   
 
More recently, the pKBHX scale
16 has become popular for measuring hydrogen bond 
basicity—the values are based on formation of a complex between the acceptor (e.g., an ether) 
and 4-fluorophenol.  Representative values for a range of Lewis bases are tabulated in Table 1–3. 
 
The data indicate a similar trend as observed in the case of association constants with p-
chlorophenol.  These data also corroborate the trend observed in the case of donor numbers 
(Table 1-1) wherein cyclic ethers (e.g., oxetane, THF) have higher hydrogen-bonding affinities 
than ketones (e.g., acetone) and acyclic ethers (e.g., diethyl ether). 
 
 
Table 1-3. Hydrogen bond basicity of selected Lewis basic moieties. 
 
 
 
 
Computational studies indicate that the gas-phase basicity of oxetane is 2.6 kcal/mol higher 
than for methyl ethyl ether, whereas the gas-phase basicities of tetrahydrofuran and diethyl ether 
are comparable.  Bordeje et al. postulate that the difference results from lengthening of C–O 
bonds upon protonation, which alleviates ring strain.  Protonation of less strained tetrahydrofuran 
would not facilitate comparable strain relief as protonation of oxetane.17  Although gas-phase 
Brønstead basicities are often not indicative of solution-phase behavior, the result suggests a 
 
Solvent 
 
Me3PO 
 
Me2SO 
 
morpholine 
 
oxetane 
 
THF 
 
(CH3)2O 
 
EtOEt 
 
 
pKBHX 
 
3.53 
 
2.54 
 
1.78 
 
1.36 
 
1.28 
 
1.18 
 
1.01 
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superior coordinating ability of oxetane due to the structural differences (namely angular strain) 
in the four- and five-membered rings.    
 
Because oxetane may exhibit enhanced basicity due to its small size and strain, epoxides 
might also be considered viable coordinating solvents; however, oxiranes are typically too 
reactive for use as reaction media. Although oxetane and oxirane have similar strain energies 
(Table 1-4, entries 1 and 2), computational models18 indicate that oxirane is greater than 106 
times more susceptible to nucleophilic addition than oxetane.  Furthermore, the cleavage of an 
aziridinium triflate in acetonitrile using DIPEA is 103 times faster than cleavage of the 
corresponding azetidinium salt.19 The enhanced reactivity of epoxides may result from the 
difference in hybridization when compared with oxetane (Table 1–4, entries 1 and 2); oxirane is 
almost sp2-hybridized, which may facilitate faster ring-opening than in the case of oxetanes. 
 
 
Table 1-4. Physical properties of cyclic ethers 
 
    Entry 
 
    Ether 
 
Strain Energy 
   (kcal/mol)20 
 
 
Hybridization21 
(%s character of  
C-H bonds) 
 
 
   Dipole 
Moment11(D) 
 
      1 
 
oxirane 
 
26.8 
 
30a 
 
         1.89  0.01 
 
      2 
 
oxetane 
 
25.2 
 
26a 
 
  1.94  0.0122 
 
      3 
 
tetrahydrofuran 
 
 5.9 
 
25b 
 
         1.75  0.01 
 
      4 
 
tetrahydropyran 
 
 0.5 
 
25b 
 
         1.58  0.03 
 
      5 
 
 
1,4-dioxane 
 
 3.3 
 
25b 
 
aThe %s character was measured using C-H coupling constants. 
bThe hybridization is assumed based on the absence of geometrical deviation 
from typical sp3-hybridized carbons.   
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1.1.1.2 Physical Properties of Oxetanes 
As discussed, oxetanes are constrained cyclic ethers; the lone pairs are more exposed as 
hydrogen bond acceptors.  The enhanced hydrogen bonding affinity of oxetanes led us to 
hypothesize that oxetanes would also coordinate strongly to positively charged organometallic 
reagents; indeed, the coordinating ability of oxetane for small cations (e.g., Li+) has been 
demonstrated experimentally and is discussed in detail in section 1.1.2.4.23,24 
 
Unlike cyclobutane,21 oxetane has a minimal inversion barrier and a relatively flat 
(unpuckered) geometry (Figure 1-1), which make oxetanes relatively flat.  These properies have  
led to the use of oxetanes as isosteric replacements for the carbonyl moiety. Carriera and Müller 
have recently reported an averaged structure of 3,3-disubstituted oxetanes.6   In this case, it was 
shown that there is slight puckering due to eclipsing interactions, but that the ring puckering 
angle is relatively small (ca. 10°) (Figure 1-1, c). 
 
Although oxetanes are less susceptible to ring-opening than epoxides, nucleophilic 
addition to trimethylene oxide is well-established.25  An example is the addition of (1,3-dithian-
2-yl)lithium to oxetane (Scheme 1-1).26 
 
 
Figure 1-1. Structural parameters for a) cyclobutane, b) oxetane, and c) 3,3-disubstituted oxetane.  The 
parameters in c) represent averaged structural parameters from data taken from the CSD (adapted from 
reference 6). 
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Scheme 1-1. Ring-opening of oxetanes using nucleophilic lithium reagents. 
  
 
 
 
 
3,3-Disubstituted oxetanes are more stable than their unsubstituted counterparts due to steric 
hindrance and the Thorpe-Ingold effect.27 Carreira and Müller28 demonstrated that 3,3-
disubstitituted oxetanes are stable to stirring in aqueous buffers over a pH range of 1-10; in 
contrast, trimethylene oxide is readily susceptible to hydrolysis under acidic conditions.29 
 
 Searles et al.30 catalogued the electron-donating properties of several substituted 
oxetanes based on the CH3OD spectra (Table 1–5).  The data indicate that substitution at the 3-
position of oxetane (entry 2) renders the oxygen moiety less donating whereas substitution at the 
2-position enhances donating ability (entry 3).  The latter result is readily explained by increased 
electron-donation by alkyl substitution.  The decreased donation from the 3,3-disubstituted 
oxetane can be explained by the Thorpe-Ingold effect; geminal substitution at the 3-position 
decreases the internal angles, consequently decreasing the overall electron-availability.  Searles 
also demonstrated that the donating-ability of the oxetane has a positive correlation with its 
proclivity toward reductive cleavage with LAH in THF at reflux.30 Although 2-substituted 
oxetanes may have superior donating ability, 3-substituted oxetanes have the optimal 
combination of donating ability and stability. 
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Table 1-5. Effect of alkyl substitution on the EPD-ability of oxetanes. 
 
1.1.2 Solvent Effects in Organometallic Reactions 
1.1.2.1 Consequences of Aggregation and Generation of Activated Anions 
In the case of reactions involving organometallic reagents, the principles governing 
solvent effects are complicated by ion-pairing and aggregation.  For example, the alkylation of 
sodium malonate 1-4 with n-butyl bromide 1-5 (Table 1-6) is significantly accelerated when 
electron-donating solvents are used as additives.32,33  The observation indicates that dissociation 
of sodium malonate oligomers produces kinetically active lower-order aggregates. Generation of 
activated anions is generally achieved by 1) increasing the size of the cation to effectively cause 
an electrostatic “mismatch” (e.g., the “cesium effect”), 2) using electron-pair-donating solvents 
that interact with cations or 3) using ligands designed for specific cation solvation (e.g., crown 
ethers).1     
 
 
 
 
Entry 
 
 
Oxetane 
 
O-D shift (cm-1)a 
 
1 
 
oxetane 
 
120 
 
2 
 
3,3-diethyloxetane 
 
115 
 
3 
 
 
2,2-diethyloxetane 
 
125 
aThe O-D shift refers to the difference in the O-D band frequency in the infrared spectrum of  a 0.1 M 
solution of methanol-d in an ether (e.g., oxetane) versus a 0.1 M solution of methanol-d in a reference 
solvent (in this case, CCl4).
30  The Lewis basicity of ethers has been positively correlated to the magnitude 
of the O-D shift.31 
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Table 1-6.  Effect of solvent on the dissociation of sodium malonate oligomers.  
 
 
 
 
 
1.1.2.2 The Effect of Ion-Pairing 
The presence of contact versus solvent-separated ion pairs can impact the 
chemoselectivity of chemical transformations.  Examples include the addition of lithium 
carbanions to enones (Tables 1-7 and 1-8).  The addition of benzaldehyde O-(trimethylsilyl)-
cyanohydrin 1-8 to enone 1-7 proceeds via 1,4-addition in ether but predominantly 1,2-addition 
in DME or THF (Table 1-7).34 Conversely, the addition of electron-donating media (e.g., 
HMPA) to the reaction between (1,3-dithian-2-yl)lithium 1-1 and 2-cyclohexen-1-one 1-10 led to 
formation of the 1,4-addition product (Table 1-8).35 Both results can be explained by the 
presence or absence of ion-pairing. The dithiane addition results are explained by the presence or 
absence of lithium cation in carbonyl activation (Figure 1-2, a); the cyanohydrin addition results 
are explained by chelation from both the carbonyl and the nitrile (Figure 1-2, b).  In electron-
donating solvents, the chelation to nitrogen is impeded, and 1,2-addition is the operative pathway 
when the reaction is kinetically controlled.  Warming the reaction performed in THF from –78 
°C to 0 °C had no effect on the product ratio of 1-9 to 1-10.   
 
 
 
 
Additive 
(5 equiv) 
 
 
None 
 
THF 
 
DME 
 
1,4-dioxane 
 
DMF 
 
HMPA 
 
k (rel.) 
 
 
1 
 
1.1 
 
6.4 
 
18 
 
19 
 
54 
  
 12 
Table 1-7. Effect of solvent on cyanohydrin additions.34 
 
 
 
 
          Entry 
 
Solvent 
 
Ratio 1-9:1-10 
 
Combined yield of 1-9 
and 1-10 (%) 
 
 
1 
 
           Et2O 
 
> 95:5  
 
84 
 
2            DME 22:78 98 
 
3            THF 25:75 Not reported 
 
 
 
Table 1-8.  Effect of solvent on dithiane additions. 
 
 
 
 
 
Entry 
 
Solvent 
 
Ratio 1-12:1-13 
 
 
  1 
 
 THF or Et2O 
 
> 99: 1 
 
  2  THF, HMPA (2 equiv) < 5:95 
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Cohen et al.36 proposed that 1,2- versus 1,4-selectivity results from a rapid equilibrium 
between contact and solvent-separated ion pairs (Scheme 1-2).  1,2-Addition to enones has a low 
activation barrier and proceeds from the contact ion pair via a four-center transition state 
(pathway I). Under kinetic control, solvent-separated ion pairs add at the 4-carbon (pathway II), 
regardless of the nature of the nucleophile.  In the case of an early transition state, kinetic 1,4-
addition is favored because the 4-carbon in acrolein has a larger LUMO coefficient than the 
carbonyl carbon.  In the case of a late transition state, the relative stabilities of the enolate anion 
and the oxyanion must be taken into account, with the enolate anion being more stable (again, 
1,4-addition would be favored).   
 
 Curtin-Hammet limitations prevented Sikorski and Reich35 from determining if the 
product distributions of the 2-lithio-1,3-dithiane additions (Table 1-8) could be correlated to the 
ground state populations of contact and solvent-separated ion pairs; the equilibrium between the 
contact-ion pairs (observed spectroscopically) and the solvent-separated ion pairs was too rapid 
for measurement.35  Nevertheless, the observed regioselectivities suggest that the kinetic reaction 
product distribution is governed by the presence or absence of ion-pairing.  Under 
thermodynamic conditions, the 1,2-addition of 2-lithio-2-phenyl-1,3-dithiane has been shown to 
be reversible, with the 1,4-addition product being formed upon warming reaction mixtures from 
–78 oC to rt regardless of solvent system.37   
 
 
 
Figure 1-2. The effect of contact ion-pairing in a) addition of dithianes to enones and b) addition of 
cyanohydrins to enones. 
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Scheme 1-2. Equilibrium and reaction pathways for contact and solvent-separated ion pairs. 
 
 
 
 
 
 
 
1.1.2.3 Aggregation of Organolithium Species  
 
 Lithium enolates typically exist as aggregates of the lithium-coordinated enolates or as 
mixed aggregates of the lithium enolate with solvent molecules or additives (e.g., HMPA, 
DMPU).  Bulky lithium amides (e.g., LDA, LiHMDS) typically exist as disolvated dimers 
(Figure 1-3).38 
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A major consequence of lithium enolate aggregation is the change in reactivity that 
occurs upon stabilization of the lithium ion by solvent molecules.  For example, the aldol 
reaction between lithium pinacolonate 1-14 and pivaldehyde 1-15 is highly exothermic in hexane 
but 12 kcal/mol less exothermic when the lithium pinacolonate aggregate is stabilized by THF 
(Table 1-9).39,40 
 
 
Figure 1-3. Structures derived from crystallographic data on lithium enolates and amides: a) Dimeric 
lithium enolate of N, N-dimethylcycloheptatrienecarboxamide, crystallized from THF. b) Dimeric lithium 
diisopropylamide, obtained as the [LDA)2•(THF)2]complex. 
a) 
Figure 1-3 a) Seebach, D. Structure and Reactivity of Lithium Enolates.  From Pinacolone to Selective 
C-Alkylations of Peptides.  Difficulties and Opportunities Afforded by Complex Structures.  Angew. 
Chem. Int. Ed. Engl. 1988, 27, 1624-1654.  Copyright Wiley-VCH Vertag GmbH & Co. KGaA.  
Reproduced with Permission. 
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Table 1-9. Effect of solvent on lithium enolate stabilization.  
 
 
 
 
 
 
1.1.2.4 .Spectroscopic Investigations of Interactions with Organolithium Species 
 
 Studies regarding the low-temperature solution structure of lithium amides have revealed 
the superior ligating properties of oxetane in comparison to THF.  Reich et al.24 determined the 
relative coordinating ability of donating solvents using 31P NMR titrations of the chiral 
organolithium reagent 1-17 (Figure 1-4).  It was discovered that the relative donor strength 
toward lithium was correlated with the rate exchange of the solvated diastereomers.  The rate of 
diastereomeric exchange was faster in the presence of weakly coordinating solvents (e.g., Me2O), 
than in stronger donor solvents (e.g., oxetane).  In fact, in the presence of 6 equiv of oxetane, an 
~1:1 ratio of solvated diastereomers was observed at -150 °C (by 31P NMR spectroscopy).   
Furthermore, by integration of phosphorus signals, the equilibrium constant for solvent exchange 
with dimethyl ether (Table 1-10) was calculated, yielding relative Ksolv values at –150 °C (Table 
1-10).  Interestingly, no solvent coordination was observed upon addition of 2-methyloxirane (up 
to 28 equiv).  
 
 
  
 No additive 
 
1 equiv TMEDA 
 
   1 equiv DME 
 
    1 equiv THF 
 
 
Haldol (kcal/mol)
 
 
-30.2 
 
-20.9 
 
-19.0 
 
-17.9 
 
aHeat of reaction data were obtained by calorimetric measurements of the reaction between 1 equiv 
lithium pinacolonate and 1 equiv electrophile.40 
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Table 1-10. Relative Ksolv values for a chelated organolithium reagent deteremined by 
31P NMR titrations. 
 
 
 
Collum and coworkers studied the effects of ethereal solvents on the equilibrium between 
dimeric aggregate 1-18 and n-solvated monomer 1-19 (Table 1-11).23 The studies indicated that 
the LiHMDS monomer 1-19 appeared at unusually low concentrations of oxetane (5.0 equiv per 
Li), and the concentration of 1-19 increased more rapidly upon addition of oxetane than upon 
addition of THF.  Furthermore, addition of just 20 equiv oxetane shifted the equilibrium toward 
the monomeric species (Table 1-11, entry 5), whereas addition of up to 40 equiv THF still favored 
the dimer (Table 1-11, entry 4).  Collum has also noted the superior coordinating properties of 
oxetane versus THF or Et2O regarding solvation of LDA
41 and lithium diethylamide.42   
 
 
 
 
Solvent 
 
Me2O 
 
THF 
 
3,3-
dimethyloxetane 
 
 
oxetane 
 
pyridine 
 
HMPA 
 
 
Ksolv (rel.) 
 
1 
 
 
7 
 
13 
 
16 
 
100 
 
2000 
Figure 1-4. Diastereomeric solvates of a chelated organolithium reagent. 
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Table 1-11. Effect of solvent on the aggregation of LiHMDS solvates.  
 
  
 
 
 
 
Another outcome of Collum’s studies on the dimer/monomer equilibrium of LiHMDS is the 
importance of substitution on the cyclic ether ligand.  Among a series of substituted 
tetrahydrofurans, 2,2-dimethyltetrahydrofuran proved the most efficient at dissociation of 
LiHMDS dimers, likely due to unfavorable steric interactions between the solvent ligand and the 
trimethylsilyl groups on the amide.  2,2,5,5-Tetramethyltetrahydrofuran was a poor solvent for 
dimer dissociation, likely due to severe solvent-solvent steric interactions on the monomer 1-19, 
driving the equilibrium back toward the dimeric aggregate 1-18.   
1.1.3 Hydrozirconation: Solvent Effects and Mechanistic Considerations 
Zirconium hydrides were first prepared by Wailes et al. in 1970,43 and their utility in 
organic synthesis was first systematically explored by Schwartz in the mid 1970’s.44,45 Since 
 
Entry 
 
 
              Solvent 
 
Ratio 1-18:1-19 
    
1 
 
ethera 
   
49:1 
 
2 2,2-dimethyltetrahydrofurana 1:34 
 
3 2,2,5,5-tetramethyltetrahydrofurana                  >50:1 
 
4 tetrahydrofurana                   2.6:1 
 
5 oxetaneb                    1:42 
 
a40 equiv solvent were used.  b20 equiv solvent were used.  
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then, Schwartz reagent (Cp2Zr(H)Cl) has been used in many important C-C bond forming 
transformations involving -systems—most commonly alkynes.46   
1.1.3.1 Mechanism of the Hydrozirconation of Alkenes 
 
Based on calculations performed by Endo et al.,47 the mechanism of hydrozirconation of 
simple olefins proceeds via alkene coordination followed by hydrometalation (Scheme 1-3).  The 
calculated activation barrier for hydrozirconation of ethylene is 15.0 kcal/mol at the RHF level of 
theory, with most of the activation energy coming from a distortion of the metal complex to 
allow for coordination of the alkene.  According to Endo’s model, alkene coordination is rate-
limiting, with the subsequent hydrometalation having little to no calculated barrier. 
 
 
Scheme 1-3. General mechanism for the hydrozirconation of alkenes. 
 
 
 
 
1.1.3.2 Effect of Solvent on the Hydrozirconation of Alkenes  
 
The effect of solvent on the rate of hydrozirconation of 1-hexene was studied (Table 1-12), 
and from these preliminary screenings oxetane appeared to increase the rate of reaction when 
used as either a solvent or cosolvent. 46 The order of reaction in both THF and oxetane was also 
determined by varying the equivalents of Schwartz reagent and 1-hexene (Table 1-13).  In both 
solvents, doubling the concentration of 1-hexene decreases the half-life approximately 2-fold, 
indicating the reaction is first-order in 1-hexene.  Doubling the concentration of Schwartz 
reagent has no effect on the rate of reaction in THF, whereas the rate of reaction increases by 
1.5-fold in oxetane.  Based on this preliminary evaluation, it appears hydrozirconation of 1-
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hexene is zeroth order in Schwartz reagent when the reaction is performed in THF but first-order 
in Schwartz reagent when the reaction is performed in oxetane. 
 
 
Table 1-12.  Effect of solvent on the hydrozirconation of 1-hexene. 
 
 
 
 
 
Entry 
 
Solvent 
 
Half-life of 1-hexene (min)a 
 
 
1 
 
        benzene 
 
2210 
 
2 
 
        benzene/oxetane, 9:1 (v/v) 
 
545 
 
3 
 
        tetrahydrofuran 
 
113 
 
4 
 
        tetrahydrofuran/oxetane, 9:1 (v/v) 
 
95 
 
5 
 
        tetrahydrofuran/oxetane, 3:1 (v/v) 
 
60 
 
6 
 
        oxetane 
 
37 
 
aHalf-life refers to the time to reach 50% conversion of 1-hexene to n-hexane when 1 equiv of 1-hexene is 
mixed with 1 equiv of Schwartz reagent. 
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Table 1-13. Effect of concentration on the rate of hydrozirconation of 1-hexene.  
 
 
 
 
From these preliminary screenings, a general description of the kinetics of hydrozirconation 
of 1-hexene was generated (Scheme 1-4).   Dissociation of the oligomeric Schwartz reagent to 
form the kinetically active species is likely operable based on the observed solvent effect.  
 
 
Scheme 1-4. General description of the kinetics of the hydrozirconation of 1-hexene. 
 
 
Entry 
 
Solvent 
 
Equiv 1-hexene 
 
Equiv Cp2Zr(H)Cl 
 
Half-life of 1-
hexene (min)a 
 
 
1 
 
tetrahydrofuran 
 
1 
 
1 
 
113 
 
2 tetrahydrofuran 2 1  58 
 
3 tetrahydrofuran 1 2 105 
 
4 oxetane 1 1  37 
 
5 oxetane 2 1  24 
 
6 oxetane 1 2  22 
 
aHalf-life refers to the time to reach 50% conversion of 1-hexene when 1 equiv of 1-hexene is mixed with 
1 equiv of Schwartz reagent. 
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Spletsoser et al.48 have also noted the solvolytic properties of oxetane when using Schwartz 
reagent to convert amides to aldehydes (Table 1-14).  Use of donating ethers such as oxetane and 
THF (entries 1 and 2) provided rapid reagent dissolution and subsequent high reaction yields.  
Using pyridine, a better electron donor, facilitated faster dissolution but poor chemical yields.  
The authors speculate that pyridine actually occupies a coordination sphere on the zirconium, 
forming a species that is too stable for the necessary exchange with the amide substrates.   
 
 
Table 1-14. Effect of solvent on the hydrozirconation of amides.  
 
 
 
 
 
 
 
Entry 
 
Solvent 
 
    Yield (%) 
 
tdiss (min)
a 
 
   
     1 
 
oxetane 
   
                95 
   
   2-3 
 
2 tetrahydrofuran 99 15 
 
3 1,4-dioxane 15 b
 
 
4 pyridine 15 1 
 
5 toluene 15 b 
 
6 chloroform  0 b 
 
aTime of dissolution refers to a qualitative observation of the time the solution became homogeneous.  
bComplete dissolution (homogeneity) was not observed. 
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1.1.3.3 Effect of Ethereal Solvents on Reactions Involving Organomagnesium Reagents 
Reactions involving organomagnesium (Grignard) are typically performed in ethereal 
solvents.  Ethereal solvents are sufficiently coordinating to solubilize the organomagnesium 
reagents while also being inert to Grignard reactivity. An example of the prototypical Grignard 
reaction—the addition of organomagnesium reagents to ketones, is shown in Scheme 1-5.49 It 
has been established (via kinetic studies) that addition of Grignard reagents to ketones is 2nd 
order in Grignard reagent, leading to a proposed mechanism involving a bimetallic intermediate 
1-20 which, upon delivery of an alkyl or aryl group to the ketone, generates the alkoxide 1-21 
and a magnesium dihalide.  The complex 1-21 and dihalide are in equilibrium with complex 1-22 
and the Grignard reagent.   
 
 
 
 
 
 
 
 
 
It has been shown that solvent basicity has dramatic effects on the outcome of Grignard 
reactions.  For example, Lewis and Wright found that using strongly basic solvents (e.g., 
pyridine) afforded only trace amounts of product when ethylmagnesium bromide was added to 
benzophenone.50 In contrast, using weakly basic solvents (e.g., ether, anisole) led to more rapid 
reactions and higher product yields.  This phenomenon is typical of Grignard additions to 
ketones—more basic solvents coordinate more strongly to the magnesium reagents, thus 
attenuating the reactivity of the reagents.  
 
Additionally, solvent effects have been observed in the case of racemization of 
configurationally stable Grignard reagents.  Patwardhan and coworkers showed that the rate of 
racemization of cyanocyclopropane 1-23 increased when switching solvents from ether to 2-
Scheme 1-5. General mechanism for the addition of Grignard reagents to carbonyl compounds. 
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methyltetrahydrofuran to tetrahydrofuran; however, the rate or epimerization with 2-MeTHF and 
THF does appear comparable within the reported experimental error (Table 1-15).51 
Nevertheless, the relationship between racemization and donating ability is indicative of a 
mechanism whereby association of solvent is followed by cleavage of the Mg-C bond.   
 
 
Table 1-15. Effect of solvent on the rate of racemization of an organomagnesium cyanocyclopropane. 
 
 
 
 
 
Reactions involving Grignard reagents are further complicated by the existence of the 
Schlenk equilibrium (Scheme 1-6) in the case of ethereal solvents.  In general, the equilibrium 
lies to the left in the case of acyclic dialkyl ethers (e.g, diethyl ether, methyl tert-butyl ether), but 
the equilibrium is shifted to the right in the case of cyclic ethers (e.g., THF, 1,4-dioxane).  A 
general equation (Scheme 1-6) showing the Schlenk equilibrium for Grignard reagents in the 
presence of THF is depicted below. 
 
Scheme 1-6. General description of the Schlenk equilibrium. 
 
  
 
 
 
Solvent 
 
Et2O 
 
THF 
 
2-MeTHF 
 
 
Kenant (s
-1) 
 
20.8 x 106  3.3 
 
150.1  4.2 
 
175.3  32.5 
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The consequence of the Schlenk equilibrium is a differing reactivity of the 
organomagnesium halide 1-25 and the diorganomagnesium reagent 1-26. Knochel and 
coworkers have performed extensive studies detailing the effect of additives (e.g., 1,4-dioxane) 
on the anionic Schlenk equilibrium (Scheme 1-7).52 One outcome of their studies was that 
additives with sufficient coordination to MgCl2 (e.g., [15]-crown-5 or 1,4-dioxane facilitated the 
Mg/Br exchange reaction of electron-rich aromatic bromides (Table 1-16). 
 
Scheme 1-7. General depiction of the anionic Schlenk equilibrium in the presence of 1,4-dioxane. 
 
 
 
      
 
Table 1-16. Mg/Br exchange reactions of 4-bromoanisole using i-PrMgCl-LiCl and various additives. 
 
 
 
 
Entry 
 
Additive (amount) 
 
Conversion (GC, %)a 
 
 
1 
 
        none 
 
31 
 
2         DMPU (10% v/v) 60 
 
3         Me(OCH2CH2)4OMe (10% v/v) 60 
 
4         1,4-dioxane (10% v/v) 100b 
 
5         [15]-crown-5 (1 equiv) 100c 
 
aConversion was determined after 24 h.  bConversion was determined after 10 h.  cConversion was 
determined after 6 h. 
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1.1.4 Solubility Enhancement Using Oxetanes: Applications in Medicinal Chemistry 
In recent years, interest in the oxetane moiety has surged, mostly due to discovery initiatives 
pioneered by Müller and Carreira.28 It was first postulated that an oxetane could replace a gem-
dimethyl group as a metabolically robust subunit that decreases the lipophilicity of the modified 
molecule (Figure 1-5).  The hypothesis was based on the similar partial molar volumes of 
oxetane (61.4 cm3/mol at 25 °C) and propane (75 cm3/mol at 25 °C) in water; therefore, 
substituting the gem-dimethyl groups with an oxetane increases polar surface area without 
changing the overall molecular size and conformation. Results from screening a range of 
oxetanes derived from oxetane-3-one revealed that oxetanes bearing aromatic substituents were 
stable across a broad pH range.  A report by the same group53 suggests that, rather than being a 
substitute for the gem-dimethyl group, the oxetane moiety may be a substitute for the carbonyl 
group.  In this case, the molar volume of oxetane is larger than formaldehyde; yet, the structural 
analogy comes from a similar disposition of the oxygen lone pairs.  An oxetane-for-carbonyl 
substitution maintains Lewis basicity and polar surface area while disrupting conjugation (e.g., in 
the case of enones or amides).  The consequences of oxetane-for-carbonyl bioisosterism may 
therefore be the creation of metabolically stable analogs with more acceptable toxicity profiles.  
 
 
 
 
 
 
The aqueous solubility enhancement as well as gain in metabolic stability from introduction 
of an oxetane was well demonstrated in the case of substrate 1-27 (Table 1-17).  Substitution of 
the methylene group with a gem-dimethyl group (1-28) increased metabolic stability at the 
Figure 1-5.  Representation of possible functional groups for which oxetane may serve as a 
bioisostere (adapted from reference 6). 
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expense of aqueous solubility (Table 1-17, entry 2).  Substitution of the methylene group with an 
oxetane group (1-29) enhanced both metabolic stability and aqueous solubility (Table 1-17, entry 
3).   
 
Table 1-17.  Selected data showing the consequences of substitution at the benzylic position with a gem-
dimethyl group or an oxetanyl group.6 
 
 
 
Entry 
 
Compound 
 
logDa 
 
Solubility 
(µmol/L) 
 
Intrinsic clearance  
(min-1/mg/µL)protein 
human (mouse) 
 
 
1 
 
 
1.8 
 
250 
 
37 (520) 
2 
 
2.5 < 4 16 (240) 
3 
 
0.8 18,000 0 (43) 
aLogD represents the logarithm of the n-octanol/water distribution coefficient at pH 7.4.  bMolar solubility 
of the neutral base, measured as an experimental thermodynamic solubility in 50 mM phosphate buffer at 
pH 9.9 at 22.5  1 C.  c Pseudo-first-order rate constants of intrinsic clearance, measured in human and 
mouse microsomes. 
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1.1.5 Preparation and Toxicological Properties of Oxetanes 
In order for oxetanes to be widely used as additives or cosolvents, affordable, scaleable 
syntheses of oxetanes must be possible.  Moreover, the compounds should have relatively low 
toxicity and mutagenicity.  In this section, general methods for oxetane synthesis and a “building 
block” approach toward 3,3-disubstituted oxetanes recently developed by Carreira are reviewed.  
Reported studies of the toxicity and alkylating abilities of oxetanes are discussed. 
1.1.5.1 Synthesis of Oxetanes 
The first reported synthesis of trimethylene oxide was reported by Reboul in 1878,54 and an 
Organic Synthesis protocol55 for its preparation via saponification and cyclization of 3-
chloropropyl acetate was submitted by Noller in 1949.  In recent years, interest in oxetanes has 
laid mostly with polymer chemists.56  Synthetic chemists have used oxetanes as precursors for 
substituted alcohols,25,57,58 larger heterocycles,59,60 or as precursors to complex crown ether 
networks.61,62 Oxetanes are also components of natural products (notably Taxol63-65), and 
recently a surge in the synthesis and manipulation of oxetane-bearing substrates has stemmed 
from a medicinal interest in these molecules.28,53,66 A summary of methods for oxetane 
preparation is provided in this section.  
1.1.5.2 Intramolecular Cyclization Reactions 
The most general method for the synthesis of oxetanes is via intramolecular displacement 
reactions.  Typically, the precursors are 3-halogenated alcohols or acetates (for intramolecular 
Williamson ether synthesis, Scheme 1-8a),67-70 or 1,3-diols. In the latter case, one-pot mono-
derivatization/cyclization procedures have been developed (e.g., Scheme 1-8b).71,72 Although the 
intramolecular displacement reaction often leads to the desired oxetane products, yields are 
typically modest, primarily due to polymerization of the substrates and side reactions 
(elimination and Wharton fragmentation reactions).73,74   A solid-support synthesis of oxetanes 
has been reported as one method for avoiding side-product formation.75 The diastereoselective 
synthesis of oxetanes substituted at C-2 using Mitsunobu conditions has also been reported.76   
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1.1.5.3 Pyrolysis of Cyclic Carbonates  
An alternative route to oxetane products is the pyrolytic decomposition of cyclic 
carbonates (Scheme 1-9), first reported by Pattison in 1957.77 The one-pot procedure involves 
generation of the carbonate (generally via reaction of the starting diol and a dialkyl carbonate) 
followed by extrusion of carbon dioxide.  The procedure is scaleable (a 200 g scale), and the 
product oxetanes can often be collected by distillation from the reaction mixture.  This synthesis 
has been completed in our laboratories as part of our program to scale-up dimeric oxetanyl 
additives and cosolvents. 
 
 
 
 
 
 
 
Scheme 1-8. Synthesis of oxetanes via intramolecular cyclization reactions. 
Scheme 1-9. Synthesis of oxetanes via pyrolysis of cyclic carbonates. 
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1.1.5.4 Synthesis of 2-Substituted Oxetanes 
 One of the earliest reports of oxetane formation was the discovery of the Paterno-Büchi 
reaction (e.g., Scheme 1-10 ) in 1909 and 1954.78  The reaction typically proceeds with excellent 
regio- and stereoselectivity but in modest yields.  Moreover, the reactions are limited in that 
there must be at least one substituent at the 2-position.  
 
 
  
 
 
 
 
2-Substituted oxetanes can also be synthesized via methylene transfer (Corey-Chaykovsky 
protocol) to ketones or epoxides (Scheme 1-11).79,80 Generally, the yields are high, and the only 
drawback is the long reaction time (typically 3 d).  
 
  
 
 
 
 
1.1.5.5 Synthesis and Functionalization of Oxetan-3-one 
 To facilitate incorporation of oxetanes onto medicinally interesting scaffolds, Carreira and 
coworkers developed a scaleable route to a useful building block, oxetan-3-one (Scheme 1-
12).7,27  Acetalization of 1,3-dihydroxy acetone dimer 1-30 to afford acetal 1-31 was followed by 
mono-tosylation (NaH, TsCl) and ring closure to afford oxetane 1-32 in 37% yield over three 
steps.  The authors reported difficulty cleaving the acetal due to substrate polymerization under 
acidic conditions. Nevertheless, treatment of a dilute solution of 1-32 with Montomorillonite K-
Scheme 1-10. Oxetane synthesis via the Paterno-Büchi reaction. 
 
Scheme 1-11. Synthesis of oxetanes via ring expansion of epoxides. 
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10 provided oxetane-3-one 1-33 in acceptable yield.  Oxetan-3-one 1-33 can be derivatized using 
Wittig reactions, and nucleophilic addition to the resulting enones affords 3,3-disustituted 
oxetanes (Scheme 1-13).  Oxetan-3-one 1-33 can also be functionalized via addition of 
organometallic reagents (Scheme 1-13) and Strecker reactions. 
 
Scheme 1-12. Scaleable synthesis of oxetan-3-one. 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.6 Toxicity and Carcinogenicity of Oxetanes 
Due to the high strain energy of the oxetane ring (25.2 kcal/mol),81 oxetanes are regarded as 
electrophiles, thus, there are many concerns that oxetanes will exhibit similar toxicity and 
mutagenecity profiles as other strained, heterocyclic alkylating agents (e.g., oxiranes, -
lactones).  Animal studies performed in 196382 and 197083 showed that oxetane and 3,3-
Scheme 1-13. Example methods for functionalizing oxetan-3-one. 
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dimethyloxetane induced tumor formation when injected into rats; yet, these data are equivocal, 
and the cause of tumors may have been from sources other than oxetanes (i.e., impurities). 
 
Recently, Gómez-Bomarelli et al. performed an extensive study regarding the alkylating 
potential and toxicity of oxetanes.84 They screened a set of simple, commercially available 
oxetanes—trimethylene oxide, 3,3-dimethyloxetane, and 3-methyl-3-oxetanemethanol.  All three 
substrates showed no indication of being mutagenic (Ames test) or genotoxic (BTC E. coli test).  
Additionally, when subjected to a comet assay, the results from using the three compounds were 
not statistically different than that of the negative control, indicating that the oxetanes are not 
capable of producing DNA strand breaks. 
 
The authors also tested cell viability in the presence of oxetanes using an MTT assay 
(using Chinese hamster lung fibroblast cells).  The oxetanes did not exhibit toxicity toward the 
cells even at the highest concentration tested (30 mM).  It can be implied that the oxetanes and 
any metabolites were not toxic to the cell line used in this study. 
 
A final and important experiment performed as part of this study was the kinetic NBP 
test, which is an in vitro, chemical assay that examines the reactivity of electrophiles toward 4-
(p-nitrobenzylpyridine (NBP).  NBP has similar nucleophilicity to DNA bases, and this assay 
can be used to predict DNA-alkylating ability of electrophiles.  Alkylation only occurred at 
acidic pH, and the half-reaction time for the alkylation of NBP by trimethylene oxide was ~1 
month; the values were 10-fold to 40-fold higher in the case of the more sterically hindered, 3,3-
substituted substrates.  The data are corroborated by the previously discussed work regarding the 
metabolic stability of 3,3-disubstituted oxetanes (section 1.1.4). 
  
 33 
1.2 RESULTS AND DISCUSSION: OXETANES IN ORGANOMETALLIC REACTIONS 
I began an exploration of using oxetanes as additives or cosolvents by testing them in 
reactions involving organolithium, organozirconium, and organomagnesium reagents.  Herein, I 
detail the design and synthesis of our oxetane-containing additives and describe results obtained 
from a series of selected test reactions with known solvent effects. 
1.2.1 3,3-Disubstituted Dimeric Oxetanyl Ethers as Additives and Cosolvents 
I synthesized possible additives or cosolvents bearing multiple oxetane functionalities.  
Although oxetane is commercially available, it is a costly solvent (typically $8–10/mL) and has 
high volatility (bp = 50 °C).  Furthermore, the ring strain of oxetane renders it susceptible to 
reacting under nucleophilic conditions; generating 3,3-disubstituted oxetanes substitute would 
attenuate reactivity while still preserving sufficient donating ability.  The overall goal was to 
generate more robust alternatives that would be used in lower quantities.  
 
As a basis for designing additives and solvents containing oxetanes, inspiration was 
drawn from known metal chelating agents such as crown ethers (e.g., [18]-crown-6 (1-34)) and 
podands (e.g.,1-35) (Figure 1-6). These additives contain oxygens in an appropriate special 
orientation for chelation and sequestering of metal ions.   Additionally, use of cyclic ethers for 
metal ion chelation has been demonstrated by Paquette and coworkers.  For example, the tris 
(2,2’,2”)-tetrahydrofuran 1-36 had an association constant for Li+ that was comparable to that of  
[15]-crown-5.85 
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Figure 1-6. Examples of ethereal ionophores. 
 
1.2.2 Synthesis of Dimeric Oxetanes 
Previously reported compounds 1-3762 and 1-3873 were first explored because they are 
accessible in 1–2 steps from commercially available materials (Figure 1-7).  Using 1-37 would 
allow for investigation of a flexible ether with oxygens that are appropriately positioned for 
possible chelation of metal ions. Spirocycle 1-38 could be considered as a more stable analog of 
oxetane itself.  
 
 
 
 
 
 
 
The synthesis of ether 1-37 was accomplished by treatment of commercially available 
alcohol 1-39 with known tosylate 1-4086 and sodium hydride (Scheme 1-14).62 Heating at reflux 
for an extended reaction time (60 h) in THF was required for acceptable conversion; the 
requirement for a long reaction time likely comes from the difficulty in reacting a neopentyl 
nucleophile with a neopentyl electrophile. 
 
 
 
Figure 1-7. Dimeric oxetane additives for initial solvent effect screens. 
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It should be noted that the starting alcohol 1-39 can be prepared on multi-gram scale by 
treating inexpensive 1,1,1-tris(hydroxymethyl)ethane with dimethyl carbonate and catalytic 
amounts of KOH and methanol.87,88 Alcohol 1-39 is distilled from the reaction mixture, thus 
obviating the need for additional purification steps; 1-39 is therefore a feasible starting material 
that can be purchased or prepared in sufficient quantities for use as a solvent precursor.  
 
Synthesis of spirocycle 1-38 was more problematic; initial attempts to reproduce the 
literature procedure72 by treating 2,2 bis(bromomethyl)-1,3-propanediol 1-41 with KOH and 
EtOH resulted in trace amounts of the desired product (Scheme 1-15).  Ethyl ether 1-43 was 
isolated as the major product—it is reasonable that 1-43 is formed from an initial intramolecular 
Williamson ether reaction of 1-41 to form bromide 1-42, followed by an intermolecular 
Williamson ether reaction between EtOH and the neopentyl bromide 1-42.  This hypothesis was 
confirmed by the independent synthesis of mono-cyclized bromide 1-42 by treatment of 1-41 
with n-BuLi in THF (Scheme 1-16).  Bromide 1-42 was subjected to the reaction conditions 
(KOH, EtOH, reflux); indeed, ethyl ether 1-43 was formed as the major product, albeit in low 
yield. 
 
 
 
 
 
Scheme 1-14. Synthesis of dimeric ether 1-37. 
Scheme 1-15. Attempted preparation of 2,6-dioxaspiro[3.3]heptane. 
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It was reasoned that attenuating solvent nucleophilicity would prevent the undesired 
intermolecular substitution reaction.  After screening many commercially available alcohols, it 
was determined that t-BuOH was the optimal choice for both efficient solvation of the starting 
diol and sufficient suppression of the undesired side reaction.  Although a reproducible method 
for the formation of 1-38 was developed, the yield was low due to the problems with isolating 
the spirocycle, which sublimes at atmospheric pressure.  To isolate spirocycle 1-38, solvent was 
removed by distillation.  Spirocycle 1-38 was collected by sublimation from the resulting residue 
after gentle heating (60 °C) at atmospheric pressure.  Due to the need to remove large volumes of 
solvent by distillation, the protocol was modified, and a binary mixture of t-BuOH and lower 
boiling THF was used; the optimized conditions are shown in Scheme 1-17.  Attempts to 
improve the isolation protocol (and consequently the isolated yield) included distilling the 
product from high-boiling, hindered alcoholic solvents (e.g., 2,2,4-trimethyl-1,3-pentandiol and 
(1R)-endo-(+)-fenchyl alcohol); however, the desired product was not collected using this 
distillation protocol.  
 
 
 
 
 
 
 
Scheme 1-16. Independent synthesis of bromide 1-42 and ethyl ether 1-43. 
Scheme 1-17. Optimized protocol for synthesis of spirocycle 1-38. 
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1.2.3 Use of Dimeric Oxetanes in Reactions Involving Organolithium Reagents. 
Because studies by Collum and Reich (Section 1.1.2.4) indicated that oxetane-solvated 
lithium aggregates to a greater extent than THF, it was worthwhile to screen reactions dependent 
on solvent interactions with organolithium species.  The addition of (1-3-dithian-2-yl)lithium 1-1 
to 2-cyclohexen-one 1-11 (Table 1-18) was tested.  Using dimeric oxetanyl ether 1-37 (up to 4 
equiv) afforded only the 1,2-addition product 1-13 (entry 3).  Spirocycle 1-38 was used in large 
excess, but, again, only the kinetic, 1,2 -addition product 1-13 (entry 4) was formed.  Because the 
1,2-addition product has been shown to be formed when contact ion-pairing is operable,35 the 
results indicate that 1-37 and 1-38 were ineffective at providing the cation solvation necessary 
for disruption of the carbonyl-lithium interaction. 
 
 
 
 
 
 
 
 
Entry 
 
Additive 
 
Ratio 1-12: 1-13a 
 
Yield (%) 
 
 
1 
 
none 
 
> 95:5 
 
74 
 
2 
 
HMPA (2 equiv) 
 
16:84b 
 
67 
 
3 
 
1-37 (4 equiv) 
 
> 95:5 
 
56 
 
4 
 
1-38 (30 equiv) 
 
>95:5 
 
78 
 
aRatios were determined by crude 1H NMR analysis.  bReich reported a ratio of <5:95.35 
    Table 1-18. Results from using dimeric oxetanes in dithiane additions to 2-cyclohexen-1-one. 
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The ability of the oxetane additives to solvate lithium aggregates was investigated by 
examining the solubility of the lithium dianion of methyl 3-nitropropanoate 1-44.  Literature 
reports document that the dianion precipitated from THF solutions but was well-solvated by 
addition of electron-donating solvents such as HMPA and DMPU.89 Dianion solubility correlated  
directly with the yield from alkylation with electrophiles.  For example, yields ranging from 0–
8% have been reported when THF was used as a solvent.  Yields as high as 85% were reported 
when 5 equiv HMPA (and a THF/HMPA, 5:1 v/v ratio) were employed.90  Therefore, the 
alkylation of the dianion of methyl 3-nitropropanoate was a suitable test system for the dimeric 
oxetane additives.  Results from testing this alkylation reaction are summarized in Table 1-19.  
 
 
Table 1-19. Results from using oxetane additives to enhance dianion solubility. 
 
 
 
 
 
Entry 
 
Solvent 
 
Yield of 1-45  
 
 
Yield of 1-46  
 
      1 
 
THF 
 
<5% 
 
-- 
 
      2 DMPU (10 equiv) 63% 4% 
 
      3 THF, HMPA (5 equiv), 5:1 (v/v) 58%a 9% 
 
      4 THF/oxetane, 5:1 (v/v) -- -- 
 
      5 THF, 1-37 (5 equiv) 3642%b 02% 
 
      6 THF, 1-38 (5 equiv) 0%b -- 
 
aThree trials were performed; yields of 1-45 were consistent (5558%).   bIn a separate trial, 1-45 was 
isolated in 14% yield. 
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The results (Table 1-19) indicated that dimer 1-37 indeed solvated the dianion because the 
alkylated product was isolated in modest yield.  Although the reaction mixture became 
heterogeneous when the dianion was formed in THF, it remained homogeneous when using 5 
equiv of dimer 1-37.  Heterogeneity was observed when spirocycle 1-38 was used as an additive.  
 
Spirocycle 1-38, although stable toward nucleophilic attack, has a rigid structure.  
Conformational changes that would accompany electron-donation to metal cations may not be 
operable on this additive.  Conversely, dimer 1-37 has a more flexible framework and would be 
capable of undergoing conformational changes upon electronic donation to cations.  Moreover, 
the ability to form 6-membered chelates or possibly bidentate complexes makes the system of 
interest, particularly given the promising preliminary result in this dianion solubility screen. 
1.2.4 Effect of Oxetane-Based Additives on the Rate of Hydrozirconation of Alkenes 
As discussed in section 1.1.3, solvent has an effect on the rate of hydrozirconation of 
alkenes.  More specifically, electron-donating solvents are postulated to disrupt aggregation of 
polymeric Schwartz reagent, thus generating the kinetically active monomeric zirconocene 
species.   
 
Based on the preliminary results reported in the Wipf group,46 the effect of solvent on the 
rate of hydrozirconation of 1-hexene was explored further.  A range of solvents with varying 
donating abilities and bulk permittivities was screened. The study was limited to ethers, aromatic 
hydrocarbons, and chlorinated hydrocarbons; carbonyl-bearing solvents (e.g., acetone, ethyl 
acetate), dimethyl sulfoxide, hexamethylphosphoramide, acetonitrile, and nitromethane are 
incompatible with Schwartz reagent. 
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1.2.4.1 Hydrozirconation in Aromatic and Chlorinated Solvents 
To expand the table of previously reported results (Table 1-12), the rate of 
hydrozirconation in aromatic hydrocarbons and chlorinated hydrocarbons was measured.  In the 
case of aromatic hydrocarbons, poor conversion was observed in toluene, and little to no 
improvement was seen upon moving to more polar aromatic hydrocarbons such as 
chlorobenzene or ,,-trifluorotoluene.  In corroboration with observations noted in the case of 
hydrozirconation of alkynes, the reaction proceeds fastest in methylene chloride (t1/2 = 40 min).  
My interest, however, was in examining the effect of increasing the electron-donating ability of 
ethereal solvents, and a range of ethers was first screened to establish the solvent scope.   
1.2.4.2 Reactions in Ethereal Solvents 
A series of ethereal solvents in the hydrozirconation of 1-hexene (Table 1-20) was screened. 
Oxetane was found to be the superior solvent (Table 1-20, entry 3).  Moreover, addition of 
oxetane to other ethereal solvents enhanced the rate of hydrozirconation.  For example, the rate 
of hydrozirconation in THF was increased when oxetane was added in a 50% v/v ratio (entry 5), 
yet it appears the effect of additional oxetane has a threshold—no significant improvement was 
made upon increasing the oxetane percentage to a 75% v/v solution (entry 6).  
 
 
 
 
 
 
 
  
 41 
 
 
 
 
 
 
Entry 
 
 
Solvent 
 
Half-life (min)a 
 
1 
 
      tetrahydropyran 
 
 1200 
 
2       tetrahydrofuran 120 
 
3       oxetane 52  4b 
 
4       tetrahydrofuran/oxetane, 3:1 112  3c 
 
5       tetrahydofuran/oxetane, 1:1 69 
 
6       tetrahydrofuran/oxetane, 1:3 65 
 
7       tetrahydropyran/oxetane, 3:1 320 
 
8       dimethoxymethane no conversion 
 
9       dimethoxyethane 870 
 
10       2-methyltetrahydrofuran < 5% conversiond 
 
11       2,5-dimethyltetrahydrofuran no conversiond 
 
12       3,3-dimethyloxetane < 5% conversiond 
 
13       diethyl ether no conversiond 
 
aHalf-lives of 1-hexene were calculated based on GC measurements (after an aqueous quench) of the 
relative concentrations of 1-hexene and n-hexane over time.  bThe data represents an average of three 
trials.  cThe data represents and average of four trials.   dMinimal or no conversion was observed after a 
period of 2 h. 
Table 1-20. Hydrozirconation of 1-hexene using ethereal solvents. 
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When the hydrozirconation reaction was performed using substituted ethereal heterocycles 
(Table 1-20, entries 10-12) as solvents, little to no conversion was observed.  The donor number 
of 2-methyltetrahydrofuran is 18 kcal/mol, which does not differ substantially from that of THF 
(20.0 kcal/mol).  Furthermore, rate retardation or no reaction was observed in solvents with 
similar or higher donor numbers than THF such as ether (Table 1-20, entry 13, DN = 19.2 
kcal/mol) and THP (Table 1-20, entry 1, DN = 22 kcal/mol).  Interestingly, using 3,3-
dimethyloxetane (Table 1-20, entry 12) as a solvent also resulted in poor conversion of 1-hexene.  
 
Clearly, donicity alone cannot explain the trend in rate differences for the 
hydrozirconation of 1-hexene.  Because Schwartz reagent contains two bulky cyclopentadienyl 
units per zirconium atom, the lack of reactivity of substituted cyclic ethers may be rationalized 
by a steric effect—the substituents prevent solvent coordination and dissociation of the 
oligomeric reagent into kinetically active monomers.    
 
I also examined the outcome of the hydrozirconation of 1-hexene using dimeric oxetane 
additives 1-37 and 1-38 with THF as a parent solvent (Table 1-21).  The data indicated that 
spirocycle 1-38 had no effect on the rate of reaction when up to 5 equiv were added (Table 1-21, 
entry 4).  Dimer 1-37 appeared to have a detrimental effect on the rate of hydrozirconation—
higher relative concentrations of dimer slowed the reaction to a greater extent.  The reaction rate 
was higher when 1-hexene was used at lower concentration (0.40 M) in a 2:1 v/v solution of 
THF/1-37 than when a more concentrated (0.60 M) solution of 1-hexene in a 1:1 v/v solution of 
THF/1-38 (Table 1-21, entry 6) was used.   
 
 I postulate that dimer 1-37 competes with THF for coordination to zirconium oligomers; 
however, dimer 1-37 does not have the same dissociating capabilities as THF.  This competitive 
coordination would inhibit production of kinetically active zirconium monomers.  A simpler 
explanation may be that dimer 1-37 is not a sufficient solvent for deaggregation of Schwartz 
reagent—increasing the concentration of 1-37 would effectively decrease the concentration of 
THF.  This second hypothesis is corroborated by the fact that no hydrozirconation is observed 
when the reaction is performed in neat 1-37 at 0 °C (Table 1-21, entry 7). 
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Entry 
 
Additive 
 
 
Half-life (min)a 
 
1 
 
none 
 
120 
 
2 
 
20% oxetane (5 equiv) 
 
120 
 
3 
 
1-38 (1.8 equiv) 
 
130 
 
4 
 
1-38 (5 equiv)  
 
110 
 
5b 
 
1-37 (5 equiv) (1-37/THF, 2:1 v/v) 
 
220 
 
6 
 
1-37 (5 equiv) (1:1 v/v) 
 
690 
 
7 
 
1-37 (neat) 
 
    no conversion 
 
aHalf-lives of 1-hexene were measured in the manner described in the footnote of Table 14.  Reported 
values are the result of a single trial.   b1-Hexene was added in an initial concentration of 0.40 M.  
Table 1-21. Effect of dimeric oxetane additives on the hydrozirconation of 1-hexene. 
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1.2.5 Synthesis of Alternative Bisoxetanyl Ethers 
Despite the modest success observed when using dimer 1-37 for enhancement of lithium 
dianion solubility (Table 1-19), I had not yet discovered an optimal oxetane-substituted additive 
for use in organometallic reactions.  I decided to develop synthetic routes for additional 
bisoxetanyl ethers 1-47 and 1-49 (Scheme 1-18).  These compounds could be generated from the 
corresponding oxetanols 1-48 and 1-50.   
 
Scheme 1-18. Synthetic plan for the synthesis of bisoxetanyl ethers. 
 
 
 
 
 
Although the target compounds do not have the stabilization of being 3,3-disubstituted 
oxetanes, two effects would be probed using these structures.  In the case of substrate 1-47, the 
oxygen atoms have a different topography in comparison to the original dimeric oxetane 1-37; 
the different special orientation may provide access to alternative modes of metal chelation.  In 
the case of substrate 1-49, the structure is less sterically encumbered due to absence of the 
methyl group at the 3-position.   Moreover, incorporation of an ethereal linkage (analogous to 1-
37) may enhance chelation properties and solubilizing ability, as in the case of dimethoxyethane 
in comparison to diethyl ether.91,92   
1.2.5.1 Synthesis of 2,2'-Oxybis(methylene)dioxetane  
The 2-substituted oxetanol rac-1-48 was synthesized using a modified version of a 
literature protocol80 wherein the alcohol was protected as an ethoxy-ether moiety (Scheme 1-19).  
A benzyl group was used instead of the ethoxy-ether to avoid aqueous workup of water-soluble 
alcohol rac-1-48. Benzyl glycidol ether rac-1-53 was readily prepared via alkylation of benzyl 
alcohol with epichlorohydrin—the product was purified by distillation.  rac-1-54 was obtained 
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via methylene-transfer methodology using trimethylsulfoxonium iodide in t-BuOK and t-
BuOH.93 The modest yield was due to formation of 1-(benzyloxy)but-3-en-2-ol; presumably, the 
ylide adds into the epoxide, but E2 elimination of dimethylsulfoxide occurs competitively with 
the SN2-type oxetane formation.  The benzyl group was removed by hydrogenation to afford 
alcohol rac-1-48. 
 
Scheme 1-19. Synthesis of alcohol rac-1-48.   
 
 
 
 
 
 
 
 
 Bisoxetanyl dimer 1-47 was prepared using a standard etherification procedure (Scheme 1-
20). Tosylate 1-56 was prepared by treatment of rac-1-48 with TsCl in pyridine.  Reaction of 
alcohol rac-1-48 with sodium hydride and tosylate rac-1-56 and heating in THF for 14 h 
afforded the desired dimer 1-47 as a mixture of dl- and meso- diastereomers.    
 
Scheme 1-20. Synthesis of dimeric oxetane 1-47.  
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I attempted to shorten the synthesis of dimer 1-47 by performing a double methylene 
transfer reaction on diglycidyl ether 1-58, which was accessed from epoxidation of allyl glycidol 
ether (Scheme 1-21).  The reaction yielded a complex mixture of oxetane-containing and olefinic 
products, and this route was therefore abandoned. 
 
Scheme 1-21. Attempted synthesis of 1-47 via a double methylene transfer reaction. 
 
 
 
 
 
1.2.5.2 Synthesis of Enantiopure Oxetanes to Generate a Diastereomerically and 
Enantiomerically Pure Bisoxetanyl Dimer. 
1-47 was synthesized as a mixture of dl- and meso- diastereomers; a diastereomerically 
and enantiomerically pure variant was synthesized for characterization (Scheme 1-22).  
Enantiomerically enriched (S)-1-53 was generated either by benzylation of commercially 
available (R)-glycidol (R)-1-59 or via hydrolytic kinetic resolution of racemic benzyl glycidyl 
ether rac-1-5394 (Scheme 1-22).  The synthesis was performed in analogous fashion to that of 1-
147—ring expansion of (S)-1-53 followed by debenzylation afforded oxetanol (S)-1-48.  
Tosylation of (S)-1-48 and etherification (in this case, using MeCN as solvent) afforded (S,S)-1-
47 as a single diastereomer (as evidenced by 1H NMR analysis). 
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Scheme 1-22. Synthesis of diastereomerically and enantiomerically pure (S,S)-1-47. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5.3 Synthesis of 3,3'-Oxybis(methylene)dioxetane  
Having completed the synthesis of (S,S)-1-47, I developed a route to dimeric ether 1-49 
via the corresponding oxetanol 1-50.  Synthesis of the alcohol 1-50 was first attempted using a 
one-pot monotosylation-cyclization procedure (Scheme 1-23).  Alkylation of diethyl malonate 1-
61 with BOMCl (1-60) afforded a mixture of mono- and di-alkylated esters.  Reduction of the 
mixture with LAH led to a 10:1 mixture of desired diol 1-63 and byproduct 1-62; the diols were 
separable by chromatography on SiO2.  Diol 1-63 was mono-tosylated and cyclized to afford 
oxetane 1-64 in modest yield.  Debenzylation of 1-64 afforded 1-50 in comparable yield to the 
debenzylations of rac- and (S)-1-54.  Although the oxetane formation proceeded in respectable 
yield, the inefficiency of the synthesis of diol 1-63 prompted development of a new approach. 
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It was hypothesized that alcohol 1-50 could be synthesized directly from mono-tosylated 
triol 1-67 (Scheme 1-24). Triol 1-66 was generated via reduction of triethyl 
methanetricarboxylate 1-65,95 which is commercially available or readily prepared by alkylation 
of diethyl malonate with ethyl chloroformate.96 Triol 1-66 was monotosylated to afford 1-67, 
which, upon drop-wise addition to a dilute, basic THF solution afforded alcohol 1-50 in modest 
yield (Scheme 1-24). This pathway was a more atom-economical approach because it obviated 
the need for a protecting group on the triol.   
 
 
 
 
 
 
 
With alcohol 1-50 in hand, the formation of bisoxetanyl ether 1-49 (Scheme 1-25) was 
attempted.  Mindful of the sluggish alkylation in the case of synthesizing dimer 1-37, alcohol 1-
50 was converted to the corresponding brosylate 1-68; brosylates are more electrophilic than the 
corresponding tosylates due to the electron-withdrawing nature of the p-bromo substituent on the 
aromatic ring. Etherification by treating alcohol 1-50 with sodium hydride and brosylate 1-68 
and refluxing the reaction mixture in THF provided the desired dimeric oxetane 1-49 in low 
yield. 
Scheme 1-23. Synthesis of 1-50 via a mono-benzylated triol. 
Scheme 1-24. Synthesis of alcohol 1-50 via a symmetrical triol. 
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1.2.6 Synthesis of Bisoxetanyl Ethers—Conclusions 
Dimeric oxetanyl ethers 1-37 and 1-38 were synthesized, and their ability to induce solvent 
effects in reactions involving organolithium and organozirconium reagents was tested.  In the 
case of additions of (1,3-dithian-2-yl)lithium to cyclohexen-1-one, neither 1-37 nor 1-38 affected 
a change in selectivity in comparison to reactions when no additive was used.  It was 
demonstrated that dimeric oxetanyl ether 1-37 improved the solubility of the lithium dianion of 
methyl 3-nitropropanoate, and this result may be pursued further in due course. 
 
Dimeric oxetanyl ethers were also tested as additives in the reaction of Schwartz reagent 
with 1-hexene.  No effect was observed when spirocycle 1-38 was used as an additive in THF 
solutions.  Use of dimeric oxetanyl ether 1-37 as an additive in THF solutions actually led to a 
decrease in reaction rate, which was indicative of either a) competitive chelation with THF but 
lack of dissociating power or b) an effective decrease in concentration of THF, which is the 
coordinating solvent capable of dissociating the polymeric Schwartz reagent.  
 
Three additional bisoxetanyl dimers 1-47, (S,S)-1-47, and 1-49 were synthesized.  In all 
cases, low yields during the synthetic sequences made scale-up difficult.  I refrained from testing 
these additives in our set of organometallic test reactions until more favorable results were 
obtained with the readily accessible oxetanyl dimers.   
Scheme 1-25. Synthesis of bisoxetanyl ether 1-49. 
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Due to the difficulty in generating large quantities of bisoxetanyl ether analogs of 1-37, I 
instead decided to replace the linking heteroatom with sulfur (Figure 1-8).  The synthesis and 
experiments performed with these new analogs are discussed in the next section. 
 
 
 
1.2.7 Synthesis and Application of Bisoxetanylsulfides and Sulfoxides 
I decided to pursue sulfur-containing analogs of 1-37 because a sulfide provides internal 
stabilization toward peroxide generation due to preferential oxidation at the sulfur versus C-H 
abstraction.  Additionally, simply changing the oxidation state of the sulfur can generate analogs 
with different physical properties. 
 
Syntheses of sulfur-based analogs of bisoxetanyl ether 1-37 (Scheme 1-26) were 
developed.  Tosylate 1-40 was dimerized to the symmetrical sulfide 1-69 using disodium sulfide.  
Initially, oxidation of sulfide 1-69 was attempted with m-CPBA in CH2Cl2, but only low yields 
(ca. 30%) of sulfoxide 1-70 were obtained.  It was discovered that the low yields were due to the 
aqueous solubility of 1-70, resulting in loss of material in the aqueous layer during workup.  
Back-extracting the aqueous layers multiple times increased the yield to 78%; however, this 
protocol would not translate well to scale-up.  Using NaIO4 in H2O/MeOH effectively oxidized 
1-69 to 1-70.  In this case, sulfoxide 1-70 was isolated after filtration of the resultant NaIO3, 
removal of MeOH and H2O in vacuo, and desalting of crude 1-70 prior to further purification by 
Figure 1-8. Strategies for generating analogs of bisoxetanyl ether 1-37. 
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recrystallization.  To confirm the structural assignment of 1-70, sulfide 1-69 was oxidized to the 
corresponding sulfone 1-71 using oxone in MeOH/H2O.  
 
 
 
 
 
 
 
 
 
 
 
 Sulfide 1-69 is a high boiling liquid (bp = 140 C at 15 Torr), whereas sulfoxide 1-70 is a 
crystalline solid (mp =  9294 C).   It was proposed that sulfide 1-69 could be used as an 
additive in reactions involving organometallic reagents.  Oxidative workup would convert sulfide 
1-69 to water-soluble sulfoxide 1-70 and facilitate removal of the additive from reaction 
mixtures. 
1.2.7.1   Preliminary Investigations of Grignard Additions  
Sulfide 1-69 was tested as an additive for addition of 1,2-dithianyllithium to 2-cyclohexen-
one (i.e., Table 1-18), but only the 1,2-addition product 1-12 was observed by crude 1H NMR 
analysis.  I turned my attention to using organomagnesium reagents (Grignard reagents).  
Grignard reagents have a wide utility for functionalizing organic scaffolds, yet, it is difficult to 
translate Grignard reactions to process scale.  In 2011, the ACS Green Chemistry Institute cited 
issues regarding the exothermicity of Grignard reactions as well as the dependence on the 
ethereal solvents diethyl ether and THF as primary reasons for the difficulty in translating 
Grignard reactions to a commercial scale.  Moreover, many Grignard reagents are commercially 
available or readily prepared by reacting Mg metal with the corresponding halides, and reactions 
Scheme 1-26. Synthesis of sulfur-functionalized bisoxetanyl dimers. 
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involving Grignard reagents typically have uncomplicated experimental setups.  The reported 
need for finding diethyl ether and THF replacements coupled with an ability to rapidly screen 
several reactions provided the motivation for studying these reactions. 
1.2.7.2 Grignard Additions to Ketones 
The addition of MeMgBr to benzaldehyde (Table 1-22) was studied; reactions were 
performed by adding an ethereal solution of MeMgBr to a solution of benzaldehyde in various 
solvent mixtures.   When sulfide 1-69 was used neat or as a 1020% (v/v) solution in heptane 
(entries 4–7), incomplete conversion of benzaldehyde to 1-phenylethanol 1-73 was observed (GC 
analysis).  In contrast, the reaction proceeded quickly in THF, solutions of 1-69 in THF (entries 
1–2), and heptane alone (entry 3).   
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In the case of reactions where sulfide 1-69 was used as an additive or cosolvent in heptane 
(Table 1-22, entries 4–6), additional product peaks were observed in the GC traces of the 
reaction mixtures (Figure 1-9).  The products were identified as benzyl alcohol 1-74, 
acetophenone 1-75, and 2-phenylpropane-2-ol 1-76.   The formation of these products can be 
explained by invoking a magnesium-Oppenauer oxidation (Scheme 1-27). 
 
 
Entry 
 
Medium 
 
Conditions 
 
Ratio 1-73:1-72 (GC) 
 
 
1 
 
    100% THF 
 
    0 C, < 5 min 
 
only 1-73 
 
2     10% 1-69/THF (v/v)     0 C, < 5 min 99 : 1 
3     100% heptane     rt, 90 min only 1-73 
4     10% 1-69/heptane (v/v)     rt, 90 min 0.96 : 1 
5     10% 1-69/heptane (v/v)     0 C, 25 min, rt 90 min 2.2 : 1 
6     20% 1-69/heptane (v/v)     0 C, 25 min, rt 90 min 1.9 : 1 
7     100% 1-69     0 C 30 min, rt 30 min 1.9 : 1 
Table 1-22. Additions of methylmagnesium bromide to benzaldehyde in presence of sulfide 1-69. 
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Figure 1-9. GC trace of the reaction reported in Table 1-22, entry 4. 
 
Scheme 1-27. Mechanism of the magnesium-Oppenauer oxidation. 
 
  
The results (Table 1-22) may be explained by an effective complexation and solubilization 
of alkoxides 1-72a by sulfide 1-69.   Enhancing the solubility of the alkoxides would render 
them more reactive to a hydride transfer process.  Moreover, the starting aldehyde 1-72 does not 
undergo complete conversion in the 1-69/heptane solvents, but complete consumption of 1-72 is 
observed using THF, 1-69/THF or heptane as solvents.  These results also support a strong 
complexation of sulfide 1-69 with magnesium; we hypothesize that the bisoxetanyl sulfide may 
also attenuate the reactivity of the methylmagnesium bromide for the carbonyl addition reaction. 
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Reports of solvent effects on the magnesium-Oppenauer oxidation have been documented. 
Byrne and Karras have studied the effect of solvent on the magnesium-Oppenauer oxidation.97 In 
the case of addition of n-BuMgBr to benzaldehyde, they observed good conversion to 1-
phenylpentan-1-one (83% yield within 1 h at rt) when dibutyl ether was used as the solvent.  The 
ketone yield decreased when the length of the alkyl chain on the ethereal solvent was decreased; 
the yields in i-Pr2O and Et2O were 67% and 33%, respectively.  Furthermore, they found that 
using THF as a solvent or a cosolvent led to poor conversion to the magnesium-Oppenauer 
products.  They reasoned that the trend in yield resulted from stronger Lewis bases coordinating 
to the magnesium alkoxide (analogous to 1-72a), thus preventing complexation with the hydride 
acceptor (analogous to 1-72).97  Their results were corroborated by a report that using Bu2O and 
t-BuOMe led to increased yields of byproducts from magnesium Oppenauer oxidations in the 
case of a process-scale synthesis of a phosphodiesterase IV isoenzyme inhibitor.98   
 
Kloetzing et al. showcased the utility of the magnesium-Oppenauer oxidation for the 
synthesis of aryl metallocenyl ketones.99 They noted the importance of using additives such as 
LiCl or DMPU to effectively solubilize the magnesium alcoholates.  
 
In the case of using 1-69 as an additive in the Grignard addition (Table 1-22), it was also 
observed that the reaction mixtures became cloudy immediately upon addition of the Grignard 
reagent.  The precipitate was assumed to be MgBr2, and it was postulated that additive 1-69 was 
shifting the Schlenk equilibrium toward the diorganomagnesium reagents.  The incomplete 
conversion of benzaldehyde 1-72 to reaction products may also be due to a lack of reactivity with 
the diorganomagnesium species.   
 
A simple reaction was studied—the addition of methylmagnesium bromide to benzaldehyde.  
From this study, two key observations were made regarding the use of sulfide 1-69 as a 
cosolvent in nonpolar solvents (e.g., heptane) or as neat solvent: a) magnesium Oppenhauer 
oxidation products were formed and b) precipitate (MgBr2) was observed, likely due to a shift in 
the Schlenk equilibrium.   
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In the next sections, experiments that were designed to evaluate the hypotheses that sulfide 
1-69 complexes with Grignard reagents or organomagensium intermediates and that sulfide 1-69 
effects the Schlenk equilibrium are discussed. 
1.2.7.3 Use of Sulfide 1-69 to Attenuate Grignard Reagent Reactivity 
It was hypothesized that sulfide 1-69 interacts with Grignard reagents; its utility was 
evaluated in reactions where decreased reactivity of Grignard reagents is desirable (Schemes 1-
28, 1-29, and 1-30).  I identified previous cases where use of the multi-functional chelating 
additive bis[2-(N,N-dimethylamino)ethyl]ether (BDMAEE) 1-77 in reactions involving Grignard 
reagents has led to increased yields or enantioselectivities.  Examples include ketone synthesis 
via additions of Grignard reagents to aryl acyl chlorides100 (Scheme 1-28) and I/Br-Mg exchange 
of aromatic halides101 with sensitive functional groups (Scheme 1-29).   Addition of 1-77 led to 
enhanced enantioselectivies in the case of the asymmetric addition of alkyl Grignard reagents to 
aldehydes (Scheme 1-30).102,103 In all cases, the superior yields and enantioselectivies could be 
explained by chelation of 1-77 to the Grignard reagents (i.e., to form 1-77a), thus attenuating the 
reactivity. 
 
Scheme 1-28. Synthesis of ketones from acid chlorides using BDMAEE-Grignard complexes. 
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Scheme 1-29. Halogen/Mg exchange reactions of aromatic halides using deactivated Grignard reagents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of sulfide 1-69 was first investigated in Grignard additions to electron deficient acyl 
chlorides—namely, addition into 4-(trifluoromethyl)benzoyl chloride 1-78 (Table 1-23).  Some 
variability in yield was observed in reactions where sulfide 1-69 was used as an additive (entry 
3); in general, the yield was only slightly improved in comparison to the case with no additive, 
whereas use of BDMAEE 1-77 resulted in a noticeably higher yield (entry 2).  Because 1-69 did 
not induce a noticeable effect on the reaction outcome, other examples where additives affect the 
results of organomagnesium reagent-mediated reactions were studied. 
 
 
 
 
 
 
 
 
 
      Scheme 1-30. Asymmetric addition of Grignard reagents to aldehydes. 
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The use of sulfide 1-69 was also tested in the noncryogenic Mg/I exchange reaction of 
aromatic substrates with sensitive functional groups.  Three substrates, 1-80, 1-81, and 1-82 
(Figure 1-10) were studied, and the results are shown in Table 1-24. 
 
 
 
 
 
Entry 
 
Additive (1.3 equiv) 
 
Yield (GC)a 
 
 
1 
 
        none 
 
31% 
 
2 
 
        BDMAEE 1-77 
 
58% 
 
3         sulfide 1-69 36%, 40%, 45% 
 
aYields were determined after quenching the reaction mixtures with saturated aqueous NH4Cl and 
extracting with ether.  The ethereal solutions were spiked with dodecane and analyzed by GC.  Yields 
were determined using a previously generated calibration curve relating the area ratios of 1-79:dodecane 
to the mmol ratios of 1-79:dodecane.  A standard sample of 1-79 was prepared by converting 1-78 to the 
corresponding Weinreb amide followed by addition of EtMgBr. 
Table 1-23. Addition of EtMgBr to p-trifluoromethylbenzoyl chloride in the presence of additives. 
Figure 1-10. Additives and substrates used for studying the Mg/I exchange reaction of aryl iodides. 
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The same trends in yield as reported by Wang et al.101 were observed.  A comparative 
increase in yield when using BDMAEE as an additive was observed.  In the case of using sulfide 
1-69 as an additive, either comparable or lower yields than in reactions where no additive was 
used were obtained.   Therefore, sulfide 1-69 is not an effective additive for use these in Mg/I 
exchange reactions.  
 
Entry 
 
Substrate (Ar-I) 
 
Additive 
 
Yielda 
 
Reported yield101 
 
 
1 
 
1-80 
 
none 
 
80% 
 
87% 
 
2 1-80 1-77 84% 96% 
 
3 1-80 1-69 71% NA 
     
 
4 1-81 none 51% 61% 
 
5 1-81 1-77 76% 87% 
 
6 1-81 1-69 54% NA 
     
 
7 1-82 none 59% 43% 
 
8 1-82 1-77 86% 95% 
 
9 1-82 1-69 49% NA 
 
a Yields were determined by GC analysis and are based on area ratios of the product methyl benzoates and 
an external standard (dodecane).  
Table 1-24. Mg/I exchange reactions in the presence of BDMAEE and sulfide 1-69. 
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Finally, sulfide 1-69 was tested as an additive in the asymmetric addition of Grignard 
reagents to aldehydes.102 I first explored the reaction reported to generate products with the 
highest enantiomeric excess—the addition of iso-butylmagnesium bromide to benzaldehyde 
Table 1-25).  Although products were obtained in high enantiomeric ratios, I could not reproduce 
the yields reported in the literature.  By using 1H NMR and GC analyses, I determined that 
formation of benzyl alcohol was the major side reaction.  It was reasoned that the alcohol may 
originate from hydride transfer from the iso-butylmagnesium bromide.  Therefore, other 
Grignard reagents (e.g., n-butylmagnesium bromide) that would be less prone to hydride transfer 
reactions were used; however, isolated yields of ca. 20% were also obtained from these 
reactions.   
 
 
Table 1-25.  Asymmetric additions of Grignard reagents to benzaldehdye in the presence of additives. 
 
 
 
 
 
 
 
Entry 
 
Additive 
 
Enantiomeric ratioa 
 
Yield 
 
 
1 
 
none 
 
NDb 
 
NDb 
 
2 
 
sulfide 1-69 
 
97.5 : 2.5 
 
~20% 
 
3 
 
BDMAEE 1-77 
 
99.5 : 0.5 
 
~20% 
 
aEnantiomeric excess was determined by HPLC analysis using a chiral OD-1 column.    bYield and e.r. 
were not determined because benzyl alcohol was the major product (GC analysis). 
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 Because a high enantiomeric ratio was obtained when sulfide 1-69 was used, I was 
interested in modifying the reaction parameters to obtain better yields.  I studied the reaction of 
methylmagnesium bromide with alternative titanium reagents. Methylmagnesium bromide was 
used as the Grignard reagent to eliminate the possibility of hydride transfer from the Grignard 
reagent.  It was hypothesized that the reduced products may also result from Meerwein-
Ponndorf-Verley reductions—that is, the hydride source was the iso-propanol ligand on the 
titanium complex.  Therefore, reactions using Ti(Ot-Bu)4, and Ti(NMe)4 as substitutes for Ti(Oi-
Pr)4 were performed.  Unfortunately, only starting material or the reduction product (i.e., benzyl 
alcohol) was observed in both cases.   
1.2.7.4 Effect of Sulfide 1-69 on the Anionic Schlenk Equilibrium 
The effect of sulfide 1-69 was next investigated using a model reaction known to depend 
on the anionic Schlenk equilibrium (Scheme 1-31).52  Knochel and coworkers postulated that 
strong  donors (e.g., chelating ethers) coordinate to MgCl2 and form an MgCl2additive 
precipitate, causing a shift in the Schlenk equilibrium and forming i-Pr2MgLiCl in situ.  The in 
situ formed reagent exhibits good reactivity toward the Br/Mg exchange reaction of electron-rich 
aromatic bromides (e.g., 4-bromoanisole).52 
 
  
Solutions of i-PrMgCl•LiCl were treated with 4-bromoanisole followed by an additive; the 
results are shown in Table 1-26.  When no additive was used, the reaction mixture remained 
homogeneous; when additives (e.g., 1,4-dioxane) were added, the mixtures immediately became 
cloudy.  The conversion in the case of using sulfide 1-69 (entry 4) as an additive was comparable 
Scheme 1-31. Reaction of i-PrMgCl and 4-bromoanisole, proceeding through an anionic Schlenk 
equilibrium. 
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to using 1,4-dioxane (entry 3).  Therefore, sulfide 1-69 may be a substitute for 1,4-dioxane or 
other coordinating ethers in reactions that proceed via an anionic Schlenk equilibrium. 
 
 
 
 
 
1.2.7.5 Additional Reactions Involving Grignard Reagents 
I also explored the reactivity of Grignard reagents in the presence of sulfide 1-69 in two 
additional reactions—the addition of ethylmagnesium bromide to benzonitrile (Table 1-27) and 
the conjugate addition reaction under copper-catalyzed (Kharash) conditions (Table 1-28).   
 
 
 
 
 
Entry 
 
Additive (1 equiv) 
 
Conversion (yield)b 
 
Reaction appearance 
 
 
1 
 
none 
 
28% (38%)c 
 
homogeneous 
 
2 
 
[15]-crown-5 
 
57%d 
 
heterogeneous 
 
3 
 
1,4-dioxane (10% v/v) 
 
86% (89%)e 
 
heterogeneous 
 
4 
 
sulfide 1-69 
 
7286% (8088%) 
 
heterogeneous 
 
aAliquots (100 µL) were quenched with saturated aqueous NH4Cl after 24 h.  The quenched aliquot was 
partitioned into ether, and the ethereal layer was analyzed by GC.  bConversion is based on the ratio of 
anisole:4-bromoanisole.  Yields were calculated using dodecane as an external standard.  cA conversion 
of 31% was reported by Krasovskiy et al.52  dA conversion of 100% after 6 h was reported by Krasovskiy 
et al.  eA conversion of 100% after 10 h was reported by Krasovskiy et al. 
S 
Table 1-26. Effect of additives on the Mg/Br exchange of 4-bromoanisole. 
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In the case of adding Grignard reagents to benzonitrile, using sulfide 1-69 slows the rate 
of reaction; furthermore, increasing the amount of 1-69 from 10% v/v (Table 1-27, entry 2) to 
20% v/v (Table 1-27, entry 3) did not have a substantial impact on the outcome.  I hypothesize 
that sulfide 1-69 may outcompete the nitrile for coordination to the Grignard reagent, thus 
attenuating the Grignard reagent reactivity.   
 
Finally, the conjugate addition of EtMgBr to enone 1-88 (Table 1-28) was tested.  When 
EtMgBr was added to a solution of sulfide 1-69 and 1-88 in ether, a slightly improved selectivity 
for the 1,4-addition product was observed (Table 1-28, entry 2); however, the isolated product 
yield decreased in comparison to the case with no additive (entry 1).  Use of substoichiometric 
amounts of sulfide (entry 3) or premixing sulfide 1-69 with the Grignard reagent (entry 4) 
afforded the same ratio of 1,2- to 1,4-addition products as the control case (entry 1).  Moreover, 
decreased product yields and more complex reaction profiles were observed when sulfide 1-69 
was used as an additive. 
 
Entry 
 
Solvent 
 
Ratio 1-86:1-87 
at t = 3 ha 
 
Ratio 1-86:1-87  
at t = 15 ha 
 
 
1 
 
      ether 
 
1.9 : 1 
 
0.05 : 1 
 
2      10% 1-69/ether (v/v) 5.1 : 1 2.6 : 1 
 
3      20% 1-69/ether (v/v) 6.4 : 1 3.1 : 1 
 
aReported ratios were determined by GC analysis of aliquots.  Ratios are corrected for instrument 
response based on an independently generated calibration curve. 
Table 1-27.  Addition of EtMgBr to benzonitrile in the presence of sulfide 1-69. 
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The decreased product yields may be attributed to a shift in the Schlenk equilibrium toward 
the diorganomagnesium species.  The effect of solvent on conjugate additions has been noted in 
the literature; Harutyunyan et al. observed that the copper-catalyzed enantioselective conjugate 
addition of Grignard reagents to enones proceeds well in TBME or Et2O but that using THF was 
detrimental to the reaction efficiency.104   Moreover, they found that adding 1,4-dioxane or the 
diorganomagnesium reagents decreased the reaction rate.  Their results supported their 
hypothesis that the shift in Schlenk equilibrium was the cause of the decreased rates—the 
diorganomagnesium reagents were less reactive than a monoalkylmagnesiums species (e.g., 
RMgBr•OEt2) in the 1,4-addition reactions.  The lower isolated yields in cases where sulfide 1-
69 was used as an additive may also be explained by a shift in the Schlenk equilibrium. 
  
 
Entry 
 
Additive 
 
Ratio 1-89:1-90 
 
Isolated Yield 
 (combined 1-89 + 1-90) 
 
 
1 
 
     none 
 
2 : 1 
 
73% 
 
2      sulfide 1-69 (2 equiv)a 1.1 : 1 42% 
 
3      sulfide 1-69 (0.2 equiv)a 2 : 1 50% 
 
4      sulfide 1-69 (2 equiv)b 2 : 1 ND 
 
aA solution of EtMgBr in Et2O was added to a solution of CuBr2, 1-88, and 1-69 at -30 C via syringe 
pump.   bEtMgBr and sulfide 1-69 were pre-mixed in Et2O and added to a solution of CuBr2 and 1-88 via 
syringe pump. 
Table 1-28. Conjugate addition reactions in the presence of sulfide 1-69. 
  
 65 
1.2.7.6 Conclusions for Use of Oxetanes as Additives in Organometallic Reactions 
Using sulfide 1-69 as an additive or solvent in reactions involving Grignard reagents likely 
causes a shift in the Schlenk equilibrium.  This hypothesis was supported by the fact that 1-69 
showed comparable effects to 1,4-dioxane when used for the Mg/Br exchange reaction of 4-
bromoanisole.  Moreover, when 1-69 was used a cosolvent in conjugate addition reactions, 
decreased yields were obtained; this observation can also be attributed to a shift in the Schlenk 
equilibrium.  For future work, the effect of sulfide 1-69 will be studied in reactions where using 
the diorganomagnesium reagents results in favorable reaction outcomes.  One example is the 
intramolecular delivery of alkyl groups through formation of an ate complex; this approach was 
used in the total synthesis of (±)-euonyminol (Scheme 1-32).105   The effects of bisoxetanyl ether 
1-37 in Grignard reactions will also be studied to determine the significance of the heteroatom 
tethering the two oxetanes.  
 
 
 
 
 
 
 
 
Scheme 1-32. Example utility of using a shift in the Schlenk equilibrium for favorable reactivity. 
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1.3 RESULTS AND DISCUSSION: USE OF MMS350 FOR AQUEOUS SOLUBILITY 
ENHANCEMENT OF SMALL ORGANIC MOLECULES 
The bifunctional sulfoxide 1-70 (MMS350) was tested for use as a DMSO substitute.  A 
comparison of the physical properties of DMSO and MMS350 is shown in Table 1-29.  
MMS350 is a crystalline solid, whereas DMSO is a viscous, hygroscopic liquid.  MMS350 may 
be an attractive DMSO alternative in terms of compound handling.  Moreover, MMS350 was 
synthesized in three steps from commercially available material (Scheme 1-17).  The synthesis 
was amenable to scale, and no chromatography was required.  The noted aqueous solubility 
(logP = -0.87) would facilitate the removal of MMS350 during workup.  
 
 
Table 1-29.  Selected physical properties of MMS350 and DMSO. 
 
 
 
 
 
         Entry 
 
       Property  
MMS350 
 
DMSO 
 
 
1 
 
melting point 
 
9394 C 
 
1619 C 
 
2 
 
boiling point 
 
NA 
 
189 C 
 
3 
 
LogP 
 
-0.87a 
 
-1.3121 
 
aThe logP (log of the octanol/water partition coefficient) value for MMS350 was determined using the 
shake-flask method. The reported value represents an average of 3 independent experiments. 
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X-ray structural data for MMS350 (Figures 1-11 and 1-12) was obtained.106  The smallest 
asymmetric unit consists of two MMS350 molecules with the oxetanyl moieties packed to 
minimize intermolecular dipoles.  Interestingly, the oxetane moieties and the sulfoxide oxygen 
are oriented in a manner that may promote cation chelation.  
 
Figure 1-11. X-ray structure of MMS350. 
 
 
 
 
 
 
 
Figure 1-12. Space-filling model of MMS350. 
1.3.1.1 Oxidation Reactions Using MMS350 as a DMSO Substitute 
DMSO is widely used as an oxidant for alcohols and halides, affording the corresponding 
aldehydes (Scheme 1-33).107 These reactions are known as the Swern and Kornblum oxidations 
(Scheme 1-33). The mechanisms of the standard Swern and Kornblum oxidations are depicted in 
Scheme 1-34.  Notable features of both mechanisms include a) nucleophilic addition of a 
sulfoxide (DMSO) b) deprotonation of an alpha-methylene hydrogen to form an intermediate 
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ylide, and c) intramolecular hydride transfer to the ylide and subsequent expulsion of dimethyl 
sulfide. 
 
Scheme 1-33. Reactions where DMSO is used an oxidant (adapted from reference 107). 
 
 
 
 
 
 
 
 
 
Scheme 1-34. Mechanism of A) the Swern oxidation and B) the Kornblum oxidation (adapted from 
reference 107). 
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Although DMSO has widespread utility as an oxidant, a major drawback to the Swern and 
Kornblum oxidation is the stoichiometric production of dimethylsulfide (DMS), which is a 
volatile, odorous liquid (bp = 3541 C).  On laboratory scale, the production of DMS is easily 
handled by good laboratory practices (e.g., use of fume hoods and washing glassware with 
bleach); however, on an industrial scale, evolution of DMS is problematic.  It was postulated that 
MMS350 may be a suitable substitute for DMSO that would generate the more tractable 
byproduct sulfide 1-69 (Scheme 1-35). 
 
 
 
 
 
 
 
To explore the possibility of using sulfoxide MMS350 in Kornblum oxidations, the 
conversion of benzyl bromide to benzaldehyde was investigated.  Mixing MMS350, benzyl 
bromide, and KHCO3 and performing the reaction as a melt (under either thermal or microwave 
conditions) resulted in decomposition of the sulfoxide.  Heating a solution of MMS350 and 
benzyl bromide in acetonitrile at 75 °C did affect ~30% (by 1H NMR analysis) conversion to 
benzaldehyde; however, this reaction was not reproducible.  Moreover, attempted oxidations of 
p-nitrobenzylbromide with MMS350 in acetonitrile solutions were unsuccessful.  To quickly 
gage the reactivity of MMS350 in comparison to DMSO, the oxidation of -bromoacetophenone 
1-94 in CD3CN (Table 1-30) was explored.  In the case of using DMSO (10 equiv) as the 
oxidant, conversion of 1-94 was apparent within 60 h, and ~96% conversion was observed after  
Scheme 1-35. Proposed Kornblum oxidation using MMS350 as an oxidant. 
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84 h; however, -bromoacetophenone was stable to MMS350 even after 2 weeks of standing in 
CD3CN.  
 
 
 
 
 
 
 
 
MMS350 was also tested in modified Swern oxidations in which cyanuric chloride 1-96108 
(Scheme 1-36) was substituted for oxalyl chloride.  Benzyl alcohol was used as the substrate, and 
only recovered benzyl alcohol and deoxygenated sulfoxide (sulfide 1-69) were observed by 
analysis of the crude 1H NMR spectrum. 
 
The results of the above experiments indicate that MMS350 does not have the same 
oxidizing properties as DMSO. In the case of the Kornblum oxidation, MMS350 may be too 
sterically encumbered for effective nucleophilic attack of the -bromoketone or benzylic 
bromide.  In the case of the modified Swern oxidations, the formation of sulfide 1-69 may 
indicate that MMS350 does indeed react with cyanuric chloride; however, the resulting complex 
or chlorosulfonium salt 1-97 may again be too sterically hindered for addition of the alcohol to 
occur (Scheme 1-36). 
 
Entry 
 
Sulfoxide 
 
Result 
 
 
1 
 
                   DMSO 
 
~96% conversion after 84 ha 
 
2                    MMS350 no conversion after > 2 weeks 
aConversion was determined by 1H NMR analysis. 
Table 1-30. Kornblum oxidation of -bromoacetophenone in the presence of sulfoxides. 
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MMS350 was not an effective DMSO substitute for the Kornblum and modified Swern 
reactions; the lack of reactivity may be a positive attribute—another application of DMSO is its 
use as a solvent in biological assays and for compound storage libraries. In these cases, a less 
reactive DMSO analog may be a useful substitute.  I thus switched my focus to exploring the use 
of MMS350 as a DMSO substitute for applications related to compound storage and high-
throughput screening.  The experiments and findings are discussed in the next section. 
 
1.3.2 MMS350—A Dimethylsulfoxide Substitute for Aqueous Solubility Enhancement of 
Small Organic Molecules 
Note: The tables, figures, and text in this section were adapted (with permission) from reference 
[122], in ASSAY and Drug Development Technologies ©2012 Mary Ann Liebert, Inc.  
 
 
 
 
 Scheme 1-36. Reaction of cyanuric chloride and MMS350 for attempted oxidation reactions. 
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1.3.2.1 Problems with Compound Storage in DMSO 
Compound libraries designated for high-throughput screening assays are often plated and 
stored in DMSO.  The storage period can last for several months to even years;109 during this 
time, compound degradation due to hydrolysis, oxidation, isomerization, and other chemical 
reactions can occur.110  There have been several studies111 documenting compound degradation 
in DMSO storage solutions; in general, it can be estimated that ~50% of samples degrade after 
12 months of storage.  Moreover, compound precipitation from stored DMSO solutions can 
occur—in one study, there was qualitative precipitation of compounds in 26% of test plates.112   
 
For use in high-throughput screening assays, compounds stored in DMSO stock solutions 
are diluted in aqueous buffers.  Many libraries are composed of high molecular weight, 
hydrophobic compounds designed to have enhanced membrane permeabilities.113 The trend 
toward designing lipophilic compounds results in libraries of materials with lower intrinsic 
aqueous solubilities.  It is currently estimated that 30%50% of compounds in screening libraries 
have aqueous solubilities of less than 10 µM.114  Compounds with low aqueous solubilities often 
precipitate upon dilution in the assay media.  When compound concentrations in assay media fall 
below the calculated concentrations, flawed conclusions regarding structure-activity-
relationships, toxicity, or efficacy are drawn.113  Additionally, compounds reported to be “clean” 
after counter-screens for off-target activities may, in fact, simply have poor solubility in the 
screening assays.115 
 
Methods for optimizing in vitro assays to address solubility issues include limiting aqueous 
dilutions, using organic solvents for serial dilutions, using cosolvents, and performing screens at 
lower concentrations.  Solubilizing agents such as 2-hydroxypropyl--cyclodextrin (HBC), 
surfactants, and commonly used pharmaceutical excipients are now frequently incorporated into 
assay plates.115 Aqueous dissolution of problematic compounds can also be enhanced by pH 
adjustment,116 salt formation,117 or chemical modification of the substrate (formation of pro-
drugs).117   Cosolvents including glycerin,112 N-methyl pyrrolidone (NMP),118 and low-
molecular-weight polyethylene glycols (PEGs, e.g., PEG 400)113 can also be used. 
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Solubilizing agents based on DMSO have been developed.  For example, poly-L-methionine 
1-98 (Figure 1-13) was shown to increase solubility of lipophilic molecules in PBS solutions 
(phosphate buffered saline).119 Due to the stability and hydrophilicity of MMS350, it was 
reasoned that it may also function as a DMSO substitute for aqueous solubility enhancement of 
lipophilic molecules; therefore, MMS350 was tested as a solubilizer and compound storage 
additive.  In the following subsections, findings regarding the use of MMS350 in chemical 
storage applications are described.  The toxicity and applicability of MMS350 to cellular and in 
vivo bioassays is discussed. 
 
 
 
  
 
 
 
 
1.3.2.2 Initial Compound Solubility Measurements 
 To evaluate the utility of MMS350 as a solubilizing agent, a test set of poorly aqueous-
soluble compounds (Figure 1-14) was chosen.  The solubility enhancement of curcumin 1-99 
was first examined.  Curcumin is a promising lead for treatment of several disorders (e.g., colon 
cancer), but its bioavailability and utility as a therapeutic agent are limited by its severely low 
aqueous solubility (0.6 µg/mL at ambient temperature, up to 7.4 µg/mL upon heating).120,121 
UV/VIS spectroscopy was used to measure the solubility of curcumin in a 25 wt% solution of 
MMS350 in water.  After equilibration at ambient temperature for 20 h in an end-over-end 
rotator, the measured solubility was 60  20 µg/mL.  Although the solubility remained low, the 
noticeable increase was encouraging.122  Moreover, curcumin is yellow in color, and I observed 
that solutions prepared in 25 wt% MMS350/water had a yellow color whereas aqueous solutions 
remained colorless.  
Figure 1-13. DMSO substitutes for aqueous solubility enhancement of lipophilic compounds. 
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Encouraged by this result, we tested a diverse set of compounds including amines, acids, 
and non-ionizable motifs (e.g., griseofulvin).  The results are shown in Figures 1518.  Each 
experiment was performed in duplicate, and the solubilization efficacy with varying wt% 
solutions of MMS350 was compared with that of DMSO.  Up to 10-fold increases in solubility 
were observed using 25 wt% solutions of MMS350 in water.  Furthermore, up to two-fold 
enhancements were observed in comparison to using the equivalent wt% solutions of DMSO in 
water.122 
 
 
 
Figure 1-14. Test set of poorly aqueous soluble compounds. 
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Figure 1-15. Solubility of quinine 1-100 in aqueous solutions with MMS350 () and  
DMSO () as cosolvents. 
 as cosolvents.    
 
Figure 1-16. Solubility of naproxen 1-101 in aqueous solutions with MMS350 () and  
DMSO () as cosolvents.   
 
Each trial was run in duplicate and each point represents the average of the duplicate trials.  In the 
case of MMS350, the pH varied from 8.7 (with no additive) to 9.4 (with a 0.25 weight fraction 
additive).  In the case of DMSO, the pH varied from 8.9 (with no additive) to 9.5 (with a 0.25 
weight fraction additive). 
 
Each trial was run in duplicate and each point represents the average of the duplicate trials.   In the 
case of MMS350, the pH varied from 4.6 (with no additive) to 4.2 (with a 0.25 weight fraction 
additive).  In the case of the DMSO, the pH varied from 4.8 to 4.4. 
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Figure 1-17. Solubility of carbendazim 1-102 in aqueous solutions with MMS350 () and  
DMSO () as cosolvents.  
 Each trial was run in duplicate and each point represents the average of the duplicate trials. In 
the case of MMS350, the pH varied from 6.7 (with no additive) to 7.0 (with a 0.15 weight 
fraction additive).  In the case of DMSO, the pH varied from 6.8 (with no additive) to 7.4 
(with a 0.25 weight fraction additive). 
 
Each trial was run in duplicate and each point represents the average of the duplicate trials. In the 
case MMS350, the pH varied from 6.3 (with no additive) to 6.8 (with a 0.20 weight fraction 
additive).  In the case of DMSO, the pH varied from 6.3 (with no additive) to 6.8 (with a 0.20 
weight fraction additive). 
 
Figure 1-18. Solubility of griseofulvin 1-103 in aqueous solutions with MMS350 () and  
DMSO () as cosolvents. 
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It was hypothesized that DMSO and MMS350 function as cosolvents rather than 
complexing agents.  Yalkowsky has developed a model (eq 4) for solubilization in cosolvent 
mixtures showing that observed solubility increases exponentially with increasing volume 
fraction of cosolvent.116,118   His model is shown in equation 14; Smix and Sw are the solubility of 
the solute in the cosolvent mixture and water, respectively,  is the solubilizing efficacy of the 
cosolvent, and fc is the volume fraction of cosolvent.  The slope of a semi-log plot () is related 
to the cosolvent’s ability to disrupt the intermolecular hydrogen bond network of water and form 
a less polar solvent mixture. The higher solubilizing efficacy of MMS350 in comparison to 
DMSO can be rationalized by comparing the logP of MMS350 (-0.87) to that of DMSO (-1.3).123  
Because MMS350 is slightly more lipophilic, the resulting solvent mixture may be effectively 
less polar. 
 
                                    Log Smix = logSw + fc                                  (4)                
 
The solubilization of a steroid in aqueous media was also tested.  Estrone 104 was chosen 
because it has a chromophore, thus its solubility could be measured using UV/VIS spectroscopy.  
The reported aqueous solubility of estrone is quite low (0.8 µg/mL),124,125 and we had difficulty 
quantifying the solubility by UV/VIS ( = 2000), even when using a 25 wt% solution of 
MMS350 in water.  Ternary mixtures of pH 9.0 buffer (Borax), NMP, and sulfoxide were tested 
(Table 1-31).  In this case, noticeable differences in in solubility were measured, and the 
solubility in the ternary mixture of pH 9.0 buffer, NMP, and DMSO was optimal (Table 1-31, 
entry 4).  It should be noted a noticeable improvement in solubility using a 3:1:1 pH 9.0 
buffer/NMP/MMS350  was still observed (Table 1-31, entry 3). 
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Table 1-31. Solubility of estrone in solutions of pH 9.0 buffer, NMP, and sulfoxide. 
 
 
Because several of the compounds in the test set contain ionizable functionalities (e.g., 
quinine, naproxen, carbendazim), the solubilization in buffered media (0.01 M pH 7.0 phosphate 
buffer) was examined (Table 1-32).  The solubility of quinine 1-100 was higher in the buffer 
(Table 1-34, entries 1–3) than in HPLC-grade water (Figure 1-15), and a correlation between wt. 
fraction MMS350 and solubility was observed. In the case of naproxen (pKa ca 4.8), the 
molecule is ionized at pH 7.0, and therefore little effect is observed upon increasing the wt% of 
the sulfoxide in pH 7.0 buffer (Table 1-32, entries 4–6). The solubility of carbendazim (Table 1-
32, entries 7–9) was consistent with that in solutions prepared in HPLC-grade water (Figure 1-
17).   This is not surprising given that the pKa of the benzimidazole is ca. 4, and therefore the 
molecule is not ionized at pH 7.0.   
 
 
 
 
 
 
Entry 
 
Medium 
 
Solubility  (µg/mL)a 
 
 
1 
 
3:1 pH 9.0 buffer/MMS350 
 
30 ± 10 
 
2 3:1 pH 9.0 buffer/NMP 63 ± 5 
 
3 3:1:1 pH 9.0 buffer/NMP/MMS350           160 ± 20 
 
4 3:1:1 pH 9.0 buffer/NMP/DMSO           230 ± 30 
 
aSolubility was determined after equilibration for 20 h at 30.0 ºC.  Data were obtained by UV/VIS 
analysis of the saturated solutions and were confirmed by analysis of independently prepared estrone 
standards.  Each entry represents a mean solubility ± standard deviation (n = 3). 
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Table 1-32. Solubility of selected compound in solutions of sulfoxide MMS350 in 0.01 M pH 7.0 
phosphate buffer. 
 
 
Entry 
 
Compound 
 
Weight percent MMS350 in 
pH 7.0 buffer 
 
Solution 
pHa 
 
Measured solubility 
(µg/mL)b 
 
 
1 
 
 
1-100 
 
0 
 
7.6 
 
1100 (780)d 
2 
 
1-100 10 8.0 1900 (1300)d 
3 
 
1-100 25 8.2 6200 (3900)d 
4 
 
1-101 0 6.0       950c 
5 
 
1-101 10 5.8     1100 
6 
 
1-101 25 5.2     1400 
7 
 
1-102 0 6.8         10 
8 
 
1-102 10 6.9         34 
9 
 
1-102 25 7.1         77 
aThe pH was measured electrochemically after excess compound was filtered from the solution.  
bMeasurements were performed in duplicate unless otherwise noted.  cAverage of 5 trials. dThe two 
numbers represent data from separate trials where entries 1-3 were run in parallel.  There was some 
variability in the results from the two trials. 
 
 
 Up to this point, the thermodynamic solubility of the test set of compounds (i.e., the 
equilibrium solubility after 20 h) was measured.  The kinetic solubility (i.e., the solubility of a 
compound after dilution of a stock solution in buffer) is often a better measure of the how the 
media will affect compound solubility in terms of high-throughput screening assays.  The kinetic 
solubility of carbendazim 1-102 and griseofulvin 1-103 was determined (Table 1-33).  Stock 
solutions (10 mM) of 1-102 and 1-103 in DMSO, NMP, or a 25% MMS350/NMP solution were 
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prepared, and aliquots (10 µL) were added directly to  pH 7.4 PBS solutions, and the solubilities 
were measured.  Across the three test media, the measured kinetic solubilities were consistent.  It 
should be noted that the observed kinetic solubility of griseofulvin was higher than previously 
reported,126 and it approached the threshold solubility of 200 µM.  However, the data were used 
to establish a general trend, and I observed no difference in kinetic solubility when using the 
three different media for stock solution preparation. 
 
 
Table 1-33. Kinetic solubility measurements of carbendazim and griseofulvin after dilution with 
phosphate buffered saline.  
1.3.2.3 Applicability of MMS350 to in vitro and in vivo Assays 
MMS350 was evaluated as a cosolvent for solutions that would be used in in vitro assays.  
The use of MMS350/NMP solutions was compared to both 100% NMP solutions and 100% 
DMSO solutions.  NMP  was needed as a cosolvent because MMS350 is a solid at room 
temperature and thus must be mixed with an appropriate cosolvent for use in preparation of 
compound stock solutions.  NMP is thermally stable, has low toxicity, and has solubilizing 
 
Entry 
 
 
Compound 
 
Medium of stock solution 
 
Kinetic solubility (µM)a 
 
1 
 
1-102 
 
      DMSO 
  
140 ± 13b 
 
2 1-102       NMP 160 ± 5 
 
3 1-102       25% MMS350/NMP 150 ± 9 
 
4 1-103       DMSO 170 ± 16 
 
5 1-103       NMP 180 ± 13 
 
6 1-103       25% MMS350/NMP 190 ± 7 
 
aData are reported as mean ± standard deviation (n = 3).  bData are reported as mean ± standard deviation 
(n = 5). 
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power superior to that of ethanol and propylene glycol.  Moreover, there are precedents for using 
NMP in bioassays and commercial pharmaceutical applications.118,127 
 
The radiometric PKD1 inhibition assay was used to test the effect MMS350 would have on 
biological assays.  The synthesis and biological evaluation of a series of structures (Figure 1-19) 
showing nanomolar to micromolar inhibitory activity toward PKD1 was disclosed by the Wipf 
group.128-130 Several compounds evaluated in this study, especially pyrimidine-containing 
structures, exhibited poor solubility not only in aqueous solutions but also in DMSO.     
 
 
 
 
          
 
 
 
 Figure 1-19. Compounds assayed for PKD1 inhibitory activity. 
 
Stock solutions of the 6 PKD1 inhibitors (Figure 1-19) at 10 mM concentrations in DMSO, 
NMP, and 25 wt% MMS350/NMP were prepared.  The solutions were used in the radiometric 
PKD1 assay to test inhibitor activity at both 1 µM and 10 µM concentrations.131 Graphs 
comparing the PKD1 activity are shown in Figures 1-20 and 1-21.  In the case of NMP, less 
inhibitory activity was generally observed, especially in the case of mcf-292-03 at inhibitor 
concentrations of 10 µM.   In general, comparable results were observed when both DMSO and 
25 wt% MMS350/NMP were used for compound solution preparation.  In the case of the 
standard PKD1 inhibitory assay, use of MMS350 did not interfere with PKD1 inhibition or the 
read-out of results. 
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     Figure 1-20. Plot of PKD1 activity with compound concentrations of 1 µM.   
 
 
 
 
 
 
 
 
 
 
 
 
Stock solutions were prepared in three different media at concentrations of 10 mM, and dilutions 
were performed using the same media.  The % PKD 1 activity is reported as the mean, and error 
bars represent SEM (n = 3).  The % PKD1 activity was determined as previously described.129 
 
Stock solutions were prepared in three different media at concentrations of 10 mM, and dilutions 
were performed using the same media.  The % PKD 1 activity is reported as the mean, and error 
bars represent SEM (n = 3).  The % PKD1 activity was determined as previously described.129 
 
Figure 1-21. Plot of PKD1 activity with compound concentrations of 10 µM. 
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1.3.2.4 MMS350 for Compound Storage—Hygroscopicity and Other Implications 
It was envisioned that solutions of MMS350 in an appropriate cosolvent (e.g., NMP) can be 
used for compound storage solutions. The test set of compounds (Figure 1-14) was stored in 25 
wt% solutions of MMS350/NMP for 6 weeks at -20 °C.  It was noted that MMS350 partially 
precipitated from the solutions at -20 °C, but no change in model compound concentrations were 
observed after thawing the storage vessels. 
  
Water absorption by storage media is a significant factor for the lifetime of library 
compounds stored in solutions. Zitha-Bovens and coworkers designed a study to construct a 
predictive model of the lifetime of compounds in DMSO solution storage solutions.110 Libraries 
comprising 1000 to 10,000 compounds were examined for compound stability across a broad 
range of temperatures in both DMSO and H2O/DMSO (20% v/v).  In general, more compound 
degradation was observed in compounds stored in H2O/DMSO; however, a small percentage of 
compound (~3%) actually decomposed in neat DMSO while maintaining stability in wet DMSO.  
A study132 performed at Abbott also indicated that water absorption induced more compound 
degradation than oxygen exposure.   
 
The degree of water absorption in 25% w/w MMS350/NMP solutions was ascertained.   I 
monitored DMSO, NMP, and 25% w/w MMS350/NMP for one week at ambient temperature 
(Table 1-34).  Although significant water absorption was observed (ca. 7000 ppm over the 
course of 7 days), the MMS350/NMP solution absorbed less water than NMP alone.  The result 
indicates that the hygroscopicity of MMS350 is low relative to NMP. 
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Table 1-34. Comparative water absorption measurements of possible compound storage media. 
 
 
1.3.2.5 Toxicity of MMS350 
Because MMS350 showed promising properties for aqueous solubility enhancement and 
possible compound storage, studies to validate the hypothesis that the compound could also be 
useful in cellular and in vivo assays were undertaken.  It was necessary to ensure that MMS350 
was not prohibitively toxic to living organisms and cell lines. Brine shrimp assays were 
performed, and the results are shown in Table 1-35. 
 
Brine shrimp floating in water containing concentrations of MMS350 up to 20 mg/mL 
showed <10% mortality after 48 h.  Shrimp incubated in water containing 50 mg/mL of 
MMS350  had 85% mortality after 24 h and 100% mortality within 48 h.  The data indicate an 
LC50 of approximately 32 mg/mL (147 mM).  In comparison, shrimp treated with DMSO at the 
same concentrations showed no mortality after 24 h and only 15% mortality after 48 h at 50 
mg/mL of DMSO.  The cellular toxicity of MMS350 was tested against a breast cancer cell line 
 
Entry 
 
Medium 
 
Water content at t = 0 
(ppm)a 
 
Water content at t = 7 d  
(ppm)a 
 
 
 
1 
 
 
     DMSO 
 
160, 170 b 
 
1080, 1130b 
2 
 
     NMP 150, 130c 12,090, 17,000c 
3 
 
     25% MMS350/NMP  
    (w/w) 
 
160, 200c 6500, 8600c 
aWater content was analyzed by Karl Fischer titration.  The two values listed represent individual vessels, 
the first value in each column corresponding to the same vessel at each time-point.  bAverage of 3 
measurements.  cAverage of 2 measurements. 
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(MDA-MB-231) and a liver cell line (HepG2) (Figures 1-22 and 1-23).133  In both cases, the 50% 
growth inhibitory concentration (GI50) for MMS350 was ~200 mM, whereas the GI50 for DMSO 
was ~800 mM.  The same concentration threshold observed in the case of brine shrimp was also 
observed; in the case of both cell lines, MMS350 had limited toxicity at concentrations up to 
~100 mM. The results indicate that MMS350 may be tolerated in biological assays in 
concentrations of up to 2% (by mass). 
 
 
Table 1-35. Brine shrimp assay results: toxicity of sulfoxide MMS350. 
 
 
 
Entry 
 
Compound 
 
Concentration 
(mg/mL) 
 
% Mortalitya 
after 24 h 
 
% Mortalitya 
after 48 h 
 
 
1 
 
       MMS350 
 
0 
 
<10 
 
10 
 
2        MMS350 1 0 0 
 
3        MMS350 5 0 0 
 
4        MMS350 20 0-10 0-10 
 
5        MMS350 50 85 100 
 
6        DMSO 0 <10 10 
 
7        DMSO 1 0 0-10 
 
8        DMSO 5 0 0-6 
 
9        DMSO 20 0 0 
 
10 
 
       DMSO 50 0 15 
aPercent mortality was determined for an average of 5 trials.  Percent mortality was determined by 
estimating the number of shrimp showing no motility after several minutes of observation. 
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Figure 1-22. Toxicity of MM350 and DMSO against a HepG2 cell line. 
Figure 1-23. Toxicity of MMS350 and DMSO against a MDA-MB-231 cell line. 
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1.3.2.6 Conclusions for MMS350 as a DMSO Substitute 
The utility of MMS350 for enhancing the aqueous solubility of small organic molecules has 
been demonstrated.  Advantages to using MMS350 as a DMSO replacement include its lower 
reactivity in oxidation reactions.  Moreover, MMS350 was used in an enzymatic assay without 
affecting the readout of results.  Although MMS350 exhibited higher toxicity than DMSO in the 
brine shrimp and cellular assays, the toxicity was sufficiently low to permit use of MMS350 for 
cellular and in vivo assay development in concentrations up to 2%.   
 
Use of MMS350 as a cosolvent for aqueous solubility enhancement showcases the utility of 
the oxetanyl moiety as a solvent scaffold.  Incorporating oxetanes onto the DMSO backbone 
generated a more lipophilic cosolvent that still maintained good aqueous miscibility.  This study 
prompts further development of using oxetanes in the design of new additives and cosolvents. 
1.4 CONCLUSIONS 
The donating ability and compact structure of oxetanes make them viable candidates as 
additives and cosolvents.  Oxetanes have a high strain energy, yet their reactivity can be 
attenuated by substitution at the 3-position.  Bisoxetanyl ether 1-37 and bisoxetanyl sulfide 1-69 
showed promising solvent effects when used as cosolvents in organolithium- and 
organomagnesium-mediated reactions, respectively. Notably, the oxetanyl additives were stable 
in the presence of the organometallic reagents studied. Further experimentation with these 
compounds is warranted in order to identify key areas where oxetanes can be used to solvate 
cations. 
 
 A bisoxetanyl sulfoxide MMS350 was evaluated as a DMSO substitute.  It was shown 
that MMS350 does not have utility as an oxidizing agent.  I took advantage of this property and 
demonstrated that MMS350 can be used as a cosolvent for aqueous solubility enhancement of 
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lipophilic compounds.  The low toxicity and stability of MMS350 make this sulfoxide suited for 
use in pharmaceutical formulations. 
 
These studies show that oxetanes are promising moieities for incorporation into solvents 
and ligand scaffolds.  Future work may involve design of oxetane-based ligands for transition-
metal mediated reactions.  I did explore the use of MMS350 as a substitute for DMSO ligands in 
the palladium-catalyzed aerobic dehydrogenation of ketones;134 yet, I observed no reaction.  It 
may still be worthwhile to explore other palladium or related transition-metal mediated reactions 
where sulfoxide-based ligands are typically used.   
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2.0        SMALL MOLECULES AS PROTECTORS AND MITIGATORS 
           AGAINST IONIZING RADIATION 
Ionizing radiation causes many physiological conditions ranging from mild nausea to severe 
health complications (e.g., sepsis) or death.135 The biological consequences of ionizing radiation 
include induction of nuclear DNA single- and double- strand breaks and a molecular damage 
response that ultimately results in cell death.136,137  Reactive nitrogen species (RNS) and reactive 
oxygen species (ROS) are implicated in a large part of the damage imparted by ionizing 
radiation. 
 
Chemical substances that are effective ROS scavengers can counteract the harmful effects of 
ionizing radiation.  The identification of agents that are protectors (administered prior to 
radiation exposure) has direct application for patients receiving clinical radiation exposure.  The 
identification of agents that mitigate the effects of systemic radiation exposure is of importance 
to military efforts, disaster relief, and counter-terrorism measures.138 In our design of 
radioprotective or radiation mitigating agents, we focused on two classes of ROS scavengers—
sulfoxides and nitroxides.  MMS350, a bifunctional, water-soluble dimethylsulfoxide analog, 
was shown to protect against and mitigate whole-body radiation damage in mice.  We have also 
undertaken a strategy for a nanoparticle-based delivery of nitroxides, which is described in 
Chapter 3. 
 
Herein, the consequences of unregulated generation of ROS and the endogenous 
mechanisms for scavenging ROS are described.  Two strategies for developing chemical 
radiation countermeasures are discussed, followed by the results obtained when using MMS350 
for radiation protection/mitigation.  Finally, there is a description of the synthesis of MMS350 
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analogs that will be used for studying the mechanism of action of MMS350 and for investigating 
the SAR of the bifunctional sulfoxide-containing molecules.  
 
2.1 INTRODUCTION 
2.1.1 Ionizing Radiation: Generation of ROS 
Ionizing radiation has an associated energy that is much greater than the bond energies of 
many molecules; therefore, homolytic bond scission can occur when ionizing radiation is 
absorbed.  Primary radiolysis products come from homolytic bond cleavage of water, generating 
hydroxyl radicals, H atoms, and solvated electrons.  These species have short life times (10-10 to 
10-9 s);139 often, they react rapidly to form secondary radicals, which have longer lifetimes (10-6 
s).  Secondary radicals can react with and damage biomolecules such as DNA, lipids, and 
proteins.   
 
A consequence of ionizing radiation damage is overproduction of ROS, which include 
hydroxyl radical (HO•), hydrogen peroxide (H2O2), and superoxide radical anion (O2
•-). It should 
be noted that reactive oxygen species are, in fact, produced as part of endogenous processes, 
mostly due to electron transport.  It has been estimated that ca. 90% of these endogenously 
generated ROS are produced in the mitochondria as a consequence of oxidative 
phosphorylation.140 There are several innate mechanisms for the efficient scavenging of ROS. 
Yet, as a result of age, pathological processes, or environmental stressors (e.g., ionizing 
radiation), the production of ROS may exceed the limitations of intrinsic scavenging 
mechanisms.138 
 
One pathway by which ROS affect cell death involves the mitochondria-specific 
phospholipid cardiolipin (CL).141-144  ROS-mediated oxidation of CL initiates migration of CL 
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from the inner to the outer mitochondrial membrane.  At this point, cytochrome c, a heme protein 
with a critical role in the electron transport chain, forms a complex with CL that acts as a CL-
specific oxygenase/peroxidase.  Oxidation of CL leads to detachment of cyt c from the 
mitochondrial membranes and ultimately the release of pro-apoptotic factors into the cytosol.141-
143 Thus, chemical agents that react with ROS can, in effect, shut down the CL-mediated cell 
death pathway. 
 
Several natural and unnatural antioxidants, which include DMSO, EtOH, vitamin C, 
vitamin E, and ubiquinol, are effective for scavenging radiolysis products and ROS.143   
Chemical reagents can be designed based on these nonspecific ROS scavengers.  Another 
strategy involves specific targeting of the mitochondria due to its role in both ROS production 
and ROS-mediated cell death pathways.140,145  In the following sections, the endogenous 
mechanisms for ROS elimination are discussed, and strategies based on both mitochondria-
targeted and nonspecific ROS scavengers are detailed. 
2.1.1.1 ROS Scavenging by Endogenous Enzymes  
Several enzymes are involved in the continuous scavenging of ROS; examples are 
depicted in Scheme 2-1.  Typical ROS scavenging mechanisms involve peroxidase-mediated 
redox chemistry of sulfide bonds and H2O2.  For example, the thioredoxin-thioredoxin reductase 
system operates via oxidation of thiols in the thioredoxin active site, forming TrxS2 and water.
146   
Similarly, glutathione peroxidase catalyzes the reaction between glutathione and H2O2, again 
generating the disulfide and water (Scheme 2-1).140  
 
 
 
 
 
Scheme 2-1. Enzymatic reactions that mitigate ROS (adapted from reference [140]).  Prx = 
peroxiredoxin; GP = glutathione peroxidase; Trx = thioredoxin; GSH = glutathione. 
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Superoxide dismutases (SODs) (Scheme 2-2) have a different mechanism of ROS 
scavenging.  SODs catalyze the dismutation of superoxide to oxygen and hydrogen peroxide—a 
general mechanism is shown in Scheme 2-2.147,148 There are several families of SOD known, and 
each is dependent on redox-active metal cofactors including Mn, Fe, Cu, and Ni. Members of the 
manganese superoxide dismutase (MnSOD) family are critical for the “shuffling” of 
mitochondrial ROS species.  In eukaryotes, these enzymes typically exist as tetramers; in the 
enzyme active site, a manganese atom catalyzes the conversion of superoxide to hydrogen 
peroxide. A general mechanism for SOD-mediated disproportionation of superoxide is shown in 
Scheme 2-2.  Briefly, the SOD-oxidized metal cofactor complex is reduced by superoxide with 
concomitant generation of oxygen.  The SOD complex (with a reduced cofactor) can be oxidized 
by superoxide with resultant formation of H2O2.  Overall, SODs convert two molecules of 
superoxide to molecular oxygen and hydrogen peroxide—the resultant hydrogen peroxide is 
further reduced by a catalase to oxygen and water.140,147,148 
 
 
 
 
 
 
 
2.1.2 TEMPO as an SOD Mimic 
Small molecules bearing stable nitroxyl radicals have been demonstrated to be effective 
mitigators of ROS.138,140,145,149-152 The nitroxyl radical (e.g., in (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl, TEMPO) mimics the redox activity of SOD by catalyzing dismutation of superoxide by 
one of two pathways (Scheme 2-3).  One proposal is that superoxide reduces the nitroxide to the 
hydroxylamine, generating molecular oxygen.  The hydroxylamine is then reoxidized to the 
Scheme 2-2. Mechanism for dismutation of superoxide by superoxide dismutase (M = Mn, Cu, Fe, Ni). 
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nitroxide by an additional molecule of superoxide, generating hydrogen peroxide (Scheme 2-3, 
A). In an alternative pathway, the nitroxide is first oxidized to the N-oxoammonium cation 
followed by subsquent reduction of the N-oxoammonium cation back to the nitroxide with 
concomitant production of molecular oxygen (Scheme 2-3, B).  In both cases, two molecules of 
superoxide are ultimately disproportionated to molecular oxygen and H2O2.
153  
 
Additionally, the N-oxoammonium cation can be reduced to the corresponding 
hydroxylamine by ascorbate in biofluids or by cellular NAD(P)-H-mediated electron transport.143  
Nitroxides are also easily reduced to hydroxylamines by electron transporting enzymes and 
ascorbate.  These hydroxylamines act as reducing agents; single electron transfer regenerates the 
nitroxides and ROS are scavenged by hydrogen transfer.143  Therefore, stabilized nitroxyl 
radicals can both catalyze dismutation of superoxide and act as precursors to other biologically 
active ROS scavengers. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-3. Mechanisms for nitroxide-catalyzed dismutation of superoxide. 
  
 94 
2.1.3 Strategies for Developing ROS Scavenging Agents 
The Wipf group and collaborators have undertaken two general strategies for 
development of ROS scavenging agents.  One major research focus is the development of agents 
that specifically target the mitochondria. It has been established that lipid peroxidation of 
mitochondria-specific phospholipid CL is associated with the deleterious effects of ionizing 
radiation.  Moreover, it has been demonstrated that mitochondrial localization of endogenous 
ROS scavenging enzymes (e.g., SOD) is correlated with successful mitigation of radiation-
induced cellular damage.154  
 
One method of mitochondria-specific targeting is the use of manganese superoxide 
dismutase-plasmid liposomes (MnSOD-PL).138,155 Using this method (in mouse models), a 
plasmid containing the transgene for MnSOD expression was administered (via a liposomal 
delivery system) to the esophagus.  Alternatively, the liposomes were delivered to the lungs by 
intra-tracheal injection or inhalation.  In all cases, a decrease in both acute and chronic symptoms 
of radiation was observed.  Although the use of the antioxidative transgene products was shown 
to be radioprotective, the time-course of administration (several hours for in vivo gene 
expression) renders it unrealistic to use this strategy in radiation mitigation.137 
 
An alternative to the MnSOD transgene approach is the use of small molecules specifically 
designed to target the mitochondria.145 Strategies for delivery of antioxidants to the mitochondria 
involve tethering ROS scavengers (e.g., TEMPO, section 2.1.3) to delivery vehicles.  Examples 
of effective vehicles include lipophilic cations145,156 such as triphenylphosphine-based 
conjugates,145,157 which take advantage of the negative membrane potential of the inner 
mitochondrial membrane.  A major research focus in the Wipf group has been the conjugation of 
TEMPO to Gramicidin S conjugates.  In the next sections, delivery vehicles designed for 
mitochondria-specific delivery of TEMPO are described. 
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2.1.4 Targeted Delivery of Nitroxides to the Mitochondria 
A current strategy for targeted delivery of nitroxides to mitochondria involves conjugation 
of nitroxides to hemigramicidin-S mimics (Figure 2-1). The design was based on the antiobiotic 
Gramicidin S, which has high permeability for bacterial cell membranes.  Because bacterial cell 
membranes are structurally similar to mitochondrial membranes, delivery systems based on 
Gramicidin S were postulated to be selectively permeable to mitochondrial membranes. To 
generate delivery systems with lower susceptibilities to protease degradation, the E-alkene 
peptide isosteres (e.g., XJB-5-131) were synthesized.158 It has been shown that the 
hemigramicidin-TEMPO conjugate XJB-5-131 localizes in mitochondria of mouse embryonic 
cells (MECs); furthermore, cells treated with XJB-5-131 were protected from an actinomycin D-
induced increase of superoxide production.152  
 
 
 
 
 
 
 
 
 
 
 
 
The radioprotective effects of XJB-5-131 and related analogs were also demonstrated. It was 
shown that these targeting peptides directed either 4-amino-TEMPO or 2-amino-6-
methylthiazone (AMT, a nitric oxide synthase antagonist) to the mitochondria, which effectively 
induced radioprotective effects.151 The simplified E-alkene isostere JP4-039 (Figure 2-1) has 
Figure 2-1. Gramicidin S and hemigramicidin S TEMPO conjugates for mitochondria-targeted delivery. 
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shown promise in mitochondrial targeting and radioprotective initiatives.  For example, JP4-039 
exhibited both radioprotective and radiation mitigating effects against Fanconi anemia (FA) cell 
lines, which have enhanced sensitivity to DNA crosslinking agents and show enhanced 
radiosensitivity.  Furthermore, use of a fluorescently labeled BODIPY-JP4-039 gave additional 
evidence that the molecule does localize to the mitochondria.  JP4-039 showed improved 
radioresistance in comparison to 4-hydroxy-TEMPO (TEMPOL), which does not have a 
mechanism for mitochondrial localization.149   
 
One drawback to the TEMPO-hemigramicidin S conjugates is their low aqueous solubility 
(JP4-039, 0.5 mg/mL; XJB-5-131, 0.04 mg/mL).159  Ongoing efforts toward developing suitable 
formulations for these compounds is in progress.  I also explored new TEMPO delivery systems 
involving pH-mediated release from nanoparticles; these systems are discussed in Chapter 3. 
2.1.5 Sulfoxides as ROS Scavengers 
 An alternative strategy to using mitochondria-targeted scavengers is to use nonspecific 
scavengers that are easy to administer (i.e., no vehicle is necessary).  DMSO and other sulfoxides 
typically have favorable aqueous solubility and have long been recognized as having protective 
properties against ionizing radiation.160-162 It is hypothesized that DMSO prevents lipid 
peroxidation, likely by scavenging reactive oxygen species, particularly OH.  The reaction of 
sulfoxides with hydroxyl radicals is well-studied.163 Sulfoxides react with hydroxyl radicals to 
generate intermediate sulfur radical species 2-2 (Scheme 2-4) that react further to generate 
methyl radical and methanesulfinic acid 2-3. Methyl radical can abstract hydrogen from another 
molecule of DMSO (or methanesulfonic acid) to generate methane and a stabilized dimethyl 
sulfoxide radical 2-1r (Scheme 2-4).164   Possible chain termination steps involve reaction with 
superoxide radical anion (in the case of the mechanism  in Scheme 2-4, at acidic pH) to generate 
hydroperoxy(methylsulfinyl)methane.163   
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DMSO is also used in analytical assays for quantitative detection of hydroxyl radicals 
(Scheme 2-5).165 Rapid reaction of DMSO with hydroxyl radical generates methyl radicals, 
which react with the fluorescamine-derivatized nitroxide 2-4, generating the O-
methylhydroxylamine product 2-5.  Product 2-5 can be analyzed and quantified by reverse-phase 
HPLC using fluorometric detection.  These assays have been used for evaluating the extent of 
hydroxyl radical formation by anti-cancer drugs (e.g., quinone-containing compounds).165   It 
should be noted that DMSO also reacts with superoxide and carbonate radicals to produce 
methyl radicals; thus, assays such as those depicted in Scheme 2-5 cannot be used as 
unambiguous determination of hydroxyl radicals in solution.  Yet, for the purposes of our studies, 
the coupling of the hydroxyl radical scavenging reaction with the nitroxide methylation is a 
viable precedent for generating synergistic therapeutic agents incorporating both sulfoxides and 
nitroxides. 
 
 
 
 
Scheme 2-4. General reaction of hydroxyl radicals with sulfoxides. 
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Scheme 2-5. Hydroxyl radical scavenging assay based on the rapid reaction of DMSO with hydroxyl 
radical. 
 
 
2.1.5.1 DMSO as a Radioprotector 
DMSO has shown radioprotective properties in both cellular assays and in vivo experiments. 
For example, it was demonstrated that golden hamster embryos (GHEs) pre-treated with DMSO 
were protected from the damaging effects of -radiation; moreover, the D0 value (dose of 
radiation that reduces a population by 67%) increased with increased DMSO concentrations.166  
Additionally, DMSO pretreatment prevented -ray induced DNA single-strand breaks (SSBs) 
and reduced the occurrence of chromatid aberrations, also in a concentration-dependent 
manner.166  In a separate study, it was shown that the 30-days lethality of mice pre-treated with 
DMSO and subjected to 9 Gy radiation was 16%; the 30-days lethality of the control, untreated 
group was 44%.167 
 
Ueda and coworkers examined the role of DMSO in preventing mouse liver lipid 
peroxidation.167 The authors used precedented assays wherein the extent of lipid peroxidation 
was determined as thiobarbituric acid reactive substance (TBA-RS); an increase in TBA-RS 
levels was observed after mice were subjected to 9 Gy whole-body irradiation, whereas mice 
pre-treated with DMSO (0.11 g, i.p. injection 30 min prior to irradiation) exhibited similar levels 
of TBA-RS as the control (non-irradiated) group.  The authors also noted that SOD activity 
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decreased in irradiated mice 10 days after irradiation, but SOD activity of DMSO-treated mice 
stayed consistent with that of mice not subjected to radiation.  A final observation from this 
study was that the mitochondria and endoplasmic reticulum of liver cells from irradiated mice 
exhibited swelling; these effects were not observed in livers from mice that were pre-treated with 
DMSO.   
2.2 RESULTS AND DISCUSSION 
2.2.1 MMS350—An Effective Radiation Mitigator? 
Although the mitochondrial targeted reagents are promising radioprotectors, they are limited 
in regard to aqueous solubility.  Based on the precedents for dimethylsulfoxide being 
radioprotective, we decided to test bifunctional dimethylsulfoxide analog MMS350 due to its 
low toxicity, high aqueous solubility, and ease of synthesis—MMS350 can be prepared in 3 steps 
from commercially available materials without the need for chromatography (see section 1.2.7).   
The synthesis is reproduced in Scheme 2-6.  Tosylate 1-40 (synthesized from commercially 
available 3-methyl-3-oxetanemethanol) was treated with disodium sulfide followed by oxidation 
with sodium periodate to afford MMS350.  
 
 
 
 
 
 
 
 Scheme 2-6. Synthesis of MMS350. 
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2.2.1.1 MMS350 is Both Radioprotective and Mitigating 
MMS350 was first tested in a screening experiment wherein 32D cl 3 cells were 
irradiated at doses of irradiation up to 7 Gy and then treated with mitigating compounds at 10 
µM.  MMS350 had efficacy similar to JP4-039.168  Because the initial screen was encouraging, 
the compound was tested for use as a radiation mitigator in C57Bl/6/HNsd mice. Mice treated 
with MMS350 had a 40-days lethality of 50% whereas 50% of the untreated mice died by day 13 
(Figure 2-2).  It was also encouraging tha using MMS350 showed similar results to using the 
known radiation protector/mitigator JP4-039.168 
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Figure 2-2. Survival curves of mice injected with 20 mg/kg MMS350 in PBS or JP4-039 in 
 cremphor el and ethanol at 4 h or 24 h after irradiation. 
 
In the course of their work toward identifying useful radiation protectors or mitigators for 
human use, Goff and coworkers discovered that some agents are highly effective in mice but 
ultimately have no human efficacy.  They have since developed an assay wherein umbilical cord 
blood progenitor cells are irradiated and treated with potential protectors/mitigators either before 
or after irradiation.169  Representative data are shown in Table 2-1.  MMS350 was protective of 
cord blood cells (colony-forming unit granulocyte macrophage (CFU-GM)) at concentrations of 
200 µM (D0  2.3  0.09; control 1.85  0.35, DMSO treated pre-treated cells 1.93  0.15).  
MMS350 was also protective in the case of burst-forming unit erythroid (BFU-E)—the D0 value 
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for cells pre-treated with MMS350 (50 µM) was 1.79  0.27, which was an improvement over 
the D0 value found for cells pre-treated with DMSO (1.34  0.33).
169   
 
 
Table 2-1. Selected data showing the effect of radioprotective agents on irradiation survival of CB 
MNC.a  
 
 
MMS350 showed similar efficacy as mitochondrial targeting agents XJB-5-131 and JP4-
039 in the in vitro and in vivo assays; however the aqueous solubility of MMS350 makes it an 
attractive candidate for further testing due to ease of administration during in vivo assays.  The 
straightforward synthesis and relatively low cost for production of MMS350 make it feasible to 
design experiments requiring large amounts of material (i.e., for animal studies).  
 
MMS350 was also tested for its effectiveness in preventing the late-stage side effects of 
radiation, in particular, fibrosis.170   It has been demonstrated that pulmonary fibrosis comes from 
bone marrow stromal cells, which migrate to the lungs via the circulatory system.  Two mouse 
 
Entry 
 
Conditions 
 
D0 value 
 
 
1 
 
              Cells only 
 
1.49  0.23 
 
2               DMSO 1.72  0.15 
 
3               XJB-5-131 (10 µM) 1.93  0.13 (p = 0.044) 
 
4               JP4-039 (10 µM) 1.99  0.13 (p = 0.029) 
 
5               MMS350 (200 µM) 2.3  0.09b (p = 0.023) 
 
aData are for cells (CFU-GM) pre-treated with the agents before irradiation.  Pairwise comparisons were 
made with the two-side two sample t-test; p-values represent comparisons between the treated cells and 
the cells-only group.  bA different “cells-only” group was used with a D0 value of 1.85  0.35. 
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models of fibrosis were used to test the effectiveness of MMS350 for protective effects against 
late-stage irradiation symptoms.  One model used C57BL/6 mice that were irradiated to 10 Gy 
and then transplanted intraveneously with luciferase positive C57BL/6J mouse bone marrow.  
The mice were periodically injected with luciferin and imaged.  A second model involved the use 
of clonal bone marrow stromal cell lines established from long-term bone marrow cultures of 
luciferase positive mice.  After irradiation of the thoracic cavity to 20 Gy, mice were 
administered (i.p.) luc+ cells.  Radiation fibrosis was indicated by an increase in luciferase 
activity in the lungs.  In the case of both studies, mice administered MMS350 in the drinking 
water showed lower degrees of luciferase activity in the lungs, which is indicative of a lower 
incidence of radiation fibrosis.  Preliminary data indicate that MMS350 is “downregulating the 
expression of VEGF and vWF, specifically in pulmonary endothelial cells.”171,172 Current 
research efforts are focused on gaining a better understanding of how MMS350 attenuates 
pulmonary fibrosis.  
2.2.2 Ongoing and Future Studies of MMS350 
We and our collaborators are planning more studies to elucidate the role of MMS350 in 
radiation protection and mitigation.  We will study the impact of MMS350 on DNA repair; in 
this regard, we are pursuing a collaboration with Bevin Engelward at MIT, who has developed 
the CometChip, a high-throughput DNA repair analysis system. 
 
Testing of MMS350 on Fanconi D2 -/- mice is also planned.  We hope that the protective 
effects of MMS350 will translate to a decrease in side effects from radiation therapy on patients 
with impaired DNA repair mechanisms.   
 
As an extension of the work, MMS350 will be explored as an agent for reducing 
osteopenia.  Julie Glowacki at Brigham and Women’s Hospital developed a mouse model for 
wound healing.  The model involves administration of ionizing radiation to the legs of normal 
C57BL6 mice, which leads to delayed bone healing (likely due to reduced antioxidant reserves).  
It was shown that using JP4-039 was beneficial to wound healing in this mouse model.  Because 
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MMS350 showed similar efficacy in the radioprotective assays as JP4-039, it seems feasible that 
MMS350 could be useful for wound healing.  Successful results with MMS350 would be 
beneficial to military efforts because MMS350 can be administered in drinking water. 
 
2.2.2.1 Control Studies with MMS399 
I also developed a control analog to ascertain the need for MMS350 versus other 
sulfoxide-containing compounds. Tetrol 2-6 (MMS399) was generated by heating MMS350 with 
aqueous sulfuric acid (Scheme 2-7).  This compound did not show radioprotective effects 
relative to DMSO or the control (untreated) cells in the 32D cl 3 survival assay.   Recently, 
however, it was demonstrated that MMS399 is not a true negative control in vivo.   It should be 
noted that DMSO itself is not a radioprotector or mitigator for cultured cells.   
 
 
 
 
 
 
 
 
One hypothesis for the difference in activity between MMS350, MMS399, and DMSO is 
that the membrane permeabilities of the analogs lead to differing degrees of efficacy.  I decided 
to generate analogs of MMS350 to develop an understanding of the physical properties and 
structural requirements for radioprotection or mitigation of these bifunctional sulfoxide 
derivatives.  I turned to the synthesis of azetidine analogs 2-7 (Figure 2-3); variation would be 
introduced at the nitrogen in the 4-membered rings, thus altering the physical properties without 
making major changes to the overall conformation. 
 
 
Scheme 2-7. Synthesis of control sulfoxide MMS399. 
  
 104 
 
 
 
 
 
2.2.2.2 Azetidines as Modules in Medicinal Chemistry 
Along with oxetanes, azetidines have become an increasingly explored structural motif 
for use as bioisosteres.  Notably, Müller and Carreira have demonstrated the utility of spirocyclic 
azetidines as replacements for piperazines, piperidines, morpholines, and thiomorpholines 
(Figure 2-4).173 For example, the spirocyclic compound 2-9 exhibits lower intrinsic aqueous 
solubility and but also a lower logD (n-octanol/water distribution coefficient at pH 7.4) than the 
corresponding N-methylpiperazine 2-8.  Interesting, the analogous sulfone-containing 
compounds show a reversal in this trend, wherein the spirocyclic compound still has an 
improved aqueous solubility but also has a high logD value.  It was also demonstrated that 
replacing the piperazynl moiety on ciprofloxacin with a spirocyclic azetidine led to improved 
metabolic stability in human microsomal assays.173 The authors postulate that the more polar 
spirocyclic azetidine compounds may have fewer interactions with membrane-bound oxidizing 
enzymes (e.g., cytochrome P450), thus leading to less metabolic degradation. 
 
The replacement of the oxetanes of MMS350 with azetidines (i.e., Figure 2-5, 2-7) has 
Figure 2-4.  Comparative aqueous solubility and liphophilicity data for spirocyclic azetidines and  
the corresponding monocyclic scaffolds. 
Figure 2-3. General structure of azetidine analogs of MMS350. 
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several implications.  Azetidines introduce basic amine functions, and the basicity can be 
modulated by introduction of different N-substituents.  The pKa of azetidine is reported to be 
11.29, making azetidine essentially identical in basicity to pyrrolidine (pKa = 11.27) and more 
basic than dimethylamine (pKa 10.73).174  The pKa of azetidines is influenced by substituents; 
for example, the measured pKa of 2-11 is 6.7 wherease the pKa of the corresponding 6-
membered analog 2-10 is 4.0.173  However, the pKa values of the spirocyclic and piperidinyl 
analogs of 2-10 and 2-11 wherein the sulfone was replaced for a methylene group were identical 
(both 9.6).170  Furthermore, variation of the nitrogen substituents will allow for changes in the 
intrinsic aqueous solubility and membrane permeability.  Geometrically, azetidines have 
puckering angles similar to cyclobutane (35°);175,176 the azetidine analogs will therefore differ 
spacially from the relatively unpuckered oxetanes. 
 
 
 
 
 
 
 
 
2.2.2.3 MMS350 Analog Synthesis—Toward Bis-azetidines 
 It was envisioned that bis-azetidines 2-7 could be obtained by reaction of  activated tetrol 
2-12 with amines (Scheme 2-8).  The activated tetrol 2-12 would be generated from 2-6 
(MMS399), which is synthesized from MMS350.  As part of a strategy for convergent analog 
generation, the plan included synthesis of a common structure 2-7 where “R” would be a readily 
cleavable protection group (e.g., benzyl).  Analogs would be generated by alkylation or reductive 
amination.   
 
 
 Figure 2-5. Comparison of the conformation of azetidine (a) and oxetane (b). 
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Starting from tetrol 2-6 (MMS399), tetratosylate 2-13 was synthesized in modest but 
usable yield (Scheme 2-9).  Reacting tetratosylate 2-13 with benzylamine using reported 
conditions (e.g., DIPEA or K2CO3 in polar, aprotic solvents such as MeCN, DMSO, or DMF 
with thermal or microwave heating) did not lead to isolation of bisazetidine 2-14.  Instead, 
formation of a new, unidentified product that decomposed rapidly upon concentration in CDCl3 
was observed.  I tested whether the product came from intramolecular reactions of sulfoxide 2-13 
versus an intermolecular reaction with benzylamine; the tetratosylate was subjected to 
representative reaction conditions (DIPEA, MeCN, thermal or microwave heating) in the 
absence of benzylamine.  In this case, conversion of 2-13 to similar, unidentified products was 
observed (Scheme 2-9).  
 
 
 
I reasoned that the instability of tetratosylate 2-13 may be due to the presence of the 
sulfoxide functional group.  Intramolecular reaction of the sulfoxide and the activated methylene 
groups to generate 5-membered intermediates is possible. Additionally, the -protons adjacent to 
Scheme 2-8. Strategy for the synthesis of bis-azetidines. 
Scheme 2-9. Initial route toward synthesis of bis-azetidines. 
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the sulfoxide are acidic—Pummerer-type rearrangements may occur.  Therefore I hypothesized 
that starting from the corresponding sulfide would be a viable alternative. 
  
The corresponding tetratosylated sulfide 2-15 (Scheme 2-10) was synthesized using by acid-
mediated opening of bisoxetanyl sulfide 1-69 followed by global tosylation to afford tetratosylate 
2-16 in moderate yield.  Subjecting 2-16 to representative reaction conditions (DIPEA, MeCN, 
microwave heating) in the absence of amine afforded starting material, indicating that sulfide 2-
16 is stable to the basic, thermal conditions. 
  
At this point, I changed strategies and use anilines rather than primary amines in the initial 
condition screening for bis-azetidine formation. I reasoned that the corresponding azetidine 
products would be more stable to standard purification conditions (e.g., silica-gel 
chromatography).  I also envisioned using the p-methoxyphenyl group as a protecting group that 
would be cleaved under oxidizing conditions (e.g., CAN or H5IO6).
177   
  
The synthesis of azetidines from sulfide 2-16 is shown in Scheme 2-10.  Sulfide 2-16 was 
treated with K2CO3 and aniline and subjected to microwave heating in acetonitrile at 140 C for 
1 h.  Gratifyingly, the desired bis-azetidine sulfide was isolated in 24% yield.  Byproducts 
including the corresponding mono-azetidine and a hydrolyzed azetidine were also identified (by 
LCMS analysis of the crude reaction mixture). Performing the same reaction under thermal 
conditions (MeCN, 100 C, overnight) also afforded the desired product 2-17 in 13% yield. 
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The yield of the bis-azetidine formation was improved by increasing the electrophilicity of 
the neopentyl- methylene groups (Scheme 2-11).  Initially, tetrabrosylated sulfide 2-20 was 
synthesized using the same conditions as the tetratosylation protocols (BsCl, KOH, 20% 
DMF/THF); however, these conditions afforded the tetrabrosylate 2-20 in consistently low yield 
(ca. 20%).  After screening alternative conditions, I found that phase-transfer conditions afforded 
the tetrabrosylate 2-20 in 36% yield (Scheme 2-11).  Reaction of the tetrabrosylate with aniline 
provided the desired bis-azetidine in 61% yield.  The p-methoxy- and p-bromo- analogs 2-21 and 
2-22 were also synthesized with the intent of further derivatizing the bis-azetidine scaffolds. 
 
  Scheme 2-11.  Synthesis of bis-azetidines using a tetrabrosylated sulfide. 
 Scheme 2-10. Synthesis of bis-azetidines from sulfide 1-69. 
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I planned to use p-methoxyphenyl (PMP)-protected bis-azetidine 2-21 for further 
diversification of the scaffold.  Sulfide 2-21 was oxidized to the corresponding sulfoxide 2-23 
with H2O2 in acetic acid (Scheme 2-12).  Optimization of the sulfide oxidation protocol is in 
progress.  Conditions for removal of the PMP-group will be screened.    
 
 
 
 
 
 
 
 
 Bis-azetidine formation was also accomplished using benzylamine and p-
toluenesulfonamide as nucleophiles (Scheme 2-13).  In the case of p-toluenesulfonyl-substituted 
azetidines, sulfide 2-25 was smoothly oxidized to the corresponding sulfoxide 2-26  and isolated 
in good yield after an aqueous workup with NaHCO3.  In the case of the alkyl (benzyl) 
substituted sulfide 2-27, oxidation afforded sulfoxide 2-14 in low yields due to loss of material in 
the aqueous layer.  Further optimization of the workup protocol (e.g., using aqueous NaOH 
instead of aqueous NaHCO3) to facilitate isolation of 2-14 is in progress. In the case of either 2-
26 or 2-14, deprotection of the bis-azetidines by detosylation of 2-26 or debenzylation of 2-14 
would allow for access to common intermediate 2-24.   
 
 
 
 
 
 
 
 
 
Scheme 2-12. Sulfide oxidation and future plans for protecting group removal. 
Scheme 2-13. Synthesis of bis-azetidines with tosyl and benzyl substituents. 
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Carreira and coworkers have demonstrated that the oxalate salts of azetidines are easily 
derivatized by reductive amination,173  Buchwald-Hartwig cross-coupling reactions,178  or 
acylation reactions179 (Scheme 2-14).  These reactions may be used to introduce diversity into 
the scaffold of bis-azetidine 2-24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3 Calculated Membrane Permeabilities of MMS350 and Analogs 
The therapeutic efficacy of DMSO, MMS350, and related analogs may depend on both 
cellular and mitochondrial membrane permeability.  To gain an understanding of the relationship 
between analog structure and membrane permeability, calculations were performed using 
QikProp software (Table 2-2).  The permeability of DMSO, MMS350, MMS399, and a series of 
bis-azetidinyl MMS350 analogs (Figure 2-6) were compared, and the results are shown in Table 
2-2. 
Scheme 2-14. Precedented methods for functionalizing azetidines. 
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Based on these calculations, it is apparent that MM350 is slightly more peremable than 
DMSO, whereas the permeability of the corresponding sulfone 1-71 is calculated to be 
significantly better in the case of Caco-2 cell permeability but comparable to MMS350 and 
related analogs in the case of MDCK cell permeability.  As expected, the permeabilities of tetrol 
MMS399 and bis-tosylate 2-26 are much lower than those of DMSO, MMS350, and the related 
bis-azetidine analogs.  It should be noted that the samples were all calculated as neutral 
molecules, and therefore the differences in pKa and consequent differences in protonation state 
of the aniline-based azetidine 2-23 and bis-benzylated azetidine 2-14 were not taken into 
account.  It is notable that the free bis-azetidine 2-28 has lower calculated permeabilities than 
MMS350 and the substituted bis-azetidines.  These values may be used (in conjunction with 
relevant experimental data) as a means of rationalizing differences in experimental efficacies 
among vastly different functional groups (e.g., free azetidine versus alkyl azetidine versus 
tosylated azetidine versus oxetane).  The calculated values do not indicate that any large 
differences in membrane permeabilities are achieved by varying the substituents on the bis-
azetidine sulfoxide analogs. 
 
Figure 2-6.  Compounds compared for calculated membrane permeabilities. 
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Table 2-2. Calculated membrane permeabilities for DMSO, MMS350, and related analogs. 
 
 
 
Entry 
 
Compound 
 
QPPCaco (nm/s)a,b 
 
QPPMDCK (nm/s)a,c 
 
 
1 
 
DMSO 
 
146 
 
2860 
 
2 
 
MMS350 
 
246 
 
3589 
 
3 
 
MMS399 
 
6 
 
71 
 
4 
 
1-71 
 
4248 
 
2362 
 
5 
 
2-14 
 
243 
 
3564 
 
6 
 
2-23 
 
232 
 
3341 
 
7 
 
2-26 
 
22 
 
264 
 
8 
 
2-28 
 
54 
 
711 
 
9 
 
2-29 
 
184 
 
 
2638 
aData were generated using QikProp, version 3.1, Schrödinger, LLC, New York, NY, 2008.  The 
following parameters were used for structure minimization: 
Forcefield: OPLS; solvent: water; electrostatic treatment: constant dielectric; dielectric constant: 1.0; 
Method: PRCG, 500 iterations, converged on energy. 
Further explanations of the QikProp calculations180 and correlations between experimental and predicted 
values181 are documented in the literature. 
b The calculations represent predicted Caco-2 cell permeability, which is typically used to model passage 
through the blood-gut barrier.182 
cThe calculations represent predicted MDCK (Mdin-Darby canine kidney) cell permeability, which is 
typically used as a general model to predict passive diffusion through cell membranes.183 
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2.3 CONCLUSIONS 
The Wipf group has developed effective small molecules for radiation protection and 
mitigation.  Efforts have focused on the design of E-alkene isostere hemigramicidin S conjugates 
for the targeted delivery of nitroxides to the mitochondria.  The bifunctional sulfoxide MMS350 
was also tested in both cellular and animal studies for its efficacy as a radiation 
protector/mitigator.  MMS350 was both protecting and mitigating in cord blood assays and in 
vivo mouse studies.  Irradiated mice that were administrated MMS350 in their drinking water 
showed lower incidences of pulmonary fibrosis, a late-stage side effect of ionizing radiation 
damage.  The low toxicity and high aqueous solubility make MMS350 an attractive candidate for 
further studies.   
 
Currently, it is hypothesized that MMS350 is a nonspecific radiation protector/mitigator 
that prevents lipid peroxidation in the same manner as DMSO and other sulfoxides—that is, by 
scavenging ROS, particularly hydroxyl radicals.  The favorable effects of MMS350 may result 
from enhanced membrane permeability (relative to DMSO).  Current efforts are focused on 
understanding the mechanism of action of MMS350 as well as in the design and study of bis-
azetidinyl sulfoxide analogs. 
 
Possible mechanisms for the scavenging effects of MMS350 under physiological conditions 
are shown in Scheme 2-15.  Reaction of MMS350 with hydroxyl radical (analogous to the 
reaction with DMSO shown in Scheme 2-4) would generate the corresponding sulfinic acid 2-30 
and a radical 2-31r.  It is feasible that radical 2-31r may rearrange to form the corresponding 
captodatively stabilized methyl ether radical 2-32r; both 2-31r and 2-32r may be quenched with 
endogenous reducing agents (e.g., ascorbate or glutathione) to generate 3,3-dimethyloxetane 2-
31 or 3-methoxy-2-methylprop-1-ene 2-32.  Radical substation with superoxide radical anion 
may also occur, resulting in radical 2-31r (and consequently the proposed 2-32r) and 
sulfonoperoxide 2-33.  Sulfonoperoxide 2-33 may undergo an internal oxidation and rearrange to 
generate sulfonate 2-34.   
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Alternatively, reaction of MMS350 with superoxide radical anion may occur via an 
hydrogen atom abstraction pathway, generating alpha-sulfoxy radical MMS350-r and H2O2.  
Reduction with endogenous reducing agents would regenerate MMS350, which can react again 
with hydroxyl radical or superoxide radical anion.  MMS350 may also react with the hydrogen 
peroxide generated to produce sulfone 1-71.  Lastly, the alpha-sulfoxy radical MMS350-r may 
react with a second molecule of superoxide radical anion, generating peroxide 2-35 which can 
rearrange to form 2-36 and water. 
 
It would be useful to perform studies to a) ascertain if radical species such as those 
proposed in Scheme 2-15 are generated by reaction of MMS350 with ROS and b) determine the 
identity of the radical species formed.  Performing analogous assays to those described in 
Scheme 2-5 wherein MMS350 is substituted for DMSO may be a useful method for determining 
the nature of the species formed in the reaction of MMS350 and hydroxyl radicals.  Trapping 
studies with stabilized nitroxides (e.g., 2-4, Scheme 2-5) and analysis by mass spectroscopy 
would facilitate identification of the radical species formed. 
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Scheme 2-15. Proposed mechanisms for scavenging of ROS by MMS350. 
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3.0  NITROXIDE FUNCTIONALIZATION OF SILICA NANOPARTICLES 
       USING AN OXAZOLINE LINKER 
This section focuses on the design of covalently modified silica nanoparticles for the pH-
mediated release of nitroxides.  In Chapter 2, the use of hemigracidin S conjugates was 
discussed, namely the use of XJB-5-131 and JP4-039 in the mitochondria-targeted delivery of 
nitroxides to the mitochondria.  Herein, an alternative and perhaps complementary approach that 
relies on environmental stimuli (i.e., pH) for controlled release of nitroxides is described. 
 
A pH-responsive release mechanism is of interest for two reasons. Nanomaterials 
typically cross the cell membrane by phagocytosis or receptor-mediated endocytosis.   At this 
point, the nanomaterials undergo a number of biological processes involving vesicular coating, 
endosome development, and lysosome degradation.  Each stage is accompanied by changes in 
pH, providing an opportunity for pH-stimulated release of therapeutics.184 
 
Additionally, a pH-responsive nanoparticle may have specific benefits for delivering 
ROS scavengers.  Often, sites of acute trauma are associated with oxidative stress (i.e., ROS 
overproduction) and a drop in pH.185  This change in pH can be used as a way to ensure targeted 
delivery of the nitroxide ROS scavengers to sites where oxidative injury is occurring. 
 
In this chapter, the design strategy for pH-responsive silica nanoparticles is discussed.  
Properties and advantages of using silica are detailed, followed by an overview of current 
methods for achieving pH-mediated release of small molecules from nanoparticles.  The 
oxazoline is then introduced as a potential linker for achieving controlled release at acidic pH.   
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3.1 INTRODUCTION 
3.1.1 Nanoparticles in Drug Delivery  
The use of nanoscale materials—materials ranging in size from 1100 nm—has become 
an effective strategy for selective drug delivery.  Classes of nanoparticles include inorganic (e.g., 
gold nanoparticles), polymeric nanoparticles, liposomal nanoparticles and nanoparticles based on 
organic superstructures (e.g., dendrimers).186  Using nanomaterials for targeted drug delivery has 
several advantages. The small size of nanoparticles makes cellular uptake via pinocytosis 
possible, thus providing a means for cellular uptake and subsequent payload release. Moreover, 
use of nanoparticles allows one to modify the pharmokinetic properties of a chemical agent 
without chemically modifying the small molecule adjuvant itself. Because the relative size of the 
nanoparticles is much larger than the small molecule drugs, the physicochemical properties of 
the nanoparticle become dominant in vivo and thus provide a protective mechanism toward 
processes that would lead to loss of active material via diffusion, intracellular trafficking, or 
other mechanisms of degradation.  Additionally, nanoparticles can be modified to incorporate 
functional molecules for diagnostic purposes187 (e.g., fluorescent labels) or to contain specific 
targeting sequences.188 The large surface area of nanoparticles makes it feasible to design a 
system that will allow for targeted delivery of high doses of active molecules.186 The use of 
nanoparticles for drug delivery is a constantly expanding and evolving field.  Herein, the focus 
will be on the controlled release of small molecules from silica nanoparticles. 
3.1.1.1 Silica Nanoparticles for Drug Delivery 
Among types of nanoparticles, silica nanoparticles are one of the more well-
characterized.  Silica nanoparticles can be predictably and controllably synthesized to have 
specific sizes and morphologies using the sol-gel process189—a method first developed by  
Stöber in the late 1960’s.190 A typical sol gel synthesis of nanoparticles involves the reaction of 
tetraethoxysilane (TEOS) with an ammonium catalyst; the size and dispersity of the resulting 
nanoparticles are controlled by the reagent concentrations, temperature, and degree of aging.189 
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Silica nanoparticles are easily modified at the surface by condensation reactions with 
trialkoxysilanes (Scheme 3-1).  
 
Scheme 3-1. Typical modification of a silica surface by condensation with trialkoxysilanes. 
 
  
. 
  Commonly used silica structures include solid-sphere silica nanoparticles and mesoporous silica 
nanoparticles (Figure 3-1).  Mesoporous silica nanoparticles (MSNs) have porous structures 
lined with empty channels that can be used to encapsulate small molecules, and organic 
functionalization of the channels can modify the physical properties of the MSNs.  Typically 
used MSNs include SBA-15 particles (having pore sizes of 6 nm in diameter) and MCM-41 
(having pore sizes of 3 nm in diameter).191  
 
 
 
 
 
 
 
Solid-sphere silica 
nanoparticle
Mesoporous silica 
nanoparticle
Figure 3-1. Main types of silica nanoparticles. 
  
 119 
3.1.1.2 Biocompatibility of Silica Nanoparticles 
Biocompatibility is an essential feature for nanoparticle-based therapeutics. The toxicity 
and inherent biocompatibility of silica nanoparticles depends on size (and corresponding surface 
area) as well as the degree of surface functionalization—the primary source of silica nanoparticle 
toxicity is non-functionalized silanol groups on the nanoparticle surface.184  The effect of silica 
nanoparticles is also strongly dependent on cell type and method of administration. 
 
Hoet and coworkers investigated the toxicity of mono-dispersed solid-sphere silica 
nanoparticles on endothelial cells.192  Smaller nanoparticles generally exhibited higher toxicity.  
For example, the viability of endothelial cells (EAHY926 cells) exposed to 100 µg/mL 
concentrations of nanoscale silica particles (14–16 nm) decreased to between 10–23% whereas 
larger particles (104 and 335 nm) only reduced cell viability to below 50% when high 
concentrations ( > 1500 µg/mL) were used.192  This study of endothelial cells is of particular 
relevance to biodistribution of nanoparticles if the route of exposure is via injection—
nanoparticle entry into circulation would expose nanoparticles to endothelial cells.  
  
Studies comparing the toxicity of solid-sphere silica nanoparticles to mesoporous 
nanoparticles have been conducted.  Generally, mesoporous nanoparticles exhibit lower cellular 
toxicity, likely due to “caging” of exposed silanol groups within the pores of the “honeycomb” 
framework of mesoporous particles.   Moreover, Tao et al. found that functionalizing the surface 
of mesoporous silica nanoparticles with amino groups reduced the cellular toxicity toward Jurkat 
(human T-cell lymphoma) cells; however, various solid-sphere silica nanoparticles exhibited 
similar toxicities regardless of the extent of surface amination.193    
  
Lin and Haynes studied the effect of solid-sphere silica nanoparticles and mesoporous silica 
nanoparticles on red blood cells (RBCs).194 As in the case of the endothelial cells, smaller 
particles (24 nm and 37 nm) showed 50% cell lysis at low concentrations (8.8 µg/mL and 18 
µg/mL, respectively; 5.5 x 1011 and 3.1 x 1011 nanoparticles/mL, respectively).  Larger particles 
(142 nm and 263 nm) had reduced hemolytic activity (TC50 values of 94 and 307 µg/mL, 
respectively, correlating to 2.8 x 1011 and 1.5 x 1010 nanoparticles/mL, respectively).  As in the 
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case of the Jurkat cells, mesoporous silica nanoparticles that were similar in size to the solid-
sphere particles had significantly reduced hemolytic activity.   
 
The toxicity of silica nanoparticles is also highly dependent on the cell type studied.  For 
example, Chang et al. showed that normal human fibroblasts, which have a long doubling time, 
were more susceptible to silica nanoparticle toxicity than tumor cell lines, which have shorter 
doubling times.195  Additionally, the toxicity of silica nanoparticles depends strongly on surface 
modifications.  Singh and coworkers developed a bioresponsive mesoporous silica nanoparticle 
coated with a (PEG)-based polymer shell.  The polymer not only attenuated the toxicity of the 
particles but also served as a stimuli-responsive “shell” that was degraded upon interaction with 
proteases at tumor sites, thus allowing for a targeted release of therapeutics.196   
 
Despite the reported cellular toxicity of solid-sphere silica nanoparticles, biocompatibility 
has been demonstrated.  For example, fluorescein isothiocyanate (FITC)-labeled silica 
nanoparticles of both 30 nm and 100 nm diameters were taken up by endothelial cells, 
specifically the human umbilical vein endothelial cells (HUVEC) cell line.  Cell viability was 
higher than 91% even at concentrations of 1 mg/mL of nanoparticles.197  Barandeh et al. also 
demonstrated that rhodamine functionalized solid-core silica nanoparticles averaging 20 nm in 
size were incorporated into neuronal tissues of both larval and adult Drosophila melanogaster; 
no deleterious effects on neuronal signaling pathways or premature cell death was observed.198  
Hu et al. report that the toxicity of silica nanoparticles to liver (HepG2) cells is low; as part of the 
same study, they also demonstrated that FITC-doped silica nanoparticles did not adversely effect 
the cell cycle in HepG2 cells.199 
  
The work described above represents only a small fraction of studies evaluating the 
biocompatibility of silica nanoparticles;184 it is apparent that the toxicity of silica nanoparticles is 
dependent on size, surface functionalization, and the cell type being affected.  The collective 
literature data may be used as a predictive tool for designing biocompatible silica nanoparticles, 
but it is still necessary to evaluate the toxicity of particular nanoparticles on a case-by-case basis. 
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3.1.1.3 Biodistribution of Silica Nanoparticles 
The fate of silica nanoparticles in vivo is still an area of active research.  The biodistribution 
of three types of 45-nm RuBPY dye-doped silica nanoparticles (non-functionalized, carboxy-
functionalized, and PEG-modified) was studied.200   The particles were administered to mice via 
iv tail vein injection, and the particles with free hydroxy groups and carboxy groups were cleared 
from the circulation (t1/2 80  30 min and t1/2 35  10 min, respectively) within 3 h of injection, 
accumulating mostly in the liver, urinary bladder, and kidney.  In contrast, the PEG-terminated 
particles had longer circulation times (t1/2 180  40 min).  The accumulation of particles in 
organs involved in urine excretion indicates that silica particles may be partially cleared via renal 
pathways in vivo.  The authors did detect intact nanoparticles in the mouse urine.  The 
phenomenon of accumulation in renal organs and partial excretion in the urine has been 
corroborated by studies of the biodistribution of mesoporous silica nanoparticles.201-203  It should 
be noted, however, that preferential accumulation in tumor cells has also been observed.203 
3.1.1.4 Endocytosis of Silica Nanoparticles 
The uptake of nanoparticles into cells can be achieved either by general phagocytosis or 
receptor-mediated endocyctosis (Figure 3-2).  In either case, it is generally thought that the inner 
cellular membrane engulfs the particle, forming an early endosome.  From here, fusion with 
lysomes containing hydrolytic enzymes will aid in the degradation of particles. Alternatively, 
particles that are not degraded may undergo exocytosis.184,186  Detailed studies performed by Hu 
and coworkers showed that FITC-doped silica nanoparticles (ranging in size from 60 nm to 600 
nm) undergo a clathrin-mediated endocytosis.  The hypothesis was supported by the observation 
that treating cell media with sucrose and amandatine-HCl decreased cellular uptake.199 It is also 
documented that the extent of cellular uptake amount is dependent on particle size.  In the case of 
nanoscale particles, surface functionalization and subsequent charge distribution can influence 
the mechanism of cellular uptake.184 
 
The overall fate of nanoscale materials after cellular uptake is still an area of ongoing 
research.  In the study by Hu et al.199 cellular fluorescence decreased over time, indicating 
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exocytosis did occur.  The rate and extent of particle exocytosis is also postulated to be a size-
dependent phenomenon, wherein larger particles are less likely to be removed from the cells.199  
The intracellular trafficking of discoidal silicon particles was studied by Serda et al.204 They 
showed that both 10- and 30-nm chitosan-coated silica particles crossed the endosomal 
membrane. 
 
  
 
Figure 3-2. General endocytotic pathways for nanoparticles (in this case, MSNs) in mammalian cells.   
Reprinted with permission from Asefa, T.; Tao, Z. Biocompatability of Mesoporous Silica 
Nanoparticles. Chem. Res. Toxicol. 2012, 25, 2265-2284.  Copyright 2012 American Chemical 
Society. 
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3.1.1.5 Use of Nanoparticles to Deliver Antioxidants 
The use of nanoparticles to scavenge ROS or RNS is an active area of research.205 
Several types of inorganic nanoparticles inherently act as antioxidants, even without surface 
modification.  For example, some ceria and yttria nanoparticles mimic the activity of superoxide 
dismutase (SOD) and catalase (CAT).206,207 These effects are dose-dependent; in fact, some 
particles that scavenge ROS are also shown to generate ROS.   
 
Conjugation of antioxidants such as Vitamin E to gold nanoparticles has been 
accomplished by self-assembly of thiol ligands derived from Trolox 3-2, an analog of -
tocopherol 3-1 (i.e., vitamin E) on gold nanoparticles (Figure 3-3).208 Radical scavenging 
abilities of the nanoparticle-bound Trolox (3-3) were greater than those for Trolox itself.  
Additionally, nanoparticle encapsulation is often used to improve the pharmokinetic properties of 
poorly soluble antioxidants.  A curcumin nanoparticle system generated by coprecipitation of 
curcumin 3-4 and polyvinylpyrrolidone exhibited enhanced antioxidant properties in comparison 
to curcumin itself.209  A similar strategy was used to improve the pharmokinetic properties of 
poorly soluble quercetin 3-5—encapsulation in poly-D,L-lactide (PLA) nanoparticles improved 
the physicochemical properties of this compound; however, no difference in antioxidant activity 
was observed for the PLA-bound quercetin versus nonencapsulated quercetin.210 
 
Figure 3-3. Example antioxidant molecules delivered using nanoparticle systems. 
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3.1.2 Stimuli-Responsive Nanoparticles and Strategies for pH-Mediated Release 
 The antioxidant 4-hydroxy-TEMPO (TEMPOL) and other small molecule nitroxides 
are rarely used therapeutically due to their short blood circulation times and rapid, nonspecific 
bioaccumulation.185 Incorporation of TEMPO into a nanoparticle would improve the 
pharmokinetic properties. Because TEMPO is also a spin label, TEMPO-functionalized 
nanoparticles may have additional utility for in vivo diagnostics.  In this next section, strategies 
for controlled release of therapeutics are discussed, emphasizing pH-mediated release.  Specific 
examples related to TEMPO-functionalized nanoparticles are highlighted. 
3.1.2.1 General Strategies for pH-Mediated Release 
Strategies for stimuli-responsive release in vivo include chemical or physical changes in 
response to variations in temperature, redox state, or enzymatic reactions.  Alternatively, external 
“triggers” such as photo-irradiation or magnetic force can be used.191   
 
 Designing nanoparticles for pH-mediated release of therapeutics is an attractive 
medicinal strategy.  Health aberrations including ischemia, infection, and inflammation are often 
accompanied by low pH conditions; moreover, oxidative stress injuries related to stroke, 
myocardial infarction, and acute kidney failure often result in lowering of physiological pH 
around the site of injury.185,211  In these cases, release of therapeutics, particularly antioxidant 
therapeutics, in response to a low pH environment would lead to tumor or injury-specific 
targeting. 
 
In terms of intracellular targeting, a pH specific release of an organelle-specific 
therapeutic may be a viable strategy.  Often, endosomal capture and disintegration of 
nanoparticles is a major problem to be overcome when designing nanoparticles for cellular 
uptake.  Yet, one can take advantage of the differential pH in the endosomes and design covalent 
linkers or self-assembling polymers that specifically degrade under the low pH conditions, thus 
releasing chemical therapeutics into the cytosol.   
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3.1.2.2 pH Responsive Polymers 
 Selective protonation of polymeric materials under acidic conditions is a strategy for 
stimuli-responsive drug release.  For example, Qiu et al. showed that amphiphilic 
polyphosphazenes containing diisopropylamino (DPA) side chains disrupted endosomal 
membranes when protonated at pH 6.606.82.212 The polymers also attenuated P-gp efflux 
activity, making this drug delivery system particularly attractive for delivery of therapeutics to 
tumor cells that overexpress P-gp.  In a related example, polyplexes from poly(aspartamide) with 
1,2-diaminoethane side chains were shown to induce pH-dependent endosomal membrane 
destabilization (Figure 3-4).213   
 
 
 
 
 
 
 
 
 
 
Another strategy involves coating mesoporous silica nanoparticles with organic micelles that 
are disrupted at acidic pH.  He and coworkers used this approach for selective release of drugs to 
tumor cells that had an intrinsically lower pH than normal cells.214 Other examples of using pH-
responsive polymeric nanoparticles include a partially carboxymethylized pullulan nanoparticle, 
which showed faster release of doxorubicin at pH 5.0 than at pH 7.4 (in vitro).215  Finally, Sung 
et al. developed a pH-responsive nanoparticle composed of chitosan and poly(-glutamic acid) 
for release of insulin.216 They found that the particles adhere to the mucus layer of the small 
intestine, where the nanoparticles are then degraded and insulin is released.  They hope their 
research will eventually lead to an orally deliverable form of insulin.  
  
Figure 3-4. Examples of polymers used for construction of pH-responsive nanoparticles. 
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Ke and coworkers developed “smart” poly(D,L-lactic-co-glycolic acid) (PLGA) 
biodegradable hollow microspheres that were incorporated with NaHCO3.
217 When the 
microspheres enter an acidic environment (e.g., early or late endosomes/lysosomes of pH 6.0 or 
5.0, respectively), the NaHCO3 reacts with acid, which generates CO2 and disrupts the polymer 
“shell,” releasing the therapeutic agent.   
3.1.2.3  pH-Mediated Release via Cleavage of Covalent Bonds 
One example of controlling drug release via pH modification involves covalent cleavage 
of a boronate ester.  Gan et al. “capped” the pores of mesoporous silica nanoparticles by covalent 
linkage of a boronic acid, which was attached to an iron oxide nanoparticle (Figure 3-5).218 
Under acidic conditions, the boronate ester bond is cleaved, “uncapping” the pores and allowing 
for release of the drug (in this case, dexamethasone).218  Use of a boronate ester as an acid-
cleavable linker was also used to “cap” mesoporous silica nanoparticles with boronic acid-
functionalized gold nanoparticles.219  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5. pH-Responsive cleavage of boronate esters for release of therapeutics. 
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3.1.2.4 pH Responsive Nanoparticles for Delivery of Nitroxides 
 Yoshitomi and coworkers have developed a pH-responsive nanoparticle for delivery of 
4-amino-TEMPO.185,211,220   They covalently attached TEMPO to the hydrophobic segment of an 
amphiphilic block copolymer (Figure 3-6).  The polymers self-assemble to generate 
biocompatible nanoparticles (~50 nm in diameter) that show longer blood circulation times (ca.  
2 h) than free TEMPOL (t1/2 ca. 15 s) and related derivatives.  They hypothesized that 
protonation of the amine of 4-amino TEMPO at low pH (6.0) results in disintegration of the 
polymer structure, exposing the nitroxide to the environment and allowing for detection by EPR 
spectroscopy.185 Therefore, they postulated that these nanomaterials could be used to probe for 
low pH conditions (e.g., ischemia) in vivo.  These functionalized particles could also be used 
therapeutically to target areas where a decrease in pH is associated with oxidative stress.  For 
example, Yoshitomi and coworkers confirmed that these nanoparticles disintegrated in ischemic 
brain areas after cerebral ischemia-reperfusion.220  They also demonstrated the utility of these 
particles in a renal ischemia-reperfusion acute kidney injury model in mice.211  
 
 
Figure 3-6. pH-Responsive polymeric nanoparticles for selective delivery of nitroxides. 
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3.1.3 Oxazolines as pH-Controllable Linkers 
Oxazolines (4,5-dihydrooxazoles) are planar structures and are weakly basic.  Oxazolines 
are hydrolyzed in acidic, aqueous solutions to afford -amino alcohols and carboxylic acids 
(Figure 3-7).174   
 
 
 
 
  
Oxazolines are present in several marine natural products including westiellamide126,133 and 
the dimeric versions of westiellamide with improved silver-complexing affinities (Figure 3-8).221  
Moreover, oxazolines can serve as precursors to the related thiazolines using thiolysis protocols.  
For example, Wipf and Venkatraman performed an oxazoline-to-thiazoline transformation in the 
synthesis of ()-Thiangazole,222 and Wipf and Uto applied an oxazoline-to-thiazoline conversion 
for the synthesis of the marine metabolite Trunkamide A .223  The metal-chelating capabilities of 
oxazolines have also been widely exploited in the context of using dimeric oxazoline ligands 
(e.g., PyBOX, tBuBOX and pHBOX) for transition metal-mediated reactions.224,225 
 
  
 
 
 
 
 
 
 
   Figure 3-8. Natural products containing oxazolines or prepared by reactions of oxazolines. 
Figure 3-7.  General structure of an oxazoline. 
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3.1.3.1 Oxazolines in Medicinal Chemistry and Use as Prodrugs 
Oxazolines can be cleaved under acidic conditions to afford carboxylic acids; therefore, 
they are often used as masking groups for acids.  Despite the predicted metabolic instability of 
oxazolines in acidic environments, oxazolines are still incorporated into medicinal chemistry 
discovery intiatives.  For example, Mycobactin S (3-9) (Figure 3-9) a natural iron chelator, was 
used as the basis for designing anti-tuberculosis agents derived from both oxazoline and oxazole 
benzyl esters.226  Oxazolines had inferior activity than the corresponding oxazoles for inhibition 
of M. tuberculosis H37RV in a fluorometric anti-tuberculosis assay.   
 
Another way to take advantage of oxazoline hydrolysis is to use these heterocycles as 
pro-drugs and acid-cleavable linkers. Heterocycles related to oxazolines, namely 
oxazolidinines227 and oxazolidinones228 (e.g., 3-10 and 3-11, Figure 3-9) have been evaluated for 
use as pro-drugs.  A pH profile for the rate of hydrolysis of oxazolidine 3-10 at 37 C was 
obtained; it was discovered that the rate of hydrolysis of oxazolidine 3-10 was highest at pH 5.5.  
The corresponding 4,5-trans-fused oxazolidinine was optimally hydrolyzed at pH 4.0.227 
Oxazolidinones such as 3-11 were also investigated as possible pro-drugs.  Compound 3-11 was 
hydrolyzed at pH 7.4 (0.1 M phosphate buffer); the half-life of compound 3-11 was 4.1 min.  
The rate of hydrolysis of 3-11 in human plasma (pH 7.4, 37 C) was about 4-fold faster (t1/2
 = 1.0 
min).  The trend of enhanced hydrolysis in human plasma versus phosphate buffer was observed 
among a series of oxazolidinones; the authors concluded that enzymes in the plasma facilitated 
oxazolidinone hydrolysis.228  
 
 
 
 
 
 
 
 
 
  Figure 3-9. Oxazolines, oxazolidines and oxazolidinones studied as potential pro-
drugs. 
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3.1.3.2 Methods for Preparation of Oxazolines 
Oxazolines can be prepared by reaction of nitriles with amino alcohols.229,230  
Alternatively, oxazolines are prepared by cyclodehydration of -hydroxy amides after activation 
of the alcohol with reagents such as SOCl2 or TsCl.  Methodologies developed in the Wipf group 
include cyclodehydration reactions using Burgess Reagent231,232  or DAST233 (Scheme 3-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.3.3  Oxazolines as Acid-Cleavable Protecting Groups and Linkers 
The use of oxazolines as protecting for carboxylic acids is well-precedented.  Typical 
examples illustrating cleavage of oxazolines to carboxylic acids are shown in Scheme 3-3.  The 
oxazoline in 3-16 was hydrolyzed under acidic conditions to the corresponding -amino ester 3-
17.  The resulting ester was then saponified under standard conditions (1 N aqueous NaOH) to 
afford acid 3-18.  Forcing acidic conditions (e.g., refluxing 6 N aqueous HCl) can be used to 
generate the carboxylic acid directly—for example, oxazoline 3-19 was converted to acid 3-20 
and aminoalcohol 3-21 (Scheme 3-3).   The stepwise oxazoline-opening/ester saponification 
pathway (e.g., conversion of 3-16 to 3-18 via 3-17) is more commonly used due to a wider 
substrate and functional group tolerance to the milder conditions. 
Scheme 3-2. General methods for oxazoline synthesis using cyclodehydration methods. 
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The rate of acid-mediated oxazoline hydrolysis depends on oxazoline substitution, 
particularly the substitution at the 2-position.  Typically, oxazolines with alkyl substituents at the 
C-2 position are hydrolyzed more quickly than oxazolines with aryl substituents at the C-2 
position, and electron density and hydrolytic proclivity are positively correlated.  The 
substitution-dependent hydrolysis of oxazolines was used in the synthesis of actinoidic acid 
derivatives; the t-butyl-substituted oxazoline in 3-22 was preferentially cleaved in the presence 
of the the 3-5-dimethoxy aryl oxazoline in the substrate, affording 3-23.234 
 
 
 
 
 
 
Scheme 3-4. Selective hydrolysis of a 2-alkyl-substituted oxazoline in the presence of a 2-aryl-substituted 
oxazoline. 
Scheme 3-3. Acidic cleavage of oxazolines to afford carboxylic acids. 
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Another example of synthetic utilization of oxazoline hydrolysis was demonstrated byWipf 
and Miller; in this case, oxazoline hydrolysis facilitated the interconversion of threonine and 
allo-threonine residues.235  A general mechanism for the oxazoline hydrolysis is shown in 
Scheme 3-5.  Acid-facilitated addition of water to the oxazoline 2-position of 3-24 generates 
hydrated intermediate 3-25.  At acidic pH, the intermediate 3-25 opens to the -amino ester 3-26.  
If the pH of the medium is raised by adding base (e.g., K2CO3), an ON acyl shift occurs to 
afford -amino amides such as 3-27.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The use of an oxazoline as a linker for solid-phase synthesis of carboxylic acids has been 
reported.236  Colwell et al. synthesized polymer-bound oxazolines 3-28 and 3-32 using 
chloromethylated poly(styrene-co-divinylbenzene (Scheme 3-6).  The polymer-bound oxazolines 
were derivatized by alkylation after deprotonation with n-butyllithium.  Hydrolysis with either 3 
N HCl/THF or H2SO4 in EtOH afforded acid 3-31 or ester 3-35 and the corresponding resin-
bound amino alcohols 3-30 and 3-34.  The authors found that the resin-bound amino alcohols 3-
30 and 3-34 could be recycled to regenerate polystyrene bound oxazolines 3-28 and 3-32.  
Moreover, an investigation of the relationship between oxazoline substitution and hydrolytic 
Scheme 3-5. Hydrolysis of oxazolines and subsequent O-N acyl shift. 
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proclivity was performed (Scheme 3-6).   In general, oxazolines substituted with smaller alkyl 
chains were hydrolyzed more quickly that those with more sterically hindered alkyl groups, thus 
indicating that steric encumbrance slows oxazoline hydrolysis.  
 
 
Based on the precedents for using oxazolines as acid-cleavable linkers, it was envisioned 
that an oxazoline could be used for pH-mediated release from a nanoparticle scaffold.  These 
studies are discussed in the next section. 
Scheme 3-6. Oxazolines as polystyrene-supported linkers for synthesis of acids and esters. 
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3.2 RESULTS AND DISCUSSION 
3.2.1 Nanoparticle Design 
The goal of the project is to develop a nanoparticle-based delivery system for reactive 
oxygen species (ROS) scavengers—namely molecules containing TEMPO.  The overall design 
strategy is depicted in Figure 3-10.  Silica nanoparticles were used as the initial nanoparticle 
system.  A discussed in section 3.1.1.1, silica nanoparticles are well-characterized and can be 
predictably generated to have particular sizes and properties—commercial samples of 
monodisperse silica nanoparticles averaging 1015 nm in size were purchased from commercial 
vendors (Nissan Chemical). More significantly, the ease of surface functionalization by 
condensation with trialkoxysilanes made it feasible to attach organic molecules in a covalent 
manner.   
 
The silica nanoparticles were elaborated with a spacer, which was further reacted with a 
molecule containing a hydrolytically labile linker—in this case, an oxazoline.  The oxazoline 
was attached to a payload ROS scavenger—in this case, TEMPO. 
 
 
  Figure 3-10. General strategy for nanoparticle functionalization. 
  
 This strategy was implemented using both phenyl-substituted and fluorescein-substituted 
imidothiolates 3-40 and 3-41 (Scheme 3-7).  The imidothiolates were synthesized by alkylation 
of the corresponding thioureas 3-42 and 3-43 with benzylic chloride 3-44.  Benzylic chloride 3-
44 was chosen as the initial alkylating agent due to ease of synthesis from commercially 
available materials and the facile incorporation of TEMPO via an amide linkage to the oxazoline.  
Advantages to this strategy include the convergent nature and the ability to incorporate a 
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fluorescent or UV-active moiety on the thiourea spacer.  In the following sections, the synthesis 
of alkylating agent 3-44 as well as the methods by which 3-44 was attached to the thiourea-
elaborated silica nanoparticles are described. 
 
 
 
 
  
3.2.2 Synthesis of Benzylic Chloride 3-44 
The initial aim was to synthesize the oxazoline-elaborated benzylic chloride via a 
standard 4-step sequence (Scheme 3-8).  Acylation of 4-chloromethylbenzoyl chloride 3-45 with 
dl-serine methyl ester hydrochoride afforded -hydroxy amide 3-46.  Cyclodehydration using 
Burgess reagent232 provided oxazoline methyl ester 3-47 in good yield.  Saponification of methyl 
ester 3-47 to generate the corresponding acid 3-48 was attempted, and the acid would then be 
coupled with 4-amino TEMPO using a standard procedure (i.e., EDCI, HOBT); however, this 
protocol resulted in varying yields.  One problem was that HOBT displaced the benzylic chloride 
to generate byproduct 3-49. The reaction was further complicated by the acid-sensitivity of the 
Scheme 3-7. Thiourea alkylation approach for nanoparticle functionalization. 
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oxazoline moiety—decreasing the pH during acidification often resulted in oxazoline opening 
and diminished yields.  
 
Scheme 3-8. Synthesis of benzylic chloride 3-44. 
 
 
 
 
Alternative procedures for amide bond formation were screened. A one-pot saponification-
amide bond formation was used to preclude the need for acidification during the conversion of 
the methyl ester to the acid.  Reagents activating the carbonyl via formation of active 
nucleofuges resulted in displacement of the benzylic chloride—for example, using the Goodman 
reagent (3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one, DEPBT) afforded the 
corresponding benzylic 3-oxy-1,2-3-benzotriazin-4(3H)-one.  Use of DPPA yielded the 
corresponding benzyl azide 3-50 in excellent yield—this result proved to be advantageous during 
the second nanoparticle functionalization approach (section 3.2.5).   
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Because the problematic substitution of the benzylic chloride was observed, 
halotripyrrolidinophosphonium hexafluorophosphates PyBroP and PyCloP were used.237  In the 
case of these reagents, the driving force for amide bond formation is expulsion of 
tripyrrolidinophosphine oxide; it is assumed that the amide bond forms directly from a reaction 
of an amine (e.g., 4-aminoTEMPO) with the acyloxyphosphonium salt.  PyCloP was stable to the 
buffered conditions (DIPEA and NaHCO3) and using this reagent reproducibly afforded the 
desired products in good yields. 
 
 
 
 
 
 
 
 
 
 
  
Scheme 3-10. Amide bond formation using halotripyrrolidinophosphonium hexafluorophosphates. 
Scheme 3-9. Synthesis of TEMPO-coupled benzylic azide 3-50. 
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To generate the thiourea-functionalized silica nanoparticles, 3-aminopropyl-elaborated silica 
particles 3-51 were synthesized by stirring a suspension of silica nanoparticles (10–15 nm) with 
3-aminopropyltriethoxysilane (Scheme 3-11).  A batch of 3-aminopropyl silica nanoparticles 3-
51 was analyzed using Transmission-Electron Microscopy (TEM), and the average particle size 
was 14 ± 4 nm. (Figure 3-11)  The loading of the resulting amine was determined to be 0.5–0.8 
mmol/g by elemental analysis (N content).  The 3-aminopropyl functionalized particles were 
reacted with either phenyl or fluorescein isothiocyanate to afford the resulting thioureas.  
Quantitative conversion was not observed, but reasonable loadings of 0.290.43 mmol/g were 
obtained (measured by elemental analysis, S content). 
 
Figure 3-11. TEM image of 3-aminopropyl silica nanoparticles. 
20 nm
Scheme 3-11. Synthesis of thiourea-functionalized silica nanoparticles. 
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Because suitable precedents for alkylation of silica-supported thioureas were not 
documented, solution-phase conditions were screened (Table 3-1).  Using DIPEA in 2-MeTHF 
was an optimal protocol; however, nanoparticles 3-42 and 3-43 did not suspend well in THF 
(i.e., aggregation was apparent).  Therefore DMF was used as the solvent for the alkylation 
reactions. 
 
 
 
 
 
 
 
 
 
 
 
Entry 
 
Conditions 
 
Yielda 
 
 
1 
 
NaHCO3 (1.8 equiv), TBAI (20 mol%), DMF, 110 C, 1 h 
 
58% 
 
2 DIPEA (2 equiv), TBAI (40 mol%), THF, reflux, 2.5 h 58% 
 
3 DIPEA (2 equiv), TBAI (40 mol%), 2-MeTHF, reflux, 2.5 h 75% 
 
4 DIPEA (2 equiv), TBAI (40 mol%), MeCN, reflux, 2.5 h 66% 
 
5 DIPEA (2 equiv), TBAI (40 mol%), DMF, 110 ºC, 30 min         65%b 
 
aReported yields were determined by crude 1H NMR analysis using Ph3CH as an internal standard.  
bThe 
reported yield is an isolated yield after purification by chromatography on SiO2.  In a separate trial, the 
product was isolated in 61% yield. 
Table 3-1. Thiourea alkylation of a model system. 
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Once it was established that the thioureas could be alkylated in moderate to good yields, 
particle-bound thioureas 3-42 and 3-43 were subjected to alkylation conditions in DMF (Scheme 
3-12).  In general, a large excess of benzylic chloride 3-44 was used in relation to the thiourea 
particles, and the particles were heated with DIPEA and degassed DMF at 90 °C for 2 h. A major 
consideration was the detection of adsorbed versus covalently linked material; therefore, the 
particles were subjected to a rigorous washing procedure.  The particles were poured into 
EtOH/H2O (9:1), and the solution was centrifuged.  The sedimented particles were resuspended 
in the EtOH/H2O mixture two additional times, and then the sedimented particles were 
resuspended in degassed DMF at 90 ºC.  The particles were then subjected to another three 
rounds of resuspension and centrifugation in EtOH/H2O and then finally washed with absolute 
EtOH and dried.  A color change was noted in the particles after alkylation: thiourea particles 3-
42 are white in color, whereas imidothiolate particles 3-40 are pale orange in color.  Similarly, 
the fluorescein-substituted thiourea particles 3-43 are yellow, whereas the corresponding 
imidothiolate particles 3-41 are orange in color. 
 
The mass recoveries of particles after the centrifugation/resuspension procedures were 
not quantitative.  The average particle mass recovery in the case of converting phenyl-substituted 
thiourea particles 3-42 to imidothiolate 3-40 was 72%; the average mass recovery for conversion 
of fluorescein-substituted particles 3-43 to 3-41 was higher (87%).  Moreover, the unreacted 
benzylic chloride 3-44 could be recovered from the combined supernatants after aqueous 
extraction and silica-gel chromatography; the recoveries ranged from 34% to 65% of the original 
mass of benzylic chloride used in the reactions. 
  
 141 
 
 
Using elemental analysis alone for loading quantification of imidothiolates 3-40 and 3-41 
would be difficult due to the ambiguity of having nitrogen content from the unreacted amines 
and unreacted thioureas.  Moreover, elemental analysis does not allow for confirmation of 
identity.  Therefore, efforts were undertaken to quantify the loading of the imidothiolate particles 
by cleaving the material from the particles and quantifying the material using either LC-MS 
analysis.  
3.2.3 Assays for Determining the Loading of the Imidothiolate Particles 
Prior to evaluating the activity of particles 3-40 and 3-41 in cellular assays, I sought to 
develop an assay to unambiguously determine the loading and identity of the imidothiolate 
particles.  I envisioned treating the functionalized nanoparticles with Raney Ni or nickel boride 
to cleave the thioether linkage and afford the corresponding toluenic derivative 3-54 (Scheme 3-
13).  
 
 
 
Scheme 3-12. Alkylation of thiourea particles with benzylic chloride 3-44. 
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The possibility of cleaving the imidothiolate was first tested on model system 3-53; 
treatment of 3-53 with Raney Ni cleanly afforded the corresponding product 3-55.  Using nickel 
boride (NiCl2/NaBH4) also facilitated clean conversion to the corresponding toluenic derivative 
3-55 (Scheme 3-14). 
 
 
  
 
 
 
 
 
 
Independent synthesis of 3-54 for use as a standard for LC-MS analysis (Scheme 3-15) was 
carried out.  It seemed feasible that standard 3-54 could be synthesized by reduction of benzylic 
chloride 3-44 with Raney Ni.  Subjecting 3-44 to the reduction conditions resulted in a mixture 
of the hydroxylamine 3-54 and the free amine 3-56.  The free amine 3-56 could be obtained as 
the exclusive product after extended reaction times with Raney Ni.  To obtain a pure sample of 
the corresponding hydroxylamine, a 3-step sequence was employed.  Reduction of 3-44 with 
Raney Ni afforded a mixture of polar products 3-54 and 3-56.  Treatment of the mixture with 
Scheme 3-13. Proposed thioether cleavage strategy for loading determination. 
Scheme 3-14. Imidothiolate cleavage using Raney Ni on a solution-phase model system. 
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Cu(OAc)2H2O afforded a mixture of amine 3-56 and nitroxide 3-57.  The nitroxide was easily 
separated from 3-56 by chromatography on SiO2, thus separating the products with an N-H bond 
from products with an N-O bond.  Finally, reduction of purified 3-57 with ascorbic acid in 
MeOH afforded a pure sample of the hydroxylamine standard 3-54. 
 
Scheme 3-15.  Reduction of benzylic chloride 3-44; synthesis of standards for LC-MS analysis 
3.2.3.1 Reductive Cleavage and Loading Quantification  
Imidothiolate particles 3-40 were subjected to a range of reducing conditions using either 
Raney Ni in THF or NiCl2/NaBH4 in mixtures of EtOH and MeOH.  Conventional stirring was 
used at first, but sonication proved to be a more effective method for executing the solid/solid 
reaction.  In all cases, however, complex LCMS traces were obtained, precluding quantification  
of products 3-56 or 3-57.   
 
Part of the difficulty in obtaining useful LC-MS data was the fact that mixtures of N-H and 
N-O products are obtained after subjection of the niroxides to reducing conditions.   An 
alternative strategy was employed where  4-amino-TEMPO would be replaced with a UV-active 
amine; loadings would be quantified using UV/VIS spectroscopy (Figure 3-12).  It was assumed 
that the alkylation yield (i.e., loading) of reacting particles 3-42 with benzylic chloride 3-44 
would be comparable that that of reacting particles 3-42 with an analogous UV-labeled benzylic 
chloride. 
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A caveat to this approach was that the choice of chromophore could not bear groups that 
would be reduced under the imidothiolate cleavage conditions.  Therefore functional groups 
common to good chromophores such as nitrile and nitro groups had to be excluded from the 
design.  Compounds analogous to vanillin—i.e., compounds with electron-donating methoxy 
groups were chosen as a suitable starting point. 
 
To implement this strategy, methoxy-substituted amides 3-58 and 3-59 were prepared by 
standard coupling procedures (Scheme 3-16).  Although the UV/VIS properties were acceptable 
for 2,5-dimethoxy derivative 3-58, the solubility was poor in most organic solvents.  The more 
soluble piperonylamine derivative 3-59 was therefore used; this derivative also had favorable UV 
properties (283 = 14,600 M
-1cm-1; 264 = 17,700 M
-1cm-1 in THF). 
 
 
 
 
 
 
 
 
 
Figure 3-12. General strategy for loading assays using UV/VIS spectroscopy. 
Scheme 3-16. Synthesis of benzylic chlorides bearing chromophores. 
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Chromophore-labeled particles 3-60 were synthesized using analogous alkylation and 
washing protocols to those with alkylation of TEMPO-elaborated substrate 3-44.  Particles 3-60 
were suspended in EtOH/MeOH, treated with NiCl2 and NaBH4, and sonicated for 1 h.  After 
filtration and concentration in vacuo, the residue was taken up in THF and analyze by UV/VIS 
spectroscopy.  After comparison to a standard curve generated from THF solutions of 3-59, the 
loadings were calculated to be ca. 0.01 mmol/g. 
 
 
 
It was also a concern that the product particles from the alkylation procedures  may contain 
a mixture of covalently bonded imidothiolate particles as well as adsorbed benzylic chloride 
(e.g., 3-59).  I designed an experiment wherein toluene derivative 3-61 was reacted with thiourea 
particles 3-42 using the standard alkylation and washing procedures (Scheme 3-18).   The 
resulting particles were then subjected to the reductive “cleavage” conditions and analyzed by 
UV/VIS spectroscopy.  Surprisingly, the apparent “loading” values calculated were similar to 
that of particles 3-60.  Thiourea particles 3-42 were also subjected to the reductive cleavage 
conditions, and, after the standard workup, analyzed the residue by UV/VIS.  The absorbance 
values were again similar to those from performing reductive cleavage of particles 3-60.  
Because the loading values calculated for 3-60 did not differ from that of the control 
experiments, it was concluded that the reductive cleavage assay was not suitable for determining 
the loading of the imidothiolate particles.  
 
Scheme 3-17. Synthesis of chromophore-labeled imidothiolate. 
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Eventually, values obtained from elemental analysis of the imidothiolates were used to 
determine loading.  By calculating the loading based on nitrogen content after each step, the final 
loading of imidothiolate particles 3-40 was calculated to be 0.051–0.070 mmol/g.  The result was 
corroborated by results from our collaborators.238 Wei Hong Fang and Valerian Kagan measured 
the amount of nitroxide in 1 mg/mL of nanoparticles in phosphate buffer; the nitroxide 
concentration of 3-40 was 12 µM, and the nitroxide concentration of a suspension of 3-41 in 
phosphate buffer was 23 µM.   Within experimental error, these concentrations correspond to 
loadings of 0.012 mmol/g and 0.023 mmol/g, respectively; the calculated loadings based on 
measuring the nitroxide signal are in agreement with the calculated loadings based on elemental 
analysis.  The loadings were, however, too low for use in the planned ROS scavenging assays. 
 
Although the nitroxide loadings were low, were were interested to ascertain if imiothiolate 
particles would be viable for use in cellular assays.  Both phenyl-substituted and fluorescein- 
substituted imiothiolate particles 3-40 and 3-41 were analyzed for macrophage uptake.231,239  
RAW 264.7 macrophages were treated with uncoated nanoparticles, nanoparticles coated with 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or nanoparticles coated with 1,2-dioleoyl-sn-
Scheme 3-18. Control reductive cleavage experiments to validate the loading quantification experiments. 
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glycero-3-[phospho-L-serine](sodium salt) (DOPS).  The uptake of particles was measured by 
EPR spectroscopy, and the results are depicted in Appendix C.  It is apparent that silica 
nanoparticles coated with phospholipids were more readily taken into cells than uncoated 
particles; moreover, particles coated with charged phospholipid DOPS were more readily taken 
up by the macrophages.  
 
It should be noted that batches of particles 3-40 and 3-41 that were stored for several 
months showed much weaker EPR signals; moreover, our collaborators noted that these batches 
were more difficult to suspend in solutions.239 Based on both the qualitative and quantitative 
information, it was noted that the functionalized SiO2 particles degraded and/or aggregated upon 
prolonged storage.  It should also be noted that attempted alkylation of thiourea-functionalized 
particles 3-42 and 3-43 that were stored for prolonged periods did not yield the desired 
imidothiolate-functionalized nanoparticles.  These observations underscore the importance of 
using freshly prepared nanoparticles for both synthetic transformations as well as for biological 
evaluation. 
 
3.2.4 Efforts to Increase Nanoparticle Loading 
It was necessary to increase the nanoparticle loading prior to performing ROS scavenging 
assays. Attempts to improve the yield of the thiourea alkylation step were made by converting 
the benzylic chloride to alternative leaving groups. In doing so, the imidothiolate alkylation 
would be carried out at lower temperatures, which may suppress side reactions or decomposition 
of the imidothiolate thioether bond.   
 
I envisioned using benzylic alcohol 3-67 (Scheme 3-19) as a building block for the 
convergent screening of different leaving groups.  Attempts to convert the benzylic chloride 3-44 
directly to the alcohol (e.g., using AgNO3 and H2O) did not provide the desired product in 
acceptable yield. TBS-protected benzylic alcohol 3-66 was accessed through the synthetic 
sequence shown in Scheme 3-19.  
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Scheme 3-19. Synthesis of benzylic alcohol for leaving group studies. 
 
 
4-Bromobenzyl alcohol 3-61 was converted to the tert-butyldimethysilyl ether 3-62.  
Lithiation of the aromatic bromide followed by quenching with CO2 afforded acid 3-63.  Acid 3-
63 was converted to the -hydroxy amide 3-64 using standard peptide-coupling conditions with 
dl-serine methyl ester hydrochloride, and cyclodehydration using Burgess reagent provided 
oxazoline 3-64 in good yield.  Because the benzylic position of oxazoline 3-64 is no longer an 
electrophilic benzylic chloride, amide-bond formation using DPPA can be performed without a 
concern for side reactions with the azide.  Thus, a one-pot procedure involving saponification 
and azeotroping the sodium salt followed by treatment with DPPA and 4-amino-TEMPO was 
used to afford amide 3-66.  Removal of the TBS group using buffered TBAF afforded the 
desired alcohol 3-67, albeit in moderate yield.  Although a successful route to alcohol 3-67 was 
developed,  a leaving group screen was performed on a simpler model system. 
   
  The corresponding alcohol of oxazoline 3-65 was chosen as a test system for both 
incorporation of leaving groups as well as in the thiourea alkylation reaction. Using the methyl 
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ester 3-68 (Scheme 3-20) would still allow for evaluation of functional group compatibility with 
the oxazoline as well as use of 1H NMR analysis for evaluation of reaction mixtures.  
Deprotection of the silyl protecting group using buffered TBAF afforded alcohol 3-68.  The 
alcohol was converted to tosylate 3-69 using p-toluenesulfonylanhydride; notably, use of p-
toluenesulfonyl chloride resulted in complex reaction mixtures, likely due to reactions of 
chloride with the oxazoline ring. Trichloroacetimidate 3-70 was also synthesized using 
trichloroacetonitrile and DBU—the acetimidate was carried forward without purification.   
 
 
 
 
With substrates 3-69 and 3-70 in hand, the model thiourea alkylation was tested. The 
tosylated substrate 3-69 reacted with thioureas at room temperature, but the reaction was 
sluggish (times ca. 20 h), and the yields were variable (ca. 40-65%), likely due to the stability of 
the tosylate in DMF.  Alkylation of a model thiourea with trichloroacetimidate 3-70 using Lewis 
acids in CH2Cl2 was also attempted, but yields were moderate and further optimization would be 
needed.  At this point, the overall strategy was changed to functionalization using a click 
chemistry approach.  
Scheme 3-20. Synthesis of model substrates for variation of the benzylic leaving group. 
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3.2.5 Click Chemistry Approach for Nanoparticle Functionalization 
It was postulated that the low loadings from the thiourea alkylation strategy may be from a) 
the instability of the imidothiolates on the silica nanoparticles or b) the inefficiency of the 
alkylation reaction on the silica-supported thiourea. The approach was changed to a click 
chemistry strategy (Scheme 3-21).  Click chemistry leads to generation of a stable functional 
group (i.e., a triazole).  Although this approach would not allow for facile incorporation of a 
fluorescent tag, it was already established (via our collaboration with Wei Hong Feng and 
Valerian Kagan)231 that the distribution of nanoparticles in the cell could be quantified by EPR 
spectroscopy.  This strategy involved using azide 3-50 in a click reaction with a silica-supported 
alkyne 3-72. 
 
 
 
A viable route for the synthesis of azide 3-50 had been discovered in the course of 
optimizing the coupling of 4-aminoTEMPO to our original benzylic chloride substrate (Scheme 
3-9). A model alkyne was used to ensure that azide 3-50 was a viable partner for the 1,3-dipolar 
cycloaddition (Scheme 3-22).  The TBDPS-protected alkyne 3-75 was chosen to limit volatility,  
and it was synthesized by selective protection of 1-amino-3-propanol to provide requisite amine 
3-74 followed by coupling of 3-74 with 5-pentynoic acid using HATU (Scheme 3-22). 
 
 
Scheme 3-21. General strategy for functionalization using click chemistry. 
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 Several conditions for the click chemistry reaction were screened (Table 3-2).  Good yields 
of model triazole 3-76 were obtained when standard conditions were used (e.g., CuI, DIPEA, 
Table 3-2, entry 1).  Because the conditions need to be amenable for use in nanoparticle 
functionalization, organic-soluble copper reagents (PPh3)3CuBr
240 and P(OEt)3CuI
241 were 
screened.  Using P(OEt)3CuI afforded the model triazole in nearly quantitative yield (Table 3-2, 
entry 3); however, stoichiometric quantities were necessary for achieving high yields. 
 
 
 
 
 
 
 
 
 
 
Scheme 3-22. Synthesis of model alkyne. 
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Silica-supported alkyne 3-72 was synthesized by condensation with alkynyl triethoxysilane 
3-77 (Scheme 3-23), which was prepared by coupling of 3-aminopropyltiethoxysilane with 5-
pentynoic acid. Heating 3-77 at reflux with silica nanoparticles in toluene afforded alkyne-
functionalized particles 3-72. 
 
 The click chemistry reactions were first performed using 4-bromobenzyl azide (Scheme 
3-23); combustion analysis could be used to measure the bromine content in the particles.  This 
analysis would unequivocally provide an estimate of the expected loading using azide 3-50. The 
loading (0.28 mmol/g, based on %Br content) was sufficiently high for pursuing the click 
 
Entry 
 
Conditions 
 
Yielda 
 
 
1 
 
CuI (1 equiv), DIPEA (50 equiv) 
THF, rt, 15 h 
 
 
75% 
2 (PPh3)3CuBr (20 mol%), DIPEA (3 equiv) 
toluene, reflux, overnight 
 
44% 
3 P(OEt)3CuI (1 equiv), DIPEA 
toluene, 5 h, rt 
98% 
 
 
aThe reported yields reflect the amount of material isolated after silica-gel chromatography. 
Table 3-2. Click chemistry reactions using azide 3-50 and a model alkyne. 
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chemistry approach.  It should be noted that a similar loading (0.20 mmol/g) was obtained when 
the same reaction was performed at room temperature rather than reflux. 
 
 
 
After verifying the viability of the click chemistry approach, azide 3-50 was subjected to the 
click chemistry conditions (Scheme 3-24).  Based on nitrogen content, the loading was estimated 
to be 0.10 mmol/g.  The same reaction was performed at room temperature, and about 2-fold 
lower loadings (0.05 mmol/g) were obtained.  
 
Scheme 3-23. Synthesis of alkyne-functionalized nanoparticles and click chemistry using 4-
bromobenzylazide. 
Scheme 3-24. TEMPO-functionalization of silica nanoparticles using click chemistry. 
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Two batches of triazole functionalized particles 3-71 submitted to our collaborators for 
analysis of nitroxide content using EPR spectroscopy.242  The results are shown in Tables 3-3 
and 3-4.  Batch A refers to particles functionalized using click conditions at room temperature, 
and Batch B refers to particles functionalized using click conditions at reflux (Scheme 3-24). 
Particles were suspended in phosphate buffer, vortexed, and gently sonicated; EPR 
measurements were performed on aliquots of these suspensions.  Three experiments were 
performed on both batches: 1) the EPR signal was measured after sonication of the particles in 
phosphate buffer (Table 3-3) 2) the sonicated samples were centrifuged, and the EPR signals of 
the supernatant and the pellet were estimated (Table 3-4), and 3) the samples were not sonicated, 
and the suspensions in the buffer were centrifuged and the EPR signal of the supernatant and 
pellet were measured (Table 3-4). 
 
 
Table 3-3.  Nitroxide content of particles suspended in phosphate buffer. 
 
 
 
 
 
 
 
Entry 
 
Batch 
 
Amount of TEMPO 
measured 
(pmol/mg particles) 
 
 
Amount of TEMPO measured (+ K3Fe(CN)6  
(pmol/mg particles) 
 
 
1 
 
A 
 
608.7  63.3 
 
660.1  79.1 
 
2 B 1472.8  98.5 1454.5  86.8 
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Table 3-4. Nitroxide content of particles after both sonication and centrifugation. 
 
   
The data indicate that the majority of the nitroxide-containing compound is not immobilized 
onto the nanoparticles but rather may have been adsorbed and released upon sonication.  Our 
collaborators noted that the EPR spectra recorded was characteristic of an isotropically rotating 
molecule, also supporting the conclusion that the material was not immobilized.242 
3.2.5.1 Ugi Approach 
Attempts to use 3-aminopropyl-functionalized silica particles 3-51 as the amine in an Ugi 
reaction (Scheme 3-25) were made. An experiment using 3-bromobenzaldehyde 3-79 and 3-
iodobenzoic acid 3-80 to generate doubly labeled nanoparticles 3-79 was performed.  The 
presence of adsorbed 3-bromobenzaldehyde 3-79 or 3-iodobenzoic acid 3-80 would be evident 
by a discrepancy in the ratio of Br : I.  Based on elemental analysis, the loading (%Br content) 
 
Entry 
 
Batch 
 
Procedure 
 
Amount of TEMPO measured 
in supernatant (pmol/mg 
particles) 
 
Amount of TEMPO 
measured in the pellet 
(pmol/mg particles) 
 
 
1 
 
A 
 
I 
 
656.8  51.6 
 
374.8  42.2 
 
2 B I 1348.4  25.8 469.4  49.3 
 
3 A II 245.3  18.3 235.6  22.8 
 
4 B II 1332.8  54.8 1150.5  52.5 
 
Procedure I. Samples were vortexed and then sonicated in phosphate buffer and centrifuged (1000 xg for 
5 min, then 15,000 xg for 20 min).  Aliquots of the supernatant and pellet (after re-suspension in buffer) 
were taken for EPR measurements.  Procedure II.  Samples were vortexed (but not sonicated) in 
phosphate buffer and centrifuged (15,000 xg for 20 min).  Aliquots of the supernatant and pellet (after re-
suspension in buffer) were taken for EPR measurements. 
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wa calculated to be 51 µmol/g.  This strategy was therefore not a viable alternative to the click 
chemistry approach. 
 
 
 
 
 
 
 
 
 
Although the three nanoparticle functionalization strategies did not afford suitable 
loadings for further biological evaluation, it was still of interest to test the applicability of using 
an oxazoline linker for controlled release.  Therefore, studies of oxazoline hydrolysis were 
undertaken, and the outcomes are detailed in the following sections. 
 
3.2.6 Oxazoline Hydrolysis of Model Systems  
To probe the hydrolytic proclivity of the oxazoline substrates, a model oxazoline was 
synthesized from p-toluic acid 3-83 (Scheme 3-26). The amide-bond coupling reactions were 
performed with cyclohexylamine instead of 4-amino-TEMPO both to avoid using an expensive 
amine for model studies and to be able to monitor the reaction progress by 1H NMR 
spectroscopy.    
 
 
 
 
Scheme 3-25. Ugi reaction on a model system. 
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Substrate 3-86 was tested for its proclivity toward hydrolysis at various pH at room 
temperature.  The compound was suspended in aqueous buffers (0.1 M) at pH 1.0 to pH 5.0. 
Complete hydrolysis was observed at pH 1.0 within 90 min; however, hydrolysis at higher pH-
values only occurred at elevated temperatures, and hydrolysis at pH 5.0 occurred only at 
temperatures greater than or equal to 100 °C.  It was hypothesized that increasing the electron 
density on the aromatic ring or using alkyl substituents on the oxazoline would increase the 
proclivity toward hydrolysis at higher pH-values. 
 
 
 
 
 
 
 
 
 
 
A general scheme for synthesis of model oxazolines is shown in Table 3-5.  Starting from 
the requisite carboxylic acid or acid chloride, amide bond formation was accomplished either by 
standard peptide coupling (e.g., using EDCI, HOBT, Et3N) in the case of acid starting materials 
or by acylation in the case of acid chloride starting materials.  Cyclodehydration was 
Scheme 3-27. Hydrolysis of model oxazoline. 
Scheme 3-26. Synthesis of model oxazoline 3-86. 
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accomplished using standard protocols—either by heating with Burgess reagent in THF232 or by 
treatment with DAST at -78 C followed by K2CO3.
233  Finally, cyclohexylamine was coupled to 
the substrates using the standard protocol of saponification, azeotroping and solvent swapping, 
and coupling via the acyl azide (i.e., using DPPA). 
 
The 2-furanyl-oxazoline 3-92a as well as the corresponding 2-benzofuranyl oxazoline 3-92b 
were synthesized.  In the case of 2-furanyl oxazoline 3-92a, 50% conversion was observed after 
1 h at pH 1.0, and complete hydrolysis was observed after stirring for 15 h; in the case of the 2-
benzofuranyl oxazoline 3-92b, only 25% conversion was observed at pH 1.0, even after 15 h.  
 
The 4-methoxyphenyl-substituted oxazoline 3-92c exhibited similar hydrolytic proclivity to 
that of the 2-furanyl-substittued oxazoline 3-92a.  Upon moving to the 2,6-dimethoxyoxazoline 
3-92d, a marked drop in hydrolytic proclivity was observed—little to no hydrolysis occurred at 
pH 1.0 even after 24 h.  It is likely that the steric encumbrance from the ortho-substitution 
superceded the effects from enhanced electron density of the dimethoxy groups. 
   
Benzyl-substituted oxazoline 3-92e exhibited a marked enhancement in proclivity toward 
hydrolysis at higher pH-values.  At pH 1.0, the substrate was hydrolyzed within 20 min; this 
same result was observed up to pH 3.0.  At pH 4.0, complete hydrolysis was observed after 2.5 h 
at rt.  At pH 5.0, however,  ~40% conversion was observed after 15 h at rt.   
 
Based on these studies, it seems reasonable to propose using a more electron-rich aromatic 
oxazoline or to use the more labile benzyl-substituted oxazoline instead of the simple phenyl-
substituted oxazoline.   However, the hydrolysis was not tested under physiological conditions 
(e.g., 37 C), and it is difficult to predict the consquences of differential oxazoline substitution in 
a cellular environment.  There is likely a delicate balance between having a prohibitively labile 
substrate and an oxazoline that hydrolyzes at an optimal rate at a specific pH. Currently, we will 
note the observed trend and use it to guide further design modifications following optimization 
of our nanoparticle functionalization and assaying strategies. 
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Entry 
 
Starting material 
 
Conditions/yield 
for 3-90a–e 
 
Conditions/yield 
for 3-91a-e 
 
Yield 
 3-92a-e 
 
 
 
1 
 
 
SerOMe•HCl, Et3N 
3-90a, 45% 
 
Burgess Reagent 
THF, reflux,  
3-91a, 66% 
 
3-92a, 79% 
 
 
 
2 
 
SerOMe•HCl, EDC, 
HOBT, Et3N,  
3-90b, 77% 
Burgess Reagent 
THF, reflux  
3-91b, 45% 
3-92b, 68% 
3 
 
SerOMe•HCl, Et3N 
3-90c, 31% 
DAST,then K2CO3 
CH2Cl2,  
3-91c, 73% 
3-92c, 45% 
4 
 
SerOMe•HCl, Et3N 
3-90d, 83% 
Burgess Reagent 
THF, reflux 
3-91d, 68% 
3-92d, 80% 
5 
 
SerOMe•HCl, EDC, 
HOBT, Et3N,  
3-90e, 60% 
Burgess Reagent 
THF, reflux  
3-91e, 45% 
3-92e, 51% 
Table 3-5. Synthesis of model oxazolines. 
  
 160 
3.2.7 Functionalization of Controlled-Pore-Glass (CPG) 
Because there were difficulties in finding a suitable spacer for the silica-nanoparticles, I 
decided to use controlled-pore-glass was used both as a model system and, potentially, as an 
alternative to the nanoscale silica particles.  The functionalization of controlled-pore-glass is well 
precedented243 and was suitable for rapidly generating models for further evaluation of pH-
mediated release of TEMPO via the oxazoline-linker strategy.  
3.2.7.1 General Strategy for Functionalization of Porous Glass 
Known succinylated-CPG were used as the basis for attaching our TEMPO-derivatives to 
CPG.   Typically, CPG is used for oligonucleotide synthesis, and a leader nucleoside is attached 
to CPG as a succinate ester (Figure 3-13).  I envisioned that an analogous linkage could be 
formed using a primary alcohol appended to our oxazoline-TEMPO system (Scheme 3-28). 
Although the ester may be unstable to the oxazoline hydrolysis conditions, it would serve as a 
suitable starting point and could be modified as needed.  Moreover, simple hydrolysis using 
sodium hydroxide would be a feasible way to quantify the loading of the functionalized glass. 
 
 
 
  
 
 
 
 
 
The requisite alcohols were generated by reaction of azide 3-50 with alkynes. This 
procedure would be convergent and allow for facile modification of the substrate (e.g., using 
alkynes with varying numbers of methylene groups).  Moreover, high yields were already 
achieved in solution-phase cycloadditions using azide 3-50. 
Figure 3-13, Typical design of succinylated CPG for oligonucleotide synthesis. 
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3.2.7.2 Synthesis of Precursors and Functionalization of CPG 
Alcohol 3-95 was synthesized by reaction of azide 3-50 with 4-pentyn-1-ol (Scheme 3-
29).  It should be noted that the purity of the copper reagent is important; if Cu(II) was present, 
diminished yields or impure product mixtures containing mixtures of oxazoline and oxazole were 
obtained.   
 
 
 
 
Scheme 3-28. Strategy for functionalization of porous glass. 
Scheme 3-29. Synthesis of alcohol 3-95. 
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With alcohol 3-95 in hand, the succinylated CPG were elaborated according to 
established protocols244 (Scheme 3-30). Briefly, treating native CPG (120/200 mesh) with 3-
aminopropyltriethoxysilane under microwave conditions afforded 3-aminopropyl-CPG 3-96.  
Loadings were calculated using trityl analysis.245 The 3-aminopropyl-CPG was converted to the 
necessary acid using succinic anhydride and DMAP in DMF (also under microwave conditions).  
In this case, the acid loading was determined by derivatization with p-nitrophenol followed by 
saponification and UV/VIS quantification of the concentration of phenoxide ion.243 The particles 
were esterified with alcohol 3-95 using standard conditions for esterification of succinylated 
CPG.244 
 
 
Loadings of triazole 3-94 were quantified by saponifying the ester and measuring the 
concentration of triazole released from the CPG (Scheme 3-31).  A known quantity of beads 
were shaken in 0.1 N NaOH (aq)/MeOH, 1:1 for at least 6 h. The liquid was transferred to a 
volumetric flask and diluted with the NaOH/MeOH solution, and the concentration of triazole 3-
95 was measured by UV/VIS spectroscopy—absorbance was measured at 247 nm, and an 
independently generated calibration curve was generated using solutions of 3-95 in 0.1 M 
aqueous NaOH/MeOH, 1:1. The loading of 3-94 was consistently between 110 and 150 µmol/g.   
Scheme 3-30. Functionalization of CPG with triazole 3-95. 
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Control experiments were performed to ensure that the measured loadings were from 
covalently attached material rather than adsorbed material (Scheme 3-32).  Triazole 3-97 was 
prepared from azide 3-50 and 1-hexyne with the click chemistry protocol used for synthesis of 
triazole 3-95 (i.e., CuI•P(OEt)3, DIPEA, toluene, rt).   Control triazole was subjected to the 
esterification conditions, washed using the protocol used for esterification reactions (i.e., 
formation of 3-94), and then subjected to the saponification conditions used for loading 
determination (0.1 M aqueous NaOH/MeOH, 1:1).  Minimal UV-absorbance was observed, and 
the measured concentrations would correspond to loadings of less than 6 µmol/g.  Succinylated 
particles 3-93 were also subjected to the to the saponification conditions, and a significant 
UV/VIS spectrum with max at 259.6 nm was obtained.  It was confirmed that this absorption 
comes from the presence of adsorbed DMAP on the succinylated particles.  Yet, because the 
absorbance values from the control experiment using succinyated particles 3-93 and triazole 3-97 
were low, significant carryover of DMAP was not a concern, and the measured loadings were a 
correct quantification of material that was covalently attached to the CPG. 
 
Scheme 3-31. Saponification of CPG-ester for loading determination. 
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 Once a covalently attached substrate with an oxazoline linker was generated, the 
functionalized porous glass was subjected to acidic media (pH 1.0).  Aliquots were filtered and 
analyzed by LC-MS.  Mass values corresponding to saponified 3-95 as well as the oxazoline-
opened, saponified product 3-98, and the serine adduct 3-99 were detected (Scheme 3-33).   
 
 
 
Scheme 3-32. Validation of the saponification assay for determination of loading on CPG. 
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Scheme 3-33. Subjection of CPG-ester 3-94 to acidic conditions. 
 
 
Because the goal was to solely cleave the serine adduct 3-99, quantification of this product 
was necessary.  A standard (isolated as the hydrochloride salt 3-99HCl) was synthesized as 
shown in Scheme 3-34.   N-Fmoc dl-serine was prepared using a known protocol246 and 
subsequently coupled with 4-amino-TEMPO to afford 3-102.   The Fmoc group was cleaved 
using piperidine, and the free amine 3-99 was treated with 4.0 M HCl in 1,4-dioxane and isolated 
as the hydrochloride salt 399HCl. Using LCMS analysis, it was evident that the product existed 
as a mixture of nitroxide 399HCl and the corresponding hydroxylamine 399HCla (Scheme 3-
34).  
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3.3 CONCLUSIONS AND FUTURE DIRECTIONS 
The functionalization of silica nanoparticles with an oxazoline linker for pH-mediated 
release of TEMPO was explored.   The first approach involved a thiourea alkylation strategy 
wherein the oxazoline was attached to particles via an imidothiolate linkage. Low loadings of 
nitroxides were achieved using this approach, and it was suspected that the majority of material 
on the particles was noncovalent, adsorbed material rather than covalently linked material.   The 
strategy was changed to using a triazole spacer, with the reasoning that this strategy would lead 
to more stable functionalized products.  Although the loadings were promising by elemental 
analysis, experiments wherein the particles were sonicated and centrifuged indicated that a large 
amount of material remained in the supernatant, which was indicative of noncovalent attachment 
of material. 
 
Scheme 3-34. Synthesis of serine adducts as standards. 
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To validate the use of an oxazoline linker, a series of model oxazolines were screened for 
hydrolytic proclivity.  Increasing electron density of oxazolines substituted with aryl groups at 
the C-2 position led to substrates that had enhanced hydrolytic proclivity.  Additionally, using 
oxazoline substituted with a benzyl group at the C-2 position was readily hydrolyzed at pH 
values up to 4.0.   
 
Currently, controlled-pore glass is being used as a model system to evaluate our 
oxazoline linker strategy.  These systems are more tractable because the larger particle size 
facilitates the filtration and washing steps (a medium-sized fritted funnel is sufficient).  
Moreover, the CPG does not form aggregates in the same manner as observed in the case of the 
smaller silica nanoparticles.  The larger size of functionalized CPG makes it simple to perform 
assays due to the distinct separation between the solid and liquid phases in the reaction mixtures.  
Once the substitution of the oxazoline linker is optimized for selective hydrolysis at 
physiological pH values, the system will be translated to more biologically relevant nanoparticle 
scaffolds.  More specifically, we will incorporate the oxazoline linker strategy into compounds 
being appended to carbon nanotubes.  The use of a pH-responsive system would be of value to 
achieve site-specific release of nitroxides at desired intracellular sites, particularly the 
mitochondria. 
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4.0                               EXPERIMENTAL SECTION 
General Experimental. Moisture-sensitive reactions were performed under an 
atmosphere of nitrogen.  THF, Et2O, and TBME were distilled from benzophenone ketyl radical 
anion.  CH2Cl2 and toluene were dried via percolation through a column packed with neutral 
Al2O3 under a positive pressure of nitrogen.  Et3N and diisopropylethylamine were distilled from 
CaH2. t-BuOH was distilled from Mg
o before use in moisture-sensitive protocols.  Oxetane was 
purchased from Alfa Aesar and filtered through activated neutral Al2O3 prior to use.  Unless 
otherwise noted, all solvents used in hydrozirconation studies were purchased from commercial 
sources, distilled from CaH2, and subsequently filtered through activated neutral Al2O3 prior to 
each experiment.   1-Hexene and 2-cyclohexen-1-one were distilled before use. Solutions of n-
BuLi were purchased from Aldrich and titrated using diphenylacetic acid.  Solutions of i-
PrMgCl•LiCl were either purchased from Aldrich or prepared according to a literature 
protocol.51 All Grignard reagents were titrated using solutions of menthol in THF with 
phenanthroline as an indicator.  All other commercial reagents were used as received unless 
otherwise stated.  (R,R)-salenCo(III)OAc,247,248 Burgess Reagent,249 (PPh3)3CuBr
233, and 
CuI•P(OEt)3
234 were prepared according to literature protocols.  
 
Curcumin (Acros, 95%), naproxen (Acros, 99%), quinine (Acros, 99%), DMSO (Aldrich, 
99.9+%), and HPLC-grade water (Aldrich, CHROMASOLV®) were purchased from 
commercial suppliers and used as received.  Carbendazim (Aldrich, 97%) was recrystallized 
from absolute EtOH, and griseofulvin (Acros, 97%) was recrystallized from toluene.  N-Methyl-
2-pyrrolidone (Acros, 99%) was distilled from CaH2 under vacuum and stored over 4 Å MS.   
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Anhydrous DMF (free of molecular sieves for use in nanoparticle functionalization) was 
purchased from Acros.  Suspensions of silica nanoparticles were purchased from Nissan 
Chemical.  Analytical thin-layer chromatography (TLC) was performed on pre-coated silica gel 
60 F-254 plates (particle size 0.040–0.050 mm, 230–400 mesh) and visualization was 
accomplished by staining with KMnO4
 or p-anisaldehyde solutions.  1H NMR spectra (300 MHz, 
CDCl3) and 
13C NMR spectra (75 MHz, CDCl3) were referenced to residual chloroform (7.27 
ppm, 1H, 77.00 ppm, 13C).  Chemical shifts () are reported in ppm using the following 
convention: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br =broad), coupling constants, and integration.  IR spectra were collected as 
attenuated-total-reflection infrared (ATR-IR) spectra.  Mass spectra were obtained on a 
Micromass Autospec double focusing instrument. UV/VIS spectra were recorded on a Perkin 
Elmer Lambda EZ210 spectrophotometer.  pH Determinations were made using a 3 mm RossTM 
glass combination micro pH electrode (model 8220BNWP) after calibration in standard buffer 
solutions (pH 4.0, 7.0, and 10.0) at rt.   Combustion analysis was performed by Atlantic 
Microlabs. 
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(3-Methyloxetan-3-yl)methanol (1-39).  This compound was purchased from 
commercial sources (Alfa Aesar) or prepared using a modified protocol:87,88  A 500-mL round-
bottom flask was charged with 1,1,1-tris(hydroxymethyl)ethane (95 g, 0.79 mol), dimethyl 
carbonate (69 mL, 0.81 mol), KOH (0.75 g, 0.013 mol) and MeOH (1.3 mL, 0.031 mol). The 
mixture was brought to reflux (bath temperature = 90 C) and heated at reflux for 15 min.  The 
reflux condenser was switched for a still-head/condenser, and MeOH was removed by 
distillation.  The receiving flask was exchanged, and vacuum was applied to the apparatus (80 
Torr). The bath was heated to 140–150 C, and the pressure was gradually lowered to 30–40 
Torr. The pressure was then lowered to ca. 15 Torr, and (3-methyloxetan-3-yl)methanol 1-39 
was collected in the receiving vessel (27.1 g).  The apparatus was allowed to cool (overnight), 
and distillation under the same conditions (ca. 15 Torr) was continued the following day.  
Additional 1-39 (16.9 g) was collected to afford (3-methyloxetan-3-yl)methanol 1-39 (44 g, 
54%) as a colorless liquid: 1H NMR (300 MHz, CDCl3)  4.53 (d, J = 5.9 Hz, 2 H), 4.40 (d, J = 
5.9 Hz, 2 H), 3.72 (s, 2 H), 1.82 (bs, 1 H),  1.31 (s, 3 H). 
 
 
 
 
 
 
3-Methyl-3-(toluenesulfonyloxymethyl)oxetane (1-40).86  To a solution of p-
toluenesulfonyl chloride (47.8 g, 191 mmol) in anhydrous pyridine (200 mL) was  slowly added 
3-methyl-3-oxetanemethanol (16.5 mL, 164 mmol).  The mixture was stirred for 2 h at rt and 
poured into a vigorously stirring mixture of ice (570 g) and water (570 mL).  The slurry was 
stirred for 0.5 h, and the precipitate was collected via filtration, washed with cold water, and 
dried under high vacuum to afford 1-40 (32.4 g, 77%) as a white solid: Mp 56.8–57.5 °C (lit.86 
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59–60 °C); 1H NMR (300 MHz, CDCl3)  7.82 (d, J = 8.3 Hz, 2 H), 7.38 (d, J = 8.5 Hz, 2 H), 
4.37, 4.35 (AB, J = 6.3 Hz, 4 H), 4.12 (s, 2 H), 2.47 (s, 3 H), 1.32 (s, 3 H).  
 
 
  
 
 
3,3'-Oxybis(methylene)bis(3-methyloxetane) (1-37).62 A solution of 3-methyl-3-
oxetanemethanol (6.0 mL, 59 mmol) in THF (300 mL) was cooled to 0 oC, and NaH (2.83 g, 
70.8 mmol, 60% in mineral oil) was added portion-wise.  The solution was warmed to rt and 
stirred for 4 h.  3-Methyl-3-tosyloxymethyloxetane 1-40 (18.1 g, 63.7 mmol) was added, and the 
reaction mixture was heated at reflux for 60 h. The mixture was cooled, and the majority of THF 
was removed in vacuo.  The concentrate was diluted with Et2O and filtered, and the filtrate was 
concentrated in vacuo.  Residual 3-methyl-3-oxetanemethanol was removed by chromatography 
on SiO2 (hexanes/EtOAc, 4:1).  Kugelrohr distillation (120–140 
oC at 15 Torr) afforded 1-37 
(8.63 g, 76%) as a colorless oil: IR (ATR) 2861, 1107, 1036, 975, 936, 831 cm-1; 1H NMR (300 
MHz, CDCl3)   4.51 (d, J = 5.7 Hz, 4 H), 4.36 (d, J = 5.7 Hz, 4 H), 3.54 (s, 4 H), 1.32 (s, 6 H); 
13C NMR (75 MHz, CDCl3)  80.0, 76.5, 40.0, 21.3; HRMS (ES) m/z calc for C10H18O3 
209.1154, found 209.1148. 
 
 
 
 
2,6-Dioxaspiro[3.3]heptane (1-38).
73
  A 3-necked 500-mL round-bottom flask was 
outfitted with a reflux condenser and an addition funnel.  The flask was charged with KOH (31.0 
g, 552 mmol) followed by t-BuOH/THF (1:1, 200 mL). The solution was heated to reflux, and a 
solution of 2,2-bis(bromomethyl)propane-1,3-diol (24.1 g, 91.3 mmol) in t-BuOH/THF (1:1, 100 
mL) was added dropwise via addition funnel over the course of 3 h.  The reflux condenser was 
exchanged for a distillation head, and t-BuOH and THF were distilled from the reaction mixture. 
The product 1-38 was sublimed from the residue (60 °C at 760 Torr) to afford 1-38 (22.3 g, 
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22%) as a white solid: Mp 88.2–89.8 °C (lit.73 89–90 °C); IR (ATR) 2939, 2866, 1223, 964, 917 
cm 
–1
;  
1
H NMR (300 MHz, CDCl3)  4.80 (s, 8 H); 
13
C NMR (75 MHz, CDCl3)  80.3, 43.6; 
MS (EI) m/z (rel. intensity) 100 (M
+
, 13), 72 (15), 69 (100), 53 (22); HRMS (EI) m/z calc for 
C5H8O2 100.0524, found 100.0528. 
 
 
 
 
 
(3-(Bromomethyl)oxetan-3-yl)methanol (1-42).  A solution of 2,2-
bis(bromomethyl)propane-1,3-diol (1.00 g, 3.82 mmol) in THF (38 mL) was treated (via 
dropwise addition) with n-BuLi (5.20 mL, 7.64 mmol, c = 1.46 M in hexanes) at –78 °C.  The 
reaction mixture was maintained at –78 °C for 100 min, warmed to rt, and THF was removed in 
vacuo.  The residue was partitioned between Et2O (30 mL) and water (50 mL), and the aqueous 
portion was extracted with EtOAc.  The combined organic layers were washed with brine, dried 
(Na2SO4) and concentrated.  The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 6:4) to afford 1-42 (294 mg, 43%) as a pale yellow oil:  IR (neat) 3406, 2954, 
2877, 1228, 1039, 974 cm
-1
; 
1
H NMR (300 MHz, CDCl3)  4.48, 4.45 (AB, J = 6.5 Hz, 4 H), 
4.00 (s, 2 H), 3.80 (s, 2 H), 1.90–1.82 (bs, 1 H); 13C NMR (75 MHz, CDCl3)  77.0, 64.3, 45.0, 
36.1; MS (EI) m/z (rel. intensity) 163 (9), 150 (14), 71 (100).  
 
 
 
 
 
 
 
Confirmation of the intermolecular Williamson ether by synthesis: (3-
(ethoxymethyl)oxetan-3-yl)methanol (1-43).   A solution of KOH (700 mg, 12.5 mmol) in 
EtOH (34 mL) was heated at reflux and treated with a solution of 1-42 (1.01 g, 5.52 mmol) 
dropwise via addition funnel.  The mixture was maintained at reflux for 1 h, cooled, and EtOH 
  
 173 
was removed in vacuo.  The residue was dissolved in Et2O and filtered through neutral Al2O3.  
Et2O was removed under reduced pressure, and the residue was purified by Kugelrohr distillation 
(50 °C at 1 Torr) to afford spirocycle 1-38 (27 mg, 5%) as a white solid.  Kugelrohr distillation  
(110 °C at 1 Torr) afforded 1-43 (110 mg, 14%) as a colorless oil:  IR (ATR) 3431, 2967, 2868, 
1377, 1109, 967 cm-1; 1H NMR (300 MHz, CDCl3)  4.48, 4.43 (AB, J = 6.2 Hz, 4 H), 3.95 (s, 2 
H), 3.79 (s, 2 H), 3.55 (q, J = 7.0 Hz, 2 H), 2.53 (bs, 1 H), 1.21 (t, J = 7.0 Hz, 3 H); 13C NMR (75 
MHz, CDCl3)  76.6, 75.1, 67.3, 67.1, 43.8, 15.0; MS (EI) m/z (rel. intensity) 147 (M
+, 44), 127 
(19), 99 (49), 84 (99), 70 (100), 69 (88), 57 (91); HRMS (EI) m/z calc for C7H15O3 (M+H) 
147.1021, found 147.1021.   
 
 
 
 
 
 
 
 
 Representative procedure for addition of 2-lithio-1,3-dithiane to 2-cyclohexen-1-
one (Table 1-18 entry 4). A solution of 1,3-dithiane (30 mg, 0.25 mmol) in THF (1.8 mL) was 
degassed (bubbling N2), cooled to -78 °C, and treated with n-BuLi (0.21 mL, 0.27 mmol, c = 
1.27 M in hexanes).  The solution was warmed to –20 °C over 75 min, stirred for an additional 
30 min at –20 °C, cooled to –78 °C, and stirred for 70 min prior to addition of a solution of 1-38 
(294 mg, 2.94 mmol) in THF (2.0 mL).  The mixture was stirred for 1 h at -78 °C, and 2-
cyclohexen-1-one (12 mg, 0.13 mmol) in THF (1.0 mL) was added via syringe. The mixture was 
stirred for 5 min, quenched with saturated aqueous NH4Cl at -78 °C, warmed to rt, diluted with 
Et2O (25 mL) and water (25 mL), and extracted with Et2O (3 x 20).  The combined organic 
layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure.  The 
residue was purified by chromatography on SiO2 (hexanes/EtOAc, 4:1) to afford 1-12 (21 mg, 
78%).     
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The product ratios of 1-12:1-13 were determined by crude 1H NMR analysis using the 
integration ratio of the singlet at 4.24 ppm in 1-12 and the doublet at 4.10 ppm in 1-13.  When 
the reaction yielded a mixture of 1-12 and 1-13, the products were co-eluted, and the isolated 
yield reflects the mass of the mixture.    
 
1-(1,3-dithian-2-yl)cyclohex-2-enol (1-12).  1H NMR (300 MHz, CDCl3)  6.00–5.92 (m, 1 H), 
5.80–5.70 (m, 1 H), 4.24 (s, 1 H), 3.00–2.80 (m, 4 H), 2.33 (s, 1 H), 2.15–1.90 (m, 4 H), 1.90–
1.70 (m, 4 H).  
3-(1,3-dithian-2-yl)cyclohexanone (1-13). 1H NMR (300 MHz, CDCl3)  4.10 (d, J = 4.9 Hz, 1 
H), 2.95–2.85 (m, 4 H), 2.61–2.32 (m, 4 H), 2.30–2.05 (m, 4 H), 1.95–1.80 (m, 1 H), 1.75–1.60 
(m, 2 H). 
 
 
 
 
 
Methyl 3-nitropropanoate (1-44).89,90  To a solution of freshly distilled acrolein (10.0 mL, 
145 mmol) and NaNO2 (15.5 g, 225 mmol) in THF (80 mL) at 0 °C was added AcOH (10.7 mL, 
186 mmol) by syringe pump over 1 h. The mixture was stirred for an additional 160 min, diluted 
with water (40 mL) and extracted with CH2Cl2 (4 x 30 mL).  The combined organic layers were 
washed with NaHCO3 (2 x), brine (2 x), and water, dried (MgSO4), and concentrated in vacuo to 
afford 3-nitropropanal (7.81 g crude) as a yellow oil.  
 
To a solution of crude 3-nitropropanal (7.81 g, 75.8 mmol), NaH2PO4•H2O (2.07 g, 15 
mmol), and 30% H2O2 (6 mL) in MeCN (60 mL) and water (20 mL) was added a solution of 
NaClO2 (7.68 g, 66 mmol) in H2O (80 mL) dropwise via addition funnel at rt. The bright yellow 
mixture was stirred for 1 h after the addition was complete, Na2SO3 was added (3 g), and the 
mixture was stirred for 20 min. The quenched mixture was acidified with 10% aqueous HCl, 
diluted with water, and extracted with EtOAc (3 x 40 mL).  NaCl was added to the aqueous 
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layer, and the aqueous layer was extracted with EtOAc (3 x 40 mL). The combined organic 
layers were dried (Na2SO4) and concentrated to afford 3-nitropropanoic acid as a white solid. 
 
Crude 3-nitropropanoic acid was dissolved in MeOH (100 mL) and H2SO4 (1.8 mL). The 
mixture was heated at reflux overnight, cooled, and concentrated to ~1/4 volume. The mixture 
was dissolved in Et2O, washed with water, dried (MgSO4) and concentrated in vacuo. The 
residue was distilled (95 °C at 6 Torr) to afford 1-44 (2.19 g, 11%) as a colorless oil: 1H NMR 
(300 MHz, CDCl3)  4.67 (t, J = 6.0 Hz, 2 H), 3.76 (s, 3 H), 3.01 (t, J = 6.0 Hz, 2 H); HRMS 
(EI) m/z calc for C4H7NO4 133.0375, found 133.0376.  
 
 
 
  
 
 
Representative Procedure for Dianion Solubility Studies (Table 1-19, entry 2):  A 
flame-dried 3-necked 250-mL round-bottom flask equipped with thermometer was charged with 
distilled THF (3.0 mL), which was degassed by sparging with nitrogen.  i-Pr2NH (0.22 mL, 1.54 
mmol) was added, and the solution was cooled to -72 oC (Tint).  To this solution was added n-
BuLi (0.670 mL, 1.54 mmol c = 2.23 M in hexanes), and the pale yellow solution was 
transferred to an ice-water bath, stirred for 20 min, and cooled back to -76 oC (Tint).  DMPU 
(0.920 mL, 7.51 mmol) was added via syringe (neat), and the resulting bright yellow solution 
was stirred for 20 min.  A solution of methyl 3-nitropropanoate (100 mg, 0.751 mmol) in THF 
(1.0 mL) was added dropwise via syringe. The solution was stirred between -76 oC and -70 oC 
for 1 h, and freshly distilled BnBr (0.12 mL, 1.0 mmol) was added slowly via syringe. The 
reaction mixture was stirred between -76 oC and -60 oC for 1 h, then gradually warmed to -25 oC 
over an additional hour.  The reaction mixture was quenched at –25 oC with glacial AcOH (0.3 
mL), followed 5 min later by water (0.5 mL).  The quenched mixture was warmed to rt and 
diluted with Et2O and water (30 mL each).  The aqueous layer was extracted with Et2O (3 x 20 
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mL), and the combined organic layers were washed with water, saturated aqueous NaHCO3, and 
water, dried (MgSO4) and concentrated.  The crude residue was purified by chromatography on 
SiO2 (hexanes/EtOAc, 9:1) to afford methyl 2-benzyl-3-nitropropanoate 1-45 (106 mg, 63%) as a 
colorless oil and methyl 2,2-dibenzyl-3-nitropropanoate 1-46 (9 mg, 4%) as a colorless oil: 
 
Methyl 2-benzyl-3-nitropropanoate (1-45).252 Rf 0.1 (hexanes/EtOAc, 9:1); 
1H NMR 
(300 MHz, CDCl3)  7.40–7.26 (m, 2 H), 7.18–7.15 (m, 3 H), 4.68 (dd, J = 14.7, 9.0 Hz, 1 H), 
4.37 (dd, J = 14.7, 4.5 Hz, 1 H), 3.75 (s, 3 H), 3.55–3.44 (m, 1 H), 3.16 (dd, J = 14.1, 6.0 Hz, 1 
H), 2.84 (dd, J = 14.0, 9.0 Hz, 1 H); MS (EI) m/z (rel. intensity) 224 ([M+H]+, 8), 163 (48), 133 
(41), 91 (99), 77 (58), 59 (63); HRMS (EI) m/z calc for C11H13NO4 (M+H) 224.0923, found 
224.0921.  
Methyl 2,2-dibenzyl-3-nitropropanoate (1-46).  Rf 0.2 (hexanes/EtOAc, 9:1); IR (ATR) 
3060, 2883, 1729, 1549, 1448, 1374, 1215 cm-1; 1H NMR (300 MHz, CDCl3)  7.38–7.25 (m, 6 
H), 7.11–7.08 (m, 4 H), 4.39 (s, 2 H), 3.62 (s, 3 H), 3.30, 3.12 (AB, J = 14.0 Hz, 4 H); 13C NMR 
(75 MHz, CDCl3)  172.7, 135.3, 130.0, 128.7, 127.5, 74.6, 52.1, 51.9, 40.7; MS (EI) m/z (rel. 
intensity) 313 (M+, 21), 282 (12), 91 (99); HRMS (EI) m/z calc for C18H19NO4 313.1314, found 
313.1305. 
 
Table 1-19, entry 3: Following the representative procedure, HMPA (0.670 mL, 3.79 
mmol) was substituted for DMPU.   After purification, 1-45 (98 mg, 58%) was isolated as a 
colorless oil and 1-46 (21 mg, 9%) was isolated as a colorless oil. 
 
Table 1-19, entry 4: Following the representative procedure, dimer 1-37 (700 mg, 3.76 
mmol) was substituted for DMPU.  After purification, 1-45 (70 mg, 42%) was isolated as a 
colorless oil, and 1-46 (5 mg, 2%) was isolated as a colorless oil.  
 
Preparation of Schwartz reagent (Cp2Zr(H)Cl).
253 To a flame-dried 2-necked 100-mL 
round-bottom flask was added zirconocene dichloride (5.0 g, 17 mmol) and THF (45 mL) at rt. 
LiAlH4 (4.27 mL, 4.27 mmol, c = 1.0 M in Et2O) was added dropwise via syringe pump (0.1 
mL/min). The reaction mixture was stirred at rt for an additional 30 min, filtered under N2 
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(Schlenk filtration), and washed with THF (4 x 10 mL), CH2Cl2 (10 mL), THF (10 mL) and Et2O 
(5 mL). The product was dried in the Schlenk filter under high vacuum overnight. Schwartz 
reagent (3.14 g, 71%) was isolated as beige solid.  The reagent was titrated by reacting 1 equiv of 
Schwartz reagent with 1 equiv of 1-hexyne in CH2Cl2 at rt and analyzing the conversion by GC 
analysis using the GC method described below.   
 
General procedure for hydrozirconation kinetics experiments. Gas chromatography 
data were obtained on an Agilent Technologies Network GC system (6890N).  Components were 
separated using an HP-5 5% phenyl methyl siloxane column (30.0 m length x 0.05 mm i.d.).  
Helium (1.0 mL/min) was used as the carrier gas.  The flame ionization detector was heated to 
250 oC and ignited using a mixture of compressed air (450 mL/min) and hydrogen (40 mL/min).  
All injections (1 L) were performed via autosampler as split injections (split ratio 50.0:1.0).  
The GC oven temperature was held constant at 40 oC for 10 min. 
 
To an oven-dried round-bottom flask under a nitrogen atmosphere was added solvent (1.0 
mL) and Schwartz reagent (155 mg, 0.605 mmol, 1 equiv).  The solution was stirred at rt for 1 
min, cooled to 0 oC, and stirred for 4 min. 1-Hexene (0.075 mL, 0.605 mmol, 0.605M) was 
added.  Aliquots of the reaction mixture were taken at 15–30 min intervals over 2.5 h.  Each 
aliquot (50–100 L) was transferred into a test tube containing water (1 mL) and Et2O (0.5 mL).  
The ethereal layer was filtered through a plug of silica and analyzed by GC, employing the 
method described above.  For each time-point, the concentration of 1-hexene was calculated 
based on the ratio of n-hexane:1-hexene in the GC trace (a calibration correlating the mole ratio 
of n-hexane:1-hexene with the area ratio of n-hexane:1-hexene was used).  Estimated half-lives 
were calculated assuming a rate expression whereby the reaction is first order in 1-hexene and 
zeroth order in Schwartz reagent (c = Ae-kt), and the measured half-lives are calculated by the 
expression t1/2 = ln(2)/k.   
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2-(Benzyloxymethyl)oxirane (rac-1-53).254    A solution of benzyl alcohol (25.0 mL, 
242 mmol) in THF (800 mL) was cooled to 0 C and treated with NaH (12.6 g, 314 mmol, 60% 
dispersion in mineral oil). The mixture was stirred for 0.5 h, and epichlorohydrin (58.0 mL, 732 
mmol) was added.  The solution was heated at reflux for 14 h, cooled, quenched with water, 
dried (MgSO4), and filtered.  The filtrate was concentrated in vacuo. Excess epichlorohydrin was 
removed by Kugelrohr distillation (60 C at 15 Torr) and further Kuglelrohr distillation (95 oC at 
2.5 Torr) afforded rac-1-53 (19.0 g, 48%) as a colorless oil:  1H NMR (300 MHz, CDCl3)  
7.37–7.28 (m, 5 H), 4.62, 4.57 (AB, J = 11.9 Hz, 2 H), 3.78 (dd, J = 11.4, 3.0 Hz, 1 H), 3.45 (dd, 
J = 11.3, 5.8 Hz, 1 H), 3.23–3.18 (m, 1 H), 2.81 (app t, J = 4.5 Hz, 1 H), 2.63 (dd, J = 5.0, 2.7 
Hz, 1 H); MS (EI) m/z (rel. intensity) 164 (M+, 44), 107 (86), 91 (100), 77 (262); HRMS (EI) m/z 
calc for C10H12O2 164.0837, found 164.0836. 
 
 
 
 
 
2-(Benzyloxymethyl)oxetane (rac-1-54).93 A solution of t-BuOK (28.2 g, 244 mmol) and 
Me3SOI (54.8 g, 224 mmol) in dry t-BuOH (350 mL) was heated at 50 °C for 1 h. A solution of 
2-(benzyloxymethyl)oxirane (rac-1-53) (20.0 g, 122 mmol) in t-BuOH (150 mL) was added 
slowly via syringe.  The reaction mixture was stirred at 50 C for 3 d, cooled, filtered, and the 
solids were washed with Et2O.  t-BuOH was removed in vacuo, and the residue was dissolved in 
water (100 mL) and Et2O (150 mL). The aqueous layer was extracted with Et2O (3 x 75 mL) and 
the combined organic layers were washed with brine, dried (MgSO4) and concentrated in vacuo.  
The residue was purified by chromatography on SiO2 (pentane/Et2O, 3:1) to afford crude rac-1-
54 (10.5 g, 48%) as a colorless oil:  1H NMR (300 MHz, C6D6)  7.40 (d, J = 7.40 Hz, 2 H), 
7.29–7.25 (m, 2 H), 7.25–7.16 (m, 1 H), 4.84 (ddt, J = 7.7, 6.7, 4.1 Hz, 1 H), 4.55, 4.50 (AB, J = 
12.2 Hz, 2 H), 4.42 (app t, J = 6.8 Hz, 2 H), 3.47 (d, J = 4.1 Hz, 2 H), 2.34 (ddt, J = 14.7, 10.1, 
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8.0 Hz, 1 H), 2.20 (ddt, J = 14.7, 10.8, 7.9 Hz, 1 H); MS (EI) m/z 178 (M+, 41), 107 (100), 92 
(70), 91 (51), 77 (60), 57 (88); HRMS (EI) m/z calc for C11H14O2 178.0994, found 178.0992.  
 
 
 
 
 
 2-Oxetanemethanol (rac-1-48).80  A solution of crude 2-(benzyloxymethyloxetane rac-
1-54 (3.79 g, 20.2 mmol) in EtOAc (200 mL) was treated with 10% Pd/C (10.8 g, 10.2 mmol).a 
The solution was purged with H2 gas (balloon), and the mixture was maintained under H2 
atmosphere. The reaction mixture was stirred for 11 h at rt, filtered through Celite, and 
concentrated in vacuo.  The residue was purified by chromatography on SiO2 (MeOH/CH2Cl2, 
5:95) to afford rac-1-48 (1.20 g, 67%) as a colorless oil:  IR (ATR) 3390, 2881, 962 cm-1; 1H 
NMR (300 MHz, CDCl3)  4.97–4.90 (m, 1 H), 4.74–4.66 (m, 1 H), 4.57–4.50 (m, 1 H), 3.76 
(ddd, J = 12.6, 4.9 2.9 Hz, 1 H), 3.61 (ddd, J = 12.4, 8.1, 4.0 Hz, 1 H), 2.73–2.54 (m, 2 H), 2.43 
(bs, 1 H); 13C NMR (75 MHz, CDCl3)  82.8, 68.9, 65.3, 22.5; MS (EI+) m/z (rel. intensity) 88 
(M+, 10), 57 (99); HRMS (EI) m/z calc for C4H8O2 88.0524, found 88.0522. 
aThe amount of Pd/C was inadvertently high (1 equiv Pd).  The reaction was repeated with lower 
loadings of Pd/C (1-10 mol%), but the yield was consistent with that reported above (62%). 
 
 
 
 
 
 
Oxetan-2-ylmethyl 4-methylbenzenesulfonate (rac-1-56).80  A solution of TsCl (2.81 g, 
14.8 mmol) in anhydrous pyridine (5.7 mL) at 0 °C was treated with 2-hydroxymethyloxetane 
rac-1-48 (0.930 mL, 11.4 mmol) via syringe. The solution was stirred for 7 h at 0 °C, diluted 
with ice-water (15 mL), and extracted with Et2O. The ethereal layer was washed with water (3 x) 
and brine, dried (MgSO4) and concentrated in vacuo. Residual pyridine was removed from the 
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concentrate by addition of benzene and concentration under reduced pressure (2 x).  The residue 
was taken up in Et2O, filtered through neutral Al2O3, and concentrated under reduced pressure to 
afford rac-1-56 (2.18 g, 79%) as a white solid: Mp 57.1–59.6 °C (lit.80 58–59 °C); IR (ATR) 
2974, 1593, 1355, 1174, 941; 1H NMR (300 MHz, CDCl3)  7.83 (d, J = 8.2 Hz, 2 H), 7.36 (d, J 
= 8.1 Hz, 2 H), 4.97–4.89 (m, 1 H), 4.65–4.57 (m, 1 H), 4.55–4.48 (m, 1 H), 4.16 (d, J = 3.8 Hz, 
2 H),  2.77–2.66 (m, 1 H), 2.63–2.52 (m, 1 H), 2.46 (s, 3 H); 13C NMR (75 MHz, CDCl3)  
144.9, 132.8, 129.9, 128.0, 78.6, 71.9, 69.0, 23.4, 21.7; MS (EI) m/z (rel. intensity) 243 (M+, 52), 
173 (82), 155 (50), 119 (100), 63 (92); HRMS (EI+) m/z calc for C11H15O4S (M+H) 243.0691, 
found 243.0690. 
 
 
 
 
 
2,2'-Oxybis(methylene)dioxetane (1-47).  A solution of alcohol rac-1-48 (0.65 mL, 7.9 
mmol) in THF (30 mL) was treated with NaH (260 mg, 10.3 mmol, 95%) at 0 °C. The mixture 
was stirred for 0.5 h at 0 °C, and a solution of tosylate rac-1-56 (2.3 g, 9.5 mmol) in THF (15 
mL) was added slowly via syringe. The reaction mixture was stirred at 50 °C for 10 h and heated 
at reflux for an additional 4 h.  The solution was filtered and concentrated in vacuo, and the 
residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1 to 100% EtOAc).  
Fractions containing the desired product were further purified by Kugelrohr distillation (80 °C < 
T < 100 °C at 2.5 Torr) to afford 1-47 (618 mg, 49%)  (mixture of dl- and meso- diastereomers) 
as a colorless oil: IR (ATR) 2993, 2877, 1448, 1110, 971, 949, 855 cm-1; 1H NMR (300 MHz, 
CDCl3)  4.89–4.89 (m, 2 H), 4.66–4.59 (m, 2 H), 4.57–4.49 (m, 2 H), 3.77–3.62 (m, 4 H), 2.69–
2.47 (m, 4 H); 13C NMR (125 MHz, CDCl3)  81.3, 75.0, 74.8, 68.9, 23.6; MS (EI) m/z (rel. 
intensity) 159 (M+, 22), 128 (68), 88 (100), 71 (91), 57 (90); HRMS (EI) m/z calc for C8H15O3 
159.1021, found 159.1020. 
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2,2’ Oxybis(methylene)dioxirane (1-58).  A solution of allyl glycidyl ether (7.1 g, 62 
mmol) in CH2Cl2 (20 mL) was treated with a solution of m-CPBA (23.0 g, 93.3 mmol) in CH2Cl2 
(120 mL), which was added dropwise via addition funnel. The white slurry was stirred for 23 h 
and quenched with 1 M aqueous Na2S2O3 (100 mL).  The aqueous layer was extracted with 
CH2Cl2 (2 x), and the combined organic layers were washed with 0.5 M aqueous NaOH, dried, 
and concentrated under reduced pressure.  Residual allyl glycidyl ether (1.2 g) was removed via 
Kugelrohr distillation to afford 1-58 (4.9 g, 60%; 75% BRSM) as a colorless oil: 1H NMR 3.85 
(ddd, J = 16.0, 11.6, 2.8 Hz, 2 H), 3.45 (ddd, J =21.0, 11.6, 6.0 Hz, 2 H), 3.22–3.15 (m, 2 H), 
2.83–2.80 (m, 2 H), 2.66–2.61 (m, 2 H). HRMS (EI+) m/z calc for C6H10O3 130.0630, found 
130.0631. 
 
Attempted formation of 1-47 via double methylene transfer to 1-58. A solution of 
Me3SOI (13.8 g, 61.5 mmol) and t-BuOK (7.11 g, 61.5 mmol) in t-BuOH (75 mL) was heated at 
50 °C for 1 h. A solution of diglycidyl ether 1-58 (2.0 g, 15 mmol) in 25 mL t-BuOH was added 
via syringe. The reaction mixture was stirred at 50 °C for 20 h (an aliquot was taken to ascertain 
starting material consumption by 1H NMR analysis). The mixture was cooled to rt and t-BuOH 
was removed in vacuo. The concentrate was diluted with water (200 mL) and CH2Cl2 (200 mL), 
and the aqueous layer was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers 
were washed with brine (twice), dried (MgSO4) and concentrated in vacuo.  The crude mixture 
(1.5 g) was subjected to Kugelrohr distillation at 3 Torr to afford several fractions of colorless oil 
(at 20 oC increments starting at 60 oC to 100 oC). Each fraction contained a mixture of olefinic 
and oxetane peaks (1H NMR analysis), and the distillate fractions were combined and subjected 
to chromatography on SiO2 (hexanes/EtOAc, 4:1).  No pure dimer 1-47 could be obtained from 
these mixtures.   
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(S)-Benzyl glycidyl ether ((S)-1-53).255  A solution of (R,R)-salenCo(III)OAc (605 mg, 
0.910 mmol) in neat benzyl glycidyl ether (30.1 g, 183 mmol) was cooled to 0 C.  Water (1.8 
mL, 100 mmol) was added dropwise over 20 min.  The reaction mixture was warmed to rt and 
stirred for 4.5 h.  The mixture was diluted with EtOAc (250 mL) and dried (Na2SO4) overnight.  
The drying agent was filtered, and the solvent was concentrated to afford a brown liquid that was 
purified by chromatography on SiO2 (hexanes/EtOAc, 9:1 to 100% EtOAc) to afford partially 
purified (S)-benzyl glycidyl ether (eluted in 9:1), which was subsequently purified by  Kugelrohr 
distillation (75 ºC < T < 85 ºC at 10–11 Torr) to afford (S)-benzyl glycidyl ether (13.40 g, 45%) 
as a colorless oil.  The enantiomeric excess was determined to be 99% by chiral HPLC analysis 
(Chiralcel OD, 2% isopropanol/hexanes, 1.0 mL/min, 220 nm) tr(major) = 12.0 min, tr(minor) = 
14.7 min: []D 15.0 (neat); 
1H NMR (300 MHz,CDCl3)  7.37–7.27 (m, 5 H), 4.63, 4.58 (AB, J 
= 12.0 Hz, 2 H), 3.79 (dd, J = 11.4, 3.0 Hz, 1 H), 3.45 (dd, J = 11.4, 5.9 Hz, 1 H), 3.23–3.18 (m, 
1 H), 2.82 (t, J = 4.5 Hz, 1 H), 2.64 (dd, J = 5.0, 2.7 Hz, 1 H).  
 
Alternative Preparation of (S)-Benzyl glycidyl ether ((S)-1-53).  A slurry of NaH (3.12 
g, 78.) mmol, 60% in mineral oil) and BnBr (19.0 mL, 159 mmol) in anhydrous DMF (120 mL) 
was cooled to 0 oC and stirred for 30 min.  To this solution was added (R)-glycidol (4.0 mL, 58 
mmol) dropwise via syringe. The reaction mixture was stirred for 5 h at rt, and the mixture was 
poured into a separatory funnel containing saturated aqueous NH4Cl (10 mL) and EtOAc (30 
mL).  The organic layer was washed with 5% aqueous NaHCO3 and water, and the combined 
aqueous layers were extracted with EtOAc (4 x 10 mL).  The combined organic layers were 
dried (Na2SO4) and concentrated.  The residue was purified by chromatography on SiO2 
hexanes/EtOAc, 9:1) to afford (S)-benzyl glycidyl ether (6.98 g, 73%) as a colorless oil. 
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(S)-2-(Benzyloxymethyl)oxetane ((S)-1-54).  A solution of t-BuOK (17.7 g, 158 mmol) 
and Me3SOI (34.9 g, 158 mmol) in t-BuOH (250 mL) was heated to 50 ºC (Tint).  The solution 
was stirred for 1 h at 50 oC.  A solution of (S)-(+) benzyl glycidyl ether (13.0 g, 79.2 mmol) in t-
BuOH (100 mL) was added via addition funnel over a period of 90 min. The foamy white 
reaction mixture was stirred at 50 oC for 90 h, cooled to rt, and diluted with water (350 mL) and 
Et2O (300 mL).  The aqueous layer was extracted with Et2O (3 x 200 mL), and the combined 
organic layers were washed with brine, dried (Na2SO4), and concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (hexanes/EtOAc, 4:1) to afford crude (S)-2-
(benzyloxymethyl)oxetane (S)-1-54 (7.79 g, 55%) as a pale yellow oil: 1H NMR (300 MHz, 
CDCl3)  7.40–7.28 (m, 5 H), 5.03–4.95 (m, 1 H), 4.72–4.56 (m, 4 H), 3.65 (dddd, J = 15.7, 
11.0, 11.0, 4.8 Hz, 2 H), 2.73–2.53 (m, 2 H).  
 
 
 
 
 
(S)-Oxetan-2-ylmethanol ((S)-1-48).  A solution of crude (S)-1-54 (7.00 g, 39.3 mmol) 
in EtOAc (350 mL) was treated with 10% Pd/C (2.09 g, 1.96 mmol) and exposed to H2 at 1 atm 
(balloon).  The mixture was stirred for 5 h at rt, and the mixture was filtered through a plug of 
Celite and washed with EtOAc and MeOH.  The solvent was removed in vacuo, and the residue 
was purified by chromatography on SiO2 (MeOH/CH2Cl2, 5:95) to afford (S)-oxetan-2-
ylmethanol (1.98 g, 57%) as a colorless oil: []D  + 7.1 (c = 5.0, CDCl3)
a; 1H NMR (300 MHz, 
CDCl3)  4.97–4.90 (m, 1 H), 4.70 (ddd, J = 8.4, 7.6, 5.9 Hz, 1 H), 4.53 (ddd, J = 9.0, 6.0, 6.0 
Hz, 1 H), 3.76 (ddd, J = 12.5, 4.6, 2.9 Hz, 1 H), 3.64 (ddd, J = 12.1, 7.8, 3.9 Hz, 1 H), 2.73–2.54 
(m, 2 H), 2.45 (bs, 1 H). 
aThe optical rotation of a separate sample of (S)-1-48 was measured: []D  + 8.6 (c = 5.8, 
CH2Cl2). 
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(S)-Oxetan-2-ylmethyl 4-methylbenzensulfonate (S-1-56).  A solution of TsCl (2.81 g, 
14.7 mmol) in anhydrous pyridine (5.7 mL) was cooled to 0 oC.  (S)-Oxetan-2-ylmethanol (S)-1-
48 (0.93 mL, 11. mmol) was added (neat) dropwise via syringe.  The mixture was stirred for 5 h, 
gradually warming to rt, and poured into a flask containing ice-water.  The aqueous mixture was 
extracted with Et2O, and the ethereal portion was washed with water and brine, dried, and 
concentrated in vacuo.  To the residue was added benzene, and the residue/benzene was 
concentrated (twice).  The residue was filtered through neutral Al2O3 and used without further 
purification. (S)-oxetan-2-ylmethyl 4-methylbenzensulfonate (S)-1-56 (1.97 g, 72%) was isolated 
as a colorless oil which solidified upon standing: 1H NMR (300 MHz, CDCl3)  7.83 (d, J = 8.4 
Hz, 2 H), 7.36 (d, J = 8.0 Hz, 2 H), 4.97–4.89 (m, 1 H), 4.61 (ddd, J = 8.6, 7.1, 5.8 Hz, 1 H), 
4.51 (ddd, J = 12.2, 9.0, 9.0 Hz, 1 H), 4.16 (d, J = 3.9 Hz, 2 H), 2.78–2.66 (m, 1 H), 2.63–2.52 
(m, 1 H), 2.46 (s, 3 H); MS (EI) m/z (rel. intensity) 242 (M+, 17), 172 (16), 156 (72), 155 (56), 
91 (89); HRMS (EI) m/z calc for C11H14O4S 242.0613, found 242.0620. 
 
 
 
 
 
 
(2S,2'S)-2,2'-oxybis(methylene)dioxetane ((S,S)-1-47).  A slurry of NaH (156 mg, 6.18 
mmol, 95%) and (S)-1-56 (1.28 g, 5.27 mmol) in anhydrous MeCN (43 mL) was treated with 
(S)-1-48 (0.350 mL, 4.29 mmol) at 0 oC (dropwise).  The solution was warmed to rt over a 
period of 30 min and subsequently heated at reflux for 27 h.  The solution was cooled to 0 oC and 
quenched by dropwise addition of water.  The mixture was dried (MgSO4), filtered, and the 
solvent was removed in vacuo. The residue was purified by chromatography on SiO2 (100% 
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EtOAc), and the isolated residue was further purified by Kugelrohr distillation (75 oC < T < 95 
oC at 15 Torr) to afford (2S, 2'S)-2,2'-oxybis(methylene)dioxetane (S,S)-1-47 (390 mg, 57%) as a 
colorless oil: []D  -5.8 (c = 5.1, CDCl3); IR (ATR) 2876, 1109, 973, 949 cm
-1; 1H NMR (500 
MHz, CDCl3) 4.99–4.95 (m, 2 H), 4.69–4.64 (m, 2 H), 4.60–4.54 (m, 2 H), 3.84–3.76 (m, 2 H), 
3.70–3.62 (m, 2 H), 2.70–2.56 (m, 4 H); 13C NMR (125 MHz, CDCl3)  81.3, 74.9, 68.9, 23.7; 
HRMS (EI) m/z calc for C8H14O3 (M+H) 159.1021, found 159.1020.  
 
 
 
 
 
 
 
2-(Benzyloxymethyl)propane-1,3-diol (1-63) and 2,2-bis(benzyloxymethyl)propane-
1,3-diol (1-62).73,256  To a solution of diethyl malonate (18.5 mL, 121 mmol) in THF (200 mL) at 
0 C was added NaH (4.83 g, 120.8 mmol, 60% dispersion in mineral oil). The solution was 
stirred at 0 C for 20 min, warmed to rt, and stirred for an additional 30 min. Benzyl 
chloromethyl ether (10.0 mL, 50.3 mmol, ~70%) was added via syringe pump (0.1 mL/min)  
After the addition was complete, the reaction mixture was stirred for an additional 10 h at rt, 
quenched at 0 C by dropwise addition of H2O, dried (MgSO4), and filtered.  Most of the solvent 
was removed in vacuo. The concentrate was diluted with EtOAc (150 mL) and water (100 mL), 
and the aqueous portion was extracted with EtOAc (3 x 50 mL). The combined organic layers 
were washed with water and brine, dried (MgSO4) and concentrated in vacuo.  Excess diethyl 
malonate was removed via Kugelrohr distillation (90 C < T < 110 C at 3 Torr).   
 
The crude mixture was dissolved in Et2O (60 mL) and added to a solution of LAH (27.7 
mL, 111 mmol, c = 4.0 M in Et2O) in Et2O (200 mL) via syringe pump at 0 C (0.10 mL/min). 
The reaction mixture was warmed to rt, stirred for 12 h, and quenched at 0 C by sequential 
addition of water (4.2 mL), 15% aqueous NaOH (4.2  mL), and water (12.6  mL).  The slurry was 
stirred for 0.5 h, and the resultant solid was filtered and washed with Et2O and EtOAc. The 
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filtrate was concentrated in vacuo, and the residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 1:1 to EtOAc, 100%) to afford 1-63 (2.33 g, 24%) and 1-62 (353 mg, 2%). 
 
1-63. Obtained as a white solid: Rf 0.3 (100% EtOAc); Mp 41.2–43.1 °C 
(hexanes/EtOAc); IR (ATR) 3321, 3252, 2855, 1726, 1452, 1366, 1092, 1028 cm-1; 1H NMR 
(300 MHz, CDCl3)  7.37–7.32 (m, 5 H), 4.54 (s, 2 H), 3.84 (t, J = 5.0 Hz, 4H), 3.66 (d, J = 5.5 
Hz, 2 H), 2.16 (t, J = 5.2 Hz, 2 H), 2.07 (sept, J = 5.5 Hz, 1 H); 13C NMR (75 MHz, CDCl3)  
137.8, 128.5, 127.8, 127.6, 73.5, 70.5, 63.3, 42.7; MS (EI) m/z (rel. intensity) 197 (M+1, 8), 196 
(M+, 14), 178 (13), 177 (18), 120 (38), 108 (66), 92 (100), 79 (83), 65 (83), 57 (79); HRMS (EI) 
m/z calc for C11H16O3 196.1099, found 196.1103. 
 
1-62. Obtained as a white solid: Rf 0.6 (100% EtOAc); Mp 69.1–70.8 °C 
(hexanes/EtOAc) (lit.256 72-73 °C); IR (ATR) 3284, 2982, 1452, 1116, 1028, 731 cm-1;  1H NMR 
(300 MHz, CDCl3)  7.39–7.31 (m, 10 H), 4.51 (s, 4 H), 3.70 (d, J = 6.0 Hz, 4 H), 3.58 (s, 4 H), 
2.55 (t, J = 6.3 Hz, 2 H); 13C NMR (75 MHz, CDCl3)  137.8, 128.5, 127.8, 127.6, 73.7, 72.1, 
65.1, 44.9; MS (API-ES) m/z (rel. intensity) 339 (100). 
 
 
 
 
 
 
 
3-(Benzyloxymethyl)oxetane (1-64).  A solution of diol 1-63 (1.31 g, 6.67 mmol) in dry 
THF (16.5 mL) was treated with n-BuLi (4.87 mL, 6.68 mmol, c = 1.37 M in hexanes). The 
solution was stirred for 0.5 h at 0 C, and a solution of TsCl (1.30 g, 6.67 mmol) in dry THF (2.5 
mL) was added slowly via syringe. The reaction mixture was stirred for 1 h and subsequently 
treated with n-BuLi (4.87 mL, 6.68 mmol, c=1.37 M in hexanes), stirred at rt for 1 h, and heated 
at reflux for 15 h.  The mixture was cooled, and the majority of the THF was removed in vacuo.  
The concentrate was diluted with water and Et2O, and the aqueous portion was extracted with 
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Et2O (3 x 30 mL). The combined organic layers were washed with water and brine, dried 
(MgSO4) and concentrated in vacuo. The residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 3:1) to afford 1-64 (542 mg, 45%) as a colorless oil: Rf  0.2 (hexanes/EtOAc, 
3:1); IR (ATR) 2954, 2861, 1448, 1377, 1107, 975, 936 cm-1;  1H NMR (300 MHz, CDCl3)  
7.40–7.28 (m, 5 H), 4.81 (dd, J = 7.8, 6.2 Hz), 4.56 (s, 2 H), 4.46 (t, J = 6.0 Hz, 2 H), 3.72 (d, J = 
6.9 Hz, 2 H), 3.33–3.19 (m, 1 H); 13C NMR (300 MHz, CDCl3)  138.0, 128.4, 127.7, 127.6, 
74.7, 73.3, 71.8, 34.9; MS (EI) m/z (rel. intensity) 178 (M+, 12),120 (100), 107 (66), 91 (86); 
HRMS (EI) m/z calc for C11H14O2 178.0994, found 178.0991. 
 
 
 
 
 
 
2-(Hydroxymethyl)propane-1,3-diol (1-66).95  To a solution of triethyl 
methanetricarboxylate (27.0 mL, 125 mmol) in degassed THF (200 mL) was added BH3•Me2S 
(40.3 mL, 399 mmol). The reaction mixture was heated at reflux for 8 h, cooled, and MeOH (170 
mL) was added dropwise by addition funnel. After gas evolution had ceased, the solvent was 
removed in vacuo, and the crude residue was dissolved in MeOH (500 mL) and stirred for 12 h 
at rt. MeOH was removed under reduced pressure and the concentrate was purified by 
chromatography on SiO2 (CHCl3/MeOH, 5:1 to 3:1) to afford a yellow oil which was 
subsequently recrystallized from THF to afford 1-66 (8.61 g, 65%) as a white solid: 1H NMR 
(300 MHz, DMSO-d6)  4.28 (t, J = 5.2 Hz, 3 H), 3.39 (t, J = 5.6, 6H), 1.59 (sept, J = 5.9 Hz, 1 
H); MS (EI) m/z (rel. intensity) 107 (M+, 23), 70 (47), 58 (97); HRMS (EI+) calc for C4H11O3 
107.0708, found 107.0709. 
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3-Hydroxy-2-(hydroxymethyl)propyl 4-methylbenzenesulfonate (1-67).  A solution of 
1-66 (8.01 g, 75.5 mmol) in THF (440 mL) was treated with NaH (2.00 g, 79.3 mmol, 95%) at 0 
°C and stirred for 0.5 h.  A solution of TsCl (14.4 g, 75.5 mmol) in THF (60 mL) was added via 
syringe pump (0.25 mL/min). After the addition was complete, the mixture was quenched by 
dropwise addition of water, dried (MgSO4), filtered and concentrated in vacuo.  The crude 
residue was purified by chromatography on SiO2 (CH2Cl2/acetone, 9:1) to afford 1-67 (7.43 g, 
38%) as a pale brown oil: IR (ATR) 3563, 3496, 2950, 1705, 1351, 1170, 960, 811 cm-1; 1H 
NMR (300 MHz, CDCl3)  7.80 (d, J = 8.3 Hz, 2 H), 7.37 d, J = 8.1 Hz, 2 H), 4.19 (d, J = 6.2 
Hz, 2 H), 3.78 (d, J = 4.8 Hz, 4 H), 2.46 (s, 3 H), 2.25–2.02 (m, 3 H); 13C NMR (75 MHz, 
CDCl3)  145.1, 132.6, 130.0, 127.9, 68.4, 61.6, 42.2, 21.6; MS (EI) m/z (rel. intensity) 260 (M
+, 
22), 173 (84), 155 (40), 91 (100) 65 (70), 58 (96); HRMS (EI) m/z calc for C11H16O5S 260.0718, 
found 260.0718. 
 
 
 
 
 
 
Oxetane-3-ylmethanol (1-50). Via cyclization of 1-67: A solution of monotosylate 1-67 
(6.0 g, 23 mmol) in THF (30 mL) was added dropwise to a solution of t-BuOK (3.92 g, 34.9 
mmol) in THF (430 mL) over 1 h. The mixture was stirred for an additional 10 min and 
quenched with water, dried (MgSO4), filtered, and concentrated in vacuo. The residue was 
purified via Kugelrohr distillation (80 °C < T < 90 °C) to afford 1-50 (860 mg, 42%). 
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Via deprotection of 1-64: A solution of 1-64 (498 mg, 2.79 mmol) in EtOAc (28 mL) 
was treated with 10% Pd/C (1.5 g, 0.14 mmol). H2 (balloon) was drawn into solution via 
vacuum, and the mixture was maintained under a H2 atmosphere for 10 h at rt. The solution was 
filtered through a short pad of neutral Al2O3, and EtOAc was evaporated under reduced pressure.  
The residue was purified by chromatography on SiO2 (10% MeOH/CH2Cl2) to afford crude 1-64 
(158 mg, 64%):  1H NMR (300 MHz, CDCl3)  4.83 (dd, J = 7.7, 6.2 Hz, 2 H), 4.49 (t, J = 5.9 
Hz, 2 H), 3.91 (d, J = 6.6 Hz, 2 H), 3.24–3.10 (m, 1 H), 1.66 (bs, 1 H); MS (EI) m/z (rel. 
intensity) 88 (M+, 17), 71 (5), 58 (90), 57 (100); HRMS (EI) m/z calc for C4H8O2 88.0524, found 
88.0521.  
 
 
 
 
 
 
 
Oxetane-3-ylmethyl-4-bromobenzenesulfonate (1-68).  A solution of BsCl (2.22 g, 
8.50 mmol) in anhydrous pyridine (3.0 mL) at 0 °C was treated with alcohol 1-50 (515 mg, 5.80 
mmol) (the alcohol was massed in a pre-weighed syringe). The mixture was stirred for 2 h at 0 
°C and subsequently poured into ice-water (15 mL) and extracted with Et2O (3 x). The combined 
organic layers were washed with water (3 x), brine, dried (MgSO4), and concentrated in vacuo.  
Residual pyridine was removed by coevaporation with benzene (2 x).  The residue was dissolved 
in EtOAc, filtered through neutral Al2O3, and concentrated to afford 1-68 (930 mg, 52%) as a 
white solid: Mp 76.8–78.6 °C; IR (ATR) 2943, 2877, 1573, 1357, 1185, 1174, 958, 928 cm-1; 1H 
NMR (300 MHz, CDCl3)  7.82–7.71 (m, 4 H), 4.78 (dd, J = 7.7, 6.6 Hz, 2 H), 4.36 (t, J = 5.9 
Hz, 2 H), 4.31 (d, J = 7.0 Hz, 2 H), 3.39–3.25 (m, 1 H); 13C NMR (75 MHz, CDCl3)  134.7, 
132.7, 129.3, 73.2, 71.1, 34.0; MS (EI) m/z (rel. intensity) 307 (M
+
, 65), 219 (185), 157 (98), 76 
(91), 70 (96), 57 (77); HRMS (EI) m/z calc for C10H12O4SBr 306.9640, found 306.9636. 
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3,3’-Oxybis(methylene)dioxetane (1-49).  A solution of alcohol 1-50 (150 mg, 1.70 
mmol) in THF (15 mL) at 0 °C was treated with NaH (47 mg, 1.9 mmol, 95%) followed by a 
solution of brosylate 1-68 (627 mg, 2.04 mmol) in THF (2 mL). The mixture was heated at reflux 
for 20 h, cooled to rt, quenched by dropwise addition of water, dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by chromatography on SiO2 (CH2Cl2/acetone, 
9:1) to afford 1-49 (77 mg, 28%) as a yellow oil: IR (ATR) 2932, 2866, 947, 973, cm
-1
; 
1
H NMR 
(300 MHz, CDCl3)  4.77 (dd, J = 7.7, 6.2 Hz, 2 H), 4.41 (t, J = 5.9 Hz, 2 H), 3.68 (d, J = 6.9 
Hz, 2 H), 3.26–3.13 (m, 1 H); 13C NMR (75 MHz, CDCl3)  74.4, 72.7, 34.7; MS (EI) m/z (rel. 
intensity) 159 (M
+
, 13), 131 (49), 88 (49), 71 (85), 57 (99); HRMS (EI) m/z calc for C8H15O3 
(M+H) 159.1021, found 159.1028.  
 
 
 
 
 
 
Optimized procedure for scale-up of bis((3-methyloxetan-3-yl)methyl)sulfane (1-69). 
A 2-necked 1-L round-bottom flask equipped with internal thermometer and maintained under 
Ar atmosphere was charged with acetonitrile (1 L, degassed by sparging with Ar) and 3-
tosyloxymethyl-3-methyl-oxetane 1-40 (108 g, 421 mmol) (added portion-wise).  A solution of 
Na2S•9H2O (59.0 g, 240 mmol) in degassed water (100 mL) was added slowly via addition 
funnel (over ~10 min).   The mixture was heated to 70 °C over a period of 45 min and then 
maintained at 70 °C for 75 min.  
 
The mixture was cooled to rt and concentrated in vacuo to ~1/4 volume.  Water (500 mL) 
and EtOAc (700 mL) were added, the layers were separated, and the aqueous layer was extracted 
  
 191 
with EtOAc (3 x 500 mL).  The combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated in vacuo. The residue was taken up in EtOAc (200 mL) and washed 
with water (2 x 50 mL) and brine (2 x 50 mL), diluted with more EtOAc (200 mL) and dried 
(Na2SO4).  The solution was filtered and concentrated in vacuo, and the crude mixture was 
purified by Kugelrohr distillation (100-mL bulbs).  The fraction distilling at 8 Torr and T < 100 
°C was discarded; the product was collected at 1–2 Torr and 120 °C to afford 3 (33.2 g, 78%) as 
a yellow-green oil:  IR (ATR) 2925, 2860, 973, 830 cm-1; 1H NMR (300 MHz, CDCl3)  4.48 (d, 
J = 5.9 Hz, 4 H), 4.39 (d, J = 5.9 Hz, 4 H), 2.93 (s, 4 H), 1.39 (s, 6 H); 13C NMR (100 MHz, 
CDCl3)  81.7, 43.6, 40.2, 22.9; HRMS (ESI) m/z calc for C10H19O2S (M+H) 203.1106, found 
203.1109. 
 
 
 
 
 
 
MMS350: 3,3'-sulfinylbis(methylene)bis(3-methyloxetane) (1-70). A 2-L 3-necked 
round-bottom flask outfitted with a mechanical stirrer was charged with a solution of 1-69 (29.7 
g, 147 mmol) in MeOH (700 mL).  The solution was cooled to 0 °C, and a solution of NaIO4 
(31.4 g, 147 mmol) in water (360 mL) was added via addition funnel over 1 h. The mixture was 
warmed to rt and stirred for 18 h. The mixture was filtered through a coarse fritted filter, and the 
white precipitate was washed with MeOH (~200 mL).  The combined filtrate and washings were 
concentrated in vacuo.  Toluene (~500 mL, added in two portions) was added to remove residual 
water.   CH2Cl2 (800 mL) was added to the residue, followed by MgSO4. The mixture was 
filtered, and the filtrate was concentrated in vacuo to afford crude MMS350 (30.6 g) as a yellow-
tinted solid.  To the flask containing the crude solid was added toluene (480 mL), and the slurry 
was heated to 60 °C to affect complete dissolution. Decolorizing carbon was added, and the 
mixture was filtered (gravity, Whatman #1 filter paper) into a 1-L Erlenmeyer flask.  Distilled 
hexanes (120 mL) was added (until slight cloudiness was observed), and the suspension was 
allowed to stand overnight.  The crystals were filtered (Buchner funnel, aspirator, Whatman #1 
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filter paper) to afford MMS350 (crop 1, 14.7 g) as white needles.  The mother liquor was 
concentrated in vacuo, and the residue was recrystallized from toluene/hexanes to afford 
additional MMS350 (9.2 g) for a combined yield of MMS350 (23.9 g, 75%) as white needles: 
Mp 94.5–96.5 °C (toluene/hexanes); IR (ATR) 2938, 2861, 1456, 1381, 1025, 969 cm-1; 1H 
NMR (400 MHz, CDCl3)  4.78 (d, J = 6.4 Hz, 2 H), 4.59 (d, J = 6.0 Hz, 2 H), 4.47 (d, J = 6.0 
Hz, 2 H), 4.42 (d, J = 6.4 Hz, 2 H), 3.36 (d, J = 12.9 Hz, 2 H), 2.72 (d, J = 12.9 Hz, 2 H), 1.59 (s, 
6 H); 13C NMR (100 MHz, CDCl3)  82.3, 81.9, 61.7, 38.3, 23.4; HRMS (ESI) m/z calc for 
C10H19O3S (M+H) 219.1055, found 219.1043. 
 
 
 
 
 
 
3,3'-Sulfonylbis(methylene)bis(3-methyloxetane) (1-71).  A suspension of oxone (650 
mg, 1.06 mmol) in water (2.0 mL) was cooled to 10 oC and treated (dropwise) with a solution of 
1-69 (108 mg, 0.533 mmol) in MeOH (2.0 mL). The solution was warmed to rt and stirred for 1 
h.  MeOH was removed in vacuo, and the aqueous layer was diluted with water (5 mL) and 
extracted with CH2Cl2 (4 x 10 mL).  The combined organic layers were washed with brine (5 
mL), dried (MgSO4), and concentrated in vacuo to afford 1-71 (120 mg, 96%) as a white solid:  
Mp 93.495.1 oC; IR (ATR) 2949, 2867, 1456, 1301, 1277, 967 cm-1; 1H NMR (400 MHz, 
CDCl3)  4.68 (d, J = 6.4 Hz, 4 H), 4.46 (d, J = 6.4 Hz, 4 H), 3.43 (s, 4 H), 1.69 (s, 6 H); 
13C 
NMR (100 MHz, CDCl3)  82.2, 62.6, 37.9, 23.3; HRMS (APCI) m/z calc for C10H19O4S (M+H) 
235.1004, found 235.1032. 
  
Alternatively, sulfone 1-71 can be prepared by oxidation of sulfoxide 1-70 (MMS350). A 
suspension of oxone (3.10 g, 5.04 mmol) in deionized water (20 mL) was cooled to ca. 10 °C 
and treated (dropwise) with a solution of MMS350 (1.10 g, 5.04 mmol) in MeOH (20 mL). The 
solution was warmed to rt and stirred for 2 h.  MeOH was removed in vacuo, and the remaining 
suspension was diluted with water (30 mL) and CH2Cl2 (80 mL), and the aqueous layer was 
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extracted with CH2Cl2 (4 x 40 mL). The combined organic layers were washed with water (20 
mL) and brine (20 mL), dried (MgSO4), and concentrated in vacuo to afford 1-71 (1.08 g); the 
material was taken up in CH2Cl2 and filtered through a short plug of SiO2, flushing with CH2Cl2 
and 5% MeOH/CH2Cl2 to afford the 1-71 (1.05 g, 89%) as a white solid. 
 
 
  
 
 
 
Representative procedure for additions of MeMgBr to benzaldehyde (Table 1-23 
entry 6).  A flame-dried Schlenk tube equipped with an internal thermometer was charged with a 
4:1 solution of sulfide 1-69 and heptane (1.00 mL).  To the solution was added freshly distilled 
PhCHO (10.0 µL, 0.0985 mmol), and the solution was placed in an ice-water bath and cooled to 
0 °C.   MeMgBr (0.11 mL, 0.25 mmol, c = 2.30 M in Et2O) was added slowly via syringe.  The 
mixture was stirred for 25 min at 0 °C and warmed gradually to rt.  The turbid reaction mixture 
was stirred for 90 min at rt, quenched with saturated aqueous NH4Cl (1 mL) and water (1 mL), 
and diluted with water (2 mL) and Et2O (10 mL). The layers were separated, and the aqueous 
layer was extracted with Et2O (3 x 5 mL), washed with water and brine, dried (MgSO4) and 
concentrated in vacuo.  The concentrate was diluted with 5.0 mL ether, and an aliquot (~200 µL) 
was analyzed by GC.   The ratio of benzaldehyde to 1-phenylethanol refers to the relative areas 
of benzaldehyde and 1-phenylethanol.   Gas chromatography data were obtained on an Agilent 
Technologies Network GC system (6890N).  Components were separated using an Alltech 
Econo-CapTM ECTM-1 column (30 in length x 0.32 mm i.d.), t(benzaldehyde) = 4.57 min and t(1-
phenylethanol) = 5.49 min.  Helium (1.0 mL/min) was used as the carrier gas.  The flame 
ionization detector was heated to 250 oC and ignited using a mixture of compressed air (450 
mL/min) and hydrogen (40 mL/min) with a makeup gas of helium (50 mL/min).  All injections 
(1 L) were performed via autosampler as split injections (split ratio 50.0:1.0).  The GC oven 
temperature was started at 90 oC and ramped at 10 oC/min to 220 oC and held at 220 oC for 5 
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min.  For runs containing high boiling materials such as 15-crown-5, the run was held at 220 oC 
for 20 min.  
 
 
 
Synthesis of 1-(4-(trifluoromethyl)phenyl)propan-1-one (1-79) as a GC standard: 
N-methoxy-N-methyl-4-(trifluoromethyl)benzamide.  A slurry of p-trifluorobenzoyl 
chloride (0.180 mL, 252 mg, 1.21 mmol) and Weinreb amine-HCl (118 mg, 1.21 mmol) in 
CH2Cl2 (8 mL) was cooled to 0 °C and treated with pyridine (0.220 mL, 2.72 mmol). The 
mixture was stirred for 30 min at 0 °C and then for 1 h at rt. To the mixture was added 1 M 
aqueous HCl (3 mL), and water (15 mL), and the aqueous layer was separated and extracted with 
Et2O (2 x 10 mL).  The combined organic layers were washed twice with saturated aqueous 
NaHCO3, once with brine, dried (MgSO4), and concentrated in vacuo to afford N-methoxy-N-
methyl-4-(trifluoromethyl)benzamide (249 mg, 88%) as a colorless oil.  Spectral data matched 
those previously reported:257 1H NMR (400 HHz, CDCl3)  7.80 (d, J = 8.2 Hz, 2 H), 7.68 (d, J = 
8.2 Hz, 2 H), 3.54 (s, 3 H), 3.39 (s, 3 H). 
 
1-(4-(Trifluoromethyl)phenyl)propan-1-one (1-79).  A solution of N-methoxy-N-
methyl-4-(trifluoromethyl)benzamide (237 mg, 1.02 mmol) in THF (20 mL) was treated at 0 °C 
with EtMgBr (0.75 mL, 1.1 mmol, c = 1.5 M in THF).  The solution was warmed gradually to rt 
over 2 h.  Additional EtMgBr (0.10 mL) was added at 0 °C, and the solution was warmed to rt 
and stirred for 30 min.  The reaction mixture was cooled to 0 °C, quenched with saturated 
aqueous NH4Cl (5 mL), and diluted with water (10 mL) and Et2O (30 mL).  The aqueous layer 
was extracted with Et2O (2 x 20 mL), and the combined organic layers were washed with brine, 
dried (MgSO4), and concentrated in vacuo. Purification by chromatography on SiO2 
(pentane/ether 4:1, then 100% EtOAc) afforded 1-79 (108 mg, 53%) as a white solid.  Spectral 
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data corresponded to those previously reported258,259:  1H NMR (300 MHz, CDCl3)  8.08 (d, J = 
8.1 Hz, 2 H), 7.74 (d, J = 8.2 Hz, 2 H), 3.05 (q, J = 7.2 Hz, 2 H), 1.26 (t, J = 7.2 Hz, 3 H).   
 
 
 Representative procedure for addition of EtMgBr to p-trifluoromethylbenzoyl 
chloride (Table 1-23, entry 2).  A solution of 1-69 (0.14 mL, 0.76 mmol) in THF (2.5 mL) was 
cooled to 0 °C, stirred for 15 min, and treated dropwise with EtMgBr (0.43 mL, 0.76 mmol).  
The solution was added using a syringe pump (0.24 mL/min) to a solution of p-
trifluoromethylbenzoyl chloride 1-78 (120 mg, 0.59 mmol) in THF (1.2 mL) (Note: the solution 
was prepared in a flame-dried Schlenk tube equipped with an internal thermometer and was 
cooled to an internal temperature of -60 °C.)  The solution temperature stayed between -55 °C 
and -60 °C throughout the addition, and the solution remained white/clear in color.  The solution 
was stirred for an additional 10 min following completion of the Grignard addition, and the 
solution was quenched at -60 °C with saturated aqueous NH4Cl (1.0 mL) and diluted with water 
(2 mL) and Et2O (3 mL). The layers were separated, and the aqueous layer was extracted with 
Et2O (2 mL), and the combined organic layers were washed with brine and then transferred to a 
10 mL volumetric flask, which was filled to the mark with Et2O. A 1.00 mL aliquot was filtered 
into a GC autosampler vial and spiked with dodecane (10 µL) and analyzed by GC. This analysis 
was performed in triplicate (i.e, 3 1.00 mL aliquots were spiked and analyzed).  GC yields are 
based on a response curve of mmol ratio 1-(4-(trifluoromethyl)phenyl)propan-1-one:dodecane 
versus respective area ratios.  
 
Gas chromatography data were obtained on an Agilent Technologies Network GC system 
(6890N).  Components were separated using an Alltech Econo-CapTM ECTM-1 column (30 in 
length x 0.32 mm i.d.), t(1-(4-(trifluoromethyl)phenyl)propan-1-one) = 5.94 min and t(dodecane) 
= 6.44 min.  Helium (1.0 mL/min) was used as the carrier gas.  The flame ionization detector was 
heated to 250 oC and ignited using a mixture of compressed air (450 mL/min) and hydrogen (40 
mL/min) with a makeup gas of helium (50 mL/min).  All injections (1 L) were performed via 
autosampler as split injections (split ratio 50.0: 1.0).  The GC oven temperature was started at 90 
oC and ramped at 10 oC/min to 220 oC and held at 220 oC for 5 min.  
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Preparation of substrates for Mg/I exchange reactions (Figure 1-10).   
 Methyl 4-iodobenzoate 1-80 was purchased from a commercial vendor and used as received.  
Methyl 3-iodobenzoate 1-81 and Methyl 4-iodo-3-methoxybenzoate 1-82 were synthesized as 
described below: 
 
 
 
 
 
Methyl 3-iodobenzoate (1-81).  A solution of 3-iodobenzoic acid (5.00 g, 20 mmol) in 
absolute MeOH (100 mL) was treated with concentrated H2SO4 (2.5 mL) and heated at reflux for 
18 h.  MeOH was removed by distillation until the pot contained ~1/4 volume of the reaction 
mixture. Upon cooling, the concentrated mixture was dissolved in ether (200 mL) and washed 
with water (150 mL), saturated aqueous NaHCO3 (50 mL) and brine (50 mL), dried (MgSO4), 
filtered, and concentrated in vacuo to afford 4.90 g white/yellow solid.  The residue was 
dissolved in MeOH (~10 mL), heated to boiling, cooled to rt, then to 0 oC. Upon cooling to 0 oC 
a white solid precipitated. The solid was collected by filtration and washed with cold MeOH 
(~10 mL) to afford methyl-3-iodobenzoate (3.67 g, 69%) as a white solid: Mp 47.3–49.0 oC 
(MeOH) (lit.260 50–52 oC); 1H NMR (400 MHz, CDCl3)  8.39 (t, J = 1.6 Hz, 1 H), 8.01 (d, J = 
7.8 Hz, 1 H), 7.90 (d, J = 7.9 Hz, 1 H), 7.20 (t, J = 7.8 Hz, 1 H), 3.93 (s, 3 H). 
 
 
 
 
Methyl 3-methoxy-4-nitrobenzoate.261 A flame-dried 50-mL round-bottom flask was 
charged with 3-hydroxy-4-nitrobenzoic acid (3.00 g, 16 mmol), dry DMF (17 mL) and powdered 
K2CO3 (6.79 g, 49 mmol). The solution was cooled to 0 
oC and MeI (2.2 mL, 36 mmol) was 
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added via syringe. The reaction mixture was warmed to rt and stirred overnight (18 h). The 
mixture was poured into water (80 mL), and the flask was rinsed with water and toluene. The 
aqueous layer was extracted with toluene (2 x 75 mL)  The combined organic layers were 
washed with 0.1 M aqueous NaOH (50 mL), water (50 mL), and brine (50 mL), dried (Na2SO4) 
and concentrated in vacuo to afford methyl 3-methoxy-4-nitrobenzoate (1.77 g, 51%) as an 
orange, crystalline solid:  1H NMR (400 MHz, CDCl3)  7.85 (d, J = 8.3 Hz, 1 H), 7.77 (d, J = 
1.4 Hz, 1 H), 7.70 (dd, J = 8.3, 1.6 Hz, 1 H), 4.03 (s, 3 H), 3.98 (s, 3 H).   
 
Methyl 4-amino-3-methoxybenzoate.261  A solution of methyl 3-methoxy-4-
nitrobenzoate (1.77 g, 8.38 mmol) in MeOH (250 mL) was treated with 10% Pd/C (360 mg) and 
stirred under an H2 atmosphere for 15 h. The reaction mixture was filtered through a pad of 
Celite, (washing with MeOH) and concentrated in vacuo to afford methyl 4-amino-3-
methoxybenzoate (1.37 g, 90% crude) as a tan solid:  Mp 126.8–128.8 oC (lit.261 128 oC);  1H 
NMR (400 MHz, CDCl3)  7.55 (dd, J = 8.2, 1.6 Hz, 1 H), 7.46 (d, J = 1.6 Hz, 1 H), 6.67 (d, J = 
8.2 Hz, 1 H), 4.21 (bs, 2 H), 3.91 (s, 3 H), 3.87 (s, 3 H).   
 
Methyl 4-iodo-3-methoxybenzoate (1-82).261  A 100-mL round-bottom flask with a 
24/40 jointed neck was charged with 4-amino-3-methoxybenzoate (1.20 g, 6.62 mmol), 
deionized water (16 ml) and 20% H2SO4 (3.6 mL). The suspension was cooled to 0 
oC and 
capped with a septum and an empty balloon. A solution of NaNO2 (503 mg, 7.29 mmol) in water 
(3.0 mL) was added slowly, and the suspension became bright yellow in color. The solution was 
stirred for 15 min, and urea (120 mg) was added, followed almost immediately by dropwise 
addition of a solution of KI (1.15 g, 6.95 mmol) in water (3.0 mL). The solution (deep brown) 
was stirred at 0 oC to rt for 20 min, and then moved to a pre-heated oil bath (50 oC) and stirred at 
50 oC for 2 h. To the reaction mixture was added a solution of saturated aqueous Na2S2O5 (~15 
mL), and the mixture was extracted with Et2O (3 x 20 mL). The aqueous layer was neutralized 
with 1 N aqueous NaOH and extracted with Et2O (once). The combined organic layers (deep 
orange/red) were washed with 1 N NaOH and brine (2x), dried (Na2SO4) and concentrated in 
vacuo to afford a crude brown residue (1.63 g).  Purification by chromatography on neutral Al-
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2O3
 (pentane/Et2O, 95:5 to 90:10) afforded 1-82 (1.03 g, 53%) as a slightly yellow oil.  The 
product was further purified by recrystallization from MeOH as follows:   
The oil was dissolved in MeOH (5 mL), heated to boiling, and cooled to -20 oC.  The crystals 
were collected by filtration and washing with cold MeOH.  The mother liquor was concentrated, 
and trituration of the resulting solid with MeOH afforded additional 1-82 (100 mg) for a total 
yield of 1-82 (700 mg, 36%) as a white solid: Mp 53.5–55.2 oC (MeOH) (lit.261 50–52 oC); 1H 
NMR (300 MHz, CDCl3)  7.87 (d, J = 8.1 Hz, 1 H), 7.46 (d, J = 1.8 Hz, 1 H), 7.38 (dd, J = 8.1, 
1.8 Hz, 1 H), 3.95 (s, 3 H), 3.93 (s, 3 H). 
 
 
 
 
General procedure for the Mg/I exchange reaction using i-PrMgCl in different 
media (Table 1-24, entry 6).101 A flame-dried 25-mL round-bottom flask was charged with 
freshly distilled THF (4.9 mL) and sulfide 1=69 (243 mg, 1.20 mmol) and cooled in an ice-water 
bath maintained at 15 oC. i-PrMgCl (0.690 mL, 1.20 mmol, c = 1.75 M in THF) was added 
slowly via syringe. (Note: the solution became cloudy and white). The solution was stirred at 15 
oC for 20 min and then methyl 3-iodobenzoate (262 mg, 1.00 mmol) in THF (0.71 mL) was 
added slowly via syringe. The ice-water bath was removed, and the reaction mixture was stirred 
at ambient temperature for 10 min.  The reaction mixture was quenched with saturated aqueous 
NH4Cl
 (1 mL) and poured into a separatory funnel.  EtOAc (10 mL) and water (5 mL) were 
added. The layers were separated, and the organic layer was washed with brine (5 mL). The 
organic layer was spiked with dodecane (100 µL). An aliquot (0.1 mL) was transferred to a GC 
autosampler vial and diluted with additional EtOAc (0.4 mL).  GC yields were determined using  
based on the area ratio of methyl benzoate and dodecane; an area ratio to mmol ratio relationship 
was determined by generating a calibration curve with known mmol ratios of methyl benzoate 
and dodecane.   Note: In the case of reactions with substrate 1-82, the GC yields are estimated 
assuming that the response of methyl 3-methoxybenzoate is similar to that of methyl benzoate. 
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Gas chromatography data were obtained on an Agilent Technologies Network GC system 
(6890N).  Components were separated using an Agilent HP-5 column (30.0 m x 320 µm x 0.25 
µm (nominal)), t(methyl benzoate) = 5.43 min,  t(dodecane) =6.43 min and t(methyl 3-
iodobenzoate) = 9.79 min.  Helium (1.0 mL/min, 6.33 psi) was used as the carrier gas.  The 
flame ionization detector was heated to 250 oC and ignited using a mixture of compressed air 
(450 mL/min) and hydrogen (40 mL/min) with a makeup gas of helium (45 mL/min).  All 
injections (1 L) were performed via autosampler as split injections (split ratio 50.0:1.0).  The 
GC oven temperature was started at 90 oC and ramped at 10 oC/min to 250 oC and held at 250 oC 
for 5 min.  
 
 
 
 
 
 
 Representative procedure for asymmetric Grignard additions to benzaldehyde 
(Table 1-25, entry 2).102  A flame-dried 10-mL round-bottom flask was flushed with Ar and 
charged with (S)-BINOL (24.2 mg, 0.0848 mmol) and distilled MTBE (2.2 mL).  Ti(Oi-Pr)4 was 
added dropwise via syringe, and the resulting bright orange/yellow solution was stirred for 30 
min at rt.  A second flame-dried 10-mL round-bottom flask was flushed with Ar and charged 
with sulfide 1-69 (229 mg, 1.13 mmol) and dry MTBE (2.2 mL) and cooled to 0 °C.  i-BuMgBr 
(1.3 mL, 1.1 mmol, c = 0.90 M in THF) was added slowly via syringe over the course of 6 min.  
The cloudy white solution was stirred for 30 min at 0 °C.  The Ti(Oi-Pr)2-BINOL solution was 
slowly added to the Grignard solution at 0 °C, and the mixture was allowed to warm to ambient 
temperature.  The mixture was stirred for a total time of 1 h at rt.  The reaction mixture was 
cooled to –5 °C (ice/salt bath), and freshly distilled PhCHO (60.0 µL, 0.565 mmol) was added 
dropwise via syringe.  The ice bath was removed, and the mixture was allowed to warm to rt.  
The mixture was stirred under Ar at rt for 20 h and quenched with 5% aqueous HCl  (3 mL) and 
extracted with Et2O (3 x 10 mL). The combined organic layers were washed with saturated 
aqueous NaHCO3 and brine, dried (Na2SO4) and concentrated in vacuo. Purification by 
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chromatography on SiO2 (pentane/Et2O, 4:1) afforded an analytically clean sample (3 mg) as 
well as other product containing impurities (11 mg).   The enantiomeric excess was determined 
to be 95% by chiral HPLC analysis (Chiralcel OD, 5% isopropanol/hexanes, 1.0 mL/min, 220 
nm) tr(major) = 7.1 min, tr(minor) = 8.0 min.  
 
Synthesis of rac-1-83 for us as an HPLC standard. 
 
 
 
 
3-Methyl-1-phenylbutan-1-ol (rac-1-83).262,263 A flame-dried Schlenk flask was charged 
with activated Mg turnings (53 mg, 2.2 mmol), distilled THF (5 mL) and 1-bromo-2-
methylpropane (0.100 mL) and an iodine crystal.   The vessel was gently warmed with a heating 
mantle until dissipation of the iodine color was observed.  Additional 1-bromo-2-methylpropane 
(0.14 mL) in THF (5 mL) was added slowly via syringe. The now cloudy solution was stirred an 
additional 2 h at rt. The mixture was cooled to 0 °C, and freshly distilled benzaldehyde (100 µL, 
0.985 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 20 min and then 
quenched with saturated aqueous NH4Cl.  The mixture was diluted with Et2O (20 mL) and water 
(10 mL), and the aqueous layer was extracted with Et2O (2 x 10 mL).  The combined organic 
layers were washed with water and brine, dried (MgSO4) and concentrated in vacuo. The crude 
material was purified by chromatography on SiO2 (pentane/Et2O, 85:15) to afford rac-1-83 (94 
mg, 58%) as a colorless oil:  1H NMR (300 MHz, CDCl3)  7.36 (d, J = 4.3 Hz, 4 H), 7.337.28 
(m, 1 H), 4.794.73 (m, 1 H), 1.801.63 (m, 2 H), 1.571.43 (m, 1 H), 0.96 (dd, J = 6.4, 1.1 Hz, 
6 H).   
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Representative procedure for Mg/Br exchange reactions of 4-bromoanisole (Table 
1-26, entry 4).  An oven-dried microwave vial equipped with stir bar was cooled under Ar 
atmosphere and back-filled with Ar 3 times.  To the flask was added a solution of i-PrMgCl-LiCl 
in THF (0.840 mL, 1.05 mmol, c = 1.25 M in THF), followed by distilled THF (0.16 mL).   4-
Bromoanisole (125 µL, 1.00 mmol) was added at rt. Sulfide 1-69 (201 mg 1.00 mmol) was 
added in one portion. (Note: sulfide 1-69 was dried by neat filtration through activated basic 
Al2O3).  The reaction mixture was stirred at rt for 24 h. The mixture was quenched with saturated 
aqueous NH4Cl (3 mL), and diluted with water (3 mL) and Et2O (10 mL).  The layers were 
separated, and the organic layer was spiked with dodecane (100 µL). An aliquot of the organic 
layer was filtered through a short cotton plug and analyzed by GC. Conversion/yields are based 
on calibrations of the relative concentration to area response of 4-bromoanisole, anisole and 
dodecane.   
 
Gas chromatography data were obtained on an Agilent Technologies Network GC system 
(6890N).  Components were separated using an Alltech Econo-CapTM ECTM-1 column (30 in 
length x 0.32 mm i.d.), t(anisole) = 3.90 min and t(dodecane) = 6.44 min, and t(4-bromoanisole) 
= 6.56 min.  Helium (1.0 mL/min) was used as the carrier gas.  The flame ionization detector was 
heated to 250 oC and ignited using a mixture of compressed air (450 mL/min) and hydrogen (40 
mL/min) with a makeup gas of helium (50 mL/min).  All injections (1 L) were performed via 
autosampler as split injections (split ratio 50.0: 1.0).  The GC oven temperature was started at 90 
oC and ramped at 10 oC/min to 220 oC and held at 220 oC for 5 min.  For experiments using high 
boiling materials such as 15-crown-5, the run was held at 220 oC for 20 min.   
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Representative procedure for addition of EtMgBr to benzonitrile (Table 1-27, entry 
2).   A flame-dried thick-walled vial was flushed with N2 and charged with distilled Et2O (1.10 
ml) and 0 sulfide 1-69 (0.13 mL, 140 mg, 0.68 mmol).  To the solution was added freshly 
distilled benzonitrile (20 µL, 0.19 mmol) and EtMgBr (0.12 mL, 0.29 mmol, c = 2.4 M in Et2O).  
The reaction mixture was stirred under N2 atmosphere for 3 h at rt.  An aliquot (100 µL) was 
removed, quenched with 1 N aqueous HCl, and partitioned into EtOAc for GC analysis. The 
reaction mixture was flushed with Ar, sealed, and stirred at rt for an additional 12 h.  The 
reaction mixture was cooled to 0 °C, and 1 N aqueous HCl (0.50 mL) was slowly added.  The 
solution was warmed to rt and stirred for 20 min.   The solution was extracted with Et2O (1 mL), 
and the ethereal layer was washed with saturated aqueous NaHCO3 and filtered for GC analysis.  
The reported ratios of benzonitrile to propiophenone are based on an area ratio to mmol ratio 
response curve of known ratios of benzonitrile and propiophenone. 
 
 Gas chromatography data were obtained on an Agilent Technologies Network GC 
system (6890N).  Components were separated using an Alltech Econo-CapTM ECTM-1 column 
(30 in length x 0.32 mm i.d.), t(benzonitrile) 4.23 min and t(propiophenone) = 6.20 min.  Helium 
(1.0 mL/min) was used as the carrier gas.  The flame ionization detector was heated to 250 oC 
and ignited using a mixture of compressed air (450 mL/min) and hydrogen (40 mL/min) with a 
makeup gas of helium (50 mL/min).  All injections (1 L) were performed via autosampler as 
split injections (split ratio 50.0: 1.0).  The GC oven temperature was started at 90 oC and ramped 
at 10 oC/min to 220 oC and held at 220 oC for 5 min.  
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Representative procedure for addition of EtMgBr to enone 1-88 (Table 1-28, entry 
3).   A flame-dried Schlenk tube cooled under N2 was charged with CuBr2 (2.2 mg, 0.010 mmol) 
and then equipped with an internal thermometer.  The tube was charged with Et2O (1.0 mL), 
followed by sulfide 1 (20 mg, ~0.02 mL, 0.010 mmol).   A solution of 14 (75.0 mg, 0.513 mmol) 
in Et2O (1.0 mL) was added at rt.  The solution was cooled to -30 °C (Tint), and the temperature 
was maintained using a cryocool.  A solution of EtMgBr (0.43 mL, 1.0 mmol, c = 2.4 M in Et2O) 
further diluted Et2O (1.5 mL) was added via syringe pump over 40 min. The reaction mixture 
was maintained at -30 °C for 2 h after the addition was complete.  The reaction mixture was 
quenched with saturated aqueous NH4Cl and extracted into Et2O (3 x). The ethereal layers were 
washed with brine, dried (MgSO4) and concentrated in vacuo. The crude concentrate was 
purified by chromatography on SiO2 (pentane/Et2O, 4:1 deactivated with 0.1% Et3N) to afford 1-
89 (27 mg, 30%) as a yellow oil and 1,2-product 1-90 (23 mg, 20%, ~80% purity) as yellow oil. 
 
1-89.264 1H NMR (400 MHz, CDCl3)  7.337.28 (m, 2 H), 7.237.18 (m, 3 H), 
3.093.02 (m, 1 H), 2.75 (d, J = 7.2 Hz, 2 H), 2.04 (s, 3 H), 1.761.65 (m, 1 H), 1.631.53 (m, 1 
H), 0.80 (t, J = 7.4 Hz, 3 H).   
 
1-90. 1H NMR (400 MHz, CDCl3)  7.23 (d, J = 7.2 Hz, 1 H), 7.34 (t, J = 7.6 Hz, 2 H), 
7.287.18 (m, 2 H), 6.62 (d, J = 16.4 Hz, 1 H), 6.30 (d, J = 16.4 Hz, 1 H), 1.69 (q, J = 7.2 Hz, 2 
H), 1.50 (b, 1 H), 1.40 (s, 3 H), 0.96 (t, J = 7.2 Hz, 3 H).   
 
Determination of LogP value of MMS350 (1-70).  The logP (octanol-water partition 
coefficient) was determined using the shake-flask method.  Three determinations were made.  A 
representative procedure is as follows:  a 250-mL separatory funnel was charged with a solution 
of MMS350 (50.0 mg) in water (50.0 mL) and n-octanol (50.0 mL).   The funnel was capped and 
inverted 100 times.  The funnel and contents were left to stand at rt (23.5 oC) for 40 h.  Aliquots 
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of both phases were analyzed by UV/VIS (214 nm for the aqueous layer and 218 nm for the 
octanol layer), and the concentration in each layer was determined using previously generated 
calibration curves.  In the case of the aqueous layer, a 10-fold dilution was necessary prior to 
measurement.  All measurements were run in triplicate.  The logP was determined as log 
([MMS350]octanol/[MMS350]aqueous), and the average logP value from the 3 trials was -0.87. 
 
 
General procedure for determination of solubility in solutions of MMS350 and HPLC-
grade water.     
 
Preparation of sulfoxide/water solutions.  Solutions of MMS350 and HPLC-grade water 
were prepared in 1 dram vials by dissolving the appropriate amount of MMS350 in HPLC-grade 
water (2.00 mL).   In the case of the 25% solution of MMS350 in H2O (w/w), MMS350 (500 
mg) was dissolved in water (1.50 mL).  Each vial was placed on a platform shaker and shaken at 
200 rpm for 30 min. 
 
Solubility measurements.  Eppendorf vials (1.5 mL size) were charged with model 
compounds in excess.  Vials were charged with HPLC-grade water (0.500 mL) or the appropriate 
3/water solution (0.500 mL).  The vials were briefly vortexed and equilibrated in an end-over-
end rotator at 30.0 °C for 20 h.  The vials were centrifuged (4000 rpm, 1300 xg, 15 min, rt) 
directly after removal from the rotator, and aliquots of the supernatant (0.400 mL) were filtered 
through 0.45 µm syringe filters. The pH of each solution was measured using a ThermoScientific 
electrode (3 mm tip).   Each solution was diluted with an appropriate volume of either absolute 
ethanol (quinine, naproxen, griseofulvin) or methanol (carbendazim).  Concentrations were 
calculated by using previously generated calibration curves.  Appropriate blanks were prepared 
by diluting aliquots (0.400 mL) of the MMS350/water solutions (or HPLC-grade water in the 
case of the control) in an analogous fashion to the sample being measured. 
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General procedure for determination of solubility in solutions of DMSO and HPLC-grade 
water.     
 
Preparation of DMSO/water solutions.  Solutions of DMSO and HPLC-grade water were 
prepared in 1 dram vials by dissolving the appropriate amount of DMSO in HPLC-grade water 
(2.00 mL).  Each vial was placed on a platform shaker and shaken at 200 rpm for 30 min. 
 
Solubility measurements.  Eppendorf vials (1.5 mL size) were charged with model  
compounds in excess.  Vials were charged with either HPLC-grade water (1.00 mL) or the 
appropriate DMSO/water solution (1.00 mL).  The vials were briefly vortexed and equilibrated 
in an end-over-end rotator at 30.0 °C for 20 h.  The vials were centrifuged directly after removal 
from the rotator (4000 rpm, 1300 xg, 15 min, rt), and aliquots of the supernatant (0.800 mL) were 
filtered through 0.45 µm syringe filters.  The pH of each solution was measured using a 
ThermoScientific electrode (3 mm tip).  Each solution was diluted with an appropriate volume of 
either absolute ethanol (quinine, naproxen, griseofulvin) or methanol (carbendazim).  
Concentrations were calculated by using previously generated calibration curves.  Appropriate 
blanks were prepared by diluting aliquots (0.800 mL) of the DMSO/water solutions (or HPLC-
grade water in the case of the control) in analogous fashion to the sample being measured. 
 
General procedure for determination of estrone solubility in solutions of MMS350 
and pH 9.0 buffer. 
 
Preparation of sulfoxide/buffer solutions.   A 25% w/w solution of MMS350 in pH 9.0 
buffer was prepared by dissolving MMS350 (565 mg) in pH 9.0 buffer (1.70 mL).  A 3:1 
buffer/NMP solution was prepared from pH 9.0 buffer (3.00 mL) and NMP (1.00 mL).  A 3:1:1 
buffer/NMP/MMS350 solution was prepared from pH 9.0 buffer (1.50 mL), NMP (0.500 mL), 
and MMS350 (515 mg).  
 
A 25% DMSO/buffer w/w solution was prepared by mixing anhydrous DMSO (1.54 mL) 
with pH 9.0 buffer (5.10 mL).  A 3:1:1  pH 9.0 buffer:NMP:DMSO solution was prepared by 
  
 206 
mixing NMP (1.50 mL), DMSO 1.40 mL, and pH 9.0 buffer (4.50 mL).  Each vial was placed on 
a platform shaker and shaken at 200 rpm for 30 min.  
 
Solubility measurements.  Eppendorf vials (1.5 mL size) were charged with estrone  in 
excess.  Vials were charged with 0.500 mL of either pH 9.0 buffer (control) or the appropriate 
solution described above.  The vials were briefly vortexed and equilibrated in an end-over-end 
rotator at 30.0 °C for 20 h.  Aliquots (0.40 mL) were filtered through 0.45 µm syringe filters. The 
pH of each solution was measured using a ThermoScientific electrode (3 mm tip).   Each 
solution was diluted with an appropriate volume of either absolute ethanol and analyzed by 
UV/VIS.  Concentrations were verified by preparing standards of estrone in the appropriate 
ethanol/sulfoxide/buffer solutions.  Appropriate blanks were prepared by diluting 0.400 mL 
aliquots of the buffer solutions (or 0.400 mL buffer in the case of the control) in analogous 
fashion to the sample being measured. 
 
General procedure for solubility determination in mixtures of sulfoxide MMS350 in pH 7.0 
buffer.   
 
Preparation of sulfoxide/buffer solutions.  In the case of a 10% w/w solution of sulfoxide 
MMS350 in 0.01 M pH 7.0 phosphate buffer, MMS350 (700 mg) was dissolved in 0.01 M Na-
2HPO4/NaH2PO4 buffer (6.30 mL) and equilibrated on a platform shaker at 200 rpm for 30 min. 
at rt.  In the case of a 25% w/w solution of sulfoxide MMS350 in 0.01 M pH 7.0 phosphate 
buffer, MMS350 (1.50 g) was dissolved in 0.01 M Na2HPO4/NaH2PO4 buffer (4.50 mL) and 
equilibrated on a platform shaker at 200 rpm for 30 min. at rt. 
 
Solubility measurements.  Eppendorf vials (1.5 mL size) were charged with model 
compounds in excess.  Vials were charged with either pH 7.0 phosphate buffer (1.00 mL) or the 
appropriate MMS350/buffer solution.  The vials were briefly vortexed and equilibrated in an 
end-over-end rotator at 30.0 °C for 20 h.  The vials were centrifuged directly after removal from 
the rotator (4000 rpm, 1300 xg, 15 min, rt), and aliquots of the supernatant (0.800 mL) were 
filtered through 0.45 µm syringe filters.  The pH of each solution was measured using a 
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ThermoScientific electrode (3 mm tip) after calibration.  Each solution was diluted with an 
appropriate volume of either absolute ethanol (quinine, naproxen) or methanol (carbendazim).  
Concentrations were determined using standard additions of a stock solution of the compound in 
either absolute ethanol (quinine, naproxen) or methanol (carbendazim) to aliquots of the diluted 
filtrates. 
 
General procedure for kinetic solubility measurements.  A polypropylene tube was 
charged with PBS solution (490 µL).  To the buffer was added a 10 mM stock solution of 
compound (10 µL).  The tube was vortexed and equilibrated on an end-over-end rotator for 15 
min at rt.  Aliquots (400 µL) were filtered through 0.45 µm syringe filters and diluted to 5.0 mL 
with absolute MeOH.  Concentrations were determined by UV/VIS analysis. 
 
General procedure for calculation of water absorption.  Oven-dried flasks capped 
with septa were cooled under a N2 atmosphere and charged with a volume of the appropriate 
solutions (DMSO, 3.0 mL; NMP, 600 µL; 25% MMS350/NMP, 600 µL).  The water content 
was determined by Karl Fischer titration using ~100 µL aliquots (t = 0 measurement).  Each 
septum was pierced with a 1.5 inch 18 gauge needle and left to stand at rt for 7 d.  The water 
content was measured at the end of this period (t = 7 d measurement) by Karl Fischer titration.  
All measurements were made in duplicate.   
 
General procedure for brine shrimp toxicity assays.265 
 Sample preparation.  Stock solutions of MMS350 were prepared by dissolving 
MMS350 (50.0 mg) in 5.0 HPLC grade water (5.0 mL), (solution A) and MMS350 (2.50 g) in 
HPLC grade water (10.0 mL) (solution B).  Stock solutions of DMSO were prepared by diluting 
DMSO (45 L) with with HPLC grade water (5.0 mL) (solution C) and DMSO (2.27 mL) with 
HPLC grade water (10.0 mL ) (solution D).   
 
In each case, 5 replicates were performed.  Each replicate was performed in a 2 dram vial 
marked at the 4 and 5 mL volume points.  To each vial was added artificial sea water (3 mL) 
followed by the appropriate volume of stock solution.  For set 1 (1.0 mg/mL), solution A (0.500 
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mL) or solution C (0.500 mL) was added.  For set 2 (5.0 mg/mL), solution B (0.100  mL) or 
solution D (0.100 mL) was added to each vial.  For set 3 (20.0 mg/mL), solution B (0.400 mL ) 
or solution D (0.400 mL) was added to each vial.  For set 4 (50.0 mg/mL), solution B (1.00 mL) 
or solution D (1.00 mL) was added to each vial.   Controls containing HPLC grade water (0.100 
mL, 0.400 mL, and 1.00 mL ) were prepared in the same manner, and five replicates of each 
control were prepared.   
 
Brine shrimp hatching.  Brine shrimp eggs (San Francisco Bay Brand) were hatched in a 
commercial salt mixture (Instant Ocean).  Constant aeration was provided using a pump and 
airstone, and illumination was maintained using a desk lamp.  The shrimp were collected in a 
separate tank after 48 h and used within 3-4 h of collection. 
 
Assay.  Brine shrimp (10) were added to each vial using a plastic transfer pipet.  After the 
shrimp were transferred, artificial sea-water was added until the volume reached the 5-mL mark.  
One drop of a yeast suspension prepared by suspending 11 mg yeast in sea-water (20 mL) was 
added to each vial.  The shrimp were counted at t = 24 h.   Another drop of freshly prepared 
yeast solution (6 mg in 10 mL sea water) was added, the vials were maintained under 
illumination, and shrimp were counted at t = 48 h. 
 
 
 
 
 
 
2,2'-Sulfinylbis(methylene)bis(2-methylpropane-1,3-diol) (MMS399).  A solution of 
MMS350 (200 mg, 0.916 mmol) in 0.5 M aqueous H2SO4 (6 mL) was heated at 65 °C for 10 h.  
The solution was neutralized with solid NaHCO3, and water was removed in vacuo.  The 
concentrated solids were suspended in EtOH and filtered through a short plug of Celite, and the 
filtrate was concentrated in vacuo.  The residue was dissolved in water, and insoluble materials 
were removed by filtration through a 0.65 µm PVDF filter. The filtrate was concentrated in 
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vacuo, and the residue was dissolved in water, transferred to a scintillation vial, and water was 
removed using the Genevac (EZ-2, 45 °C) to afford MMS399 (226 mg, 97%) as a viscous pale 
yellow oil:  IR (ATR) 3314, 3294, 2929, 1463, 1035 cm-1; 1H NMR (400 MHz, D2O)
a  3.60–
3.52 (m, 8 H), 2.96, 2.93 (AB, J = 14.0 Hz, 4 H), 1.07 (s, 6 H);  13C NMR (100 MHz, D2O)  
66.4, 66.3, 59.3, 41.2, 18.9; HRMS (HESI) m/z calc for C10H23O5S (M+H) 255.1261, found 
255.1266. 
a NMR samples were spiked with acetone, and chemical shifts () are recorded in ppm 
and referenced to acetone (1H NMR, 2.22; 13C NMR, 30.89). 
 
 
 
 
 
 
2,2'-Sulfinylbis(methylene)bis(2-methylpropane-3,2,1-triyl)tetrakis(4-
methylbenzenesulfonate) (2-13).   A solution of MMS399 (2-6) was prepared by adding DMF 
(8 mL, 4 mL per vial) between 2 20-mL scintillation vials of pre-weighed MMS399 samples and 
sonicating under an Ar atmosphere.  THF (16 mL) was divided between the vials, followed by 
TsCl (3.64 g, 19.1 mmol), also divided between the vials.    
 
The solution of MMS399 and TsCl was added to a suspension of powdered KOH (2.86 
g, 50.9 mmol) in THF (16 mL) at 0 °C via syringe pump (0.6 mL/min). The mixture was stirred 
at 0 °C for 1 h and at rt overnight.  The mixture was concentrated in vacuo, and the residue was 
partitioned between water (80 mL) and CH2Cl2 (200 mL). The aqueous layer was extracted with 
CH2Cl2 (1 x 100 mL).  The combined organic layers were washed with water and brine, dried 
(MgSO4), and concentrated in vacuo. Purification by chromatography (ISCO 40 g silica 
cartridge; 100% hexanes over 15 min; 0%–100% EtOAc to 12 min; 100% EtOAc) afforded 2-13 
(928 mg) as a viscous oil that was contaminated with DMF.  The oil was taken up in EtOAc (50 
mL) and washed with water (3 x 20 mL) and brine, dried (MgSO4), and concentrated in vacuo to 
afford 2-13 (780 mg, 26%) as a white foam:  IR (ATR) 2960, 1596, 1355, 1171, 956 cm-1; 1H 
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NMR (400 MHz, CDCl3)  7.777.73 (m, 8 H), 7.37 (t, J = 7.9 Hz, 8 H), 3.96, 3.90 (AB, J = 
10.0 Hz, 4 H), 3.92, 3.90 (AB, J = 10.0 Hz, 4 H), 2.70 (d, J = 13.7 Hz, 2 H), 2.51 (d, J = 13.6 Hz, 
2 H), 2.47 (s, 6 H), 2.46 (s, 6 H), 1.12 (s, 6 H); 13C NMR (100 MHz, CDCl3)  145.5, 145.3, 
132.1, 132.0, 130.1, 130.1, 128.0, 128.0, 71.8, 71.6, 57.9, 39.1, 21.7, 18.4;  
HRMS (ESI) m/z calc for C38H46O13NaS5 (M+Na) 893.1440, found 893.1433. 
 
 
 
 
 
 
 
2,2'-Thiobis(methylene)bis(2-methylpropane-1,3-diol) (2-15). A suspension of sulfide 1-
69 (1.50 g, 7.41 mmol) in 0.5 M aqueous H2SO4 (45 mL) was heated at 65 °C overnight.  Upon 
cooling, the solution was neutralized with solid NaHCO3, and water was removed in vacuo, The 
partially concentrated sample was coevaporated with EtOH. The resulting solids were taken up 
in EtOH, and the mixture was filtered through Celite. The filtrate was concentrated in vacuo. The 
concentrated material was dissolved in water (40 mL) and divided between four 20-mL 
scintillation vials, and water was removed using the Genevac (EZ-2) to afford crude tetrol 2-15 
(1.98 g, 112%) as a white solid: 1H NMR (500 MHz, D2O)
a  3.48 (s, 8 H), 2.62 (s, 4 H), 0.92 (s, 
6 H); HRMS (HESI) m/z calc for C10H23O4S (M+H) 239.1312, found 239.1305. 
 a NMR samples were spiked with acetone, and chemical shifts () are recorded in ppm and 
referenced to acetone (1H NMR, 2.22). 
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2,2'-Thiobis(methylene)bis(2-methylpropane-3,2,1-triyl)tetrakis(4-
methylbenzenesulfonate) (2-16). A solution of 2-6 (MMS399) (1.2 g, 5.0 mmol) and TsCl (6.2 
g, 33 mmol) in DMF (12 mL) and THF (24 mL) was added via syringe pump (0.6 mL/min) to a 
suspension of powdered KOH (4.9 g, 87 mmol) in THF (24 mL) at 0 °C. The reaction mixture 
was warmed to rt and stirred for 12 h. THF was removed in vacuo, and the concentrate was 
partitioned between EtOAc (200 mL) and water (100 mL). The aqueous layer was extracted with 
EtOAc (3 x 100 mL), and the combined organic layers were washed with water (3 x 100 mL) 
and brine (100 mL), dried (MgSO4), and concentrated in vacuo. The crude residue was purified 
by chromatography (ISCO, 80 g silica cartridge, linear gradient of 0-100% EtOAc/hexanes over 
30 min; product elutes at 50%–60% EtOAc/hexanes) to afford 2-16 (1.69 g, 40%) as a yellow 
foam: 1H NMR (500 MHz, CDCl3)  7.74 (d, J = 8.3 Hz, 8 H), 7.37 (d, J = 8.1 Hz, 8 H), 3.80, 
3.75 (AB, J = 9.6 Hz, 8 H), 2.50 (s, 12 H), 2.38 (s, 4 H), 0.86 (s, 6 H); 13C NMR (125 MHz, 
CDCl3)  145.1, 132.0, 129.9, 127.7, 71.2, 39.7, 38.6, 21.5, 17.9. 
 
 
 
 
 
2,2'-Thiobis(methylene)bis(2-methylpropane-3,2,1-triyl)tetrakis(4-
bromobenzenesulfonate) (2-20). A 100-mL round-bottom flask was charged with crude 2-15 
(548 mg, 2.30 mmol). The tetrol 2-15 was dissolved in a minimal amount of water (5 mL), and 
50% aqueous NaOH (15 mL) was added, followed immediately by Bu4NHSO4 (312 mg, 0.920 
mmol).  A solution of 4-bromobenzensulfonyl chloride (9.40 g, 36.8 mmol) in 1,2-
dichloroethane was slowly added (CAUTION: slight exotherm).  The slurry was stirred 
vigorously for 30 min at rt and subsequently heated at reflux for 3.5 h. The mixture was cooled 
and diluted with CH2Cl2 (250 mL) and water (100 mL). The aqueous layer was extracted with 
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CH2Cl2 (100 mL), and the combined organic layers were washed with water and brine, dried 
(MgSO4), and concentrated in vacuo to afford crude yellow oil. The crude residue was purified 
by chromatography on SiO2 (deactivated with 0.1% Et3N; hexanes/EtOAc 9:1 to 7:3) to afford 2-
20 (0.93 g, 36%) as a white foam: IR (ATR) 1573, 1359, 1184, 1172 cm-1; 1H NMR (500 MHz, 
CDCl3)  7.73 (s, 16 H), 3.87, 3.81 (AB, J = 9.6 Hz, 8 H), 2.44 (s, 4 H), 0.91 (s, 6 H); 
13C NMR 
(125 MHz, CDCl3)  134.2, 132.8, 129.4, 129.3, 71.5, 39.9, 38.7, 18.1; HRMS (ESI) m/z calc for 
C34H34O12NaS5Br4 (M+Na) 1132.7285, found 1132.7296. 
 
 
 
 
 
 
Bis((3-methyl-1-phenylazetidin-3-yl)methyl)sulfane (2-17). An oven-dried microwave 
vial was charged with 2-20 (137 mg, 0.123 mmol), MeCN (0.50 mL), aniline (45 µL, 0.49 
mmol) and K2CO3 (170 mg, 1.23 mmol).  Argon was bubbled through the solution for 5 min. 
The vial was flushed with Ar and placed in a pre-heated oil bath (90 °C) and heated at 90 °C for 
12 h. Upon cooling, the mixture was diluted with CH2Cl2 (10 mL) and water (3 mL). The 
aqueous layer was extracted with CH2Cl2 (2 x 5 mL), and the combined organic layers were 
washed with 1 M aqueous NaOH (3 mL), and brine (5 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude residue was purified by chromatography on SiO2 (deactivated 
with 0.1% Et3N, hexanes/EtOAc, 9:1) to afford 2-17 (26.5 mg, 61%) as a yellow solid: Mp 90–
92 °C; IR (ATR) 2954, 2836, 1599, 1500, 1474, 1353, 1174 cm-1; 1H NMR (500 MHz, CDCl3)  
7.22 (t, J = 7.9 Hz, 4 H), 6.74 (t, J = 7.4 Hz, 2 H), 6.46 (d, J = 7.7 Hz, 4 H), 3.71 (d, J = 6.9 Hz, 4 
H), 3.58 (d, J = 6.9 Hz, 4 H), 2.94 (s, 4 H), 1.41 (s, 6 H); 13C NMR (125 MHz, CDCl3)  151.6, 
128.9, 117.3, 111.3, 62.4, 45.1, 36.1, 24.3; HRMS (ESI) m/z calc for C22H29N2S (M+H) 
353.2051, found 353.2039. 
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Bis((1-(4-methoxyphenyl)-3-methylazetidin-3-yl)methyl)sulfane (2-21). An oven-dried 
microwave vial maintained under Ar atmosphere was charged with 2-20 (173 mg, 0.155 mmol), 
dry MeCN (0.90 mL), p-anisidine (88 mg, 0.71 mmol), and K2CO3 (248 mg, 1.79 mmol).  Argon 
was bubbled through the solution for 10 min. The vial was flushed with Ar, sealed, and placed in 
a pre-heated oil bath (90 °C) and heated at 90 ºC for 12 h.  Upon cooling, the mixture was diluted 
with CH2Cl2 (20 mL) and water (5 mL). The aqueous layer was extracted with CH2Cl2 (10 mL), 
and the combined organic layers were washed with 1 M aqueous NaOH (5 mL) and brine (10 
mL), dried (MgSO4), and concentrated in vacuo. The crude residue was purified by 
chromatography on SiO2 (deactivated with 0.1% Et3N, hexanes/EtOAc, 9:1) to afford 2-21 (45.2 
mg, 71%) as a yellow solid: Rf 0.3 (hexanes/EtOAc, 8:2); Mp 76.0–77.2 °C; IR (ATR) 2949, 
2828, 1508, 1478, 1232, 1036 cm-1; 1H NMR (400 MHz, CDCl3)  6.846.80 (m, 4 H), 
6.446.40 (m, 4 H), 3.76 (s, 6 H), 3.66 (d, J = 6.8 Hz, 4 H), 3.53 (d, J = 6.8 Hz, 4 H), 2.93 (s, 4 
H), 1.40 (s, 6 H); 13C NMR (100 MHz, CDCl3)  152.1, 146.5, 114.7, 112.6, 63.1, 55.8, 45.1, 
36.1, 24.3; HRMS (ESI) m/z calc for C24H33N2O2S (M+H) 413.2263, found 413.2253. 
 
 
 
 
 
 
 
Bis((1-(4-bromophenyl)-3-methylazetidin-3-yl)methyl)sulfane (2-22). An oven-dried 
conical microwave vial equipped with stir bar was charged with 2-20 (200 mg, 0.179 mmol), dry 
MeCN (0.50 mL), p-bromoaniline (123 mg, 0.718 mmol), and K2CO3 (248 mg, 1.79 mmol). 
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Argon was bubbled through the solutionn for 5 min. The vial was flushed with Ar, sealed, and 
placed in a pre-heated oil bath (90 °C) and heated at 90 °C for 12 h. Upon cooling, the mixture 
was diluted with CH2Cl2 (10 mL) and water (5 mL), and the aqueous layer was extracted with 
CH2Cl2 (10 mL). The combined organic layers were washed with 1 N aqueous NaOH (5 mL) 
and brine (5 mL), dried (MgSO4), and concentrated in vacuo. Purification by chromatography on 
SiO2 (deactivated with 0.1% Et3N, hexanesEtOAc, 9:1) afforded 2-22 (48.1 mg, 53%) as a 
yellow solid: Mp 139–141 °C; IR (ATR) 2952, 2842, 1588, 1489, 1353, 807 cm-1; 1H NMR (500 
MHz, CDCl3)  7.29 (d, J = 8.5 Hz, 4 H), 6.31 (d, J = 8.5 Hz, 4 H), 3.68 (d, J = 6.9 Hz, 4 H), 
3.54 (d, J = 6.9 Hz, 4 H), 2.91 (s, 4 H), 1.41 (s, 6 H); 13C NMR (125 MHz, CDCl3)  150.4, 
131.6, 113.0, 109.3, 62.4, 44.9, 36.1, 24.4. 
 
 
 
 
 
 
 
 
 
3,3'-Sulfinylbis(methylene)bis(1-(4-methoxyphenyl)-3-methylazetidine) (2-23). A 
solution of 2-21 (40 mg, 0.097 mmol) in glacial AcOH (1.2 mL) was treated with H2O2 (ca. 
30%, 11 µL, ca. 0.11 mmol). The mixture (which became purple in color almost immediately) 
was stirred at rt for 15 h. The mixture was concentrated in vacuo to ~1/5 volume and diluted with 
CH2Cl2 (25 mL) and saturated aqueous NaHCO3 (10 mL). The aqueous layer was extracted with 
CH2Cl2 (10 mL), and the combined organic layers were dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a crude brown residue (53 mg). 
Purification by chromatography on SiO2 (deactivated with 0.1% Et3N, hexanes/EtOAc, 1:2) 
afforded recovered 2-21 (9.0 mg) as well as 2-23 (24.5 mg, 59%) as a pink solid: IR (ATR) 
2950, 2844, 1588, 1508, 1234, 813 cm-1; 1H NMR (500 MHz, CDCl3)  6.82 (d, J = 8.8 Hz, 4 
H), 6.42 (d, J = 8.9 Hz, 4 H), 3.95 (d, J = 7.1 Hz, 2 H), 3.783.76 (m, 2 H), 3.76 (s, 6 H), 3.67 
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(d, J = 6.8 Hz, 2 H), 3.62 (d, J = 7.1 Hz, 2 H), 3.29 (d, J = 13.1 Hz, 2 H), 2.83 (d, J = 13.0 Hz, 2 
H), 1.60 (s, 6 H); 13C NMR (125 MHz, CDCl3)  152.4, 146.2, 114.7, 112.8, 63.9, 63.5, 63.3, 
55.8, 34.0, 24.6; HRMS (ESI) m/z calc for C24H32N2O3S 429.2212, found 429.2227. 
 
 
 
 
 
 
Bis((3-methyl-1-tosylazetidin-3-yl)methyl)sulfane (2-25).   An oven-dried thick-walled 
glass tube was charged with 2-20 (200 mg, 0.179 mmol), dry MeCN (0.9 mL), p-
toluenesulfonamide (123 mg, 0.718 mmol) and K2CO3 (248 mg, 1.79 mmol).  Ar was bubbled 
through the mixture for 10 min, and the vial was sealed and heated at 90 ºC overnight (15 h). 
Upon cooling, the mixture was diluted with CH2Cl2 (15 mL) and water (10 mL), and the aqueous 
layer was extracted with CH2Cl2 (10 mL). The combined organic layers were washed with 1 M 
aqueous NaOH and brine, dried (MgSO4), and concentrated in vacuo.   Chromatography on SiO2 
(hexanes/EtOAc, 2:1 with ~1% Et3N) afforded 2-25 and mixed fractions,  The collected fractions 
were combined and repurified by chromatography on SiO2 (hexanes/EtOAc, 9:1 to 2:1 to 1:1) to 
afford 2-25 (48.5 mg, 53%) as a viscous yellow oil: IR (ATR) 2960, 1596, 1448, 1339, 1154 cm-
1; 1H NMR (300 MHz, CDCl3)  7.56 (d, J = 8.2 Hz, 4 H), 7.39 (d, J = 8.0 Hz, 4 H), 3.54 (d, J = 
8.0 Hz, 4 H), 3.40 (d, J = 8.0 Hz, 4 H), 2.49 (s, 4 H), 2.47 (s, 6 H), 1.07 (s, 6 H); 13C NMR (100 
MHz, CDCl3)  144.1, 131.4, 129.7, 128.3, 60.5, 43.9, 34.5, 23.7, 21.6; HRMS (HESI) m/z calc 
for C24H33N2O4S3 (M +H) 509.1597, found 509.1585. 
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3,3'-(sulfinylbis(methylene))bis(3-methyl-1-tosylazetidine (2-26).  A solution of 2-25 
(45 mg, 0.088 mmol) in glacial AcOH (1 mL) was treated with H2O2 (ca. 3% aqueous, 0.11 mL, 
ca. 0.11 mmol) and stirred at rt for 12 h. The solution (which was colorless) was concentrated in 
vacuo to ~1/5 volume and diluted with saturated aqueous NaHCO3 (5 mL) and CH2Cl2 (20 mL). 
The aqueous layer was extracted with CH2Cl2 (10 mL), and the combined organic layers were 
dried (Na2SO4), and concentrated in vacuo to afford 2-26 (crude, 43 mg, 93%) as a viscous 
colorless oil that solidifies upon standing: 1H NMR (300 MHz, CDCl3)  7.73 (d, J = 8.2 Hz, 4 
H), 7.39 (d, J = 8.1 Hz, 4 H), 3.86 (d, J = 8.3 Hz, 2 H), 3.67 (d, J = 8.0 Hz, 2 H), 3.57 (d, J = 8.0 
Hz, 2 H), 3.49 (d, J = 8.3 Hz, 2 H), 2.90 (d, J = 13.0 Hz, 2 H), 2.49 (d, J = 12.8 Hz, 2 H), 2.48 (s, 
6 H), 1.33 (s, 6 H); HRMS (HESI) m/z calc for C24H33N2O5S3 (M+H) 525.1546, found 525.1536. 
 
 
 
 
 
 
 
An oven-dried thick-walled vial was charged with 2-27 (700 mg, 0.628 mmol), dry 
MeCN (3.1 mL), benzylamine (0.27 mL, 2.5 mmol), and K2CO3 (868 mg, 6.28 mmol). Ar was 
bubbled through the solution for 10 min. The vial was sealed and heated at 90 ºC overnight (15 
h). Upon cooling, the mixture was diluted with CH2Cl2 (40 mL) and water (10 mL), and the 
aqueous layer was extracted with CH2Cl2 (20 mL). The combined organic layers were washed 
with 1 M aqueous NaOH and brine, dried (MgSO4), and concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:2 with 1% Et3N to 100% 
EtOAc to 5% MeOH/EtOAc) to afford 2-27 (150 mg, ~63% crude).  Reported characterization 
data represent data obtained from an analytical sample from a separate batch of material: IR 
  
 217 
(ATR) 2947, 2902, 1644, 1493, 1450 cm-1; 1H NMR (500 MHz, CDCl3)  7.347.24 (m, 10 H), 
3.65 (s, 4 H), 3.13 (d, J = 7.2 Hz, 4 H), 3.00 (d, J = 7.2 Hz, 4 H), 2.84 (s, 4 H), 1.3 (s, 6 H); 13C 
NMR (125 MHz, CDCl3)  138.4, 128.3, 128.2, 126.8, 64.9, 63.4, 45.2, 35.9, 24.6; HRMS 
(HESI) m/z calc for C24H33N2S (M+H) 381.2359, found 381.2352. 
 
 
 
 
 
 
 
Methyl 2-(4-(chloromethyl)benzamido)-3-hydroxypropanoate (3-46).  A flame-dried 
250-mL round-bottom flask was charged with dl-serine methyl ester hydrochloride (6.59 g, 41.9 
mmol), dry CH2Cl2 (60 mL), and Et3N (5.9 mL, 42 mmol). To this cloudy solution was added a 
solution of 4-(chloromethyl)benzoyl chloride (5.09 g, 26.1 mmol) in dry CH2Cl2 (60 mL) slowly 
via syringe in 3 portions.  The cloudy solution was stirred at rt for 15 h and subsequently diluted 
with CH2Cl2 (100 mL), washed with water and brine, dried (MgSO4) and concentrated in vacuo.  
The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to elute bis-a2-
(4-(chloromethyl)-N-(4-(chloromethyl)benzoyl)benzamido)-3-hydroxypropanoate (Rf  0.47 
hexanes/EtOAc, 1:1).  Subsequent elution with 100% EtOAc afforded 3-46 (4.64 g, 65%) as a 
white solid:  Mp 83.4–85.1 oC (CH2Cl2); IR (ATR) 3360, 1728, 1620, 1258, 1053 cm
-1; 1H NMR 
(300 MHz, CDCl3)  7.81 (d, J = 8.3 Hz, 2 H), 7.45 (d, J = 8.3 Hz, 2 H), 7.19 (d, J = 6.8 Hz, 1 
H), 4.86 (dt, J = 7.3, 3.6 Hz, 1 H), 4.60 (s, 2 H), 4.12–4.01 (m, 2 H), 3.81 (s, 3 H), 2.93 (bs,1 H); 
13C NMR  171.0, 167.0, 141.3, 133.3, 128.7, 127.6, 63.3, 55.1, 52.9, 45.3. 
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Methyl 2-(4-(chloromethyl)phenyl)-4,5-dihydrooxazole-4-carboxylate (3-47).  A 
solution of methyl 2-(4-chloromethyl)benzamido)-3-hydroxypropanoate 3-46 (984 mg, 3.65 
mmol) in distilled THF (20 mL) was treated with Burgess Reagent (1.15 g, 4.83 mmol).  The 
solution was heated at reflux for 1 h, cooled to rt, and the resulting white precipitate was 
removed via Buchner filtration. The filtrate was concentrated in vacuo, and the residue was 
dissolved in CH2Cl2 and concentrated onto SiO2.  Purification via chromatography on SiO2 
(hexanes/EtOAc, 2:1) afforded 3-47 (754 mg, 82%) as a white solid; Mp 70.0–71.8 oC (CH2Cl2);  
IR (ATR) 2959, 1735, 1636, 1213, 1084 cm-1; 1H NMR (300 MHz, CDCl3)  7.99 (d, J = 8.3 Hz, 
2 H), 7.45 (d, J = 8.3 Hz, 2 H), 4.97 (dd, J = 10.6, 8.0 Hz, 1 H), 4.72 (t, J = 8.3 Hz, 1 H), 4.65–
4.58 (m, 1 H), 4.61 (s, 2 H), 3.83 (s, 3 H); 13C NMR (75 MHz, CDCl3)  171.5, 165.8, 141.1, 
129.0, 128.5, 126.9, 69.6, 68.6, 52.7, 45.4; HRMS (EI) m/z calc for C12H12ClNO3 253.0506, 
found 253.0512.  
 
 
 
 
 
 
 
 
2-(4-(chloromethyl)phenyl)-N-(1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl)-4,5-
dihydrooxazole-4-carboxamide (3-44).  A solution of 3-47 (305 mg, 1.20 mmol) in THF (15 
mL) was treated with 1 N aqueous NaOH (1.80 mL, 1.80 mmol) and stirred at rt for 1 h.  
NaHCO3 (500 mg, 5.95 mmol) was added, and the solvent was removed in vacuo.  Residual 
water was removed coevaporation with benzene (3 x).  To the residue was added a solution of 4-
amino TEMPO (415 mg, 2.35 mmol) in anhydrous DMF, and additional DMF was added to 
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bring the total volume to 30 mL.  The solution was cooled to 0 oC, and DIPEA (0.10 mL, 6.0 
mmol) and PyCloP (602 mg, 1.43 mmol) were added.  The ice bath was removed, and the 
solution was stirred for 1 h at rt.  The reaction mixture was poured into EtOAc (500 mL), and the 
resulting solution was washed successively with 5% NaHSO4 (100 mL), 5% NaHCO3 (100 mL), 
water, and brine, dried (Na2SO4), and concentrated.  The residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 1:2) to afford 3-44 (367 mg, 78%) as a peach-colored 
foam. IR (ATR) 3392, 2971, 1640, 1510, 1359, 1239, 1081 cm-1; HRMS (EI) m/z calc for 
C20H27ClN3O3 392.1741, found 392.1737. 
 
NMR characterization was carried out on the corresponding hydroxylamine (3-44a), 
which was obtained as follows: the analyte was dissolved in MeOH and treated with excess 
ascorbic acid.  Once the color turned from orange to clear, the solution was diluted with ether 
and washed with sat. NaHCO3(aq), water, and brine, dried (MgSO4) and concentrated: 
1H NMR 
(300 MHz, CDCl3)  7.97 (d, J = 8.0 Hz, 2 H), 7.48 (d, J = 8.0 Hz, 2 H), 6.44 (d, J = 8.0 Hz, 1 
H), 4.83 (app t, J = 9.6 Hz, 1 H), 4.71 (app t, J = 9.6 Hz, 1 H), 4.64–4.58 (m, 3 H), 4.63 (s, 2 H), 
4.24–4.11 (m, 1 H), 1.93 (dt, J = 12.5, 3.3 Hz,1 H), 1.80 (dt, J = 12.5, 3.2 Hz, 1 H), 1.46–1.31 
(m, 2 H), 1.22 (s, 3 H), 1.20 (s, 3 H), 1.19 (s, 3 H), 1.15 (s, 3 H); 13C NMR (75 MHz, CDCl3)  
170.6, 165.4, 141.1, 128.6, 128.4, 126.7, 70.3, 68.7, 58.7, 45.2, 45.0, 40.6, 32.1, 19.4. 
 
 
 
 
 
 
 
2-(4-(Azidomethyl)phenyl)-N-(1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl)-4,5-
dihydrooxazole-4-carboxamide (3-50).  A solution of 3-47 (499 mg, 1.97 mmol) in absolute 
MeOH (20.0 mL) was treated with 1 N aqueous NaOH (2.4 mL, 2.4 mmol) at rt.  The solution 
was stirred for 2 h at rt, NaHCO3 (830 mg, 9.85 mmol) was added, and the solvent was removed 
in vacuo.  Residual water was removed via coevaporation with benzene (2 x).  To the dried 
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mixture was added a solution of 4-amino TEMPO (700 mg, 3.94 mmol) in dry DMF, followed 
by additional DMF to bring the total volume to 40 mL.  The solution was cooled to 0 oC, and 
DIPEA (1.64 mL, 9.85 mmol) and DPPA (1.32 mL, 5.91 mmol) were added.  The reaction 
mixture was stirred for 33 h, gradually warming to rt.  The mixture was quenched with saturated 
aqueous NaHCO3 (16 mL) and stirred an additional 1 h. The mixture was partitioned between 
water (100 mL) and Et2O (100 mL), and the aqueous layer was extracted with Et2O until the 
ethereal layer showed no orange color.  The combined organic layers were washed with water (6 
x), brine, dried (Na2SO4) and concentrated in vacuo. Purification by chromatography on SiO2 
(hexanes/EtOAc,1:2) afforded 3-50 (658 mg, 83%) as an orange foam:  IR (ATR) 3388, 3343, 
2971, 2095, 1640, 1239, 1081 cm-1; EI-MS m/z 400 ([M+H]+, 20), 399 (M+, 13), 372 (8), 341 
(6), 201 (26), 124 (99), 84 (73).  HRMS (EI) m/z calc for C20H28N6O3 (M+H) 400.2223, found 
400.2214. 
 
NMR analysis was performed after reducing 3-50 to the corresponding hydroxylamine 
(3-50a) by dissolving 3-50 in MeOH and treating with ascorbic acid. After the solution turned 
from orange to colorless, the solution was diluted with Et2O  and washed with saturated aqueous 
NaHCO3, water, and brine, dried and concentrated in vacuo:  
1H NMR (500 MHz, CDCl3)  8.00 
(d, J = 8.2 Hz, 2 H), 7.41 (d, J = 8.1 Hz, 2 H), 6.42 (d, J = 7.9 Hz, 1 H), 4.83 (dd, J = 11.0, 8.4 
Hz, 1 H), 4.71 (dd, J = 11.0, 8.8 Hz, 1 H), 4.61 (t, J = 8.6 Hz, 1 H), 4.43 (s, 2 H), 4.27 (b, 1 H), 
4.22–4.14 (m, 1 H), 1.93 (dt, J = 12.6, 3.4 Hz, 1 H), 1.81 (dt, J = 12.5, 3.4 Hz, 1 H), 1.45–1.33 
(m, 2 H), 1.22 (s, 3 H), 1.20 (s, 3 H), 1.19 (s, 3 H), 1.16 (s, 3 H); 13C NMR (125 MHz, CDCl3)  
170.7, 165.5, 139.3, 128.8, 127.9, 126.8, 70.4, 68.8, 58.8, 54.1, 45.1, 40.7, 32.2, 19.5. 
 
 
 
 
 
Representative procedure for synthesis of 3-aminopropyl functionalized nanoparticles 
(3-51).  To a solution of cyclohexane (10 mL) and absolute EtOH (20 mL) in a 250-mL round-
bottom flask was added commercial IPAST solution (6.17 g, 1.85 g SiO2, 30 wt% in i-PrOH).  
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The suspension was stirred vigorously using a pearl-shaped stir bar, and 3-
aminopropyltriethoxysilane (1.85 mL, 7.79 mmol) was added dropwise via syringe.  The 
solution, which became cloudy within minutes of the addition, was stirred vigorously at rt for 2 
h.  The reaction mixture was poured into a 50 mL Falcon tube and water (~5 mL) was added. 
The tube was centrifuged (4400 rpm, 3000 xg, 15 min).   The supernatant was decanted, and the 
sediment was suspended in EtOH (30 mL) and sonicated (ultrasonic bath) for 30 min.   This 
washing procedure was repeated, and at this point, it was clear some aggregates that were not 
suspending were present. The suspension was decanted away from the aggregates into a clean 50 
mL Falcon tube and centrifuged (4400 rpm, 3000 xg, rt, 15 min). The sediment was suspended in 
EtOH (30 mL) and sonicated for 30 min. The tube was centrifuged as above, the supernatant was 
decanted, and the resultant sediment was dried under Ar and subsequently under N2 and finally 
under high vacuum at 50 oC for 4 h.  Final drying under high vacuum for 20 h at rt afforded 
functionalized nanoparticles (1.27 g) as a white solid:  Anal. Found for (SiO2)nC3H8N: C, 3.12; 
H, 0.85; N, 1.10. 
 
 
 
 
 
Representative procedure for phenylthiourea-functionalized silica particles (3-42).  
Dried 3-aminopropyl-functionalized particles 3-51 (330 mg) were suspended in dry THF (15 
mL) and stirred for 5 min.  Phenylisothiocyanate (1.50 mL, 12.5 mmol) was added dropwise via 
sringe at rt.  The reaction mixture was stirred for 25 h at rt and poured into a 50-mL Falcon tube.  
The tube was centrifuged (4400 rpm, 3000 xg, 10 min, rt) to give an off-white pellet (Note: the 
supernatant was bright yellow in color).  The pellet was resuspended in EtOH, sonicated for 30 
min, and centrifuged (4400 rpm, 3000 xg, 10 min, rt).  The 
resuspension/sonication/centrifugation procedure was repeated four times.  The pellet from the 
final washing was dried under a stream of N2 for 3 days to afford a white powdery solid (225 
mg): Anal. Found for Anal. Found for (SiO2)nC10H13N2S: C, 4.17; H, 0.70; N, 1.14; S, 0.94.  
Note: Loading values were typically 0.31–0.41 mmol/g, based on %S content. 
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Representative procedure for fluorescein-thiourea-functionalized silica particles (3-
42).  Dried 3-aminopropyl-functionalized particles 3-51 (275 mg) were suspended in dry THF 
(15 mL) and stirred for 10 min.  Fluorescein isothiocyanate (105 mg, 0.256 mmol) was added, 
and the bright orange suspension (which gradually became bright yellow in color) was stirred for 
25 h at rt.  The mixture was poured into a 50-mL Falcon tube.  The tube was centrifuged (4400 
rpm, 3000 xg, 10 min, rt) to give an orange pellet.  The pellet was resuspended in EtOH, 
sonicated for 30 min, and centrifuged (4400 rpm, 3000 xg, 10 min, rt).  The 
resuspension/sonication/centrifugation procedure was repeated four times.  The pellet from the 
final washing was dried under a stream of N2 for 3 days to afford bright yellow powder (172 
mg): Anal. Found for Anal. Found for (SiO2)nC24H20N2O5S: C, 5.61; H, 0.87; N, 1.17; S, 0.34.  
 
 
 
 
1-Phenyl-3-propylthiourea (3-52).266  A solution of n-propylamine (0.700 mL, 8.51 mmol) 
and phenylisothiocyanate (1.00 mL, 8.35 mmol) in distilled THF (15.0 mL) was stirred at rt for 6 
h.  THF was removed in vacuo, and the residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 3:1) to afford 1-phenyl-3-propylthiourea (1.62 g, quant.) as a white solid: Mp 
60.9–62.8 oC (CH2Cl2) (lit.
266 Mp 59–60 (EtOH)); 1H NMR (300 MHz, CDCl3)  7.71 (b, 1 H), 
7.477.42 (m, 2 H), 7.327.29 (m, 1 H), 7.227.20 (m, 2 H), 6.02 (b, 1 H), 3.62, 3.59 (AB, J = 
7.1 Hz, 2 H), 1.661.54 (m, 2 H), 0.92 (t, J = 7.4 Hz, 3 H). 
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Independent synthesis of model system: (Z)-methyl2-(4-((N-phenyl-N'-
propylcarbamimidoylthio)methyl)phenyl)-4,5-dihydrooxazole-4-carboxylate (3-53). A 
solution of 1-phenyl-3-propylthiourea (217mg, 1.12 mmol), DIPEA (0.130 mL, 0.787 mmol), 
TBAI (65 mg, 0.18 mmol), and 3-47 (109 mg, 0.430 mmol) in DMF (6.5 mL) was heated at 110 
°C for 30 min. The mixture was cooled, poured into water (25 mL), and diluted with Et2O (50 
mL). The aqueous layer was extracted with Et2O (3 x 20 mL). The combined organic layers were 
washed with water (3 x) and brine (once), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (packed using hexanes/EtOAc/Et3N 
47.5:47.5:5.0, eluted with hexanes/EtOAc, 1:1) to afford 3-53 (108 mg, 61%) as a yellow foam: 
1H NMR (300 MHz, CDCl3)  7.93 (d, J = 8.2 Hz, 2 H), 7.38 (d, J = 7.1 Hz, 2 H), 7.327.27 (m, 
4 H), 7.03 (t, J = 7.4 Hz, 1 H), 6.89 (d, J = 7.6 Hz, 2 H), 4.96 (dd, J = 10.6, 7.9 Hz, 1 H), 4.70 
(app t, J = 8.3 Hz, 1 H), 4.60 (app t, 1 H), 4.464.35 (b, 1 H), 4.023.92 (b, 1 H), 3.83 (s, 3 H), 
3.753.69 (m, 1 H), 3.233.16 (b, 1 H), 1.521.42 (m, 2 H), 1.311.19 (m, 2 H), 0.86 (t, J = 7.4 
Hz, 3 H); 13C NMR (75 MHz, CDCl3)  171.5, 165.9, 149.3, 141.9, 129.0, 128.8, 128.8, 125.8, 
122.6, 122.0, 69.5, 68.5, 52.7, 44.9, 34.9, 22.8, 11.2. 
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Representative procedure for alkylation of thiourea-functionalized nanoparticles 
with 3-44 to form imidothiolate particles 3-40.   An oven-dried 25-mL round-bottom flask was 
charged with particles 3-42 (54.9 mg), TBAI (44.1 mg, 0.119 mmol) and 3-44 (125 mg, 0.318 
mmol).  To the flask was added anhydrous, degassed DMF (11 mL) (degassed using freeze-
pump-thaw; 3 x).  DIPEA (0.13 mL, 0.75 mmol) was added, and the mixture was placed into a 
pre-heated oil bath and heated at 110 C for 2 h.  After cooling, the mixture was poured into a 
50-mL Falcon tube containing EtOH/water, 9:1 (30 mL), and the tube was centrifuged (4400 
rpm, 3000 xg, 10 min, rt).  The supernant was decanted, and the sediment was diluted with 
EtOH/water (9:1, 20 mL), sonicated, and centrifuged (4400 rpm, 3000 xg, 10 min, rt).  This 
washing procedure was repeated, and the resulting sediment was resuspended in degassed DMF 
(10 mL), and heated at 90 C for 20 min.  After cooing, the mixture was poured into a 50-mL 
Falcon tube and diluted with EtOH/water, 9:1 (20 mL) and centrifuged (4400 rpm, 3000 xg, 10 
min, rt).  The supernatant was decanted, and the sediment was diluted with EtOH/water, 9:1 (20 
mL), sonicated (20 min), and centrifuged as described above.  This washing procedure was 
repeated two additional times, and the resulting pellet was transferred to a 15-mL Falcon tube 
using EtOH (7 mL), sonicated (20 min), and centrifuged as described.  The supernatant was 
decanted, and the pellet was resuspended in absolute EtOH (7 mL), and washed using EtOH as 
described (3 x).  The final pellet was dried under a stream of N2 to afford pale tan-colored 
particles (22.6 mg).  
 
The combined supernatants collected before resuspension in DMF were diluted with 
water (200 mL) and estracted with Et2O (200 mL).  The ethereal layer was washed with water 
and brine, dried (Na2SO4), and concentrated in vacuo.  Purification by chromatography on SiO2 
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(hexanes/EtOAc, 1:2) afforded recovered 3-44 (48 mg). Anal. Found for (SiO2)nC30H35N5O3S: C, 
5.69; H, 0.97; N, 1.28; S, 0.46. 
 
Loadings were determined by elemental analysis, taking into account the loadings of the 
precursor and thiourea and amine nanoparticles.  The combusion analysis and loading 
calculations are depicted in Table 4-1. 
 
 
Table 4-1. Tabulated elemental analysis data for imidothiolate-functionalized silica nanoparticles. 
 
Entry 
 
Batch 
 
%C 
 
%H 
 
%N 
 
%S 
 
Loading based on % 
N (mmol/g) 
 
Loading based on % 
S (mmol/g) 
 
 
1 
 
“Blank” 
particles 
 
0.20 
 
0.69 
 
0.0 
 
0.0 
  
 
2 
 
Amine 3-51A 
 
3.53 
 
0.89 
 
1.17 
 
ND 
 
0.83 
 
 
 
 
Thiourea 3-42A 
 
5.21 
 
0.86 
 
1.30 
 
ND 
 
0.093 
 
ND 
  
Imidothiolate 3-
40A 
 
6.40 
 
0.98 
 
1.42 
 
ND 
 
0.029 
 
ND 
        
3 Amine 3-51A 2.23 0.68 0.72 0.0 0.51  
  
Thiourea 3-42A 
 
3.71 
 
0.74 
 
0.84 
 
0.75 
 
0.079 
 
0.23 
  
Imidothiolate 3-
40A 
 
5.42 
 
0.93 
 
1.07 
 
0.27 
 
0.055 
 
        
 
4 
 
Amine 3-51A 
 
3.38 
 
0.76 
 
1.12 
 
0.0 
 
0.80 
 
  
Thiourea 3-42A 
 
4.17 
 
0.70 
 
1.1 
 
0.84 
  
0.26 
  
Imidothiolate 3-
40A 
 
5.69 
 
0.97 
 
1.28 
 
0.46 
 
0.043 
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Alkylation of fluorescein-substituted thiourea-functionalized nanoparticles with 3-
44 to form imidothiolate particles 3-41.  The same procedure was described for formation of 
imiothiolate particles 3-40 was used with the following amounts of reagents: particles 3-43 (56.2 
mg), TBAI (45.3 mg, 0.123 mmol), 3-44 (125 mg, 0.318 mmol), and anhydrous, degassed DMF 
(11 mL).  Upon washing and drying under N2, bright orange colored particles (38.5 mg) were 
collected. Anal. Found for (SiO2)nC30H35N5O3S: C, 8.02; H, 1.10; N, 1.41; S, 0.22.  Recovered 3-
44 (43 mg) was isolated after workup and chromatography as described in the case of 
imiodthiolate particles 3-40. 
 
   
 
 
 
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-p-tolyl-4,5-dihydrooxazole-4-
carboxamide (3-54).  A solution of 3-44 (31.5 mg, 0.0802 mmol) in THF (2.0 mL) was treated 
with Raney Ni (~50 mg, taken from a 50% slurry in water and washed with THF but not 
completely dried) and stirred for 1 h 45 min at rt.  The mixture was filtered through Celite and 
concentrated in vacuo.  The residue was taken up in MeOH (1.0 mL) and treated with 
Cu(OAc)2H2O (1.4 mg, 0.0080 mmol) and stirred open to air for 1.5 h.  The mixture was 
concentrated in vacuo, and the residue was taken up into CHCl3 and washed with water.  The 
aqueous layer was extracted with CHCl3 (twice), and the combined organic layers were washed 
with water and brine, dried (Na2SO4) and concentrated, and dried under high vacuum overnight 
to afford the corresponding N-oxyl radical 3-57 (11.1 mg, 38%) as an orange solid.  The solid 
was dissolved in MeOH (1 mL) and treated with excess ascorbic acid (24 mg).  The solution was 
shaken until the orange color turned to colorless.  The solution was then diluted with Et2O and 
washed with saturated aqueous NaHCO3, water, and brine, dried (MgSO4) and concentrated in 
vacuo to afford 3-54 (9.0 mg, 31% overall) as a colorless, amorphous foam:  1H NMR (300 
MHz, CDCl3)  7.87 (d, J = 8.1 Hz, 2 H), 7.27–7.25 (m, 2 H). 6.46 (d, J = 7.8 Hz, 1 H), 4.81 (dd, 
J = 10.8, 8.2 Hz, 1 H), 4.68 (dd, J = 10.8, 8.6 Hz, 1 H), 4.58 (t, J = 8.3 Hz, 1 H), 4.25–4.11 (m, 1 
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H),  2.43 (s, 3 H), 1.94 (dt, J = 12.5, 3.5 Hz, 1 H), 1.81 (dt, J = 12.6, 3.5 Hz, 1 H), 1.49–1.33 (m, 
2 H), 1.23 (s, 3 H), 1.22 (s, 3 H), 1.20 (s, 3 H), 1.17 (s, 3 H). 
 
 
 
 
 
 
 
2-(4-(Chloromethyl)phenyl)-N-(2,5-dimethoxybenzyl)-4,5-dihydrooxazole-4-
carboxamide (3-58). A solution of 3-47 (308 mg, 1.21 mmol) in THF (15 mL) was treated with 
1 N aqueous NaOH (1.80 mL, 1.80 mmol) and stirred for 30 min at rt.  NaHCO3 (504 mg, 6.00 
mmol) was added, and THF was removed in vacuo. Residual water was removed by 
coevaporation with benzene (3 x). The residual white solid was dissolved in DMF, and a solution 
of 2,5-dimethoxybenzylamine (429 mg, 2.57 mmol) in DMF was added (30 mL total volume 
DMF).  Sonication (ultrasonic bath) was employed to move the white solid from the sides of the 
vessel into the reaction mixture. To this solution was added DIPEA (1.00 mL, 6.05 mmol) and 
PyCloP (624 mg, 1.48 mmol). The reaction mixture was stirred for 1 h at rt. The mixture was 
diluted with EtOAc (400 mL) and washed successively with 5% aqueous NaHSO4 (200 mL), 5% 
aqueous NaHCO3, water (2 x 200 mL), and brine (100 mL), dried (MgSO4) and concentrated in 
vacuo.  Purification by chromatography on SiO2 (hexanes/EtOAc, 1:1 to 100% EtOAc) afforded 
3-58 (348 mg, 73%) as a white solid: IR (ATR) 3267, 2963, 1653, 1633, 1552, 1502, 1232, 1057 
cm-1; 1H NMR (300 MHz, CDCl3)  7.97 (d, J = 8.4 Hz, 2 H), 7.46 (d, J = 8.5 Hz, 2 H), 6.85-
6.84 (m, 1 H), 6.78-6.77 (m, 2 H), 4.87 (dd, J = 10.5, 8.6 Hz, 1 H), 4.74-4.64 (m, 2 H), 4.62 (s, 2 
H), 4.50 (dd, J = 14.7, 6.2 Hz, 1 H), 4.42 (dd, J = 14.7, 6.0 Hz, 1 H), 3.78 (s, 3 H), 3.74 (s, 3 H); 
13C NMR (75 MHz, CDCl3)  171.2, 165.5, 153.5, 151.8, 141.3, 128.8, 128.5, 127.1, 126.9, 
115.5, 113.2, 111.3, 70.7, 69.1, 55.8, 55.7, 45.4, 39.2; HRMS (ES) m/z calc for C20H21ClN2O4Na 
(M+Na) 411.1088, found 411.1075.  
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N-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-(4-(chloromethyl)phenyl)-4,5-dihydrooxazole-
4-carboxamide (3-59). A solution of 3-47 (311 mg, 1.23 mmol) in THF (15 mL) was treated 
with 1 N aqueous NaOH (1.80 mL, 1.80 mmol) and stirred for 0.5 h at rt. NaHCO3 (515 mg, 6.13 
mmol) was added, and the solvent was removed in vacuo. Residual water was removed by 
coevaporation with benzene (3 x).  To the white residue was added a solution of 3,4-
methylenedioxybenzylamine (380 mg, 2.45 mmol) in DMF, and additional DMF was added to 
bring the total volume to 30 mL. The reaction vessel was sonicated (ultrasonic bath) to bring all 
material from the sides of the flask into solution, and DIPEA (1.00 mL, 6.13 mmol) and PyCloP 
(466 mg, 1.48 mmol) were added.  The colorless solution was stirred for 1 h at rt.   The solution 
was diluted with EtOAc (400 mL) and washed successively with 5% aqueous NaHSO4 (150 
mL), 5% aqueous NaHCO3 (150 mL), water (twice), and brine, dried (Na2SO4) and concentrated 
in vacuo. The residue was taken up in CH2Cl2 and concentrated onto SiO2, after which 
purification by chromatography on SiO2 (hexanes/EtOAc, 1:1) afforded 3-59 (326 mg, 71%) as a 
white solid: Mp 158.8161.4 oC; IR (ATR) 3267, 2898, 1647, 1631, 1534, 1498, 1252, 1073 cm-
1; 1H NMR (300 MHz, CDCl3)  7.95 (d, J = 8.4 Hz, 2 H), 7.45 (d, J = 8.5 Hz, 2 H), 6.94 (bs, 1 
H), 6.79–6.75 (m, 3 H) 5.95 (s, 2 H), 4.90 (dd, J = 10.8, 8.6 Hz, 1 H), 4.774.64 (m, 2 H), 4.61 
(s, 2 H), 4.47 (dd, J = 14.7, 6.5 Hz, 1 H), 4.30 (dd, J = 14.7, 5.6 Hz, 1 H); 13C NMR (75 MHz, 
CDCl3)  171.5, 165.7, 147.9, 147.0, 141.3, 131.6, 128.9, 128.6, 126.9, 121.1, 108.3, 101.1, 70.6, 
69.1, 45.4, 43.0; MS (EI) m/z (rel. intensity) 374 ([M+], 14), 372 ([M+], 40), 337 (10), 203 (100); 
HRMS (EI) m/z calc for C19H17ClN2O4 372.0877, found 372.0870. 
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Nanoparticle functionalization with 3-59.  A suspension of particles 3-42 (54.7 mg) in 
anhydrous DMF (12.5 mL) was sonicated (ultrasonic water bath) for 20 min.  To the suspension 
was added DIPEA (0.14 mL, 0.80 mmol), TBAI (38.6 mg, 0.105 mmol) and 3-59 (119 mg, 
0.319 mmol).  The solution placed in a pre-heated oil bath and heated at 110 oC for 2 h.  After 
cooling, the reaction mixture was poured into a 50-mL Falcon tube containing EtOH/water 9:1, 
and the tube was further diluted with EtOH/water 9:1 until the total volume reached 25 mL. The 
tube was centrifuged (3200 rpm, 2135 xg, 10 min, rt). The supernatant was removed via pipet, 
and the sediment was suspended in 9:1 EtOH/water (25 mL), sonicated for 15 min, and 
centrifuged (3000 rpm, 1877 xg, 10 min, rt). This washing process (re-suspension, sonication, 
centrifugation) was carried out two additional times.  The sediment was then suspended in DMF 
(20 mL) and heated at 100 oC with stirring for 30 min. After cooling, the mixture was diluted 
with 9:1 EtOH/water and washed 3 x in the same manner as described above. The sediment 
remaining after the last wash was transferred to a 15 mL Falcon tube (using EtOH to transfer) 
and diluted with EtOH to the 6.5 mL mark. The tube was centrifuged (3000 rpm, 1877 xg, 5 min, 
rt), the supernatant was removed by pipet, and the sediment was suspended in EtOH and 
centrifuged under the same conditions.  This washing process was repeated three times, and 
finally the last sediment was transferred to a clean 15 mL Falcon tube (using absolute EtOH for 
transfer) and dried under a stream of N2 to afford pale orange particles (35.6 mg).   
 
 The combined supernatants from the first washes were combined and diluted with water 
and Et2O. The aqueous portion was extracted with Et2O (3 x), and the combined organic layers 
were washed with water and brine, dried (Na2SO4) and concentrated in vacuo. The crude residue 
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was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to afford recovered chloride 3-59 
(77.6 mg), as a pale yellow solid.   
 
 
 
 
 
 
 
 
N-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-p-tolyl-4,5-dihydrooxazole-4-carboxamide (3-
61).  A solution of 3-59 (150 mg, 0.402 mmol) in THF (45 mL) was treated with Raney Ni (3.45 
g, taken from an aqueous slurry and washed with THF) and stirred at rt for 45 min.  The mixture 
was filtered through Celite, and the Celite plug was flushed with EtOH.  The filtrate was 
concentrated in vacuo, and the residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 1:1) to afford 3-61 (102 mg, 75%) as a white solid: 1H NMR (300 MHz, 
CDCl3)  7.84 (d, J = 8.2 Hz, 2 H), 7.23 (d, J = 8.0 Hz, 2 H), 6.98 (b, 1 H), 6.796.75 (m, 3 H), 
5.95 (s, 2 H), 4.88 (dd, J = 10.9, 8.5 Hz, 1 H), 4.72 (dd, J = 10.9, 8.7 Hz, 1 H), 4.61 (t, J = 8.5 
Hz, 1 H), 4.47 (dd, J = 14.7, 6.4 Hz, 1 H), 4.30 (dd, J = 14.6, 5.6 Hz,1 H), 2.41 (s, 3 H). 
 
 Procedure for “Blank” Reaction with 3-61 and particles 3-42.  A solution of PITC 
nanoparticles 3-42 (23.5 mg) were suspended in anhydrous DMF (6.2 mL) and sonicated for 20 
min (ultrasonic bath). The suspension was treated with TBAI (17.8 mg, 0.0482 mmol), DIPEA 
(0.065 mL, 0.37 mmol), and a solution of 3-61 (49.3 mg, 0.146 mmol). The solution was heated 
at 110 oC for 2 h (pre-heated oil bath). After cooling, the mixture was poured into a 50-mL 
Falcon tube, containing 10 mL of EtOH/water, 9:1.  The tube was centrifuged (3200 rpm, 2135 
xg, 10 min, rt). The supernatant was removed by pipet, and the sediment was suspended in 
EtOH/water 9:1 (25 mL) and sonicated for 25 min. The tube was centrifuged using the same 
conditions as described above, and the supernatant was removed via pipet.  The washing 
procedure was repeated two additional times (3 washes total after the initial DMF dilution).  The 
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sediment was diluted with DMF (15 mL) and transferred to a 50 mL round-bottom flask  
(transfer pipet), and this solution was vigorously stirred and heated at 90 oC for 20 min. The 
mixture was cooled and poured into a 50 mL Falcon tube and diluted with 9:1 ethanol/water (10 
mL). The solution was sonicated, and subsequently centrifuged (3200 rpm, 2135 xg, 10 min, rt). 
The supernatant was decanted, and the particles were suspended in 9:1 EtOH/water (25 mL) and 
centrifuged (3200 rpm, 2135 xg, 10 min, rt). This was repeated, and the supernatant was 
decanted, and the particles were suspended in EtOH and transferred to a 15-mL Falcon tube (7 
mL EtOH were used total). The tube was centrifuged (3200 rpm, 2135 xg, 5 min, rt), the 
supernatant was decanted, and the particles were suspended in EtOH (7 mL), sonicated, and 
centrifuged under the same conditions as above. This washing procedure was repeated four 
times, and finally the supernatant was decanted and the particles were suspended in EtOH (4 
mL), transferred to a clean pre-weighed 15 mL Falcon tube, sonicated, and dried under N2 to 
afford pale orange-colored particles (12.8 mg).   
 
The initial supernatants were combined and diluted with water and Et2O. The aqueous 
layer was extracted with Et2O (3 x), and the combined organic layers were washed with water (3 
x), and brine, dried (Na2SO4) and concentrated in vacuo.  Purification by chromatography on 
SiO2 (hexanes/EtOAc, 1:1) afforded recovered 3-61 (38.9 mg), as a yellow solid.  
 
 
General procedure for thioether cleavage of UV-active model system 3-60.  A 
suspension of piperonyl-labeled nanoparticles 3-60 (11.3 mg) in absolute EtOH (1.0 mL) were 
treated with NiCl2 (63 mg, 0.49 mmol) and then (slowly) NaBH4 (36 mg, 0.95 mmol), affording 
a black solid and much H2 evolution.  The slurry was sonicated (ultrasonic bath) for 1 h, and then 
filtered through a plug of Celite, flushed with EtOH (~25 mL total EtOH), and the filtrate was 
concentrated. The residue was taken up in distilled THF (sonication was employed to move 
residue from the sides of the flask into solution) and diluted to 10 mL in a volumetric flask.   
Aliquots of this solution were analyzed by UV/VIS at 283 nm and 264 nm.  The absorbance 
values were correlated to a standard curve to ultimately afford loading values of 0.014 mmol/g 
(283 nm) and 0.011 mmol/g (264 nm).   
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(4-Bromobenzyloxy)(tert-butyl)dimethylsilane (3-61).267,268 A solution of 4-
bromobenzyl alcohol (10.0 g, 52.9 mmol), TBSCl (12.1 g, 79.4 mmol), and imidazole (7.28 g, 
106 mmol) in CH2Cl2 (110 mL) was stirred at rt for 11 h. The mixture was poured into ice-water 
(300 mL), and the aqueous layer was extracted with CH2Cl2 (3 x 100 mL). The combined 
organic layers were washed with saturated aqueous NaHCO3 (150 mL), water (150 mL), and 
brine (150 mL), dried (Na2SO4) and concentrated in vacuo. The crude residue was purified by 
Kugelrohr distillation (110 oC < T < 135 oC at 2 Torr) to afford 3-61 (15.2 g, 95%) as a colorless 
oil: 1H NMR (300 MHz, CDCl3)  7.46 (d, J = 8.4 Hz, 2 H), 7.21 (d, J = 8.1 Hz, 2 H), 4.69 (s, 2 
H), 0.95 (s, 9 H), 0.10 (s, 6 H); MS (EI) m/z (rel. intensity) 302 ([M+], 1.5), 300 ([M+]. 1.6), 245 
(98), 243 (96), 171 (58), 169 (62); HRMS (EI) m/z calc for C13H21BrOSi 300.0545, found 
300.0533. 
 
 
s 
 
 
4-((tert-Butyldimethylsilyloxy)methyl)benzoic acid (3-63).269 A flame-dried 250-mL 
round-bottom flask was charged with 3-62 (5.00 g, 16.6 mmol) and THF (60 mL), and the 
solution was cooled to -78 oC. After stirring for 30 min at -78 oC, n-BuLi (9.30 mL, 18.3 mmol, c 
= 1.97 M in hexanes) was added drop-wise via syringe over a period of 25 min.  The solution 
was stirred at -78 oC for and additional 15 min, and CO2 was bubbled through the solution for 5 
min.  The mixture was quenched at -78 oC with saturated aqueous NaHSO4 (20 mL), and the 
reaction vessel was warmed to rt. The mixture was diluted with water (100 mL) and EtOAc (150 
mL), and the aqueous layer was extracted with EtOAc (3 x 100 mL). The combined organic 
layers were washed with water and brine, dried (Na2SO4) and concentrated in vacuo.   Residual 
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water was removed by coevaporation with benzene.  Upon drying under high vacuum, 3-63 (3.91 
g, 88%) was obtained as a white solid:  1H NMR (300 MHz, CDCl3)  8.08 (d, J = 8.3 Hz, 2 H), 
7.44 (d, J = 8.3 Hz, 2 H), 4.82 (s, 2 H), 0.97 (s, 9 H), 0.13 (s, 6 H); HRMS (ES) m/z calc for 
C14H22O3SiNa (M+Na) 289.1236, found 289.1212.  
 
 
 
 
 
 
 
Methyl 2-(4-((tert-butyldimethylsilyloxy)methyl)benzamido)-3-hydroxypropanoate 
(3-64). A solution of 3-63 (2.00 g, 7.51 mmol) in CH2Cl2 (80 mL) was treated with dl-
SerOMeHCl (1.79 g, 11.3 mmol), HOBT-hydrate (1.49 g, 9.76d\ mmol), Et3N (1.60 mL, 11.4 
mmol), and EDC•HCl (1.58 g, 8.26 mmol). The solution was stirred at rt for 12 h and 
subsequently diluted with CH2Cl2 (150 mL). The solution was washed with 0.1 M aqueous citric 
acid (2 x 150 mL), saturated aqueous NaHCO3 (150 mL), and brine (150 mL), dried (Na2SO4), 
and concentrated in vacuo.  The crude yellow residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 1:1) to afford 3-64 (2.02 g, 73%) as a colorless oil: IR (ATR) 3433, 2950, 
1741, 1638, 1210, 1083 cm-1; 1H NMR (300 MHz, CDCl3)  7.81 (d, J = 8.3 Hz, 2 H), 7.40 (d, J 
= 8.4 Hz, 2 H), 7.15 (d, J = 7.1 Hz, 1 H), 4.87 (dt, J = 7.2, 3.5 Hz, 1 H), 4.79 (s, 2 H), 4.10–4.01 
(m, 1 H), 3.82 (s, 3 H), 2.89 (t, J = 5.3 Hz, 1 H), 0.95 (s, 9 H), 0.11 (s, 6 H); 13C NMR (75 MHz, 
CDCl3)  171.1, 167.5, 145.8, 131.9, 127.2, 126.0, 64.4, 63.6, 55.1, 52.9, 25.9, 18.4, -5.3; MS 
(EI) m/z (rel. intensity) 367 (M+, 0.14), 310 (100), 249 (65); HRMS (EI+) m/z calc for C18H-
29NO5Si 367.1815, found 367.1821.  
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Methyl2-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-4,5-dihydrooxazole-4-
carboxylate (3-65). An oven-dried round-bottom flask was charged with a solution of 3-64 (2.53 
g, 6.88 mmol) in THF (80 mL), and the solution was treated with Burgess reagent (1.97 g, 8.26 
mmol) and heated at reflux for 1 h. After cooling, the reaction solution was filtered to remove a 
white solid, which was subsequently washed with THF.  The filtrate was concentrated onto SiO2 
and purified by chromatography on SiO2 (hexanes/EtOAc, 2:1) to afford 3-65 (1.78 mg, 74%) as 
a colorless oil that solidifies upon standing: Mp 49.7-52.0 oC; IR (ATR) 2950, 1735, 1640, 1210, 
1083 cm-1; 1H NMR (300 MHz, CDCl3)  7.95 (d, J = 8.4 Hz, 2 H), 7.37 (d, J = 8.4 Hz, 2 H), 
4.95 (dd, J = 10.6, 7.9 Hz, 1 H), 4.78 (s, 2 H), 4.69 (dd, J = 8.8, 7.8 Hz, 1 H), 4.59 (dd, J = 10.6, 
8.7 Hz, 1 H), 3.82 (s, 3 H), 0.94 (s, 9 H), 0.097 (s, 6 H); 13C NMR (75 MHz, CDCl3)  171.7, 
166.2, 145.6, 128.5, 125.7, 125.4, 69.4, 68.6, 64.5, 52.7, 25.9, 18.4, -5.3; MS (EI) m/z (rel. 
intensity) 349 ([M+], 17), 292 (100), 218 (38); HRMS (EI) m/z calc for C18H27NO4Si 349.1709, 
found 349.1712.  
 
 
 
 
 
 
 
2-(4-((tert-Butyldimethylsilyloxy)methyl)phenyl)-N-(1-hydroxy-2,2,6,6-
tetramethylpiperidin-4-yl)-4,5-dihydrooxazole-4-carboxamide (3-66).  A solution of 3-65 
(300 mg, 0.858 mmol) in THF (8.5 mL) was treated with 1 N aqueous NaOH (1.30 mL, 1.30 
mmol) and stirred at rt for 90 min.   NaHCO3 (354 mg, 4.21 mmol) was added, and the solvent 
was removed in vacuo. Residual water was removed by coevaporation with toluene (3 x 15 mL). 
To the crude white solid was added a solution of 4-amino TEMPO (300 mg, 1.75 mmol) in 
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anhydrous DMF (10 mL) and residual DMF was added to bring the total volume to 17 mL. 
Sonication (ultrasonic bath) was employed to help with dissolution. The solution was cooled in 
an ice bath to ~0 oC and DIPEA (0.71 mL, 4.3 mmol) and DPPA (0.56 mL, 2.6 mmol) were 
added, and the reaction mixture was warmed to rt and stirred for 20 h. The mixture was cooled to 
0 oC and quenched with saturated aqueous NaHCO3 (12 mL) and stirred for 90 min. The mixture 
was t poured into water (100 mL) and extracted with Et2O (1 x 100 mL and 2 x 30 mL). The 
combined organic layers were washed with water (3 x 70 mL) and brine (1 x 70 mL), dried 
(Na2SO4) and concentrated in vacuo.  Purification by chromatography on SiO2 (hexanes/EtOAc, 
1:2) afforded 3-66 (371 mg, 88%) as a peach-colored foam:  IR (ATR) 3340, 2926, 1668, 1638, 
1507, 1082, 833 cm-1; MS (EI) m/z (rel. intensity) 489 (M+, 17), 488 (26), 431 (47), 290 (52); 
HRMS (EI) m/z calc for C26H42N3O4Si 488.2945, found 488.2939. 
 
NMR data was carried out on the corresponding hydroxylamine (3-66a): a sample of 3-
66 (94.5 mg) was dissolved in MeOH (5 mL), treated with ascorbic acid (88 mg) and shaken for 
~1 min (until the solution color changed from orange to colorless). The solution was dissolved in 
Et2O (20 mL) and washed twice with saturated aqueous NaHCO3, followed by water and brine, 
dried (MgSO4) and concentrated in vacuo.  CDCl3 (filtered through basic Al2O3) was added and 
the solution was concentrated in vacuo to afford (107 mg, > 100%) of the hydroxylamine.  The 
hydroxylamine was dissolved in CDCl3 (filtered through Al2O3): 
1H NMR (300 MHz, CDCl3)  
7.95 (d, J = 8.1 Hz, 2 H), 7.41 d, J = 8.1 Hz, 2 H), 6.46 (b d, J = 8.0 Hz, 1 H), 4.854.78 (m, 1 
H), 4.80 (s, 2 H), 4.72–4.66 (m, 1 H), 4.60 (t, J = 8.5 Hz, 1 H), 4.48 (bs, 1 H), 4.244.11 (m, 1 
H), 1.93 (dt, J = 12.5, 3.3 Hz, 1 H), 1.80 (dt, J = 12.5, 3.4 Hz, 1 H), 1.461.25 (m, 2 H), 1.22 (s, 
3 H), 1.20 (s, 3 H), 1.20 (s, 3 H), 1.16 (s, 3 H), 0.96 (s, 9 H), 0.12 (s, 6 H); 13C NMR (75 MHz, 
CDCl3)  170.2, 165.3, 145.0, 127.6, 125.0, 124.6, 69.6, 68.1, 63.7, 58.1, 44.5, 40.0, 31.5, 25.0, 
18.8, 17.5, -6.2. 
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N-(1-oxo-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-(hydroxymethyl)phenyl)-4,5-
dihydrooxazole-4-carboxamide (3-67).  A solution of 3-66 (78.3 mg, 0.160 mmol) in THF 
(1.10 mL) was treated with a solution of TBAF and AcOH (0.50 mL, 0.48 mmol, 0.95 mmol 
TBAF) and stirred at rt for 2.5 h. The reaction mixture was quenched with saturated aqueous 
NH4Cl (2 mL) and water (2 mL), and the aqueous layer was extracted with EtOAc (3 x 15 mL). 
The combined organic layers were washed with saturated aqueous NaHCO3 (10 mL), water (10 
mL), and brine (10 mL), dried (Na2SO4) and concentrated in vacuo.  The crude residue was 
purified by chromatography on SiO2 (hexanes/EtOAc, 4:1 to 1:1, then 100% EtOAc) to afford 3-
67 (29.3 mg, 49%) as an orange foam.  
 
 For the purpose of characterization, the material was converted to the corresponding 
hydroxylamine (3-67a).  A sample was dissolved in MeOH (~2 mL), treated with ascorbic acid 
(15 mg), shaken until the color went from orange to colorless, and diluted with Et2O (15 mL).  
The ethereal layers were washed with saturated aqueous NaHCO3, water, and brine, dried 
(MgSO4), filtered, and concentrated in vacuo: 
1H NMR (400 MHz, CDCl3)  7.99 (d, J = 8.0 Hz, 
2 H), 7.48 (d, J = 8.1 Hz, 2 H), 6.47 (d, J = 8.0 Hz, 1 H), 4.86–4.82 (m, 1 H), 4.82 (s, 2 H), 4.72 
(dd, J = 10.9, 8.7 Hz, 1 H), 4.62 (t, J = 8.5 Hz, 1 H), 4.254.15 (m, 1 H), 1.95 (dt, J = 12.6, 3.4 
Hz, 1 H), 1.82 (dt, J = 12.6, 3.5 Hz, 1 H), 1.48–1.42 (m, 1 H), 1.40–1.34 (m, 1 H), 1.28 (bs, 1 H), 
1.24 (s, 3 H), 1.22 (s, 3 H), 1.21 (s, 3 H), 1.18 (s, 3 H); 13C NMR (100 MHz, CDCl3)  170.7, 
165.7, 144.9, 128.4, 126.4, 125.8, 70.1, 68.7, 64.4, 45.0, 40.5, 32.0, 19.4. 
 
 
 
 
 
 
  
 237 
 
 
 
Methyl 2-(4-(hydroxymethyl)phenyl)-4,5-dihydrooxazole-4-carboxylate (3-68).  A 
solution of 3-65 (704 mg, 2.01 mmol) in THF (14 mL) was treated with a solution of TBAF and 
AcOH (3.0 mL, 2.9 mmol TBAF, 1.4 mmol AcOH) at rt.  The mixture was stirred for 0.5 h at rt 
and quenched with saturated aqueous NH4Cl (14 mL), followed by water (14 mL) and extracted 
with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (50 mL), dried 
(Na2SO4) and concentrated in vacuo. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 4:1, then 100% EtOAc) to afford 3-68 (369 mg, 78%) as a white solid: Mp 
86.187.2 oC (hexanes/EtOAc); IR 3284, 1728, 1640, 1226, 1041, 1032 cm-1; 1H NMR (300 
MHz, CDCl3)  7.89 (d, J = 8.3 Hz, 2 H), 7.35 (d, J = 8.4 Hz, 2 H), 4.90 (dd, J = 10.6, 7.9 Hz, 1 
H), 4.694.64 (m, 3 H), 4.57 (dd, J = 10.6, 8.7 Hz, 1 H), 3.79 (s, 3 H), 3.09 (bs, 1 H); 13C NMR 
(75 MHz, CDCl3)  171.6, 166.3, 145.3, 128.7, 126.4, 125.6, 69.5, 68.3, 64.3, 52.7; MS (EI) m/z 
(rel. intensity) 235 (M+, 2.3), 176 (100); HRMS (EI+) m/z calc for C12H13NO4 235.0845, found 
235.0843.  
 
 
 
 
 
Methyl 2-(4-(tosyloxymethyl)phenyl)-4,5-dihydrooxazole-4-carboxylate (3-69). A 
solution of 3-68 (184 mg, 0.782 mmol) in CH2Cl2 (3.0 mL) was added via syringe pump (0.24 
mL/min) to a solution of Ts2O (574 mg, 1.74 mmol), Et3N (0.24 mL, 1.71 mmol) and DMAP 
(10.0 mg, 0.0837 mmol) in CH2Cl2 (6.0 mL) maintained at 0 
oC.  Following completion of the 
addition, the reaction mixture was stirred for 2 h, gradually warming to rt.  The mixture was 
diluted with CH2Cl2 (20 mL), washed with water (15 mL), and the aqueous layer was extracted 
with CH2Cl2 (10 mL).  The combined organic layers were washed with water and brine, dried 
(Na2SO4), and concentrated in vacuo to afford a red/brown residue. The residue was purified by 
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chromatography on SiO2 (hexanes/EtOAc, 1:1) to afford 3-69 (232 mg, 76%) as a viscous 
yellow-tinted oil that solidifies to a white solid upon standing: Mp 87.990.0 oC (CH2Cl2); IR 
(ATR) 3017, 2965, 1735, 1638, 1349, 1169 cm-1; 1H NMR (300 MHz, CDCl3)  7.93  (d, J = 8.3 
Hz, 2 H), 7.80 (d, J = 8.3 Hz, 2 H), 7.34 (d, J = 8.1 Hz, 2 H), 7.30 (d, J = 8.4 Hz, 2 H), 5.09 (s, 2 
H), 4.96 (dd, J = 10.6, 8.0 Hz, 1 H), 4.70 (app t, J = 8.4 Hz, 1 H), 4.60 (dd, J = 10.7, 8.8 Hz, 1 
H), 3.83 (s, 3 H), 2.45 (s, 3 H); 13C NMR (75 MHz, CDCl3)  171.5, 165.7, 145.0, 137.1, 132.9, 
129.9, 128.9, 128.0, 128.0, 127.4, 70.9, 69.6, 68.6, 52.8, 21.6; MS (ES) m/z (rel. intensity) 412 
([M+Na]+),  85), 389 (M+, 25); HRMS (ES) m/z calc for C19H19NO6SNa (M+Na) 412.0831, 
found 412.0818. 
 
 
 
 
 
 
Methyl 2-(4-((2,2,2-trichloro-1-iminoethoxy)methyl)phenyl)-4,5-dihydrooxazole-4-
carboxylate (3-70).  A solution of 3-68 (52.4 mg, 0.223 mmol) in CH2Cl2 (1.3 mL) was treated 
with DBU (5.0 uL, 0.031 mmol) and cooled in an ice-water bath. After the solution was stirred 
for 10 min, trichloroacetonitrile (30 uL, 0.29 mmol) was added via syringe. The solution (which 
became yellow in color) was stirred for 30 min at 0 oC.  The solvent was removed in vacuo to 
afford crude 3-70 as a brown residue (102 mg) which became a tan foam when placed under high 
vacuum. The material was used without further purification.  Characteristic data are reported: 1H 
NMR (300 MHz, CDCl3)  8.01 (d, J = 8.3 Hz, 2 H), 7.49 (d, J = 8.2 Hz, 2 H), 5.39 (s, 2 H), 
4.97 (dd, J = 10.6, 7.9 Hz, 1 H), 4.71 (app t, 1 H), 4.61 (dd, J = 10.6, 8.7 Hz, 1 H), 3.83 (s, 3 H). 
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3-(tert-Butyldiphenylsilyloxy)propan-1-amine (3-74).270 A solution of 3-amino-1-
propanol (1.00 mL, 12.9 mmol) and TBDPSCl (5.20 mL, 19.4 mmol) in dry CH2Cl2 (25 mL) 
was treated (slowly) with distilled Et3N (3.60 mL, 25.6 mmol).  The reaction mixture was stirred 
at rt for 4 h and subsequently diluted to 150 mL with CH2Cl2, washed with saturated aqueous. 
NH4Cl (100 mL), water (100 mL) and brine (100 mL), dried (MgSO4) and concentrated.  The 
crude residue was purified by chromatography on SiO2 (100% CH2Cl2 then 
CH2Cl2/MeOH/NH4OH (aq), 100 : 10 : 1) to afford 3-74 (2.68 g, 66%) as a viscous yellow oil:  
1H NMR (300 MHz, CDCl3)  7.68 (dd, J = 7.0, 1.9 Hz, 4 H), 7.477.36 (m, 6 H), 3.75 (t, J = 
6.0 Hz, 2 H), 2.85 (t, J = 6.8 Hz, 2 H), 1.70 (quint, J = 6.4 Hz, 2 H), 1.17 (bs, 2 H), 1.06 (s, 9 H); 
HRMS (ESI) m/z calc for C19H28NOSi  (M+H) 314.1940, found 314.1924. 
 
 
 
 
 
N-(3-(tert-Butyldiphenylsilyloxy)propyl)pent-4-ynamide (3-75).   A solution of 3-74 
(200 mg, 0.638 mmol) and 4-pentynoic acid (63 mg, 0.64 mmol) in anhydrous DMF (5.3 mL) 
was treated with DIPEA (0.22 mL, 1.3 mmol) and HATU (291 mg, 0.766 mmol). The reaction 
mixture turned bright yellow in color upon addition of the HATU. The reaction mixture was 
stirred at rt for 17.5 h, and subsequently brine (20 mL) was poured into the mixture.  The 
aqueous layer was extracted with EtOAc (3 x 30 mL), and the combined organic layers were 
washed with 0.5 N aqueous HCl (10 mL), water (20 mL), saturated aqueous NaHCO3 (10 mL), 
water, and brine, dried (MgSO4), and concentrated in vacuo.  Purification by chromatography on 
SiO2 (hexanes/EtOAc, 1:1) afforded 3-75 as a white solid (209 mg, 83%): Mp 70.972.7 
oC; IR 
(ATR) 3326, 3280, 3071, 1963, 1637, 1547, 1429, 1099 cm-1; 1H NMR (400 MHz, CDCl3)  
7.73–7.66 (m, 4 H), 7.537.32 (m, 6 H), 5.97 (bs, 1 H), 3.78 (t, J = 4.2 Hz, 2 H), 3.41 (app q, J = 
4.3 Hz, 2 H), 2.48 (ddd, J = 5.5, 5.5, 1.9 Hz, 2 H), 2.26 (t, J = 5.5 Hz, 2 H), 1.94 (t, J = 2.0 Hz, 1 
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H), 1.76 (app quint, J = 4.4 Hz, 2 H), 1.09 (s, 9 H); 13C NMR (100 MHz, CDCl3)  170.6, 135.5, 
133.3, 129.8, 127.8, 83.0, 69.0, 62.7, 37.7, 35.3, 31.4, 26.9, 19.1, 14.9; MS (EI) m/z (rel. 
intensity) 416 ([M+Na], 93), 265 (100); HRMS m/z calc for  C24H31NO2SiNa (M+Na) 416.2022, 
found 416.2009.  
 
 
 
 
 
 
 
2-(4-((4-(3-(3-(tert-Butyldiphenylsilyloxy)propylamino)-3-oxopropyl)-1H-1,2,3-
triazol-1-yl)methyl)phenyl)-N-(1-oxo-2,2,6,6-tetramethylpiperidin-4-yl)-4,5-
dihydrooxazole-4-carboxamide (3-76).  A flame-dried microwave vial was charged with model 
alkyne 3-75 (49.0 mg, 0.125 mmol), degassed toluene (2.5 mL), azide 3-50 (57.0 mg, 0.143 
mmol), CuI•P(OEt)3 (44 mg, 0.12 mmol), and DIPEA (65 L, 0.37 mmol).  The reaction 
mixture was stirred under N2 atmosphere for 5 h.  Additional alkyne (12.2 mg, 0.0310 mmol) 
was added, and the reaction mixture was stirred at rt overnight (12 h).  The mixture was 
concentrated in vacuo and purified by chromatography on SiO2 (CH2Cl2/MeOH, 95:5) to afford 
model triazole 3-76 (111 mg, 98%) as a pale orange foam. IR (ATR) 3502, 3335, 2930, 1642, 
1540, 1105, 1085 cm-1; HRMS (ESI) m/z calc for C44H58N7O5SiNa (M+Na) 815.4166, found 
815.4177. 
 
NMR characterization was carried out on the corresponding hydroxylamine, which was 
formed as follows:  the analyte (94.4 mg) was dissolved in MeOH (3.0 mL) and treated with 
ascorbic acid (115 mg). The solution was shaken until the color change from orange to colorless 
was complete. The mixture dissolved in ether (10 mL) and washed with equi-volume amounts of 
saturated aqueous NaHCO3, water, and brine, dried (MgSO4), filtered and concentrated in vacuo: 
1H NMR (300 MHz, CDCl3)  7.95 (d, J = 8.0 Hz, 2 H), 7.667.64 (m, 4 H), 7.447.36 (m, 6 H), 
7.307.27 (m, 2 H), 6.41 (d, J = 8.0 Hz, 1 H), 5.96 (bs, 1 H), 5.50 (s, 2 H), 4.80 (dd, J = 10.4, 8.7 
  
 241 
Hz, 1 H), 4.67 (app t, 1 H), 4.59 (t, J  = 8.6 Hz, 1 H), 4.234.10 (m, 1 H), 3.71 (t, J = 5.5 Hz, 2 
H), 3.33 (bs, 2 H), 2.99 (t, J = 6.9 Hz, 2 H), 2.46 (t, J = 6.9 Hz, 2 H), 2.18 (b, 1 H), 1.92 (dt, J = 
12.5, 3.2 Hz, 1 H), 1.78 (dt, J = 12.5, 3.2 Hz, 1 H), 1.73–1.64 (m, 2 H), 1.451.26 (m, 2 H), 1.21 
(s, 3 H), 1.19 (s, 3 H), 1.18 (s, 3 H), 1.14 (s, 3 H), 1.06 (s, 9 H); 13C NMR (75 MHz, CDCl3)  
171.3, 170.5, 165.1, 147.0, 138.5, 135.2, 133.0, 129.5, 128.9, 127.6, 127.5, 127.0, 121.3, 70.3, 
68.7, 62.1, 58.6, 53.2, 45.0, 40.6, 37.1, 35.2, 32.1, 31.2, 26.6, 21.1, 19.4, 18.8. 
 
 
 
 
 
 
N-(3-(Triethoxysilyl)propyl)pent-4-ynamide (3-77).   A flame-dried 250-mL round- 
bottom flask was charged with 4-pentynoic acid (1.0 g, 10 mmol), CH2Cl2 (100 mL), (3-
aminopropyl)triethoxysilane (4.80 mL, 20.5 mmol), and EDC•HCl (2.93 g, 15.3 mmol).  The 
reaction mixture was stirred under N2 atmosphere at rt for 18 h and concentrated in vacuo. The 
residue was purified by chromatography on SiO2 (deactivated with 0.5% Et3N; hexanes/EtOAc, 
1:1) to afford 3-77 (1.64 g, 53%) as a yellow oil: IR (ATR) 3292, 3286, 2971, 1644, 1545, 1074 
cm-1; 1H NMR (400 MHz, CDCl3)  5.87 (bs, 1 H), 3.83 (q, J = 7.0 Hz, 6 H), 3.28 (dd, J = 12.8, 
6.8 Hz, 2 H), 2.54 (ddd, J = 7.2, 7.2, 2.6 Hz, 2 H), 2.39 (t, J = 7.1 Hz, 2 H), 2.00 (t, J = 2.6 Hz, 1 
H), 1.681.61 (m, 2 H), 1.24 (t, J = 7.0 Hz, 9 H), 0.670.63 (m, 2 H); 13C NMR (100 MHz, 
CDCl3)  170.7, 82.9, 69.0, 58.2, 41.7, 35.2, 22.7, 18.1, 14.7, 7.6; HRMS (ESI) m/z calc for 
C14H27NO4SiNa 324.1607, found 324.1608. 
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Preparation of alkyne-functionalized nanoparticles (3-72).  An oven-dried 50-mL 
round bottom flask equipped with stir bar and condenser was charged with nanoscale SiO2 (250 
mg) and dry toluene (20 mL).  (Note: SiO2 was obtained by drying a commercial IPAST 
suspension under N2 and subsequently drying the recovered particles for 24 h in a vacuum oven.)  
To this stirring suspension was added a solution of 3-77 (505 mg, 1.68 mmol) in dry toluene (5 
mL), and the reaction mixture was heated at reflux for 3 h. The mixture was cooled to rt, and the 
contents were transferred to a 50-mL Falcon tube, using EtOH for transfer.   Some aggregates 
were discarded.  The tube was centrifuged (4400 rpm, 3000 xg, 30 min, rt), the supernatant was 
decanted, and the sediment was suspended in dry toluene, sonicated (ultrasonic bath), and 
centrifuged (4400 rpm, 3000 xg, 30 min, rt).  This washing procedure was repeated two 
additional times, and the final sediment was dried under N2, then dried under high vacuum for 24 
h to afford 3-77 (200 mg) as white particles: IR (KBr) 3306, 1650, 1554 cm-1; Anal. Found for 
(SiO2)nC14H26NO4Si: C, 7.07; H, 1.05; N, 1.05.  (Note: These particles are 3-72, batch 1).   
 
A separate batch of particles 3-72 was synthesized using the same protocol (3-72, batch 
2: Anal. Found for (SiO2)nC14H26NO4Si: C, 8.15; H, 1.26; N, 1.14. 
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Bromide model particles  (3-78). An oven-dried thick-walled vial was charged with 
particles 3-72 (batch 2) (35.5 mg, 0.0289 mmol based on a loading of 0.81 mmol/g) and 
CuI•P(OEt)3 (12 mg, 0.034 mmol). The vial was back-filled with N2 (3 x).  Degassed toluene 
(1.0 mL), 4-bromobenzyl azide (15 mg, 0.071 mmol) and DIPEA (15 L, 0.091 mmol) were 
added. The mixture was placed in a pre-heated oil bath and heated at 70 oC under N2 atmosphere 
for 16 h.  Upon cooling, the mixture was transferred to a 15-mL Falcon tube using additional 
toluene (2 mL) for transfer and dilution.  The tube was centrifuged (4400 rpm, 3000 xg, 15 min, 
rt). The colorless supernatant was removed via pipet.  The sediment was suspended in toluene (3 
mL), sonicated (ultrasonic bath) for 30 min, and centrifuged (4400 rpm, 3000 xg, 15 min, rt). 
This washing procedure was repeated, and the sediment was suspended in dry toluene (3 mL) 
and heated at reflux for 20 min. Upon cooling, the mixture was centrifuged, and the sediment 
was suspended in anhydrous THF (3 mL), sonicated for 20 min, and centrifuged (4400 rpm, 
3000 xg, 15 min, rt). The supernatant was removed, and the sediment was suspended in absolute 
EtOH (4 mL), sonicated for 5 min, and centrifuged (4400 rpm, 3000 xg, 15 min, rt). The 
particles were suspended in EtOH (4 mL) and centrifuged under the same conditions, the 
supernatant was decanted, and the particles were dried under N2, then in a vacuum oven at 100 
oC for 2 days to afford model particles 3-78 (15.3 mg) as white particles: Anal. Found for (SiO-
2)nC15H19BrN4O: C, 9.67; H, 1.17; N, 2.31; Br, 2.26. 
 
 
 
 
 
 
 
 
  
 244 
 
 
 
 
 
 
TEMPO-functionalized nanoparticles (3-71, Batch A). An oven-dried thick-walled 
vial was charged with particles 3-72 (batch 1) (73.1 mg, 0.0548 mmol based on a loading of 0.75 
mmol/g), azide 3-50 (40.1 mg, 0.100 mmol), and CuIP(OEt)3 (28.0 mg, 0.0785 mmol). The 
tube was back-filled with N2 (3 x).  Degassed toluene (1.0 mL) was added followed by DIPEA 
(35 L, 0.21 mmol).  The mixture was stirred for 15 h at rt under a N2 atmosphere.  The reaction 
mixture was transferred to a 15-mL Falcon tube using additional toluene (3 mL) for transfer and 
dilution. The tube was centrifuged (4400 rpm, 3000 xg, 10 min, rt). The supernatant was 
removed via pipet.  The sediment was suspended in toluene (4 mL), sonicated (ultrasonic bath) 
for 20 min, and centrifuged (4400 rpm, 3000 xg, 10 min, rt). This washing procedure was 
repeated, and the sediment was suspended in dry toluene (4 mL) and heated at reflux for 20 min. 
Upon cooling, the mixture was centrifuged, the supernatant removed, and the sediment was 
suspended in anhydrous THF (4 mL), sonicated for 20 min, and centrifuged (4400 rpm, 3000 xg, 
15 min, rt). The supernatant was removed, and the sediment was suspended in absolute EtOH (4 
mL), sonicated for 20 min, and centrifuged (4400 rpm, 3000 xg, 15 min, rt).  The EtOH wash 
was repeated, and the particles were dried under N2, then under high vacuum (2 mmHg) at 60 
oC 
for 12 h to afford 3-71 (Batch A) (56.6 mg) as pale orange colored particles: Anal. Found for 
(SiO2)nC28H39N7O4: C, 9.21; H, 1.24; N, 1.60. 
 
TEMPO-functionalized nanoparticles (3-71 Batch B).  The analogous procedure for 
synthesis of 3-71 Batch A was used with the following amounts of reactants/reagents: particles 
3-72 (batch 1) (34 mg, 0.026 mmol based on a loading of 0.75 mmol/g), azide 3-50 (40.1 mg, 
0.100 mmol), and complex CuI•P(OEt)3 (14.0 mg, 0.0393 mmol), degassed toluene (1.0 mL), 
and DIPEA (20 uL, 0.12 mmol).  Instead of stirring at rt, the mixture was placed in a pre-heated 
oil bath and stirred under N2 atmosphere at 70 
oC for 16 h.   After using the washing protocol 
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described in the case of 3-71 Batch A, the particles were dried under N2, then in a vacuum oven 
at 100 oC for 2 days to afford particles 3-71 Batch B (22.6 mg) as orange particles: Anal. Found 
for (SiO2)nC28H39N7O4: C, 9.67; H, 1.29; N, 1.95. 
 
 
 
 
 
 
 
Procedure for model Ugi functionalization of nanoparticles (3-82).   
A flame-dried thick-walled vial equipped with stir bar was charged with particles (3-51) 
(100 mg) and distilled THF (1.3 mL). To the vigorously stirring suspension was added distilled 
3-bromobenzaldehyde (29 L, 0.25 mmol), and the mixture was stirred at rt under N2 
atmosphere for 90 min.  3-Iodobenzoic acid (62 mg, 0.25 mmol) was added, followed by n-
butylisocyanide (52 L, 0.50 mmol). The reaction mixture was stirred at rt for 1 h and then at 60 
oC for 24 h.  Upon cooling, the reaction mixture was transferred via pipet to a 15-mL Falcon 
tube, using additional EtOH (1 mL) to help transfer particles. The tube was centrifuged (4400 
rpm, 3000 xg, 10 min). The supernatant was removed via pipet, and the collected sediment was 
dried under N2 overnight.  The dried particles were transferred to an eppendorf nylon 0.22 m 
centrifugal filter, and EtOH was placed on top of the filter. The tube was centrifuged (6000 rpm, 
3000 xg, 1h, rt).  Additional EtOH was added to fill the top of the filter, and the tube was 
centrifuged under the same conditions.  This wash was repeated twice, and the particles were 
collected and dried in the vacuum oven (44 h, -10 in Hg, 100 oC) to afford functionalized 
particles 3-82 (17 mg) as a pale yellow powder:  Anal. Found for (SiO2)nC22H25BrIN2O2: C, 
5.85; H, 0.93; N, 0.73; Br, 0.41; I, 2.73. 
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General procedure for the preparation of -hydroxy amides 3-84 and 3-90a-e using 
the corresponding carboxylic acids (Procedure A).   A solution of acid (1.0 equiv) and dl-
serine methyl ester hydrochloride (1.5 equiv) in dry CH2Cl2
 (ca. 0.1 M) was treated with HOBT-
hydrate (1.3 equiv) and Et3N (1.5 equiv).  The solution was cooled to 0 C and treated with 
EDCHCl (1.1 equiv).  The mixture was stirred overnight and diluted with CH2Cl2 and washed 
with 0.1 M aqueous citric acid, saturated aqueous NaHCO3, and brine, dried (Na2SO4), and 
concentrated in vacuo.  
 
General procedure for the preparation of -hydroxy amides 3-90a-e using the 
corresponding acid chlorides (Procedure B).  A slurry of dl-serine methyl ester hydrochloride 
(1.6 equiv) and Et3N (1.6 equiv) in CH2Cl2 (0.2 M in acid chloride) was cooled to 0 C and 
treated with acid chloride (1.0 equiv).  The reaction mixture was warmed to rt and stirred at rt 
overnight.  The mixture was diluted with CH2Cl2 and washed with 5% aqueous NaHSO4 and 
brine, dried (Na2SO4), and concentrated in vacuo.  
 
 
 
 
 
 
 
Methyl 3-hydroxy-2-(4-methylbenzamido)propanoate (3-84).271  Following General 
procedure A, p-toluic acid (1.00 g, 7.34 mmol) was converted to 3-84.  After purification on 
SiO2 (hexanes/EtOAc, 1:1 then 1:2) 3-84 (1.15 g, 66%) was obtained as a white solid: 
1H NMR 
(300 MHz, CDCl3)  7.74 (d, J = 8.3 Hz, 2 H), 7.26 (d, J = 8.0 Hz, 2 H), 7.07 (bd, J = 6.4 Hz, 1 
H), 4.88 (dt, J = 7.0, 3.6 Hz, 1 H), 4.08 (dd, J = 5.9, 3.6 Hz, 2 H), 3.84 (s, 3 H), 2.58 (t, J = 5.9 
Hz, 1 H), 2.41 (s, 3 H).  
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Methyl 2-(furan-2-carboxamido)-3-hydroxypropanoate (3-90a).272 Following General 
procedure B, 2-furoyl chloride (0.500 mL, 4.98 mmol) was converted to 3-90a.  After 
purification by chromatography on SiO2 (hexanes/EtOAc, 1:1 then 100% EtOAc)  3-90a (478 
mg, 45%)  was obtained as a white solid: 1H NMR (300 MHz, CDCl3)  7.50 (m, 1 H), 7.24 (bs, 
1 H), 7.17 (d, J = 3.3 Hz, 1 H), 6.53 (dd, J  = 3.6, 1.8 Hz, 1 H), 4.85 (dt, J = 7.4, 3.6 Hz, 1 H), 
4.124.02 (m, 2 H), 3.84 (s, 3 H), 2.44 (bs, 1 H). 
 
 
 
 
 
 
 
 
Methyl 2-(benzofuran-2-carboxamido)-3-hydroxypropanoate (3-90b).  Following 
General procedure A, 2-benzenefurancarboxylic acid (500 mg, 3.02 mmol) was converted to 3-
90b (615 mg, 77%), which was isolated as an analytically pure yellow solid and used without 
further purification: Mp 82.184.0 oC; IR (ATR) 3412, 3303, 2958, 1748, 1630, 1594, 1513, 
1438, 1177 cm-1; 1H NMR (300 MHz, CDCl3)  7.717.68 (m, 1 H), 7.567.52 (m, 3 H), 
7.487.42 (m, 1 H), 4.92 (dt, J = 7.5, 3.5 Hz, 1 H), 4.194.05 (m, 2 H), 3.87 (s, 3 H), 2.42 (bt, J 
= 4.5 Hz, 1 H); 13C NMR (100 MHz, CDCl3)  170.6, 159.0, 154.8, 147.8, 127.3, 127.2, 123.7, 
122.7, 111.9, 111.2, 63.2, 54.6, 52.9; MS (ES) m/z (rel. intensity) 286 ([M+Na], 95), 268 (100); 
HRMS (ES) m/z calc for C13H13NO5Na 286.0691, found 286.0695. 
 
 
 
  
 248 
 
 
 
 
Methyl 3-hydroxy-2-(4-methoxybenzamido)propanoate (3-90c).273  Following 
General procedure B, p-methoxybenzoyl chloride (0.500 mL, 3.69 mmol) was converted to 3-
90c.  Purification by chromatography on SiO2 (hexanes/EtOAc, 1:1, then 100% EtOAc) afforded 
3-90c (0.286 g, 31%) as an amorphous white solid: 1H NMR (300 MHz, CDCl3)  7.8 (d, J = 8.9 
Hz, 2 H), 7.03 (bd, J = 6.5 Hz, 1 H), 6.93 (d, J = 8.9 Hz, 2 H), 4.87 (dt, J = 7.0, 3.6 Hz, 1 H), 
4.06 (bt, J = 3.9 Hz, 2 H), 3.86 (s, 3 H), 3.83 (s, 3 H), 2.73 (bt, J = 5.3 Hz, 1 H). 
 
 
 
 
 
 
 
Methyl 2-(2,6-dimethoxybenzamido)-3-hydroxypropanoate (3-90d).  Following General 
procedure B, 2,6-dimethoxybenzoyl chloride (1.0 g) was converted to 3-90d (1.18 g, 84%), 
which was isolated as a white solid and used without further purification: 1H NMR (300 MHz, 
CDCl3)  7.31 (t, J = 8.4 Hz, 1 H), 6.69 (d, J = 6.7 Hz, 1 H), 6.59 (d, J = 8.4 Hz, 2 H), 4.87 (dt, J 
= 6.8, 3.4 Hz, 1 H), 4.27 (dd, J = 11.4, 3.4 Hz, 1 H), 3.98 (dd, J = 11.4, 3.3 Hz, 1 H), 3.84 (s, 6 
H), 3.83 (s, 3 H), 2.64 (bs, 1 H).  
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Methyl 3-hydroxy-2-(2-phenylacetamido)propanoate (3-90e).  Following General 
procedure A, phenyl acetic acid (808 mg, 5.93 mmol) was converted to 3-90e (840 mg, ~60%) 
which was isolated as a (crude) viscous yellow oil and used without further purification: 1H 
NMR (300 MHz, CDCl3)  7.417.28 (m, 5 H), 6.40 (bs, 1 H), 4.65 (dt, J = 7.2, 3.7 Hz), 
4.003.86 (m, 2 H), 3.76 (s, 3 H), 3.64 (s, 2 H), 2.47 (bs, 1 H). 
 
General procedure for conversion of -hydroxy amides to the corresponding 
oxazolines using Burgess Reagent.   A solution of -hydroxy amides (1.0 equiv) in distilled 
THF (0.1 M) was treated with Burgess reagent (1.2 equiv) and heated at reflux for 1 h.  Upon 
cooling, the mixture was concentrated onto SiO2 and purified by chromatography on SiO2. 
 
 
 
 
 
 
Methyl 2-p-tolyl-4,5-dihydrooxazole-4-carboxylate (3-85).271  Following the general 
procedure, 3-84 (995 mg, 4.19 mmol) was converted to 3-85.  Purification by chromatography on 
SiO2 (hexanes/EtOAc, 2:1) afforded 3-85 (704 mg, 77%) as a white solid: 
1H NMR (300 MHz, 
CDCl3)  7.87 (d, J = 8.2 Hz, 2 H), 7.22 (d, J = 8.0 Hz, 2 H), 4.95 (dd, J = 10.6, 7.9, 1 H), 4.69 
(app t, J = 8.3 Hz, 1 H), 4.59 (dd, J = 10.6, 8.7 Hz, 1 H), 3.82 (s, 3 H), 2.40 (s, 3 H). 
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Methyl 2-(furan-2-yl)-4,5-dihydrooxazole-4-carboxylate (3-91a).  Following the 
general procedure, 3-90a (470 mg, 2.20 mmol) was converted to 3-91a.  Purification by 
chromatography on SiO2 (hexanes/EtOAc, 1:1 then 100% EtOAc) afforded crude 3-91a (284 
mg, 66%) as a viscous yellow oil: 1H NMR (300 MHz, CDCl3)  7.577.56 (m, 1 H), 7.04 (d, J 
= 3.4 Hz, 1 H), 6.50 (dd, J = 3.5, 1.8 Hz, 1 H), 4.95 (dd, J = 10.4, 7.9 Hz, 1 H), 4.69 (t, J = 8.6 
Hz, 1 H), 4.56 (dd, J = 10.4, 8.7 Hz, 1 H), 3.81 (s, 3 H). 
 
 
 
 
 
 
 
Methyl 2-(benzofuran-2-yl)-4,5-dihydrooxazole-4-carboxylate (3-91b).  Following 
the general procedure, 3-90b (508 mg, 1.93 mmol) was converted to 3-91b.  Purification by 
chromatography on SiO2 (hexanes/EtOAc, 2:1 then 1:1) to afforded crude 3-91b as a white solid 
(215 mg, ~45%): 1H NMR (300 MHz, CDCl3)  7.687.57 (m, 1 H), 7.457.39 (m, 1 H), 7.38 (s, 
1 H), 7.337.26 (m, 1 H), 5.03 (dd, J = 10.5, 8.0 Hz, 1 H), 4.77 (t, J = 8.4 Hz, 1 H), 4.65 (dd, J = 
12.3, 8.7 Hz, 1 H), 3.84 (s, 3 H). 
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Methyl 2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxylate (3-91c).274 (DAST 
was used instead of Burgess Reagent). A flame-dried round-bottom flask cooled under N2 
atmosphere was charged with a solution of 3-90c (257 mg, 1.01 mmol) in dry CH2Cl2 (6 mL). 
The solution was cooled to -78 oC and stirred for 10 min.  DAST (0.15 mL, 1.1 mmol) was 
added drop-wise via syringe, and the solution was stirred at -78 oC for 1 h.  Anhydrous K2CO3 
(210 mg, 1.52 mmol) was added, and the solution was warmed to rt and stirred for 2 h. Saturated 
aqueous NaHCO3 (6 mL) was slowly added, and the solution was diluted with water (~10 mL) 
and CH2Cl2 (15 mL).  The layers were separated, and the organic layer was washed twice with 
brine, dried (MgSO4) and concentrated in vacuo to afford 3-91c (172 mg, 72%) as a white solid: 
1H NMR (300 MHz, CDCl3)  7.967.91 (m, 2 H), 6.946.89 (m, 2 H), 4.93 (dd, J = 10.5, 7.8 
Hz, 1 H), 4.67 (dd, J = 8.6, 8.0 Hz, 1 H), 4.57 (dd, J = 10.5, 8.7 Hz, 1 H), 3.86 (s, 3 H), 3.82 (s, 3 
H). 
 
 
 
 
 
 
 
 
Methyl 2-(2,6-dimethoxyphenyl)-4,5-dihydrooxazole-4-carboxylate (3-91d). Following 
the general procedure, 3-90d (890 mg, 3.14 mmol) was converted to 3-91d.  Purification by 
chromatography on SiO2 (hexanes/EtOAc, 1:1, then 100% EtOAc) to afforded 3-91d (566 mg, 
68%) as a viscous yellow oil that foams upon drying under vacuum. 
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Methyl 2-benzyl-4,5-dihydrooxazole-4-carboxylate (3-91e). Following the general 
procedure, 3-90e was converted to 3-91. Purification by chromatography on SiO2 
(hexanes/EtOAc, 1:1) afforded crude 3-91e (381 mg, 49%) as a pale yellow oil: 1H NMR (300 
MHz, CDCl3)  7.367.29 (m, 5 H), 4.76 (dd, J = 10.3, 8.1 Hz, 1 H), 4.50 (app t, J = 8.3 H), 4.40 
(dd, J = 10.5, 8.8 Hz, 1 H), 3.80 (s, 3 H), 3.693.68 (m, 2 H).  
 
 
General procedure for converstion of oxazoline methyl esters to the corresponding N-
cyclohexylamides.  A solution of ester (1.0 equiv) in distilled THF (0.1 M) was treated with 1 M 
aqueous NaOH (1.5 equiv).  The solution was stirred at rt for 20 min.  NaHCO3 (5.0 equiv) was 
added, and the solvent was removed in vacuo.  Residual water was removed by coevaporation of 
the residue with toluene (3 x).  Anhydrous DMF (0.05 M) was added, and the solution was 
placed under Ar atmosphere and treated with DIPEA (5.0 equiv).  The solution was cooled to 0 
C, and DPPA (3.0 equiv) was added.  The reaction mixture was warmed to rt and stirred at rt 
overnight.  The mixture was cooled to 0 C and quenched with saturated aqueous NaHCO3 (1.5 x 
reaction volume) and stirred for 1 h. The mixture was poured into water and diluted with EtOAc. 
The layers were separated, and the aqueous layer was extracted with EtOAc (2 x). The combined 
organic layers were washed with water (3 x) and brine, dried (Na2SO4) and concentrated in 
vacuo.   
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N-Cyclohexyl-2-p-tolyl-4,5-dihydrooxazole-4-carboxamide (3-86) Following the 
general procedure, 3-85 (302 mg, 1.38 mmol) was converted to 3-86. Subsequent purification by 
chromatography on SiO2 (hexanes/EtOAc, 2:1, then 1:1) afforded crude 3-86 (392 mg, 99%) as a 
white solid:  IR (ATR) 3281, 2932, 1638, 1551, 1234, 1079 cm-1;  1H NMR (300 MHz, CDCl3)  
7.887.85 (m, 2 H), 7.277.24 (m, 2 H), 6.57 (bd, J = 7.7 Hz, 1 H), 4.80 (dd, J = 10.9, 8.3 Hz, 1 
H), 4.68 (dd, J = 10.8, 8.5 Hz, 1 H), 4.57 (t, J = 8.4 Hz, 1 H), 3.863.72 (m, 1 H), 2.42 (s, 3 H), 
2.001.93 (m, 1 H), 1.871.81 (m, 1 H), 1.761.59 (m, 3 H), 1.451.32 (m, 2 H), 1.241.07 (m, 
3 H); 13C NMR (75 MHz, CDCl3)  170.9, 166.2, 142.5, 129.2, 128.4, 124.3, 70.6, 69.0, 47.9, 
33.0, 32.9, 25.5, 24.8, 24.8, 21.6.  
 
 
 
 
 
 
N-Cyclohexyl-2-(furan-2-yl)-4,5-dihydrooxazole-4-carboxamide (3-92a).  Following 
the general procedure, 3-91a (280 mg, 1.43 mmol) was converted to 3-92a.  Purification by 
chromatography on SiO2 (hexanes/EtOAc, 1:1) afforded crude 3-92a (298 mg, 79%) as a white 
solid: 1H NMR (300 MHz, CDCl3)  7.59 (dd, J = 1.7, 0.8 Hz, 1 H), 7.02 (dd, J = 3.5, 0.6 Hz, 1 
H), 6.53 (dd, J = 3.5, 1.7 Hz, 1 H), 4.83 (dd, J = 12.3, 5.5 Hz, 1 H), 4.67 (dd, J = 10.8, 8.6 Hz, 1 
H), 4.57 (t, J = 8.6 Hz, 1 H), 3.833.72 (m, 1 H).  
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2-(Benzofuran-2-yl)-N-cyclohexyl-4,5-dihydrooxazole-4-carboxamide (3-92b).  
Following the general procedure, 3-91b (215 mg, 0.877 mmol) was converted to 3-92b. 
Purification by chromatography on SiO2 (hexanes/EtOAc, 1:1) afforded crude 3-92b (187 mg, 
68%) as a white solid:  1H NMR (400 MHz, CDCl3)  7.68 (d, J = 5.9 Hz, 1 H), 7.62 (d, J= 6.3 
Hz, 1 H), 7.44 (t, J = 6.2 Hx, 1 H), 7.37 (s,  1 H), 7.30 (t, J = 5.5 Hz, 1 H), 6.59 (bd, J = 5.9 Hz, 1 
H), 4.92 (dd, J = 8.1, 6.5 Hz, 1 H), 4.75 (dd,  J = 8.1, 6.5 Hz, 1 H), 4.67 (t, J = 6.5 Hz, 1 H), 
3.843.70 (m, 1 H), 1.991.92 (m, 1 H), 1.891.84 (m, 1 H), 1.771.58 (m, 3 H), 1.431.29 (m, 
2 H), 1.271.08 (m, 3 H).  
 
 
 
 
 
 
 
 
N-Cyclohexyl-2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide (3-92c). An 
alternative procedure was used in this case: A solution of 3-91c (172 mg, 0.731 mmol) in THF (7 
mL) was treated with 1 N aqueous NaOH (1.1 mL, 1.1 mmol) and stirred at rt for 30 min.  
NaHCO3 (307 mg, 3.66 mmol) was added, and the solvent was removed in vacuo. Residual 
water was removed by coevaporation with toluene (3 x 10 mL).  To the white residue was added 
anhydrous DMF (14 mL), cyclohexylamine (0.170 mL, 1.47 mmol), DIPEA (0.61 mL, 3.6 
mmol) and PyBroP (413 mg, 0.877 mmol).  The mixture was stirred at rt for 1 h 45 min, and 
diluted with EtOAc (150 mL).  This solution was washed with 5% aqueous NaHSO4 (100 mL), 
5% aqueous NaHCO3 (100 mL), water (2 x 100 mL) and brine, dried (Na2SO4), and concentrated 
in vacuo.  The crude residue was dissolved in CH2Cl2 and concentrated onto SiO2.  Subsequent 
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purification by chromatography on SiO2 (hexanes/EtOAc, 1:1) afforded 3-92c (100 mg, 45%) as 
a white solid:  IR (ATR) 3428, 3284, 2932, 1643, 1611, 1515 cm-1; 1H NMR (400 MHz, CDCl3) 
 7.947.91 (m, 2 H), 6.966.93 (m, 2 H), 6.57 (bd, 1 H), 4.80 (dd, J = 8.2, 6.2 Hz, 1 H), 4.68  
(dd, J = 8.2, 6.5 Hz, 1 H), 4.56 (t, J = 6.3 Hz, 1 H), 3.87 (s, 3 H), 3.833.73 (m, 1 H), 1.991.96 
(m, 1 H), 1.861.83 (m, 1 H), 1.751.59 (m, 3 H), 1.441.30 (m, 2 H), 1.241.06 (m, 3 H); 13C 
NMR (100 MHz, CDCl3)  171.0, 165.9, 126.6, 130.2, 119.5, 113.8, 70.6, 69.1, 55.4, 47.9, 33.0, 
32.9, 25.5, 24.8, 24.8; MS (ES) m/z (rel. intensity) 325 ([M+Na]+, 80), 303 (M+, 100), 221 (75); 
HRMS (ES) m/z calc for C17H22N2O3Na 325.1528, found 325.1529. 
 
 
 
 
 
 
 
 
N-cyclohexyl-2-(2,6-dimethoxyphenyl)-4,5-dihydrooxazole-4-carboxamide (3-92d).  
Following the general procedure, 3-91d (560 mg, 2.11 mmol) was converted to 3-92d.. 
Purification by chromatography on SiO2 (100% EtOAc) afforded 3-92d (564 mg, 80%): 
1H 
NMR (300 MHz, CDCl3)  7.35 (t, J = 8.4 Hz, 1 H), 6.67 (d, J = 8.1 Hz, 2 H), 6.60 (d, J = 8.5 
Hz, 2 H), 4.85 (dd, J = 10.4, 6.9 Hz, 1 H), 4.694.56 (m, 2 H), 3.84 (s, 6 H), 2.051.93 (m, 2 H), 
1.931.61 (m, 2 H), 1.401.25 (m, 3 H), 1.210.93 (m, 3 H). 
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2-Benzyl-N-cyclohexyl-4,5-dihydrooxazole-4-carboxamide (3-92e).  Following the 
general procedure, 3-91e (370 mg, 1.69 mmol) was converted to 3-92e. Purification by 
chromatography on SiO2 (hexanes/EtOAc, 1:1) afforded (crude) 3-92e (245 mg, 51%) as a white 
solid:  1H NMR (300 MHz, CDCl3)  7.387.28 (m, 5 H), 6.39 (bd, J = 7.4 Hz, 1 H), 4.62 (app t, 
J = 9.5 Hz, 1 H), 4.524.42 (m, 1 H), 3.803.69 (m, 1 H), 3.66 (s, 2 H), 1.91 (d, J = 11.5 Hz, 1 
H), 1.80 (d, J = 12.9 Hz, 1 H), 1.711.65 (m, 3 H), 1.711.65 (m, 3 H), 1.421.30 (m, 2 H), 
1.221.04 (m, 3 H). 
 
 
 
 
 
 
 
 
N-(1-Oxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-((4-(3-hydroxypropyl)-1H-1,2,3-
triazol-1-yl)methyl)phenyl)-4,5-dihydrooxazole-4-carboxamide (3-95). An oven-dried 25-mL 
round-bottom flask was charged with 3-50 (280 mg, 0.701 mmol), dry toluene (13.5 mL), 4-
pentyn-1-ol (83 µL, 0.90 mmol), and DIPEA (0.37 mL, 2.1 mmol). The solution was degassed (3 
freeze-pump-thaw cycles) and CuI•POEt3 (250 mg, 0.70 mmol) was added. The solution was 
stirred at rt under Ar atmosphere for 24 h, and solvent was concentrated in vacuo. Purification by 
chromatography on SiO2 (10% MeOH/CH2Cl2) afforded 3-95 (228 mg, 67%) as an orange foam: 
IR (ATR) 3409, 2934, 1640, 1514, 1361 cm-1; HRMS (ESI) m/z calc for C25H36N6O4 (M+H) 
484.2798, found 484.2799.  NMR data were obtained after reduction to the corresponding 
hydroxylamine: 
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N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-((4-(3-hydroxypropyl)-1H-
1,2,3-triazol-1-yl)methyl)phenyl)-4,5-dihydrooxazole-4-carboxamide (3-95a).  A solution of 
3-95 (73.0 mg, 0.151 mmol in dry MeOH (1.5 mL) was treated with (L)-ascorbic acid (27 mg, 
0.15 mmol). The solution was stirred under an Ar atmosphere at rt for 30 min. The solution was 
diluted with EtOAc (30 mL) and washed with saturated aqueous NaHCO3 (3 mL), water (3 mL), 
and brine (3 mL), dried (MgSO4), filtered, and concentrated in vacuo. The concentrate was 
coevaporated with CDCl3 (filtered through basic Al2O3) to afford the corresponding 
hydroxylamine (62.3 mg, 85%) as a white foam: 1H NMR (500 MHz, CDCl3)  7.98 (d, J = 8.2 
Hz, 2 H), 7.32 (d, J = 8.1 Hz, 2 H), 7.27 (s, 1 H), 6.40 (d, J = 7.9 Hz, 1 H), 5.56 (s, 2 H), 4.81 
(dd, J = 11.0, 8.5 Hz, 1 H), 4.70 (dd, J = 10.9, 8.8 Hz, 1 H), 4.61 (t, J = 8.6 Hz, 1 H), 4.204.11 
(m, 1 H), 3.71 (t, J = 6.0 Hz, 2 H), 2.83 (t, J = 7.2 Hz, 2 H), 1.961.91 (m, 3 H), 1.80 (dt, J = 
12.5, 3.4 Hz, 1 H), 1.42 (t, J = 12.4 Hz, 1 H), 1.34 (t, J = 12.4 Hz, 1 H), 1.22 (s, 3 H), 1.20 (s, 3 
H), 1.19 (s, 3 H), 1.15 (s, 3 H); 13C NMR (125 MHz, CDCl3)  170.3, 165.0, 147.8, 138.3, 128.8, 
127.5, 126.9, 120.6, 70.1, 68.6, 61.4, 53.2, 44.8, 40.4, 31.5, 21.7, 19.3. 
 
 
 
 
 
 
 
 
Representative procedure for preparation of (3-aminopropyl)-functionalized CPG 
(3-96).244 A microwave tube (2–5 mL size) was charged with native controlled pore glass (120-
200 mesh/500 Å pore, 616 mg) and (3-aminopropyl)triethoxysilane (3.0 mL). The tube was 
sealed and subjected to microwave heating (Biotage reactor) at 100 oC for 2 x 1 min then 1 x 5 
min. The contents were filtered using a medium-sized fritted funnel, and the solids were washed 
with toluene (2 x 20 mL), MeOH (2 x 20 ml), CH2Cl2 (2 x 20 mL), and distilled hexanes (2 x 20 
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mL). The solid (616 mg) was removed and placed into a 20 mL scintillation vial covered in 
punched aluminum foil for storage in a dessicator.   
 
 Representative procedure for determination of the loading of (3-aminopropyl)-
functionalized CPG via trityl analysis.245    
Preparation of DMT reagent.   DMTCl (423 mg, 1.25 mmol) was placed in a 15-mL 
polypropylene Falcon tube, followed by distilled THF (2.5 mL), AgNO3 (211 mg, 1.25 mmol) 
and distilled pyr (0.50 mL). The tube was capped with a septum and Ar balloon and mixed on the 
vortex for 4 min.  The tube was centrifuged (2000 rpm, 5 min). 
 
Protocol for loading determination.  A sample of 3-aminopropyl functionalized porous 
glass 3-96 (20-50 mg) was added to a 1-dram vial and dried under high vacuum overnight.  To 
the vial was added the DMT reagent solution (0.50 mL).  The vial was flushed with Ar and 
shaken (200 rpm) for 20 min. The functionalized CPG was collected by filtration onto a medium-
sized fritted funnel and washed at least three times each with DMF, THF, and Et2O. The bright 
pink beads were transferred to a 1 dram vial and dried under high vacuum.  A portion of the 
sample (6-8 mg) was weighed directly into a 50-mL volumetric flask. The sample was diluted to 
the line with a 3% Cl3CCO2H/CH2Cl2 w/v solution and analyzed from 600 nm to 400 nm 
(UV/VIS).   Due to high absorbance values, 5-fold dilutions of the sample was made using 3% 
Cl3CCO2H/CH2Cl2 w/v, and the diluted solution was analyzed from 600 nm to 400 nm 
(UV/VIS).  Concentrations (and consequent loadings) were calculated based on the absorbance 
values at 504 nm using an extinction coefficient of 76 mLcm-1µmol-1.  Measurements were made 
in triplicate.Loadings were typically in the range of 100150 µmol/g.  Representative data from 
loading determination after several batch functionalizations are depicted in Table 4-2. 
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Table 4-2. Loadings of 3-aminopropyl functionalized CPG. 
 
 
 
 
 
 
 
 
Representative procedure for preparation of succinylated CPG (3-93).244 A 
microwave vial was charged with 3-aminopropyl functionalized CPG 3-96 (512 mg, based on a 
loading = 144 µmol/g) followed by a solution of succinic anhydride (1.25 g, 12.5 mmol) and 
DMAP (150 mg, 1.23 mL) in anhydrous DMF (3.5 mL). The vial was subjected to heating in the 
Biotage microwave reactor at 100 ºC (2 x 1 min, then 1 x 5 min).  The solid CPG was collected 
by filtration through a medium-sized fritted funnel. The solid was washed with MeOH (3 x 15 
mL), CH2Cl2 (3 x 15 mL), EtOAc (3 x 15 mL), and hexanes (3 x 15 mL). The solids were 
 
Entry 
 
Batch of CPG 3-96 
 
Loading (µmol/g) 
 
 
1 
 
3-96A 
 
125a 
 
2c 3-96B 130  20 
 
3d 3-96C 77b  4 
 
4 3-96D 114  11 
 
5 3-96E 153a 
 
6 3-96F 150a  50 
 
aSingle measurement.  bMean  standard deviation (n = 3 trials). cFunctionalization conditions were as 
follows: µwave 1 x 1 min, then 5 min.  dFunctionalization conditions were as follows: µwave, 5 min. 
  
 260 
collected into a 20 mL scintillation vial, capped with foil (with punched holes) and stored in the 
dessicator for 4 days. 
 
 Representative procedure for determination of the loading of succinylated CPG.243   
A sample of succinylated CPG (75.7 mg) was dried under high vacuum overnight in a 1-dram 
vial.  To the vial was added 4-nitrophenol (9 mg, 0.07 mmol) EDC (11 mg, 0.06 mmol), distilled 
pyr (0.50 mL), and distilled Et3N (40 µL, 0.1 mmol). The vial was shaken (200 rpm) at rt 
overnight.   The solid was collected by filtration through a medium-sized fritted funnel and 
washed with pyridine, MeOH, and CH2Cl2 and dried under high vacuum to afford esterified CPG 
(62.4 mg).  A sample of the esterified porous glass (11–13 mg) was weighed directly into a 25-
mL volumetric flask.  The flask was filled to the line with 0.1 M aqueous NaOH and analyzed 
from 600 nm to 300 nm (UV/VIS).  Concentrations (and consequent loading) was calculated 
based on the absorbance values at 400.5 nm using an extinction coefficient of 15.7 mLcm-1µmol-
1.  Loadings from the respective precursor amine batches are shown in Table 4-3. 
 
Table 4-3. Loadings of succinylated CPG. 
 
Entry 
 
Batch of precursor 3-96 (loading) 
 
Batch of CPG 3-93 
 
Loading (µmol/g) 
 
 
1 
 
                 3-96B (130  20) 
 
 
3-93B 
 
85 
 
2                  3-96C (77  4) 
 
3-93C 56 
3                  3-96D (114  11) 
 
3-93D 139 
4                  3-96E (153) 
 
3-93E 156 
5                  3-96F (150  50)_ 
 
3-93F 101 
6 
 
                 3-96G (ND) 3-93G 142 
7 
 
                 3-96H (ND) 3-93H 150 
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Representative procedure for esterification of succinylated CPG with triazole 3-95 
(3-94).   A 20-mL scintillation vial was charged with succinylated particles  (456 mg, 0.0648 
mmol, loading =150 µmol/g) and treated with a solution of alcohol 3-95 (147 mg, 0.304 mmol), 
DMAP (8.0 mg, 0.065 mmol) and anhydrous DMF (2.5 mL).  Et3N (45 µL, 0.32 mmol) and 
EDC•HCl (66 mg, 0.34 mmol) were added. The vial was capped, sealed, and shaken (100 rpm) 
on a platform shaker at rt overnight (15 h).  The solids were collected by filtration on a medium-
sized fritted funnel and washed with CH2Cl2 (3 x 30 mL), MeOH (3 x 30 mL) and hexanes (3 x 
30 mL). The very pale orange beads were dried under high vacuum, and CPG (490 mg) was 
collected. 
 
To recover unreacted triazole 3-95, the filtrate (prior to washing) was diluted with CH2Cl2 
(10 mL) and washed with water (2 x 5 mL) and brine (5 mL), dried (MgSO4), filtered, and 
concentrated in vacuo.  The residue was purified by chromatography (ISCO, 4 g SiO2 cartridge, 
0–20% MeOH/CH2Cl2) to afford recovered 3-95 (72.6 mg).   
 
Representative procedure for determination of loading via saponification of 
nitroxide-functionalized CPG. A sample of functionalized CPG 3-94 (16.0 mg) was 
weighed into a 1-dram vial.  The CPG was treated with 0.1 M aqueous NaOH/MeOH (1:1, v/v) 
(1.0 mL), and the vial was shaken (200 rpm) for 6 h at rt.  The solution was transferred to a 25-
mL volumetric flask, and the flask was filled to the mark with the 0.1 M aqueous NaOH/MeOH 
(1:1, v/v).  The sample was analyzed from 400 nm to 200 nm (UV/VIS).  The concentration (and 
consequent loading) was calculated based on the absorbance at 249 nm using an extinction 
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coefficient of 17 mLcm-1µmol-1.  Note: the extinction coefficient was calculated based on a 
previously generated calibration curve generate from solutions of  triazole 3-95 in 0.1 M aqueous 
NaOH/MeOH, 1:1. 
 
Loadings were typically 100–150 µmol/g.  Loadings from different batches of esterified 
CPG 3-94 are tabulated in Table 4-4. 
 
Table 4-4. Loadings of CPG esterified with triazole 3-95. 
 
 
Entry 
 
Batch of precursor 3-93 (loading, µmol/g) 
 
Batch of CPG 3-94 
 
Loading (µmol/g) 
 
 
1 
 
3-93D (139) 
 
 
3-94A 
 
100 ± 10 
 
2 3-93E (156) 
 
3-94B 110 
3 3-93E (156) 
 
3-94C 118 
4 3-96E (156) 
 
3-94D 153 
5    3-96H (150 )_ 
 
3-94E 156 
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2-(4-((4-Butyl-1H-1,2,3-triazol-1-yl)methyl)phenyl)-N-(1-oxy-2,2,6,6-
tetramethylpiperidin-4-yl)-4,5-dihydrooxazole-4-carboxamide (3-97).  An oven-dried thick-
walled vial was charged with a solution of 3-50 (50 mg, 0.13 mmol) in toluene (0.83 mL), 
followed by additional toluene (1.7 mL).  1-Hexyne (17 µL, 0.15 mol) and DIPEA (65 µL, 0.38 
mmol) were added. The solution was degassed using the freeze-pump-thaw method (three 
cycles). Upon warming to rt and flushing with N2, CuI•P(OEt)3 (45 mg, 0.13 mmol) was quickly 
added. The solution was stirred at rt for 51 h. The reaction mixture was concentrated in vacuo, 
and the residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:2 to 100% EtOAc) 
to afford 3-97 (40 mg, 67%) as an orange foam: HRMS (ESI) m/z calc for C26H38N6O3 (M+H) 
482.3005, found 482.3021. 
 
For NMR characterization, a sample of 3-97 was converted to the corresponding 
hydroxylamine (3-97a):  A sample of 3-97 (11.1 mg) was dissolved in MeOH (0.5 mL) and 
shaken with ascorbic acid (5 mg) until the solution was colorless. The solution was dissolved in 
Et2O (~3 mL) and washed with minimal amounts of saturated aqueous NaHCO3 and brine, 
filtered through a small plug of MgSO4, and concentrated in vacuo to afford the corresponding 
hydroxylamine 3-97a (8.0 mg): 1H NMR (400 MHz, CDCl3)  7.97 (d, J = 8.2 Hz, 2 H), 7.31 (d, 
J = 8.2 Hz, 2 H), 7.22 (s, 1 H), 6.39 (d, J = 8.0 Hz, 1 H), 5.56 (s, 2 H), 4.81 (dd, J = 10.9, 8.4 Hz, 
1 H), 4.70 (dd, J = 10.2, 6.6 Hz, 1 H), 4.60 (t, J = 6.4 Hz, 1 H), 4.224.12 (m, 1 H), 2.71 (t, J = 
7.6 Hz, 2 H), 1.93 (dt, J = 12.6, 3.4 Hz, 1 H), 1.80 (dt, J =  12.5, 3.4 Hz, 1 H), 1.681.60 (m, 2 
H), 1.451.31 (m, 5 H), 1.22 (s, 3 H), 1.20 (s, 3 H), 1.19 (s, 3 H), 1.15 (s, 3 H), 0.92 (t, J = 7.4 
Hz, 3 H);  13C NMR (100 MHz, CDCl3)  170.5, 165.2, 148.9, 138.7, 128.9, 127.6, 127.0, 120.3, 
70.3, 68.7, 53.2, 44.9, 40.5, 31.9, 31.2, 29.3, 25.1, 22.0, 19.4, 13.5.  
 
  
 264 
 Procedure for covalency test of CPG.  An oven-dried 1-dram vial was charged with 
succinylated particles 3-93 (100 mg, loading ~139 µmol/g). A second oven-dried vial was 
charged with triazole 3-97 (20 mg, 0.040 mmol), DMAP (15 mg, 0.12 mmol) and anhydrous 
DMF (0.50 mL). This solution was transferred to the vial containing the succinylated CPG under 
Ar atmosphere.  Et3N (10 µL, 0.070 mmol) was added, followed by EDC•HCl (13 mg, 0.070 
mmol). The vial was capped, sealed, and shaken (100 rpm) on a platform shaker at rt overnight 
(19 h).  The solids were collected on a medium-sized fritted funnel and washed with CH2Cl2 (3 x 
15 mL), MeOH (3 x 15 mL), and hexanes (3 x 15 mL). The white solid CPG (98 mg) was 
collected in a 1-dram vial and dried under high vacuum for 5 h. 
 
 Three samples (17 mg each) of the CPG were weighed into 1-dram vials and treated 
with 0.1 M aqueous NaOH/MeOH (1:1 v/v) (1.0 mL) and shaken (200 rpm) at rt overnight.  The 
contents of each vial were transferred to a 25-mL volumetric flask, and each flask was filled to 
the mark with 0.1 M aqueous NaOH/MeOH (1:1 v/v).  The samples were analyzed from 400 nm 
to 200 nm, and the absorbance at 248 nm (0.051, 0.052, 0.071) would correspond to loadings of 
4-6 µmol/g assuming triazole 3-97 has the same extinction coefficient as triazole 3-95  (17 
mLcm-1µmol-1).  Note: The extinction coefficient of triazole 3-97 in 0.1 M aqueous 
NaOH/MeOH, 1:1 was determined to be 15.4 mLcm-1µmol-1. 
 
 Due to having some absorbance at 248 nm, succinylated particles 3-93 (16.6 mg) were 
treated with 0.1 M aqueous NaOH/MeOH (1:1 v/v) (1.0 mL) and shaken (200 rpm) at rt 
overnight.  The contents of the vial were transferred to a 25-mL volumetric flask, and each flask 
was filled to the mark with 0.1 M aqueous NaOH/MeOH (1:1 v/v).  The sample was analyzed 
from 400 nm to 200 nm, and absorbance (with a maximum at 259.6 nm) was observed.  The 
absorbance was confirmed to be adsorbed DMAP after analyzing an independently prepared 
DMAP standard.   
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N-(9-Fluorenylmethoxycarbonyl)-dl-serine (3-101).246 dl-Serine (1.0 g, 9.5 mmol) was 
suspended in 10% aqueous Na2CO3 (17 mL) and 1,4-dioxane (8 mL) and cooled to 0 °C.  A 
solution of Fmoc-OSu (3.2 g, 9.5 mmol) in 1,4-dioxane (15 mL) was added over a period of 30 
min using an addition funnel.  The reaction mixture was stirred overnight, and the solvent was 
removed in vacuo.  Water (75 mL) was added, the suspension was washed with Et2O, and the 
aqueous layer was acidified with 1 M aqueous citric acid to pH ~3–4.  The aqueous layer was 
extracted with EtOAc (3 x 70 mL), and the combined EtOAc layers were dried (MgSO4), filtered 
and concentrated.   Coevaporation of the crude residue with CH2Cl2 afforded a white foam (3.7 
g).  The crude product was recrystallized from hot CH2Cl2 (~60 mL) and hexanes (~30 mL, 
added after boiling the crude product in CH2Cl2).  After standing for 2 h, 3-101 was isolated 
(1.71 g, 55%).   The mother liquor was concentrated in vacuo, and this first crop of material was 
combined with the mother liquor.  Boiling CH2Cl2 (~50 mL) was added.  Upon cooling, 3-101 
(2.74 g, 88%) precipitated as a white powder:  1H NMR (400 MHz, MeOD)  7.79 (d, J = 7.5 
Hz, 2 H), 7.68 (t, J = 6.4 Hz, 2 H), 7.38 (t, J = 7.4 Hz, 2 H), 7.30 (t, J = 7.2 Hz, 2 H), 4.38 (dd, J 
= 10.4, 7.0 Hz, 1 H), 4.344.22 (m, 3 H), 3.84 (dddd, J = 11.3, 11.3, 11.3, 5.0 Hz, 2 H); HRMS 
(ESI) m/z calc for C18H16NO5 (M-H) 326.1028, found 326.1059. 
 
 
 
 
 
 
 
(9H-Fluoren-9-yl)methyl 3-hydroxy-1-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-
ylamino)-1-oxopropan-2-ylcarbamate (3-102).  A suspension of 3-101 (50 mg, 0.15 mmol) in 
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CH2Cl2 (1.0 mL) was cooled to 0 °C and treated with a solution of 4-amino TEMPO (39 mg, 
0.23 mmol) in CH2Cl2 (0.50 mL) followed by HOBT (23 mg, 0.17 mmol), DMAP (21 mg, 0.17 
mmol) and EDC•HCl (35 mg, 0.18 mmol).  The reaction mixture was warmed to rt and stirred 
for 21 h. The mixture was diluted with CH2Cl2 (10 mL) and washed with 0.1 M aqueous citric 
acid (2 x 5 mL), saturated aqueous NaHCO3 (5 mL), and brine (5 mL), dried (MgSO4), and 
concentrated in vacuo. Purification by chromatography on SiO2 (hexanes/EtOAc, 1:1 to 1:2 to 
1:3) afforded 3-102 (43.4 mg, 59%) as an orange foam.  LCMS data were obtained using an 
Agilent (Varian HPLC) Pursuit XRs Ultra 2.8 C18 column (50 x 2.0 mm) (Rt 9.20 min, 0.50 
mL/min, 20% to 100% MeCN/water over 5 min): MS (ESI) m/z 503.3 (M+Na).   The 
corresponding hydroxylamine was also detected as a minor product by LCMS (Rt 8.34 min): MS 
(ESI) m/z 504.2.   
 
 
 
 
 
 
2-Amino-3-hydroxy-N-(1-oxy-2,2,6,6-tetramethylpiperidin-4-yl)propanamide (3-99).  
An oven-dried 10-mL flask was charged with 3-102 (121 mg, 0.252 mmol) followed by 20% 
piperidine/CH2Cl2 (2.5 mL). The mixture was stirred at rt for 30 min.  The mixture was 
concentrated onto SiO2 and purified by chromatography on SiO2 (CHCl3/MeOH, 95:5 to 
CHCl3/MeOH, 90:10 to CHCl3/MeOH/aqueous NH4OH 90:9:1) to afford 3-99 (56.6 mg, 87%) 
as an orange foam.  The product 3-99 was taken on directly to the following step. 
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2-Amino-3-hydroxy-N-(1-oxy-2,2,6,6-tetramethylpiperidin-4-yl)propanamide 
hydrochloride salt (3-99HCl).  A solution of free amine 3-99 (56.6 mg, 0.219 mmol) in dry 
1,4-dioxane (2.5 mL) was treated with  a solution of HCl in 1,4-dioxane (0.11 mL, 0.44 mmol, c 
= 4.0 M in 1,4-dioxane). The orange solution quickly turned to a turbid, yellow suspension. After 
30 min of stirring, the mixture was filtered (fritted funnel) and the yellow solids were washed 
with dry Et2O. Upon drying under high vacuum overnight 3-99HCl (60.3 mg, 93%) was 
collected as a bright yellow solida:  IR (ATR) 3545, 2947, 1664, 1459, 1385 cm-1; 1H NMR (400 
MHz, MeOD) 4.35 (t, J = 11.9 Hz, 1 H), 3.943.92 (m, 2 H), 3.873.82 (m, 1 H), 2.192.16 
(m, 2 H), 2.02 (t, J = 13.1 Hz, 2 H), 1.52 (s, 6 H), 1.50 (s, 6 H); 13C NMR (100 MHz, MeOD) 
167.8, 69.8, 61.7, 56.2, 42.6, 42.5, 41.0, 28.2, 20.4. 
 
Both the nitroxide 3-99 and the corresponding hydroxylamine 3-99a were detected by 
LCMS using an analytical C18 column (150 mm x 4.6 mm)  (Rt 3-99 2.38 min, Rt 3-99a 2.02 
min, 0.50 mL/min, 3% MeCN/water for 5 min, then 3% MeCN/water to 95% MeCN/water to 12 
min, 0.50 mL/min): 
3-99: HRMS (HESI) m/z calc for C12H25O3N3 (M+H) 259.1890, found 259.1876. 
3-99a: HRMS (HESI) m/z calc for  C12H26O3N3 (M+H) 260.1969, found 260.1953. 
aNote: Upon coevaporation of the solid with MeOD, the solid became a pale orange color. 
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APPENDIX A: SELECTED 1H NMR AND 13C NMR SPECTRA 
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APPENDIX B: X-RAY DATA FOR MMS350 
Table B-1. Crystal data and structure refinement for MMS350. 
 
Identification code  sprach3a 
Empirical formula  C10 H18 O3 S 
Formula weight  218.30 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 21.605(5) Å a= 90°. 
 b = 9.786(3) Å b= 90°. 
 c = 10.348(3) Å g = 90°. 
Volume 2188.0(10) Å3 
Z 8 
Density (calculated) 1.325 Mg/m3 
Absorption coefficient 2.484 mm-1 
F(000) 944 
Crystal size ? x ? x ? mm3 
Theta range for data collection 2.04 to 72.69°. 
Index ranges -26<=h<=26, -12<=k<=12, -12<=l<=12 
Reflections collected 22534 
Independent reflections 3848 [R(int) = 0.1174] 
Completeness to theta = 72.69° 88.3 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3848 / 0 / 253 
Goodness-of-fit on F2 4.403 
Final R indices [I>2sigma(I)] R1 = 0.2702, wR2 = 0.6295 
  
 292 
R indices (all data) R1 = 0.4840, wR2 = 0.6681 
Largest diff. peak and hole 1.860 and -2.106 e.Å-3 
 
Table B-2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103)for 
MMS350.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________
__  
 x y z U(eq) 
______________________________________________________________________________
__   
S(1) -4363(1) 2371(6) 3691(3) 87(2) 
O(1) -4360(5) 3324(14) 4690(9) 115(5) 
C(1) -3674(4) 2648(15) 2685(12) 57(4) 
S(2) 640(1) 2708(5) 3798(3) 71(2) 
C(2) -3086(5) 2590(20) 3452(12) 75(5) 
O(2) -2358(4) 3870(12) 3838(9) 77(3) 
O(3) -6264(5) 4243(16) 3355(14) 137(6) 
C(3) -2968(6) 3760(20) 4335(17) 84(6) 
O(4) 638(4) 1575(12) 2757(9) 77(3) 
C(4) -2506(6) 3021(12) 2715(14) 71(5) 
O(5) -1280(4) 733(12) 4091(10) 89(4) 
C(5) -2999(6) 1070(17) 4118(14) 77(5) 
C(6) -4931(6) 2680(20) 2503(13) 88(5) 
O(6) 2658(5) 1244(13) 3697(12) 89(4) 
C(7) -5590(7) 2630(20) 3063(15) 103(7) 
C(8) -5769(8) 3780(20) 4090(30) 130(10) 
C(9) -6093(6) 3396(19) 2216(14) 96(6) 
C(10) -5779(8) 1170(20) 3590(20) 111(8) 
C(11) 62(5) 2257(18) 5031(12) 82(5) 
C(12) -583(5) 2430(30) 4423(11) 89(6) 
C(13) -781(7) 1422(18) 3301(18) 82(6) 
C(14) -1093(5) 1551(14) 5263(11) 57(4) 
C(15) -767(7) 3960(20) 3994(18) 97(6) 
C(16) 1313(4) 2412(15) 4858(11) 54(3) 
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C(17) 1894(6) 2570(20) 4059(12) 75(5) 
C(18) 2475(6) 2120(30) 4747(14) 120(10) 
C(19) 2042(5) 1410(20) 3230(15) 92(7) 
C(20) 1999(5) 4010(16) 3347(12) 62(4) 
 
 
Table B-3.   Bond lengths [Å] and angles [°] for MMS350. 
_____________________________________________________  
S(1)-O(1)  1.393(10) 
S(1)-C(6)  1.763(13) 
S(1)-C(1)  1.837(12) 
C(1)-C(2)  1.499(11) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
S(2)-O(4)  1.546(10) 
S(2)-C(16)  1.845(10) 
S(2)-C(11)  1.839(15) 
C(2)-C(3)  1.49(2) 
C(2)-C(4)  1.527(18) 
C(2)-C(5)  1.65(2) 
O(2)-C(3)  1.418(16) 
O(2)-C(4)  1.465(15) 
O(3)-C(8)  1.39(2) 
O(3)-C(9)  1.488(19) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
O(5)-C(14)  1.509(14) 
O(5)-C(13)  1.511(17) 
C(5)-H(5A)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5C)  0.9800 
C(6)-C(7)  1.54(2) 
  
 294 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
O(6)-C(19)  1.426(13) 
O(6)-C(18)  1.44(2) 
C(7)-C(10)  1.58(3) 
C(7)-C(9)  1.584(16) 
C(7)-C(8)  1.60(2) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-H(10A)  0.9800 
C(10)-H(10B)  0.9800 
C(10)-H(10C)  0.9800 
C(11)-C(12)  1.538(14) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)  1.58(2) 
C(12)-C(15)  1.61(3) 
C(12)-C(14)  1.65(2) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
C(16)-C(17)  1.511(15) 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(17)-C(19)  1.46(2) 
C(17)-C(18)  1.510(17) 
C(17)-C(20)  1.61(2) 
C(18)-C(19)  1.96(2) 
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C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
 
O(1)-S(1)-C(6) 114.0(9) 
O(1)-S(1)-C(1) 108.6(7) 
C(6)-S(1)-C(1) 98.3(6) 
C(2)-C(1)-S(1) 112.4(8) 
C(2)-C(1)-H(1A) 109.0 
S(1)-C(1)-H(1A) 109.1 
C(2)-C(1)-H(1B) 109.2 
S(1)-C(1)-H(1B) 109.2 
H(1A)-C(1)-H(1B) 107.9 
O(4)-S(2)-C(16) 107.7(5) 
O(4)-S(2)-C(11) 108.1(7) 
C(16)-S(2)-C(11) 94.9(5) 
C(1)-C(2)-C(3) 116.0(14) 
C(1)-C(2)-C(4) 114.7(9) 
C(3)-C(2)-C(4) 87.2(11) 
C(1)-C(2)-C(5) 110.8(13) 
C(3)-C(2)-C(5) 114.8(11) 
C(4)-C(2)-C(5) 111.5(11) 
C(3)-O(2)-C(4) 92.5(10) 
C(8)-O(3)-C(9) 93.6(13) 
O(2)-C(3)-C(2) 89.6(12) 
O(2)-C(3)-H(3A) 113.7 
C(2)-C(3)-H(3A) 113.8 
O(2)-C(3)-H(3B) 113.7 
C(2)-C(3)-H(3B) 113.7 
H(3A)-C(3)-H(3B) 111.0 
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O(2)-C(4)-C(2) 86.6(11) 
O(2)-C(4)-H(4A) 114.2 
C(2)-C(4)-H(4A) 114.2 
O(2)-C(4)-H(4B) 114.2 
C(2)-C(4)-H(4B) 114.2 
H(4A)-C(4)-H(4B) 111.4 
C(14)-O(5)-C(13) 90.4(9) 
C(2)-C(5)-H(5A) 109.5 
C(2)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5B) 109.5 
C(2)-C(5)-H(5C) 109.4 
H(5A)-C(5)-H(5C) 109.5 
H(5B)-C(5)-H(5C) 109.5 
C(7)-C(6)-S(1) 112.1(10) 
C(7)-C(6)-H(6A) 109.2 
S(1)-C(6)-H(6A) 109.2 
C(7)-C(6)-H(6B) 109.2 
S(1)-C(6)-H(6B) 109.2 
H(6A)-C(6)-H(6B) 107.9 
C(19)-O(6)-C(18) 86.2(10) 
C(6)-C(7)-C(10) 113.3(16) 
C(6)-C(7)-C(9) 114.3(14) 
C(10)-C(7)-C(9) 116.1(15) 
C(6)-C(7)-C(8) 116.9(17) 
C(10)-C(7)-C(8) 110.4(15) 
C(9)-C(7)-C(8) 82.5(13) 
O(3)-C(8)-C(7) 92.8(15) 
O(3)-C(8)-H(8A) 113.1 
C(7)-C(8)-H(8A) 113.2 
O(3)-C(8)-H(8B) 113.1 
C(7)-C(8)-H(8B) 113.1 
H(8A)-C(8)-H(8B) 110.5 
O(3)-C(9)-C(7) 89.7(10) 
O(3)-C(9)-H(9A) 113.7 
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C(7)-C(9)-H(9A) 113.7 
O(3)-C(9)-H(9B) 113.7 
C(7)-C(9)-H(9B) 113.7 
H(9A)-C(9)-H(9B) 110.9 
C(7)-C(10)-H(10A) 109.5 
C(7)-C(10)-H(10B) 109.5 
H(10A)-C(10)-H(10B) 109.5 
C(7)-C(10)-H(10C) 109.5 
H(10A)-C(10)-H(10C) 109.5 
H(10B)-C(10)-H(10C) 109.5 
C(12)-C(11)-S(2) 107.7(10) 
C(12)-C(11)-H(11A) 110.1 
S(2)-C(11)-H(11A) 110.2 
C(12)-C(11)-H(11B) 110.2 
S(2)-C(11)-H(11B) 110.2 
H(11A)-C(11)-H(11B) 108.5 
C(11)-C(12)-C(13) 118.4(15) 
C(11)-C(12)-C(15) 116.2(15) 
C(13)-C(12)-C(15) 108.1(12) 
C(11)-C(12)-C(14) 109.3(13) 
C(13)-C(12)-C(14) 83.0(11) 
C(15)-C(12)-C(14) 117.8(13) 
O(5)-C(13)-C(12) 94.3(13) 
O(5)-C(13)-H(13A) 112.8 
C(12)-C(13)-H(13A) 112.9 
O(5)-C(13)-H(13B) 112.9 
C(12)-C(13)-H(13B) 112.9 
H(13A)-C(13)-H(13B) 110.3 
O(5)-C(14)-C(12) 91.9(9) 
O(5)-C(14)-H(14A) 113.3 
C(12)-C(14)-H(14A) 113.3 
O(5)-C(14)-H(14B) 113.3 
C(12)-C(14)-H(14B) 113.3 
H(14A)-C(14)-H(14B) 110.6 
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C(12)-C(15)-H(15A) 109.4 
C(12)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
C(12)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
C(17)-C(16)-S(2) 108.2(8) 
C(17)-C(16)-H(16A) 110.0 
S(2)-C(16)-H(16A) 110.1 
C(17)-C(16)-H(16B) 110.1 
S(2)-C(16)-H(16B) 110.0 
H(16A)-C(16)-H(16B) 108.4 
C(19)-C(17)-C(18) 82.4(14) 
C(19)-C(17)-C(16) 114.9(15) 
C(18)-C(17)-C(16) 113.7(11) 
C(19)-C(17)-C(20) 112.6(12) 
C(18)-C(17)-C(20) 110.9(13) 
C(16)-C(17)-C(20) 117.3(16) 
O(6)-C(18)-C(17) 92.7(11) 
O(6)-C(18)-C(19) 46.6(7) 
C(17)-C(18)-C(19) 47.8(9) 
O(6)-C(18)-H(18A) 113.2 
C(17)-C(18)-H(18A) 113.1 
C(19)-C(18)-H(18A) 135.0 
O(6)-C(18)-H(18B) 113.2 
C(17)-C(18)-H(18B) 113.2 
C(19)-C(18)-H(18B) 114.5 
H(18A)-C(18)-H(18B) 110.5 
O(6)-C(19)-C(17) 95.2(11) 
O(6)-C(19)-C(18) 47.1(7) 
C(17)-C(19)-C(18) 49.9(9) 
O(6)-C(19)-H(19A) 112.7 
C(17)-C(19)-H(19A) 112.7 
C(18)-C(19)-H(19A) 114.1 
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O(6)-C(19)-H(19B) 112.7 
C(17)-C(19)-H(19B) 112.7 
C(18)-C(19)-H(19B) 135.7 
H(19A)-C(19)-H(19B) 110.2 
C(17)-C(20)-H(20A) 109.5 
C(17)-C(20)-H(20B) 109.5 
H(20A)-C(20)-H(20B) 109.5 
C(17)-C(20)-H(20C) 109.5 
H(20A)-C(20)-H(20C) 109.5 
H(20B)-C(20)-H(20C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table B-4.   Anisotropic displacement parameters  (Å2x 103) for MMS350.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 61(2)  145(5) 54(3)  29(3) -27(2)  2(3) 
O(1) 144(9)  159(13) 44(7)  -51(8) -12(6)  -21(8) 
C(1) 54(7)  44(7) 72(9)  -1(8) -31(6)  -10(6) 
S(2) 64(2)  97(4) 50(2)  -4(2) -24(2)  -5(2) 
C(2) 37(6)  141(16) 45(8)  48(10) -10(5)  -1(8) 
O(2) 59(6)  112(9) 61(6)  20(7) -12(5)  -24(5) 
O(3) 124(9)  172(15) 114(10)  -60(10) -67(8)  13(9) 
C(3) 49(8)  121(16) 84(12)  -25(12) 3(8)  -18(9) 
O(4) 81(6)  100(8) 52(6)  -15(6) -16(5)  4(5) 
C(4) 76(9)  40(8) 98(11)  -12(8) -57(8)  6(6) 
O(5) 88(7)  116(10) 63(7)  -1(7) -7(5)  -37(6) 
C(5) 77(9)  96(14) 57(10)  49(9) -4(7)  17(8) 
C(6) 86(10)  117(14) 60(10)  3(11) -13(8)  -31(10) 
O(6) 83(7)  115(10) 69(8)  -4(8) -2(6)  24(6) 
C(7) 95(12)  147(18) 66(10)  8(13) -52(9)  52(12) 
C(8) 78(11)  104(16) 210(30)  -72(19) -5(14)  39(11) 
C(9) 94(10)  136(17) 60(10)  -4(10) -50(8)  -13(9) 
C(10) 86(11)  87(15) 160(20)  45(15) 28(13)  8(10) 
C(11) 74(8)  104(12) 69(10)  -45(10) -31(8)  25(9) 
C(12) 63(8)  183(19) 22(7)  -36(10) -14(6)  -13(11) 
C(13) 58(9)  85(13) 101(15)  -20(12) 8(9)  -10(8) 
C(14) 41(6)  78(10) 50(8)  2(7) -15(5)  5(6) 
C(15) 79(10)  114(15) 98(14)  30(14) -3(9)  38(10) 
C(16) 58(7)  65(8) 38(7)  -31(7) -2(5)  20(7) 
C(17) 72(9)  129(15) 24(7)  0(9) -18(6)  -24(9) 
C(18) 63(9)  260(30) 37(9)  0(14) -11(7)  13(12) 
C(19) 40(7)  172(19) 63(11)  -27(12) -25(7)  8(9) 
C(20) 51(7)  96(12) 38(7)  24(8) -13(6)  -5(7) 
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Table B-5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for MMS350. 
________________________________________________________________________________  
 x  y  z  U(eq) 
______________________________________________________________________________
__  
  
H(1A) -3661 1944 1998 68 
H(1B) -3705 3553 2262 68 
H(3A) -3230 4572 4152 101 
H(3B) -2984 3521 5263 101 
H(4A) -2208 2272 2555 86 
H(4B) -2591 3545 1915 86 
H(5A) -3379 819 4580 115 
H(5B) -2652 1096 4728 115 
H(5C) -2915 392 3444 115 
H(6A) -4859 3588 2112 105 
H(6B) -4893 1986 1811 105 
H(8A) -5896 3408 4938 155 
H(8B) -5442 4482 4204 155 
H(9A) -5915 3929 1492 116 
H(9B) -6431 2795 1909 116 
H(10A) -5674 476 2940 167 
H(10B) -6225 1148 3756 167 
H(10C) -5553 980 4389 167 
H(11A) 121 1300 5315 99 
H(11B) 105 2862 5793 99 
H(13A) -947 1902 2533 98 
H(13B) -445 789 3045 98 
H(14A) -904 988 5953 68 
H(14B) -1433 2119 5616 68 
H(15A) -428 4359 3493 145 
H(15B) -843 4514 4765 145 
H(15C) -1142 3928 3464 145 
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H(16A) 1313 3080 5576 64 
H(16B) 1294 1481 5231 64 
H(18A) 2770 2874 4906 144 
H(18B) 2391 1613 5557 144 
H(19A) 1778 601 3408 110 
H(19B) 2027 1637 2299 110 
H(20A) 2387 3981 2855 92 
H(20B) 2022 4740 3993 92 
H(20C) 1653 4187 2757 92 
______________________________________________________________________________
__  
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APPENDIX C: DATA FOR MACROPHAGE UPTAKE OF IMIDOTHIOLATE 
FUNCTIONALIZED SILICA NANOPARTICLES 
 
Figure C-1. Macrophage uptake by imidothiolate-functionalized silica nanoparticles. 
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